<SEC-DOCUMENT>0001140361-25-017747.txt : 20250507
<SEC-HEADER>0001140361-25-017747.hdr.sgml : 20250507
<ACCEPTANCE-DATETIME>20250507171553
ACCESSION NUMBER:		0001140361-25-017747
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250507
DATE AS OF CHANGE:		20250507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36728
		FILM NUMBER:		25922735

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ef20047548_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 07 19:58:08 UTC 2025 -->
<!-- Created by CompSci Resources, LLC on Sat May 03 19:25:17 UTC 2025 -->
<html xmlns:adma="http://admabiologics.com/20250331" xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
 <head>
  <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
 <body><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div>

  </div><hr style="border-top: 3px solid black; border-bottom: 1px solid black; border-left: none; border-right: none; height: 2px;"/><div style="text-align: center; font-size: 14pt;"><span style="font-weight: bold;">UNITED STATES</span>
  </div><div style="text-align: center; font-size: 14pt;">
   <span style="font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</span>
  </div><div>
  </div><div style="text-align: center; font-size: 12pt;">
   <span style="font-weight: bold;">WASHINGTON, D.C. 20549</span>
  </div><div>
  </div><div style="text-align: center; font-weight: bold;">&#160;</div><div>
  </div><div style="text-align: center; font-weight: bold; font-size: 18pt;">FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-9495">10-Q</ix:nonNumeric></div><div style="text-align: center; font-weight: bold;">&#160;</div><div>
   <span> (Mark One)</span>
  </div><div>
  </div><div style="text-indent: -36pt; padding-left: 36pt;"> <div style="float: left; width: 36.0pt; white-space: nowrap;"> <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport" id="ixv-26"><span>&#9746;</span></ix:nonNumeric> </div> <div> <span>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span> </div> </div><div>
  </div><div style="margin-left: 36pt; clear: both;"> <span>For the quarterly period ended </span><span style="text-decoration:underline"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-9496">March 31, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-9497">2025</ix:nonNumeric></ix:nonNumeric></span> </div><div>
  </div><div style="text-align: center;">
   <span>OR</span>
  </div><div>
  </div><div style="text-indent: -36pt; padding-left: 36pt;"> <div style="float: left; width: 36.0pt; white-space: nowrap;"> <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-40"><span>&#9744;</span></ix:nonNumeric> </div> <div> <span>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span> </div> </div><div>
  </div><div style="margin-left: 36pt; clear: both;">
   <span>For the transition period from ________ to ________</span>
  </div><div>
  </div><div style="text-align: center;"> <span>Commission file number </span><ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-50"><span style="text-decoration: underline;">001-36728</span></ix:nonNumeric> </div><div>
  </div><div style="text-align: center; font-size: 24pt;"> <ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-54"><span style="color: rgb(0, 0, 0); font-weight: bold; text-decoration: underline;">ADMA BIOLOGICS, INC.</span></ix:nonNumeric> </div><div>
  </div><div style="text-align: center;">
   <span style="color: rgb(0, 0, 0);">(Exact name of registrant as specified in its charter)</span>
  </div><div>


  </div><table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin: auto; width: 100%;"> <tr><td style="width: 49%;"/><td style="width: 2%;"/><td style="width: 49%;"/></tr><tr style="vertical-align: top; height: 12.4pt;"> <td style="padding: 0px; vertical-align: bottom; text-align: center;"> <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-67"><span style="text-decoration: underline;">Delaware</span></ix:nonNumeric> </td><td style="vertical-align: bottom; text-align: center;">&#160;</td> <td style="padding: 0px; vertical-align: bottom; text-align: center;"> <ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-71"><span style="text-decoration: underline;">56-2590442</span></ix:nonNumeric> </td> </tr><tr style="vertical-align: top;"> <td style="vertical-align: bottom; text-align: center;"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">(State or other jurisdiction of incorporation or organization)</span></td><td style="vertical-align: bottom; text-align: center;">&#160;</td> <td style="vertical-align: bottom; text-align: center;"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">(I.R.S. Employer Identification No.)</span></td> </tr> </table><div>


  </div><table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin: auto; width: 100%; color: rgb(0, 0, 0);"> <tr><td style="width: 49%;"/><td style="width: 2%;"/><td/></tr><tr style="vertical-align: top; height: 12.4pt;"> <td style="padding: 0px; text-align: center;"> <span style="color: rgb(0, 0, 0); text-decoration: underline;"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-9498">465 State Route 17</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-9499">Ramsey</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-9500">New Jersey</ix:nonNumeric></span> </td><td style="text-align: center;">&#160;</td> <td style="padding: 0px; width: 49.96%; text-align: center;"> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-90"><span style="color: rgb(0, 0, 0); text-decoration: underline;">07446</span></ix:nonNumeric> </td> </tr> <tr style="vertical-align: top; height: 12.4pt;"> <td style="padding: 0px; text-align: center;"> <span style="color: rgb(0, 0, 0);">(Address of principal executive offices)</span> </td><td style="text-align: center;">&#160;</td> <td style="padding: 0px; width: 49.96%; text-align: center;"> <span style="color: rgb(0, 0, 0);">(Zip Code)</span> </td> </tr> <tr style="vertical-align: top; height: 5.4pt;"> <td colspan="3" style="padding: 0px; text-align: center;">&#160;</td> </tr> </table><div style="text-align: center;"> <span style="color: rgb(0, 0, 0); text-decoration: underline;">(<ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-9501">201</ix:nonNumeric>) <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-9502">478-5552</ix:nonNumeric></span> </div><div>

  </div><div style="text-align: center;">
   <span style="color: rgb(0, 0, 0);">(Registrant&#8217;s telephone number, including area code)</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: rgb(0, 0, 0);">(Former name, former address and former fiscal year, if changed since last report)</span>
  </div><div>
  </div><div style="text-align: center;">&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: rgb(0, 0, 0);">Securities registered pursuant to Section 12(b) of the Act:</span>
  </div><div>


  </div><table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr><td style="width: 33%;">&#160;</td><td style="width: 34%;">&#160;</td><td style="width: 33%;">&#160;</td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 5.4pt; border-width: 2px; border-style: solid; border-color: black;"> <div style="text-align: center;"> <span style="color: rgb(0, 0, 0);">Title of each class</span> </div> </td> <td style="padding: 0px 5.4pt; border-width: 2px; border-style: solid; border-color: black;"> <div style="text-align: center;"> <span style="color: rgb(0, 0, 0);">Trading Symbol(s)</span> </div> </td> <td style="padding: 0px 5.4pt; border-width: 2px; border-style: solid; border-color: black;"> <div style="text-align: center;"> <span style="color: rgb(0, 0, 0);">Name of each exchange on which registered</span> </div> </td> </tr> <tr style="vertical-align: top;"> <td style="padding: 0px 5.4pt; border-width: 2px; border-style: solid; border-color: black;"> <div style="text-align: center;"> <ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-132"><span style="color: rgb(0, 0, 0);">Common Stock</span></ix:nonNumeric> </div> </td> <td style="padding: 0px 5.4pt; border-width: 2px; border-style: solid; border-color: black;"> <div style="text-align: center;"> <ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-136"><span style="color: rgb(0, 0, 0);">ADMA</span></ix:nonNumeric> </div> </td> <td style="padding: 0px 5.4pt; border-width: 2px; border-style: solid; border-color: black;"> <div style="text-align: center;"> <span style="color: rgb(0, 0, 0);"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-9503">Nasdaq</ix:nonNumeric> Global Market</span> </div> </td> </tr> </table><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;"> <span>Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-9504">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160;&#160;No &#9744;</span> </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;"> <span>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-9505">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160;&#160;No &#9744;</span> </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span>
  </div><div>


  </div><table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin: auto; width: 100%;"> <tr><td/><td/><td style="width: 34%;"/></tr><tr style="vertical-align: top; height: 12.4pt;"> <td style="padding: 0; width: 12.22%;"> <div style="margin-left: 18pt;">&#160; </div> </td> <td style="padding: 0; width: 54.12%;"> <div> <span style="color: rgb(0, 0, 0);"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-9506">Large accelerated filer</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span>&#9746;</span> </div> </td> <td style="padding: 0px;"> <div> <span style="color: rgb(0, 0, 0);">Accelerated filer&#160;&#160;&#160;&#160;&#9744;</span> </div> </td> </tr> <tr style="vertical-align: top; height: 12.4pt;"> <td style="padding: 0; width: 12.22%;"> <div style="margin-left: 18pt;">&#160; </div> </td> <td style="padding: 0; width: 54.12%;"> <div> <span style="color: rgb(0, 0, 0);">Non-accelerated filer&#160;&#160;&#160;&#160;&#9744;</span> </div> </td> <td style="padding: 0px;"> <div> <span style="color: rgb(0, 0, 0);">Smaller reporting company&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-9507">&#9744;</ix:nonNumeric></span> </div> </td> </tr> <tr style="vertical-align: top; height: 12.4pt;"> <td style="padding: 0; width: 12.22%;"> <div>&#160; </div> </td> <td style="padding: 0; width: 54.12%;"> <div>&#160; </div> </td> <td style="padding: 0px;"> <div> <span style="color: rgb(0, 0, 0);">Emerging growth company&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-188"><span>&#9744;</span></ix:nonNumeric> </div> </td> </tr> </table><div style="text-indent: 36pt; text-align: justify;">
   <span>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style=" color: #000000;">&#9744;</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;"> <span>Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes &#9744;&#160;&#160;&#160;&#160;No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-9508">&#9746;</ix:nonNumeric></span> </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;"> <span>As of May 2, 2025, there were <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-9509">238,734,246</ix:nonFraction> shares of the issuer&#8217;s common stock outstanding.</span> </div><div>
  </div><div>&#160;
  </div><div>


  </div><hr style="border-top: 1px solid black; border-bottom: 3px solid black; border-left: none; border-right: none; height: 2px;"/><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="display: none; text-align: center">1</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center; font-weight: bold;">
   <span>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: center; font-weight: bold;">
   <span>INDEX</span>
  </div><div>


  </div><table id="tableOfContents0" style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: 0px;">
   <tr><td style="width: 4%;">&#160;</td><td style="width: 10%;">&#160;</td><td style="width: 81%;">&#160;</td><td style="width: 5%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td colspan="3" style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#PART_I">PART I FINANCIAL INFORMATION</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
   </tr><tr style="vertical-align: top;">
    <td colspan="3">&#160;</td>
    <td>&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      Item 1.
     </div>
    </td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#Item_1_Financial_Statements">Financial Statements</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; text-align: right;">&#160;</td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#BALANCE_SHEETS">Condensed Consolidated Balance Sheets as of March 31, 2025 (Unaudited) and December 31, 2024</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">


      1
     </td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#STATEMENTS_OF_OPERATIONS">Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2025 and 2024</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">


      2
     </td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#STOCKHOLDERS_EQUITY_U">Unaudited Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity for the Three Months Ended March 31, 2025 and 2024</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">


      3
     </td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#CASH_FLOWS">Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2025 and 2024</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">


      4
     </td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIAL_STATEMENTS_UNAUDITED">Notes to Unaudited Condensed Consolidated Financial Statements</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">


      5
     </td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      Item 2.
     </div>
    </td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#Managements_Discussion_and_Analysis_of_Financial_Condition_and_Results_of_Operations">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">


      20
     </td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      Item 3.
     </div>
    </td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#Quantitative_and_Qualitative_Disclosures_About_Market_Risk">Quantitative and Qualitative Disclosures About Market Risk.</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">29</td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      Item 4.
     </div>
    </td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#Controls_and_Procedures">Controls and Procedures.</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">


      30</td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td colspan="3" style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#PART_II">PART II OTHER INFORMATION</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">
     <div>
      31</div>
    </td>
   </tr><tr style="vertical-align: top;">
    <td colspan="3">&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      Item 1.
     </div>
    </td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#Legal_Proceedings">Legal Proceedings</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">


      31</td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      Item 1A.
     </div>
    </td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#Risk_Factors">Risk Factors.</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">


      31</td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      Item 2.
     </div>
    </td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#Unregistered_Sales_of_Equity_Securities_and_Use_of_Proceeds">Unregistered Sales of Equity Securities and Use of Proceeds.</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">


      60</td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      Item 3.
     </div>
    </td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#Defaults_Upon_Senior_Securities">Defaults Upon Senior Securities.</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">


      60</td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      Item 4.
     </div>
    </td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#Mine_Safety_Disclosures">Mine Safety Disclosures.</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">


      61</td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      Item 5.
     </div>
    </td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#Other_Information">Other Information.</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">


      61</td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px 5.4pt 0px 5px;">&#160;</td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      Item 6.
     </div>
    </td>
    <td style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#Exhibits">Exhibits.</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">


      61</td>
   </tr><tr style="vertical-align: top;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td colspan="3" style="padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px;">
     <div>
      <a href="#SIGNATURES">SIGNATURES</a>
     </div>
    </td>
    <td style="padding: 0px 5.4pt 0px 5px; vertical-align: bottom; text-align: right;">
     <div>
      63
     </div>
    </td>
   </tr>
  </table><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">This Quarterly Report on Form 10-Q includes our trademarks, trade names and service marks, such as &#8220;ASCENIV</span><sup style="color: rgb(0, 0, 0);">&#8482;</sup><span style="color: rgb(0, 0, 0);">,&#8221; &#8220;Nabi-HB</span><sup style="color: rgb(0, 0, 0);">&#174;</sup><span style="color: rgb(0, 0, 0);">&#8221; and &#8220;BIVIGAM</span><sup style="color: rgb(0, 0, 0);">&#174;</sup><span style="color: rgb(0, 0, 0);">,&#8221; which are protected under applicable intellectual property laws and are the property of ADMA Biologics, Inc., or its subsidiaries. Solely for convenience, trademarks, trade names and service marks referred to in this report may appear without the </span><sup style="color: rgb(0, 0, 0);">&#174;</sup><span style="color: rgb(0, 0, 0);">, </span><sup style="color: rgb(0, 0, 0);">&#8482;</sup><span style="color: rgb(0, 0, 0);"> or </span><sup style="color: rgb(0, 0, 0);">SM</sup><span style="color: rgb(0, 0, 0);"> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</span>
  </div><div>
  </div><div>&#160;
  </div><div>



  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center">i</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-align: center;"><span style="font-weight: bold;">Special Note Regarding Forward-Looking Statements</span>
  </div><div style="text-align: center;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">This Quarterly Report on Form 10-Q contains certain &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, (the &#8220;Exchange Act&#8221;), and such forward-looking statements involve risks and uncertainties. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions that are not historical facts and typically are identified by use of terms such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; or the negative thereof, or other variations or comparable terminology, although some forward-looking statements are expressed differently. The forward-looking statements included herein represent management&#8217;s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. These statements include, among others, statements about: </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our ability to further commercialize ASCENIV and BIVIGAM;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -36pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our plans to develop, manufacture, market, launch and expand our commercial infrastructure and commercialize our current and future products and the success of such efforts;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>the safety, efficacy and expected timing of and our ability to obtain and maintain regulatory approvals for our current products and product candidates, the labeling or nature of any such approvals, and whether any of our current products may be subject to post-marketing restrictions or withdrawal from the market;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>the achievement of or expected timing, progress and results of clinical development, clinical trials and potential regulatory approvals for our product candidates;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our dependence upon our third-party customers, suppliers and vendors and their compliance with applicable regulatory requirements;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our belief that we have addressed the delays experienced with final drug product current Good Manufacturing Practices (&#8220;cGMP&#8221;) release testing by our third-party vendors by adding additional release testing laboratories to our U.S. Food and Drug Administration (&#8220;FDA&#8221;)-approved consortium listed in our drug approval documents;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our ability to obtain adequate quantities of FDA-approved plasma with proper specifications;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our plans to increase our supplies of source plasma (including source plasma containing certain levels of antibodies to Respiratory Syncytial Virus), our ability to obtain and maintain regulatory compliance and reliance on third-party supply agreements as well as any extensions to such agreements;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>the potential indications for our products and product candidates;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>potential investigational new product applications;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>the acceptability of any of our products, including ASCENIV, BIVIGAM and Nabi-HB, for any purpose, including FDA-approved indications, by physicians, patients or payers;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our plans to evaluate the clinical and regulatory paths to grow the ASCENIV franchise through expanded FDA-approved uses;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Federal, state and local regulatory and business review processes and timing by such governmental and regulatory agencies of our business and regulatory submissions;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>concurrence by the FDA with our conclusions concerning our products and product candidates;</span></div>
  <div>&#160;</div></div><div>
  </div><div style="margin: 0in 0in 0in 0.5in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt;font-family:Symbol;mso-ascii-font-family:&quot;Times New Roman&quot;; mso-fareast-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;; mso-char-type:symbol;mso-symbol-"><span style="mso-char-type: symbol;mso-symbol-">&#9679;</span></span><span style="font-size: 10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;"><span style="mso-tab-count: 1">&#160;&#160;&#160;&#160;&#160;</span>the comparability of results of our hyperimmune and immune
globulin (&#8220;IG&#8221;) products to other comparably run hyperimmune and immune
globulin clinical trials;</span></div><div style="text-align: justify; clear: both;">&#160;</div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">ii</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>


  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>the potential for ASCENIV and BIVIGAM to provide meaningful clinical improvement for patients living with </span><span style="color: rgb(0, 0, 0);">Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;) or Inborn Errors of Immunity,</span><span> or other immune deficiencies or any other condition for which the products may be prescribed or evaluated;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our ability to market and promote Nabi-HB in a highly competitive environment with increasing competition from other antiviral therapies and to generate meaningful revenues from this product;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our intellectual property position and the defense thereof, including our expectations regarding the scope of patent protection with respect to ASCENIV, SG-001 or other future pipeline product candidates;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our ability to develop, manufacture, receive regulatory approval and commercialize our potential pipeline of any new hyperimmune globulins, including SG-001;</span>
    </div>
  </div><div>
  </div><div style="margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our manufacturing capabilities, third-party contractor capabilities and vertical integration strategy;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our plans related to the expansion and efficiencies of our manufacturing capacity, yield improvements, supply-chain robustness, in-house fill-finish capabilities, distribution and other collaborative agreements and the success of such endeavors;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our estimates regarding revenues, net income, Adjusted EBITDA, expenses, capital requirements, ASCENIV&#8217;s growth, ability to maintain profitability and positive cash flows and the potential need for and availability of additional financing;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>production yield and revenue and earnings benefits following FDA approval of our innovative yield enhancement production process, and the timing associated with realizing such benefits;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our ability to realize our deferred tax assets or the need for a valuation allowance, or the effects of changes in tax laws on our deferred tax assets;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our estimates of future taxable income, which could have a material impact on our financial condition or financial results;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our estimates of future effective tax rates and corresponding tax obligations, which could have a material impact on our financial condition or financial results;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>possible or likely reimbursement levels for our currently marketed products;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>estimates regarding market size, projected growth and sales of our existing products as well as our expectations of market acceptance of ASCENIV and BIVIGAM; </span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>pandemics, or a resurgence of a pandemic, may adversely affect our business, financial condition, liquidity or results of operations; and</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>future domestic and global economic conditions including, but not limited to, supply chain constraints, inflationary pressures or performance or geopolitical conditions, including the continuing conflicts in Europe and in the Middle East and surrounding areas, international trade and U.S. tariff policies or trade wars, and any anticipated effects of such factors on the pricing and availability of imported raw materials used in the production of our products.</span>
    </div>
  </div><div>
  </div><div style="text-indent: -36pt; padding-left: 36pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">These statements may be found under the &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of this Quarterly Report on Form 10-Q.&#160;&#160;Our actual results could differ materially from those contained in the forward-looking statements due to the factors described in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 and in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. Any forward-looking statement included or incorporated by reference in this Quarterly Report on Form 10-Q reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions related to our operations, industry and future growth. These forward-looking statements speak only as of the dates such statements are made, and we undertake no obligation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">iii</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-align: center; font-weight: bold;">
   <a id="PART_I" title="PART I"></a><span>PART I</span>
  </div><div>
  </div><div style="text-align: center; font-weight: bold;">
   <span>FINANCIAL INFORMATION</span></div><div>
  </div><div><a id="Item_1_Financial_Statements" title="Item 1.                 Financial Statements."></a></div><h2 style="margin-bottom: 0in; font-size: 10pt;">Item 1.<span style="mso-tab-count:1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Financial
Statements.</h2><div style="text-align: center; font-weight: bold;">&#160;</div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span><span style="text-transform: uppercase;">&#160;</span>
  </div><div>
  </div><div style="text-align: center;">
   <a id="BALANCE_SHEETS" title="BALANCE SHEETS"></a><span style="font-weight: bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</span>
  </div><div>
  </div><div style="margin-left: -13.5pt;">&#160;
  </div><div>

  </div><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top; height: 23.0pt;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="width : 9%; text-align : center; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; vertical-align : bottom; white-space : nowrap; ">

     <div><span style="font-weight: bold;">March 31,</span></div><span style="font-weight: bold;"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">2025</span><br/></span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align : center; width : 9%; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; vertical-align : bottom; white-space : nowrap; ">

     <div><span style="font-weight: bold;">December 31,</span></div><span style="font-weight: bold;"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">2024</span><br/></span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center; width: 9%; padding-left: 10px;">


      (Unaudited)
     </td><td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center; padding-left: 10px;">


      <span style="font-style: italic;">(In thousands, except share data)</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">ASSETS</span>
     </div>
    </td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Current assets:
     </div>
    </td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Cash and cash equivalents
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-9510">71,625</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-9511">103,147</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">
     <div>
      Accounts receivable, net
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" unitRef="usd" id="ixv-9512">99,412</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" unitRef="usd" id="ixv-9513">49,999</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Inventories
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-9514">172,188</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-9515">170,235</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">
     <div>
      Prepaid expenses and other current assets
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-9516">8,589</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-9517">8,029</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 20px;">
     <div>
      Total current assets
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-9518">351,814</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-9519">331,410</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Property and equipment, net
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-9520">57,710</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-9521">54,707</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Intangible assets, net
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-9522">452</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-9523">460</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Goodwill
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" unitRef="usd" id="ixv-9524">3,530</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" unitRef="usd" id="ixv-9525">3,530</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Deferred tax assets, net
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" unitRef="usd" id="ixv-9526">80,855</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" unitRef="usd" id="ixv-9527">84,280</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Right-to-use assets
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-9528">8,020</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-9529">8,634</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Deposits and other assets
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="adma:DepositsAndOtherNoncurrentAssets" scale="3" unitRef="usd" id="ixv-9530">8,188</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="adma:DepositsAndOtherNoncurrentAssets" scale="3" unitRef="usd" id="ixv-9531">5,657</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">TOTAL ASSETS</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-9532">510,569</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-9533">488,678</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">LIABILITIES AND STOCKHOLDERS' EQUITY </span>
     </div>
    </td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Current liabilities:
     </div>
    </td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">
     <div>
      Accounts payable
     </div>
    </td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-9534">20,607</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-9535">20,219</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Accrued expenses and other current liabilities
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" unitRef="usd" id="ixv-9536">31,560</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" unitRef="usd" id="ixv-9537">33,962</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">
     <div>
      Current portion of deferred revenue
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" unitRef="usd" id="ixv-9538">143</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" unitRef="usd" id="ixv-9539">143</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Current portion of lease obligations
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-9540">1,188</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-9541">1,218</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 20px;">
     <div>
      Total current liabilities
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-9542">53,498</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-9543">55,542</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Senior notes payable, net of discount
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeniorLongTermNotes" scale="3" unitRef="usd" id="ixv-9544">72,527</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeniorLongTermNotes" scale="3" unitRef="usd" id="ixv-9545">72,337</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Deferred revenue, net of current portion
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" unitRef="usd" id="ixv-9546">1,512</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" unitRef="usd" id="ixv-9547">1,547</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      End of term fee
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="adma:LongTermLiabilityEndOfTermFeePayable" scale="3" unitRef="usd" id="ixv-9548">1,313</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="adma:LongTermLiabilityEndOfTermFeePayable" scale="3" unitRef="usd" id="ixv-9549">1,313</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Lease obligations, net of current portion
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-9550">8,298</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-9551">8,561</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Other non-current liabilities
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-9552">2</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-9553">360</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">TOTAL LIABILITIES</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-9554">137,150</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-9555">139,660</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">COMMITMENTS AND CONTINGENCIES</span>
     </div>
    </td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><div style="-sec-ix-hidden: hidden-fact-0">&#160;</div></td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">STOCKHOLDERS' EQUITY </span>
     </div>
    </td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td> <div> Preferred Stock, $<ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-9556"><ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-9557">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-9558"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-9559">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-9560"><ix:nonFraction contextRef="c3" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-9561"><ix:nonFraction contextRef="c2" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-9562"><ix:nonFraction contextRef="c3" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-9563">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding </div> </td>
    <td style="text-align: left; font-weight: bold; width: 1%;">&#160;</td><td style="text-align: right; font-weight: bold; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" unitRef="usd" id="ixv-9564"> - </ix:nonFraction></td><td style="text-align: left; font-weight: bold; width: 1%;">&#160;</td><td style="text-align: left; font-weight: bold;">&#160;</td>
    <td style="text-align: left; font-weight: bold; width: 1%;">&#160;</td><td style="text-align: right; font-weight: bold; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" unitRef="usd" id="ixv-9565"> - </ix:nonFraction></td><td style="text-align: left; font-weight: bold; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;"> <div style="text-indent : -10px; "> Common Stock - voting, $<ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-9566"><ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-9567">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-9568"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-9569">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-9570"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-9571">238,532,252</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-9572"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-9573">236,620,545</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2025 and December 31, 2024 </div> </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-9574">24</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-9575">24</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Additional paid-in capital
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-9576">655,074</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-9577">657,577</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Accumulated deficit
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-9578">281,679</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-9579">308,583</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      <span style="font-weight: bold;">TOTAL STOCKHOLDERS' EQUITY </span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9580">373,419</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9581">349,018</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY </span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-9582">510,569</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-9583">488,678</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><div>&#160;
  </div><div>
  </div><div style="text-align: center;">
   The accompanying notes are an integral part of these condensed consolidated financial statements.
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">1</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <a id="STATEMENTS_OF_OPERATIONS" title="STATEMENTS OF OPERATIONS"></a><span style="font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">(Unaudited) </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">Three Months ended March 31,</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center; padding-left: 10px;">


      <span style="font-style: italic;">(In thousands, except share and per share data)</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: center; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      <span style="font-weight: bold;">REVENUES</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-9584">114,802</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-9585">81,875</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Cost of product revenue
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-9586">53,705</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-9587">42,767</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 20px;">
     <div>
      <span style="font-weight: bold;">Gross profit </span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" unitRef="usd" id="ixv-9588">61,097</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" unitRef="usd" id="ixv-9589">39,108</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      <span style="font-weight: bold;">OPERATING EXPENSES:</span>
     </div>
    </td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">
     <div>
      Research and development
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-9590">826</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-9591">450</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Plasma center operating expenses
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCostAndExpenseOperating" scale="3" unitRef="usd" id="ixv-9592">1,286</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCostAndExpenseOperating" scale="3" unitRef="usd" id="ixv-9593">1,005</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">
     <div>
      Amortization of intangible assets
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" unitRef="usd" id="ixv-9594">25</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" unitRef="usd" id="ixv-9595">193</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Selling, general and administrative
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-9596">24,079</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-9597">15,639</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 20px;">
     <div>
      <span style="font-weight: bold;">Total operating expenses</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-9598">26,216</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-9599">17,287</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">INCOME FROM OPERATIONS</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" unitRef="usd" id="ixv-9600">34,881</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" unitRef="usd" id="ixv-9601">21,821</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">OTHER INCOME (EXPENSE):</span>
     </div>
    </td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Interest income
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-9602">608</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-9603">384</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">
     <div>
      Interest expense
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" unitRef="usd" id="ixv-9604">1,975</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" unitRef="usd" id="ixv-9605">3,769</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Other expense
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-9606">64</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-9607">35</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 20px;">
     <div>
      <span style="font-weight: bold;">Other expense, net</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-9608">1,431</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-9609">3,420</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">INCOME BEFORE INCOME TAXES</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-9610">33,450</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-9611">18,401</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">
     <div>
      Provision for income taxes
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-9612">6,546</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-9613">595</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>&#160;</td>
    <td style="text-align: right; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">NET INCOME</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-9614">26,904</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-9615">17,806</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">BASIC EARNINGS PER COMMON SHARE</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares" id="ixv-9616">0.11</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares" id="ixv-9617">0.08</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      <span style="font-weight: bold;">DILUTED EARNINGS PER COMMON SHARE</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" unitRef="usdPershares" id="ixv-9618">0.11</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" unitRef="usdPershares" id="ixv-9619">0.08</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      <span style="font-weight: bold;">WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING:</span>
     </div>
    </td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">
     <div>
      <span style="font-weight: bold;">Basic </span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-9620">237,775,476</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-9621">228,874,847</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      <span style="font-weight: bold;">Diluted</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-9622">244,676,350</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-9623">236,414,374</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span>The accompanying notes are an integral part of these condensed consolidated financial statements.</span>
  </div><div>
  </div><div style="text-align: center;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">2</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center; margin-left: -4.5pt;">
   <span style="font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</span>
  </div><div>
  </div><div style="text-align: center; margin-left: -4.5pt;">
   <a id="STOCKHOLDERS_EQUITY_U" title="STOCKHOLDERS&#8217; EQUITY (U"></a><span style="font-weight: bold;">STOCKHOLDERS&#8217; EQUITY (Unaudited)</span>
  </div><div>
  </div><div style="text-align: center; margin-left: -4.5pt;">
   <span style="font-style: italic;">(In thousands, except share data)</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 54%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td colspan="20" style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">For the Three Months Ended March 31, 2025</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="text-align: center;">&#160;</td>
    <td colspan="8" style="text-align: center; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial;">&#160;</td>
    <td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Additional</span></td><td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center; width: 9%;">&#160;</td><td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Total</span></td><td style="text-align: center; width: 1%;">&#160;</td>
   </tr><tr style="vertical-align: top;">
    <td style="text-align: center; padding-left: 10px;">&#160;</td>
    <td colspan="8" style="text-align: center; padding-left: 10px; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;"> Common Stock </span>
     </td>
    <td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Paid-in</span>&#160;</td><td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Accumulated</span>&#160;</td><td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Stockholders'</span>&#160;</td><td style="text-align: center; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="text-align: center;">&#160;</td>
    <td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Shares</span></td><td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Amount</span></td><td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Capital</span></td><td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">&#160;Deficit</span></td><td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;">Equity</span></td><td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      <span style="font-weight: bold;">Balance at December 31, 2024</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-9624">236,620,545</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9625">24</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9626">657,577</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-9627">308,583</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">)&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9628">349,018</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">
     <div style="text-indent : -10px; ">
      Stock-based compensation
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">          -      </td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9629"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9630">4,624</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9631"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9632">4,624</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Cashless exercise of warrants
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" scale="0" unitRef="shares" id="ixv-9633">866,302</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:fixed-zero" name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-9634"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:fixed-zero" name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-9635"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:fixed-zero" name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-9636"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-9637"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="white-space: nowrap; padding-left: 10px;">
     <div style="text-indent : -10px; ">
      Vesting of restricted stock units, net of shares withheld for taxes
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" scale="0" unitRef="shares" id="ixv-9638">1,016,005</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:fixed-zero" name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" scale="3" unitRef="usd" id="ixv-9639"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" scale="3" sign="-" unitRef="usd" id="ixv-9640">7,228</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:fixed-zero" name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" scale="3" unitRef="usd" id="ixv-9641"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" scale="3" sign="-" unitRef="usd" id="ixv-9642">7,228</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Exercise of stock options
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-9643">29,400</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-9644"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-9645">101</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-9646"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-9647">101</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Net income
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">          -      </td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-9648"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-9649"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-9650">26,904</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-9651">26,904</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      <span style="font-weight: bold;">Balance at March 31, 2025</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-9652">238,532,252</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-9653">24</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-9654">655,074</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-9655">281,679</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-9656">373,419</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><div>&#160;
  </div><div>


  </div><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 54%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td colspan="20" style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">
     <div>
      <span style="font-weight: bold;">For the Three Months Ended March 31, 2024</span>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="text-align: center; padding-left: 10px;">&#160;</td>
    <td colspan="8" style="text-align: center; padding-left: 10px; border-width: initial; border-style: none; border-color: initial;">
     <div style="text-indent: -7.2pt; padding-left: 7.2pt;"><br/></div>
    </td>
    <td style="text-align: center; width: 1%;">&#160;</td><td style="width: 9%; text-align: center;">&#160;<span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Additional</span></td><td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center; width: 9%;">&#160;</td><td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Total</span>&#160;</td><td style="text-align: center; width: 1%;">&#160;</td>
   </tr><tr style="vertical-align: top;">
    <td style="text-align: center;">&#160;</td>
    <td colspan="8" style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Common Stock</span></td>
    <td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Paid-in</span></td><td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Accumulated</span></td><td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Stockholders'</span><br/></td><td style="text-align: center; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="text-align: center;">&#160;</td>
    <td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Shares</span></td><td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Amount</span></td><td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Capital</span></td><td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Deficit</span></td><td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td><td style="text-align: center; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Equity</span><br/></td><td style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      <span style="font-weight: bold;">Balance at December 31, 2023</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-9657">226,063,032</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9658">23</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9659">641,439</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; vertical-align: bottom;">(<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-9660">506,256</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">)&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9661">135,206</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Stock-based compensation
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;">         -      </td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9662"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9663">2,141</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9664"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9665">2,141</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Cashless exercise of warrants
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" scale="0" unitRef="shares" id="ixv-9666">4,545,503</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:fixed-zero" name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-9667"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:fixed-zero" name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-9668"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:fixed-zero" name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-9669"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:fixed-zero" name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-9670"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">
     <div style="text-indent : -10px; ">
      Vesting of Restricted Stock Units, net of shares withheld for taxes
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" scale="0" unitRef="shares" id="ixv-9671">774,889</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:fixed-zero" name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" scale="3" unitRef="usd" id="ixv-9672"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" scale="3" sign="-" unitRef="usd" id="ixv-9673">2,476</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:fixed-zero" name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" scale="3" unitRef="usd" id="ixv-9674"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" scale="3" sign="-" unitRef="usd" id="ixv-9675">2,476</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Exercise of stock options
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-9676">386,341</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-9677"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-9678">1,029</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-9679"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-9680">1,029</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Net income
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">         -      </td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-9681"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-9682"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-9683">17,806</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-9684">17,806</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      <span style="font-weight: bold;">Balance at March 31, 2024</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-9685">231,769,765</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-9686">23</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-9687">642,133</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-9688">488,450</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-9689">153,706</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><div>&#160;
  </div><div>
  </div><div style="text-align: center;">
   The accompanying notes are an integral part of these condensed consolidated financial statements.
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">3</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <a id="CASH_FLOWS" title="CASH FLOWS"></a><span style="font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">(Unaudited)</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">Three Months Ended March 31,</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center; padding-left: 10px; vertical-align: middle;">


      <i>(In thousands)</i>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</span>
     </div>
    </td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Net income
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; padding-left: 10px; width: 9%; vertical-align: bottom;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-9690">26,904</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; padding-left: 10px; width: 9%; vertical-align: bottom;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-9691">17,806</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>

   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">
     <div>
      <span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Adjustments to reconcile net income to net&#160;</span>cash provided used in operating activities:
     </div>
    </td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 20px;">
     <div>
      Depreciation and amortization
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-9692">1,969</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-9693">2,114</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 20px;">
     <div>
      Loss on disposal of fixed assets
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" unitRef="usd" id="ixv-9694"> -&#160;&#160;&#160; </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" sign="-" unitRef="usd" id="ixv-9695">23</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 20px;">
     <div>
      Deferred income tax provision
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-9696">3,425</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-9697"> -&#160;&#160;&#160; </ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 20px;">
     <div>
      Stock-based compensation
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-9698">4,624</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-9699">2,141</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 20px;">
     <div>
      Amortization of debt discount
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" unitRef="usd" id="ixv-9700">190</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" unitRef="usd" id="ixv-9701">253</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 20px;">
     <div>
      Amortization of license revenue
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="adma:AmortizationOfLicenseRevenue" scale="3" sign="-" unitRef="usd" id="ixv-9702">36</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="adma:AmortizationOfLicenseRevenue" scale="3" sign="-" unitRef="usd" id="ixv-9703">36</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Changes in operating assets and liabilities:
     </div>
    </td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 20px;">
     <div>
      Accounts receivable
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" unitRef="usd" id="ixv-9704">49,413</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" unitRef="usd" id="ixv-9705">22,200</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 20px;">
     <div>
      Inventories
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" unitRef="usd" id="ixv-9706">1,953</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" unitRef="usd" id="ixv-9707">4,826</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 20px;">
     <div>
      Prepaid expenses and other current assets
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd" id="ixv-9708">2,596</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd" id="ixv-9709">1,593</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 20px;">
     <div>
      Deposits and other assets
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="adma:IncreaseDecreaseInDepositsAndOtherAssets" scale="3" sign="-" unitRef="usd" id="ixv-9710">120</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="adma:IncreaseDecreaseInDepositsAndOtherAssets" scale="3" unitRef="usd" id="ixv-9711">982</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 20px;">
     <div>
      Accounts payable
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-9712">142</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-9713">447</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 20px;">
     <div>
      Accrued expenses
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-9714">2,401</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" unitRef="usd" id="ixv-9715">772</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 20px;">
     <div>
      Other current and non-current liabilities
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-9716">650</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" unitRef="usd" id="ixv-9717">677</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 20px;">
     <div>
      Net cash used in operating activities
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-9718">19,675</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-9719">2,218</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      <span style="font-weight: bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</span>
     </div>
    </td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 20px;">
     <div>
      Purchase of property and equipment
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-9720">4,701</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-9721">2,347</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 20px;">
     <div>
      Acquisition of intangible assets
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" unitRef="usd" id="ixv-9722">19</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" unitRef="usd" id="ixv-9723">15</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 20px;">
     <div>
      Net cash used in investing activities
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-9724">4,720</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-9725">2,362</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</span>
     </div>
    </td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 20px;">
     <div>
      Taxes paid on vested restricted stock units
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="adma:TaxesPaidOnVestedRestrictedStockUnits" scale="3" unitRef="usd" id="ixv-9726">7,228</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="adma:TaxesPaidOnVestedRestrictedStockUnits" scale="3" unitRef="usd" id="ixv-9727">2,476</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 20px;">
     <div>
      Net proceeds from the exercise of stock options
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd" id="ixv-9728">101</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd" id="ixv-9729">1,029</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 20px;">
     <div>
      Net cash used in financing activities
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" sign="-" unitRef="usd" id="ixv-9730">7,127</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" sign="-" unitRef="usd" id="ixv-9731">1,447</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="padding-left: 10px; width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="font-weight: bold;">
     <div>
      Net decrease in cash and cash equivalents
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-9732">31,522</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%;">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-9733">6,027</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="font-weight: bold;">
     <div>
      Cash and cash equivalents - beginning of period
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-9734">103,147</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-9735">51,352</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="font-weight: bold;">
     <div>
      Cash and cash equivalents - end of period
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-9736">71,625</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; padding-left: 10px; width: 9%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-9737">45,325</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: center; font-weight: bold;">
   <span style="font-weight: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">4</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <a id="NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIAL_STATEMENTS_UNAUDITED" title="NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)"></a><span style="font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span>
  </div><div>
  </div><div style="margin-left: 27pt;">&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-2570"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">1.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">ORGANIZATION AND BUSINESS</span>
    </div>
  </div>
  <div style="clear: both;">&#160;
  </div>
  <div style="text-indent: 33.75pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">ADMA Biologics, Inc. (&#8220;ADMA&#8221; or the &#8220;Company&#8221;) is a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company&#8217;s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.</span>
  </div>
  <div style="text-indent: 33.75pt;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div>
  <div style="text-indent: 33.75pt; text-align: justify;"> <span style="color: rgb(0, 0, 0);">ADMA operates through its wholly owned subsidiaries ADMA BioManufacturing, LLC (&#8220;ADMA BioManufacturing&#8221;) and ADMA BioCenters Georgia Inc. (&#8220;ADMA BioCenters&#8221;). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of certain assets held by the Company&#8217;s former third-party contract manufacturer, which included the U.S. Food and Drug Administration (&#8220;FDA&#8221;)-licensed BIVIGAM and Nabi-HB immunoglobulin products, and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the &#8220;Boca Facility&#8221;). ADMA BioCenters is the Company&#8217;s source plasma collection business with <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment" scale="0" unitRef="Facility" id="ixv-9738">ten</ix:nonFraction> plasma collection facilities located throughout the United States, all of which hold an approved license with the FDA.</span> </div>
  <div style="text-indent: 33.75pt;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div>
  <div style="text-indent: 33.75pt; text-align: justify;"> <span style="color: rgb(0, 0, 0);">The Company has <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="adma:NumberOfFDAApprovedProduct" scale="0" unitRef="Product" id="ixv-9739">three</ix:nonFraction> FDA-approved products, all of which are currently marketed and commercially available: (i) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an intravenous immune globulin (&#8220;IVIG&#8221;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;) or Inborn Errors of Immunity, for which the Company received FDA approval in April&#160;&#160;2019 and commenced first commercial sales in October 2019; (ii) BIVIGAM (Immune Globulin Intravenous, Human), an IVIG product indicated for the treatment of PI, and for which the Company received FDA approval in May 2019 and commenced commercial sales in August 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (&#8220;HBsAg&#8221;) and other listed exposures to Hepatitis B. In addition to its commercially available immunoglobulin products, the Company generates revenues from the sale of intermediates that result from the immunoglobulin production process and from time to time provides contract manufacturing and laboratory services for certain clients. The Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.</span> </div></ix:nonNumeric><div>
  </div><div style="text-indent: 33.75pt;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div>
  </div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-2591"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">2.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span>
    </div>
  </div>
  <div style="clear: both;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-2598"><div> <span style="font-style: italic; text-decoration: underline;">Principles of consolidation and basis of presentation</span></div></ix:nonNumeric>

  <div>&#160;</div><ix:continuation continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2" id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><div style="text-indent: 36pt; text-align: justify;">
   <span>The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (the &#8220;FASB&#8221;). </span>
  </div></ix:continuation>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:continuation continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_3" id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2"><div style="text-indent: 36pt; text-align: justify;">
   <span>The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2024 included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 18, 2025. All intercompany balances and transactions have been eliminated in consolidation. The preparation of our interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed. We have made reasonable estimates and judgments of such items within our financial statements and there may be changes to those estimates in future periods. </span>
  </div></ix:continuation>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_3"><div style="text-indent: 36pt; text-align: justify;">
   <span>During the three months ended March 31, 2025 and 2024, comprehensive income was equal to the net income amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year.</span>
  </div></ix:continuation></ix:nonNumeric><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">5</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-2631"><div> <span style="font-style: italic; text-decoration: underline;">Use of Estimates</span> </div></ix:nonNumeric>
  <div>&#160;
  </div>
  <ix:continuation id="_UseOfEstimates-c0_cont_1"><div style="text-indent: 36pt; text-align: justify;">
   <span>The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include rebates deducted from gross revenues and estimates related to Company&#8217;s effective tax rate.</span>
  </div></ix:continuation>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="ixv-2639"><div> <span style="font-style: italic; text-decoration: underline;">Fair Value of Financial Instruments</span> </div></ix:nonNumeric>
  <div>&#160;
  </div>
  <ix:continuation id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1"><div style="text-indent: 36pt; text-align: justify;">
   <span>The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company&#8217;s senior credit facility (see Note 6) approximates fair value, based on a Level 3 classification under the fair value hierarchy, due to the variable interest rate on this debt.&#160;&#160;</span>
  </div></ix:continuation>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" continuedAt="_ReceivablesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ReceivablesPolicyTextBlock" id="ixv-2647"><div> <span style="font-style: italic; text-decoration: underline;">Accounts Receivable</span> </div></ix:nonNumeric>
  <div>&#160;
  </div>
  <ix:continuation id="_ReceivablesPolicyTextBlock-c0_cont_1"><div style="text-indent: 36pt; text-align: justify;"> <span>Accounts receivable is reported at realizable value, net of allowances for customer credits and credit losses in the amount of $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" scale="6" unitRef="usd" id="ixv-9740">3.0</ix:nonFraction> million and $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" scale="6" unitRef="usd" id="ixv-9741">0.2</ix:nonFraction> million at March 31, 2025 and December 31, 2024, respectively. </span><span style="color: rgb(33, 37, 41);">The Company extends credit to its customers based upon an evaluation of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition, payment history and associated credit risk of customers are performed on an ongoing basis.</span><span> Based on these evaluations, the Company has concluded that its credit risk is minimal. At March 31, 2025 and December 31, 2024, <ix:nonFraction contextRef="c25" decimals="INF" format="ixt-sec:numwordsen" name="adma:NumberOfCustomers" scale="0" unitRef="Customer" id="ixv-9742">three</ix:nonFraction> customers accounted for an aggregate of approximately <ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-9743">85</ix:nonFraction>% and <ix:nonFraction contextRef="c26" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-9744">91</ix:nonFraction>%, respectively, of the Company&#8217;s total accounts receivable.</span> </div></ix:continuation>
  <div style="margin-left: 18pt;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-2657"><div> <span style="font-style: italic; text-decoration: underline;">Inventories</span> </div></ix:nonNumeric>
  <div>&#160;
  </div>
  <ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_2" id="_InventoryPolicyTextBlock-c0_cont_1"><div style="text-indent: 33.75pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Raw materials inventory consists of various materials purchased from suppliers, including normal source plasma and Respiratory Syncytial Virus (&#8220;RSV&#8221;) high titer plasma, used in the production of the Company&#8217;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable supplies and depreciation. The Boca Facility overhead allocation to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#8217;s FDA-approved products relative to the total square footage of the facility.</span>
  </div></ix:continuation>
  <div style="text-indent: 33.75pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div>
  <ix:continuation id="_InventoryPolicyTextBlock-c0_cont_2"><div style="text-indent: 33.75pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. </span>
  </div></ix:continuation>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="ixv-2670"><div> <span style="font-style: italic; text-decoration: underline;">Goodwill</span> </div></ix:nonNumeric>
  <div>&#160;
  </div>
  <ix:continuation continuedAt="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_2" id="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_1"><div style="text-indent: 36pt; text-align: justify;"> <span>Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at March 31, 2025 and December 31, 2024 was $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" unitRef="usd" id="ixv-9745"><ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" unitRef="usd" id="ixv-9746">3.5</ix:nonFraction></ix:nonFraction> million. All of the Company&#8217;s goodwill is attributable to its ADMA BioManufacturing business segment.&#160;&#160;</span> </div></ix:continuation>
  <div style="text-align: justify; margin-left: 18pt;">&#160;
  </div>
  <ix:continuation id="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_2"><div style="text-indent: 36pt; text-align: justify;"> <span>The Company did <ix:nonFraction contextRef="c0" decimals="0" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairmentLoss" scale="0" unitRef="usd" id="ixv-9747"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairmentLoss" scale="0" unitRef="usd" id="ixv-9748">no</ix:nonFraction></ix:nonFraction>t record any impairment charges related to goodwill for the three months ended March 31, 2025 and 2024.</span> </div></ix:continuation></ix:continuation><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">6</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="ixv-2699"><div> <span style="font-style: italic; text-decoration: underline;">Revenue Recognition</span> </div></ix:nonNumeric>
  <div>&#160;
  </div>
  <ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><div style="text-indent: 36pt; text-align: justify;"> <span>Revenues are comprised of (i) revenues from the sale of the Company&#8217;s immunoglobulin products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company&#8217;s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediates; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest AG (&#8220;Biotest&#8221;) in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="adma:DeferredRevenueRemainingAmortizationPeriod" id="ixv-9749">22</ix:nonNumeric> years. </span> </div></ix:continuation>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><div style="text-indent: 36pt; text-align: justify;">
   <span>Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based on when the product is shipped or delivered, depending on the sales terms, and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#8217;s immunoglobulin products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, wholesaler distribution and related fees, customer incentives, including prompt pay discounts, wholesaler chargebacks, group purchasing organization fees and reimbursements for patient assistance. These estimates are based on historical experience and certain other assumptions, and while the Company believes that such estimates are reasonable, they are subject to change based on future experience and other factors. </span>
  </div></ix:continuation>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_4" id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><div style="text-indent: 36pt; text-align: justify;">
   <span>For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company. &#160;&#160;&#160;&#160;</span>
  </div></ix:continuation>
  <div style="text-align: justify; margin-left: 18pt;">&#160;
  </div>
  <ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_5" id="_RevenueRecognitionPolicyTextBlock-c0_cont_4"><div style="text-indent: 36pt; text-align: justify;">
   <span>Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.</span>
  </div></ix:continuation>
  <div style="margin-left: 18pt;">&#160;
  </div>
  <ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_5"><div style="text-indent: 36pt; text-align: justify;"> <span>For the three months ended March 31, 2025, <ix:nonFraction contextRef="c27" decimals="0" format="ixt-sec:numwordsen" name="adma:NumberOfCustomers" scale="0" unitRef="Customer" id="ixv-9750">three</ix:nonFraction> customers represented an aggregate of approximately <ix:nonFraction contextRef="c27" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-9751">74</ix:nonFraction>% of the Company&#8217;s consolidated revenues. For the three months ended March 31, 2024, <ix:nonFraction contextRef="c28" decimals="0" format="ixt-sec:numwordsen" name="adma:NumberOfCustomers" scale="0" unitRef="Customer" id="ixv-9752">two</ix:nonFraction> customers represented an aggregate of approximately <ix:nonFraction contextRef="c28" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-9753">70</ix:nonFraction>% of the Company&#8217;s consolidated revenue. </span> </div></ix:continuation>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" continuedAt="_CostOfSalesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock" id="ixv-2723"><div> <span style="font-style: italic; text-decoration: underline;">Cost of Product Revenue</span> </div></ix:nonNumeric>
  <div>&#160;
  </div>
  <ix:continuation id="_CostOfSalesPolicyTextBlock-c0_cont_1"><div style="text-indent: 36pt; text-align: justify;">
   <span>Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA-approved products, intermediates and the collection of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the activities of these operations are attributable to new products or processes in development, the expenses are classified as research and development expenses. </span>
  </div></ix:continuation>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-2731"><div> <span style="color: rgb(0, 0, 0); font-style: italic; text-decoration: underline;">Earnings/loss Per Common Share</span><span style="color: rgb(0, 0, 0); font-style: italic;">&#160;&#160;</span> </div></ix:nonNumeric>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-2736"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><div style="text-indent: 36pt;"> <span>For the three months ended March 31, 2025, basic and diluted earnings per share are calculated as follows:</span> </div></ix:continuation>
  <div>&#160;
  </div>

  <ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 89%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top; height: 23.0pt;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-top: none; border-left: none; border-right: none; border-bottom: 2px solid black;">&#160;</td><td style="text-align: center; width: 9%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none; white-space: nowrap;">



      <span style="font-weight: bold;">Three Months Ended
<br/>
      March 31, 2025</span>
     </td><td style="text-align: center; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Net income available to common stockholders ($000's) (numerator)
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-9754">26,904</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Weighted-average number of common shares (denominator)
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-9755">237,775,476</ix:nonFraction></td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Basic earnings per common shares
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares" id="ixv-9756">0.11</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Weighted-average number of common shares
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-9757">237,775,476</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Potential shares of common stock arising from outstanding stock options
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" unitRef="shares" id="ixv-9758">3,987,814</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Potential shares of common stock arising from outstanding warrants
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c30" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" unitRef="shares" id="ixv-9759">47,536</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Potential shares of common stock arising from unvested RSUs
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"><ix:nonFraction contextRef="c31" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" unitRef="shares" id="ixv-9760">2,865,524</ix:nonFraction></td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Total shares - diluted (denominator)
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-9761">244,676,350</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-left: none; border-right: none; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Diluted earnings per common share
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" unitRef="usdPershares" id="ixv-9762">0.11</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table></ix:continuation></ix:nonNumeric></ix:continuation><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">7</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><div style="text-indent: 36pt;"> <span>For the three months ended March 31, 2025 and 2024, there were <ix:nonFraction contextRef="c0" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-9763"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-9764">no</ix:nonFraction></ix:nonFraction> shares with an anti-dilutive effect that needed to be excluded from the earnings per share computation. </span> </div></ix:continuation>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-2835"><div> <span style="font-style: italic; text-decoration: underline;">Recent Accounting Pronouncements</span> </div></ix:nonNumeric>
  <div>&#160;
  </div>
  <ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><div style="text-indent: 36pt; text-align: justify;">
   <span>In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): </span><span style="font-style: italic;">Improvements to Income Tax Disclosures</span><span>. This Update requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid and became effective for public business entities for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that this Update may have on the Company&#8217;s consolidated financial statements.</span>
  </div></ix:continuation>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><div style="text-indent: 27pt; text-align: justify;">
   <span>In November 2024, the FASB issued ASU No. 2024-03, </span><span style="font-style: italic;">Income Statement - Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures</span><span> (Subtopic 220-40). The amendments in this Update require disclosure, in the notes to the financial statements, of specified information about certain costs and expenses, including but not limited to, purchases of inventory, employee compensation and selling expense. This Update becomes effective for fiscal years beginning after December 15, 2026. The Company is currently evaluating the impact that this Update may have on the Company&#8217;s consolidated financial statements.</span>
  </div></ix:continuation></ix:continuation><div>
  </div><div style="margin-left: 18pt;">&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InventoryDisclosureTextBlock" id="ixv-2853"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">3.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">INVENTORIES</span>
    </div>
  </div>
  <div style="margin-left: 27pt; clear: both;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ixv-2860"><div style="text-indent: 36pt;"> <span>The following table provides the components of inventories:</span> </div>
  <div style="text-align: center;">&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width : 9%; white-space : nowrap; ">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">March 31, <br/>

      2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align : center; width : 9%; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; ">



      <span style="font-weight: bold;">December 31,<br/>

      2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center;">


      <span style="font-style: italic;">(In thousands)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Raw materials
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" unitRef="usd" id="ixv-9765">75,819</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" unitRef="usd" id="ixv-9766">60,473</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Work-in-process
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="3" unitRef="usd" id="ixv-9767">49,780</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="3" unitRef="usd" id="ixv-9768">61,641</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Finished goods
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" unitRef="usd" id="ixv-9769">46,589</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" unitRef="usd" id="ixv-9770">48,121</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Total inventories
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-9771">172,188</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-9772">170,235</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table></ix:nonNumeric><div style="text-align: center;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>Raw materials includes plasma and other materials expected to be used in the production of ASCENIV, BIVIGAM and Nabi-HB. These materials will be consumed in the production of goods expected to be available for sale or otherwise have alternative uses that provide a probable future benefit.&#160;&#160;</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the Company&#8217;s immunoglobulin products. </span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available for commercial sale, as well as plasma collected at the Company&#8217;s plasma collection centers that is expected to be sold to third-party customers. </span>
  </div></ix:nonNumeric><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">8</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span>
  </div><div>
  </div><div style="margin-left: 27pt;">&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-2957"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">4.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">PROPERTY AND EQUIPMENT</span>
    </div>
  </div>
  <div style="clear: both;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-2964"><div style="text-indent: 36pt;"> <span>Property and equipment and related accumulated depreciation are summarized as follows:</span> </div>
  <div>&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">March 31, 2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">December 31, 2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center;">


      <span style="font-style: italic;">(In thousands)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Manufacturing and laboratory equipment
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9773">21,916</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9774">21,305</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Office equipment and computer software
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9775">6,142</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9776">5,772</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Furniture and fixtures
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9777">5,939</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9778">5,840</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Construction in process
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9779">11,225</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9780">8,149</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Leasehold improvements
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9781">21,103</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9782">21,066</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Land
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9783">4,339</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9784">4,339</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Buildings and building improvements
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9785">22,542</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9786">21,788</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9787">93,206</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-9788">88,259</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Less: Accumulated depreciation
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-9789">35,496</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-9790">33,552</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Total property and equipment, net
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-9791">57,710</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-9792">54,707</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table></ix:nonNumeric><div>&#160;
  </div>
  <div style="text-indent: 36pt;"> <span style="color: rgb(0, 0, 0);">The Company recorded depreciation expense on property and equipment for the three months ended March 31, 2025 and 2024 of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" unitRef="usd" id="ixv-9793"><ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" unitRef="usd" id="ixv-9794">1.9</ix:nonFraction></ix:nonFraction> million.</span> </div></ix:nonNumeric><div>
  </div><div style="margin-left: 27pt;">&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="ixv-3098"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">5.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span>
    </div>
  </div>
  <div style="margin-left: 18pt; clear: both;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="ixv-3105"><div style="text-indent: 36pt;"> <span>Accrued expenses and other current liabilities at March 31, 2025 and December 31, 2024 are as follows:</span> </div>
  <div>&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">March 31, 2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap; vertical-align: middle;">


      <span style="font-weight: bold;">December 31, 2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center;">


      <span style="font-style: italic;">(In thousands)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Accrued rebates
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="adma:AccruedRebatesCurrent" scale="3" unitRef="usd" id="ixv-9795">4,847</ix:nonFraction></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="adma:AccruedRebatesCurrent" scale="3" unitRef="usd" id="ixv-9796">4,155</ix:nonFraction></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Accrued distribution fees
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" unitRef="usd" id="ixv-9797">12,115</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" unitRef="usd" id="ixv-9798">11,565</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Accrued incentives
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedBonusesCurrent" scale="3" unitRef="usd" id="ixv-9799">1,671</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedBonusesCurrent" scale="3" unitRef="usd" id="ixv-9800">5,892</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Accrued interest
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrent" scale="3" unitRef="usd" id="ixv-9801">1,893</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrent" scale="3" unitRef="usd" id="ixv-9802">2,857</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Accrued testing
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="adma:AccruedTestingCurrent" scale="3" unitRef="usd" id="ixv-9803">463</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="adma:AccruedTestingCurrent" scale="3" unitRef="usd" id="ixv-9804">827</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Accrued payroll and other compensation
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="3" unitRef="usd" id="ixv-9805">1,924</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="3" unitRef="usd" id="ixv-9806">3,332</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Income taxes payable
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" unitRef="usd" id="ixv-9807">6,601</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" unitRef="usd" id="ixv-9808">3,481</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Other
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-9809">2,046</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-9810">1,853</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Total accrued expenses and other current liabilities
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" unitRef="usd" id="ixv-9811">31,560</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" unitRef="usd" id="ixv-9812">33,962</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-3226"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">6.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">DEBT </span>
    </div>
  </div>
  <div style="clear: both;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock" id="ixv-3233"><div style="text-indent: 36pt;"> <span>A summary of outstanding senior notes payable is as follows:</span> </div>
  <div>&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">March 31, 2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">December 31, 2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center;">


      <span style="font-style: italic;">(In thousands)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Term loan
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c55" decimals="-5" format="ixt:num-dot-decimal" name="adma:SeniorNotesPayableBeforeDebtDiscount" scale="3" unitRef="usd" id="ixv-9813">32,500</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c56" decimals="-5" format="ixt:num-dot-decimal" name="adma:SeniorNotesPayableBeforeDebtDiscount" scale="3" unitRef="usd" id="ixv-9814">32,500</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Revolving credit facility
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c57" decimals="-5" format="ixt:num-dot-decimal" name="adma:SeniorNotesPayableBeforeDebtDiscount" scale="3" unitRef="usd" id="ixv-9815">42,500</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c58" decimals="-5" format="ixt:num-dot-decimal" name="adma:SeniorNotesPayableBeforeDebtDiscount" scale="3" unitRef="usd" id="ixv-9816">42,500</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Less:
     </div>
    </td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">
     <div>
      Debt discount
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" unitRef="usd" id="ixv-9817">2,473</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" unitRef="usd" id="ixv-9818">2,663</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Senior notes payable
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeniorLongTermNotes" scale="3" unitRef="usd" id="ixv-9819">72,527</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeniorLongTermNotes" scale="3" unitRef="usd" id="ixv-9820">72,337</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table></ix:nonNumeric><div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: rgb(0, 0, 0);">On December 18, 2023 (the &#8220;Ares Closing Date&#8221;), the Company and all of its subsidiaries entered into a new senior secured credit facility (the &#8220;Ares Credit Agreement&#8221;) with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation (collectively, &#8220;Ares&#8221;). The Ares Credit Agreement provided for a total of $<ix:nonFraction contextRef="c46" decimals="-6" format="ixt:num-dot-decimal" name="adma:SeniorNotesPayableBeforeDebtDiscount" scale="6" unitRef="usd" id="ixv-9821">135.0</ix:nonFraction> million in senior secured credit facilities (the &#8220;Ares Credit Facility&#8221;) consisting of (i) a term loan in the aggregate principal amount of $<ix:nonFraction contextRef="c47" decimals="-5" format="ixt:num-dot-decimal" name="adma:SeniorNotesPayableBeforeDebtDiscount" scale="6" unitRef="usd" id="ixv-9822">62.5</ix:nonFraction> million and (ii) a revolving credit facility in the aggregate principal amount of $<ix:nonFraction contextRef="c48" decimals="-5" format="ixt:num-dot-decimal" name="adma:SeniorNotesPayableBeforeDebtDiscount" scale="6" unitRef="usd" id="ixv-9823">72.5</ix:nonFraction> million (collectively, the &#8220;Ares Loans&#8221;), both of which were fully drawn on the Ares Closing Date. The Ares Credit Facility has a maturity date of <ix:nonNumeric contextRef="c49" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-9824">December 20, 2027</ix:nonNumeric> (the &#8220;Ares Maturity Date&#8221;).</span> </div></ix:nonNumeric><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">9</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_1"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: rgb(0, 0, 0);">Borrowings under the term loan bear interest at the adjusted Term SOFR for a <span style="-sec-ix-hidden: hidden-fact-2">three</span>&#8209;month tenor in effect on the day that is <ix:nonNumeric contextRef="c51" continuedAt="adma_NumberOfBusinessDays-c51_cont_1" format="ixt-sec:durwordsen" name="adma:NumberOfBusinessDays" id="ixv-9825">two</ix:nonNumeric> business<ix:continuation id="adma_NumberOfBusinessDays-c51_cont_1"> days</ix:continuation> prior to the first day of the applicable calendar quarter plus <ix:nonFraction contextRef="c51" decimals="4" format="ixt:num-dot-decimal" name="adma:DebtInstrumentApplicableMargin" scale="-2" unitRef="pure" id="ixv-9827">6.50</ix:nonFraction>% (the &#8220;Initial <span style="-sec-ix-hidden: hidden-fact-3">SOFR</span> Term Loan Applicable Margin&#8221;). Borrowings under the revolving facility bear interest at the adjusted Term SOFR for a <span style="-sec-ix-hidden: hidden-fact-4">three</span>&#8209;month tenor in effect on the day that is <ix:nonNumeric contextRef="c54" continuedAt="adma_NumberOfBusinessDays-c54_cont_1" format="ixt-sec:durwordsen" name="adma:NumberOfBusinessDays" id="ixv-9828">two</ix:nonNumeric> business<ix:continuation id="adma_NumberOfBusinessDays-c54_cont_1"> days</ix:continuation> prior to the first day of the applicable calendar quarter</span><span style="color: rgb(0, 0, 0); font-style: italic;">&#160;</span><span style="color: rgb(0, 0, 0);">plus</span><span style="color: rgb(0, 0, 0); font-style: italic;">&#160;</span><span style="color: rgb(0, 0, 0);"><ix:nonFraction contextRef="c54" decimals="4" format="ixt:num-dot-decimal" name="adma:DebtInstrumentApplicableMargin" scale="-2" unitRef="pure" id="ixv-9830">3.75</ix:nonFraction>% (the &#8220;SOFR Revolving Facility Applicable Margin&#8221;). As of March 31, 2025 and December 31, 2024, the interest rate on the term loan was approximately <ix:nonFraction contextRef="c55" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-9831">10.80</ix:nonFraction>% and <ix:nonFraction contextRef="c56" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-9832">10.85</ix:nonFraction>%, respectively, and the interest rate on the revolving facility was approximately <ix:nonFraction contextRef="c57" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-9833">8.05</ix:nonFraction>% and <ix:nonFraction contextRef="c58" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-9834">8.34</ix:nonFraction>%, respectively. </span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: rgb(0, 0, 0);">On the Ares Maturity Date, the Company is required to pay Ares the entire outstanding principal amount underlying the Ares term loan and revolving loan (together, the &#8220;Ares Loans&#8221;) and any accrued and unpaid interest thereon. Prior to the Ares Maturity Date, there are <ix:nonFraction contextRef="c59" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="6" unitRef="usd" id="ixv-9835">no</ix:nonFraction> scheduled principal payments on the Ares Loans. After giving effect to the principal payments made during the year ended December 31, 2024, the Company is required to make <ix:nonNumeric contextRef="c49" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" id="ixv-9836">quarterly</ix:nonNumeric> interest payments to Ares of approximately $<ix:nonFraction contextRef="c49" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="6" unitRef="usd" id="ixv-9837">1.8</ix:nonFraction> million. The Company may prepay the outstanding principal under the revolving facility, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon <ix:nonNumeric contextRef="c49" continuedAt="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal-c49_cont_1" format="ixt-sec:durwordsen" name="adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" id="ixv-9838">three</ix:nonNumeric> business<ix:continuation id="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal-c49_cont_1"> days</ix:continuation>&#8217; prior written notice with no prepayment premium. However, in the event the Company pays down an aggregate amount under the revolving facility that is greater than <ix:nonFraction contextRef="c60" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" unitRef="pure" id="ixv-9840">50</ix:nonFraction>% of the $<ix:nonFraction contextRef="c61" decimals="-5" format="ixt:num-dot-decimal" name="adma:SeniorNotesPayableBeforeDebtDiscount" scale="6" unitRef="usd" id="ixv-9841">72.5</ix:nonFraction> million commitment amount, the Company will still be required to pay interest on <ix:nonFraction contextRef="c60" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" unitRef="pure" id="ixv-9842">50</ix:nonFraction>% of this amount, or $<ix:nonFraction contextRef="c62" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" unitRef="usd" id="ixv-9843">36.3</ix:nonFraction> million, through the Ares Maturity Date. The Company may prepay the outstanding principal on the term loan, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon <ix:nonNumeric contextRef="c49" continuedAt="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal-c49_alt_0_cont_1" format="ixt-sec:durwordsen" name="adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" id="ixv-9844">three</ix:nonNumeric> business<ix:continuation id="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal-c49_alt_0_cont_1"> days</ix:continuation>&#8217; prior written notice, subject to the payment to Ares of a prepayment premium equal to (i) the present value as of such date of all remaining required interest payments on the principal amount being repaid plus <ix:nonFraction contextRef="c63" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" unitRef="pure" id="ixv-9846">1.5</ix:nonFraction>% of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Ares Closing Date, (ii) <ix:nonFraction contextRef="c64" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" unitRef="pure" id="ixv-9847">1.5</ix:nonFraction>% of the prepaid principal amount, if prepaid after the first anniversary of the Ares Closing Date and on or prior to the second anniversary of the Ares Closing Date, or (iii) <ix:nonFraction contextRef="c65" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" unitRef="pure" id="ixv-9848">1.0</ix:nonFraction>% of the prepaid principal amount, if prepaid on or prior to the third anniversary of the Ares Closing Date. As further discussed in Note 14 &#8211; Subsequent Events, on May 6, 2025, the Company repaid $<ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" unitRef="usd" id="ixv-9849">30.0</ix:nonFraction> million against the term loan using a draw of $<ix:nonFraction contextRef="c67" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" unitRef="usd" id="ixv-9850">30.0</ix:nonFraction> million against the revolving credit facility made on May 5, 2025; accordingly, the outstanding balance of the term loan facility as of May 6, 2025 was $<ix:nonFraction contextRef="c68" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-9851">2.5</ix:nonFraction> million and the outstanding balance of the revolving loan facility as of May 6, 2025 was $<ix:nonFraction contextRef="c69" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-9852">72.5</ix:nonFraction> million.&#160;&#160;</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: rgb(0, 0, 0);">All of the Company&#8217;s obligations under the Ares Credit Agreement are secured by a first-priority lien and security interest in substantially all of the Company&#8217;s tangible and intangible assets, including intellectual property and all of the equity interests in the Company&#8217;s subsidiaries. The Ares Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar debt financings. The negative covenants include certain financial covenants, including maximum total leverage ratios and a $<ix:nonFraction contextRef="c70" decimals="-5" format="ixt:num-dot-decimal" name="adma:MinimumLiquidityCovenantsCreditFacilities" scale="6" unitRef="usd" id="ixv-9853">15.0</ix:nonFraction> million minimum liquidity covenant, and also restrict or limit the Company&#8217;s ability and the ability of the Company&#8217;s subsidiaries to, among other things and subject to certain exceptions contained in the Ares Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#8217;s or the Company&#8217;s subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Ares Credit Agreement); engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company&#8217;s ability to make loan repayments under the Ares Credit Agreement. As of March 31, 2025, the Company was in compliance with all of the covenants contained in the Ares Credit Agreement.</span> </div>
  <div style="text-indent: 36pt; text-align: justify; color: rgb(0, 0, 0);">
   <span>&#160;</span>
  </div>
  <div style="text-indent: 36pt; text-align: justify; color: rgb(0, 0, 0);"> <span>Events of Default on the Ares Loans include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. If there is an event of default, the Company will incur an increase in the rate of interest on the Ares Loans of <ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" scale="-2" unitRef="pure" id="ixv-9854">2</ix:nonFraction>% per annum.</span> </div></ix:continuation><div>
  </div><div style="color: rgb(0, 0, 0);">&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-3355"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">7.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">STOCKHOLDERS&#8217; EQUITY </span>
    </div>
  </div>
  <div style="clear: both;">&#160;
  </div>
  <div>
   <span style="font-style: italic; text-decoration: underline;">Preferred Stock</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt;"> <span>The Company is currently authorized to issue up to <ix:nonFraction contextRef="c2" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance" scale="6" unitRef="shares" id="ixv-9855"><ix:nonFraction contextRef="c3" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance" scale="6" unitRef="shares" id="ixv-9856">10</ix:nonFraction></ix:nonFraction> million shares of preferred stock, $<ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-9857"><ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-9858">0.0001</ix:nonFraction></ix:nonFraction>, par value per share. There were <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-9859"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-9860">no</ix:nonFraction></ix:nonFraction> shares of preferred stock outstanding at March 31, 2025 and December 31, 2024.</span> </div></ix:nonNumeric><div>
  </div><div style="margin-left: 18pt;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">10</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><div>
   <span style="font-style: italic; text-decoration: underline;">Common Stock</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>As of March 31, 2025 and December 31, 2024, the Company was authorized to issue <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-9861"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-9862">300,000,000</ix:nonFraction></ix:nonFraction> shares of its common stock, $<ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-9863"><ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-9864">0.0001</ix:nonFraction></ix:nonFraction> par value per share, and <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-9865">238,532,252</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-9866">236,620,545</ix:nonFraction> shares of common stock were outstanding as of March 31, 2025 and December 31, 2024, respectively. After giving effect to shares reserved for the issuance of warrants and for awards issued under the Company&#8217;s equity incentive plans, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-9867">36,622,488</ix:nonFraction> shares of common stock were available for issuance as of March 31, 2025. </span> </div>
  <div>&#160;
  </div>
  <div>
   <span style="font-style: italic; text-decoration: underline;">Warrants</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>On January 7, 2025, affiliates of a former noteholder of the Company exercised warrants to purchase an aggregate of <ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-9868">966,554</ix:nonFraction> shares of common stock on a cashless basis, and the Company issued <ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-9869">866,302</ix:nonFraction> shares of common stock to these entities. On January 10, 2024, a former noteholder of the Company exercised a warrant to purchase <ix:nonFraction contextRef="c73" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" unitRef="shares" id="ixv-9870">4</ix:nonFraction> million shares of the Company&#8217;s common stock on a cashless basis and the Company issued <ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-9871">1,977,514</ix:nonFraction> shares of common stock to this noteholder. On March 8, 2024, affiliates of a former noteholder exercised warrants to purchase an aggregate of <ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-9872">3,388,681</ix:nonFraction> shares of the Company&#8217;s common stock on a cashless basis and the Company issued <ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-9873">2,482,205</ix:nonFraction> shares of common stock to such noteholders. On March 14, 2024, an entity associated with another former noteholder of the Company exercised a warrant to purchase <ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-9874">169,651</ix:nonFraction> shares of the Company&#8217;s common stock on a cashless basis and the Company issued <ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-9875">85,784</ix:nonFraction> shares of common stock to this entity. </span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>On February 24, 2024, a warrant to purchase <ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-9876">34,800</ix:nonFraction> shares of the Company&#8217;s common stock held by a former noteholder of the Company expired in accordance with its terms. At March 31, 2024 and December 31, 2023, the Company had outstanding warrants to purchase an aggregate of <ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-9877">4,909,774</ix:nonFraction> and <ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-9878">12,502,906</ix:nonFraction> shares, respectively, of common stock, with weighted-average exercise prices of $<ix:nonFraction contextRef="c21" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-9879">2.51</ix:nonFraction> and $<ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-9880">2.32</ix:nonFraction> per share, respectively, with expiration dates ranging between October 2024 and May 2030.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>There were <ix:nonFraction contextRef="c2" decimals="0" format="ixt:fixed-zero" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-9881">no</ix:nonFraction> outstanding warrants as of March 31, 2025 and outstanding warrants to purchase <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-9882">966,554</ix:nonFraction> shares of common stock as of December 31, 2024. </span> </div>
  <div style="margin-left: 18pt;">&#160;
  </div>
  <div>
   <span style="font-style: italic; text-decoration: underline;">Equity Incentive Plans</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>The fair value of stock options granted under the Company&#8217;s equity incentive plans was determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimate. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-9883">The following assumptions were used to determine the fair value of options granted during the three months ended March 31, 2025 and 2024:</ix:nonNumeric></span> </div>
  <div>&#160;</div>

  <ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1"><table cellpadding="0" style="font-size: 9.5pt; border-collapse: collapse; border-spacing: 0px; width: 100%; margin-left: auto; margin-right: auto;">
 <tr><td style="width: 79%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td></tr><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes">
  <td valign="top">&#160;</td>
  <td colspan="3" style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b>Three Months Ended March 31,</b></div>
  </td>
 </tr>
 <tr style="mso-yfti-irow:1">
  <td valign="top">&#160;</td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; text-align: center;" valign="top">
  <div><b>2025</b></div>
  </td>
  <td style="padding: 0in 5.4pt 0in 5px; text-align: center;" valign="top">&#160;</td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; text-align: center;" valign="top">
  <div><b>2024</b></div>
  </td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="vertical-align: bottom;" valign="top">
  <div>Expected term</div>
  </td>
  <td style="padding-top : 0in; padding-right : 5.4pt; padding-bottom : 0in; text-align : center; vertical-align : bottom; white-space : nowrap; " valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"><ix:nonNumeric contextRef="c83" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-9884">5.5</ix:nonNumeric> - <ix:nonNumeric contextRef="c84" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-9885">6.3</ix:nonNumeric> years</span></div> </td>
  <td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top">&#160;</td>
  <td style="padding-top : 0in; padding-right : 5.4pt; padding-bottom : 0in; text-align : center; vertical-align : bottom; white-space : nowrap; " valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"><ix:nonNumeric contextRef="c85" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-9886">5.5</ix:nonNumeric> - <ix:nonNumeric contextRef="c86" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-9887">6.3</ix:nonNumeric> years</span></div> </td>
 </tr>
 <tr style="mso-yfti-irow:3">
  <td valign="top">
  <div>Volatility</div>
  </td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"><ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-9888">66</ix:nonFraction>%</span></div> </td>
  <td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top">&#160;</td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"><ix:nonFraction contextRef="c88" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-9889">66</ix:nonFraction>%</span></div> </td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Dividend yield</div>
  </td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"><ix:nonFraction contextRef="c87" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-9890">0.0</ix:nonFraction></span></div> </td>
  <td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top">&#160;</td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"><ix:nonFraction contextRef="c88" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-9891">0.0</ix:nonFraction></span></div> </td>
 </tr>
 <tr style="mso-yfti-irow:5;mso-yfti-lastrow:yes">
  <td valign="top">
  <div>Risk-free interest rate</div>
  </td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"><ix:nonFraction contextRef="c87" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-9892">4.40</ix:nonFraction>%</span></div> </td>
  <td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top">&#160;</td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"><ix:nonFraction contextRef="c88" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-9893">4.29</ix:nonFraction>%</span></div> </td>
 </tr>
</table></ix:continuation></ix:continuation><div>&#160;</div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">11</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-3487"><div style="text-indent: 36pt;"> <span>A summary of the Company&#8217;s option activity under the Company&#8217;s equity incentive plans and related information is as follows:</span> </div>


  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">


      <span style="font-weight: bold;">Shares</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom; white-space: nowrap;">




      <span style="font-weight: bold;">Weighted <br/>

      Average <br/>

      Exercise Price</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Options outstanding, vested and expected to vest at December 31, 2024
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c89" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-9894">5,141,516</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c89" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-9895">3.90</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Forfeited
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(<ix:nonFraction contextRef="c87" decimals="INF" format="ixt:num-dot-decimal" name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" scale="0" sign="-" unitRef="shares" id="ixv-9896">1,101</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-9897">1.29</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Expired
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(<ix:nonFraction contextRef="c87" decimals="INF" format="ixt:num-dot-decimal" name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" scale="0" sign="-" unitRef="shares" id="ixv-9898">10,480</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-9899">4.89</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Granted
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c87" decimals="INF" format="ixt:num-dot-decimal" name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" scale="0" unitRef="shares" id="ixv-9900">683,720</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-9901">16.07</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Exercised
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c87" decimals="INF" format="ixt:num-dot-decimal" name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" scale="0" sign="-" unitRef="shares" id="ixv-9902">39,173</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-9903">6.61</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Options outstanding, vested and expected to vest at March 31, 2025
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c90" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-9904">5,774,482</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-9905">5.32</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Options exercisable
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c90" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-9906">3,086,687</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-9907">3.21</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table></ix:nonNumeric><div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>As of March 31, 2025, the Company had $<ix:nonFraction contextRef="c77" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" unitRef="usd" id="ixv-9908">12.7</ix:nonFraction> million of unrecognized compensation expense related to options granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c78" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-9909">3.1</ix:nonNumeric> years.&#160;&#160;</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="ixv-3596"><div style="text-indent: 36pt; text-align: justify;"> <span>The Company&#8217;s RSUs generally vest annually over a period of <ix:nonNumeric contextRef="c79" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-9910">four years</ix:nonNumeric> for employees and semi-annually over a period of <ix:nonNumeric contextRef="c80" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-9911">one year</ix:nonNumeric> for directors. A summary of the Company&#8217;s unvested RSU activity and related information is as follows: </span> </div>


  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">Shares</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">




      <span style="font-weight: bold;">Weighted <br/>

      Average Grant <br/>

      Date Fair Value</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Balance at December 31, 2024
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-9912">5,745,990</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c91" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-9913">5.50</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Granted
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-9914">1,658,458</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-9915">16.11</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Vested
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(<ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-9916">1,455,350</ix:nonFraction></td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-9917">4.17</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Forfeited
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-9918">93,611</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-9919">6.64</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Balance at March 31, 2025
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-9920">5,855,487</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-9921">8.82</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
  </table></ix:nonNumeric><div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>As of March 31, 2025, the Company had $<ix:nonFraction contextRef="c81" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" unitRef="usd" id="ixv-9922">48.3</ix:nonFraction> million of unrecognized compensation expense related to unvested RSUs granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c82" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-9923">3.4</ix:nonNumeric> years.</span> </div>
  <div style="text-align: justify; margin-left: 9pt;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="ixv-3676"><div style="text-indent: 36pt; text-align: justify;"> <span>Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for the three months ended March 31, 2025 and 2024 was as follows:&#160;&#160;</span> </div>


  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align : center; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; ">


      <span style="font-weight: bold;">Three Months Ended March 31,</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="text-align: center;">
     <div>
      <span style="font-style: italic;">(in thousands)</span>
     </div>
    </td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Research and development
     </div>
    </td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-9924">39</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-9925">17</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Plasma center operating expenses
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-9926">77</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-9927">39</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Selling, general and administrative
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-9928">3,873</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-9929">1,841</ix:nonFraction></td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Cost of product revenue
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-9930">635</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-9931">244</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Total stock-based compensation expense
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-9932">4,624</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-9933">2,141</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table></ix:nonNumeric></ix:continuation><div style="text-align: justify;">&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-3767"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">8.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">RELATED PARTY TRANSACTIONS</span>
    </div>
  </div>
  <div style="margin-left: 18pt; clear: both;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>The Company leases an office building and equipment from Areth, LLC (&#8220;Areth&#8221;) pursuant to an agreement for services effective as of January 1, 2016, as amended from time to time, and pays monthly rent on this facility in the amount of $<ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-9934">10,000</ix:nonFraction>. Either party may terminate the agreement by providing the other party with one year&#8217;s prior written notice. Rent expense for the three months ended March 31, 2025 and 2024 amounted to $<ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-9935"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-9936">30,000</ix:nonFraction></ix:nonFraction>. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Board, and Adam S. Grossman, the Company&#8217;s President and Chief Executive Officer. The Company also reimburses Areth for office, warehousing and building related (common area) expenses, equipment and certain other operational expenses, which were not material to the consolidated financial statements for the three months ended March 31, 2025 and 2024.</span> </div></ix:nonNumeric><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">12</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><div style="text-indent: 36pt; text-align: justify;"> <span>During the three months ended March 31, 2025 and 2024, the Company purchased certain specialized equipment and repair services used for the collection and processing of source plasma from GenesisBPS in the amount of $<ix:nonFraction contextRef="c105" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="6" unitRef="usd" id="ixv-9937">34</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c106" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="6" unitRef="usd" id="ixv-9938">0.1</ix:nonFraction> million, respectively. Genesis is owned by Dr. Grossman and Adam Grossman. </span> </div></ix:continuation><div>
  </div><div>&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-3799"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">9.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">COMMITMENTS AND CONTINGENCIES</span>
    </div>
  </div>
  <div style="margin-left: 18pt; clear: both;">&#160;
  </div>
  <div>
   <span style="font-style: italic; text-decoration: underline;">General Legal Matters</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>From time to time, the Company is or may become subject to certain legal proceedings and claims arising in connection with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#8217;s liquidity, results of operations or financial condition. </span>
  </div>
  <div style="margin-left: 18pt;">&#160;
  </div>
  <div>
   <span style="font-style: italic; text-decoration: underline;">Vendor Commitments</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>Pursuant to the terms of a plasma purchase agreement dated as of November 17, 2011 (the &#8220;2011 Plasma Purchase Agreement&#8221;), the Company agreed to purchase from its former contract manufacturer an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum volume from the counterparty, and under the original 2011 Plasma Purchase Agreement the Company was permitted to also collect high-titer RSV plasma from up to <ix:nonFraction contextRef="c107" decimals="0" format="ixt-sec:numwordsen" name="adma:NumberOfPlasmaCollectionFacilities" scale="0" unitRef="Facility" id="ixv-9939">five</ix:nonFraction> wholly owned ADMA plasma collection facilities.&#160;&#160;During 2015, the Company amended the 2011 Plasma Purchase Agreement to (i) allow the Company to collect its raw material RSV high-titer plasma from any number of wholly owned ADMA plasma collection facilities and (ii) allow the Company to purchase its raw material RSV high-titer plasma from other third-party collection organizations, in each case, provided that the annual minimum volumes from the Company&#8217;s former contract manufacturer were met, thus allowing the Company to expand its reach for raw material supply as it executes its commercialization plans for ASCENIV. On December 10, 2018, the Company&#8217;s former contract manufacturer assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations Limited (&#8220;Grifols&#8221;) as its successor-in-interest, effective January 1, 2019. Effective October 1, 2024, the Company entered into an Amended and Restated Plasma Purchase Agreement with Grifols (the &#8220;A&amp;R Grifols Agreement&#8221;) with a term expiring in <span style="-sec-ix-hidden: hidden-fact-5">September 2039</span>, after which it may be renewed for <ix:nonFraction contextRef="c109" decimals="0" format="ixt-sec:numwordsen" name="adma:NumberOfRenewalTerms" scale="0" unitRef="Term" id="ixv-9940">two</ix:nonFraction> additional multi-year periods if agreed to by the parties. Pursuant to the A&amp;R Grifols Agreement, Grifols supplies, on a non-exclusive basis, to ADMA BioManufacturing a minimum of <ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="adma:QuantityOfRespiratorySyncytialVirusPlasmaUsed" scale="0" unitRef="L" id="ixv-9941">35,000</ix:nonFraction> liters of RSV plasma annually to be used in the manufacture of ASCENIV, with an escalating price per liter depending on the volume supplied in a given <ix:nonNumeric contextRef="c108" format="ixt-sec:durmonth" name="adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" id="ixv-9942">12</ix:nonNumeric>-month period, with a minimum annual price increase every <ix:nonNumeric contextRef="c108" format="ixt-sec:durmonth" name="adma:IncreaseInMinimumAnnualPriceTerm" id="ixv-9943">12</ix:nonNumeric> months. Additionally, Grifols will be entitled to receive a fixed bonus payment in the event that a specified liter amount of high-titer plasma is supplied to the Company in any <ix:nonNumeric contextRef="c108" format="ixt-sec:durmonth" name="adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" id="ixv-9944">12</ix:nonNumeric>-month period during the term of the A&amp;R Grifols Agreement.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>Effective August 6, 2024, the Company entered into a Plasma Purchase Agreement with KEDPlasma LLC (&#8220;KEDPlasma&#8221;) with a term expiring in <span style="-sec-ix-hidden: hidden-fact-6">July 2031</span>, after which it may be renewed for an additional <span style="-sec-ix-hidden: hidden-fact-7">five</span>-year period if agreed to by the parties (the &#8220;KEDPlasma Agreement&#8221;). Pursuant to the KEDPlasma Agreement, KEDPlasma supplies, on a non-exclusive basis, to ADMA BioManufacturing a minimum of <ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="adma:QuantityOfRespiratorySyncytialVirusPlasmaUsed" scale="0" unitRef="L" id="ixv-9945">35,000</ix:nonFraction> liters of RSV plasma annually commencing with the <ix:nonNumeric contextRef="c109" format="ixt-sec:durmonth" name="adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" id="ixv-9946">12</ix:nonNumeric>-month period ending July 31, 2026, with an escalating price per liter depending on the volume supplied in a given <ix:nonNumeric contextRef="c109" format="ixt-sec:durmonth" name="adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" id="ixv-9947">12</ix:nonNumeric>-month period. The price per liter of high-titer plasma supplied pursuant to the KEDPlasma Agreement is also scheduled to increase on an annual basis. Additionally, KEDPlasma will be entitled to receive a fixed bonus payment in the event that a specified liter amount of RSV plasma is supplied to the Company in any <ix:nonNumeric contextRef="c109" format="ixt-sec:durmonth" name="adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" id="ixv-9948">12</ix:nonNumeric>-month period during the term of the KEDPlasma Agreement.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>On June 6, 2017, the Company entered into a Plasma Supply Agreement with its former contract manufacturer, pursuant to which the counterparty supplies, on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="adma:PlasmaSupplyAgreementTerm" id="ixv-9949">10</ix:nonNumeric>-year term. On July 19, 2018, the Plasma Supply Agreement was amended to provide, among other things, that in the event the counterparty elects not to supply in excess of ADMA BioManufacturing&#8217;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit percentage of the price that ADMA BioManufacturing pays to the counterparty, then the counterparty shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, the Company&#8217;s former contract manufacturer assigned its rights and obligations under the Plasma Supply Agreement to Grifols, effective January 1, 2019.</span> </div></ix:nonNumeric><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">13</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span>
  </div><div>
  </div><div style="margin-left: 18pt; color: rgb(0, 0, 0);">&#160;
  </div><div>
  </div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><div>
   <span style="font-style: italic; text-decoration: underline;">Post-Marketing Commitments</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>In connection with the FDA&#8217;s approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. For the three months ended March 31, 2025 and 2024, the Company incurred expenses related to this study in the amount of $<ix:nonFraction contextRef="c112" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-9950">0.6</ix:nonFraction> million and $<ix:nonFraction contextRef="c113" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-9951">0.3</ix:nonFraction> million, respectively. During the remainder of 2025, the Company expects to incur expenses of approximately $<ix:nonFraction contextRef="c114" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-9952">0.3</ix:nonFraction> million to complete this study, which is required to be completed by June 2026.</span> </div>
  <div>&#160;
  </div>
  <div>
   <span style="font-style: italic; text-decoration: underline;">Other Commitments</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure under these arrangements is unknown as of March 31, 2025. The Company does not anticipate recognizing any significant losses relating to these arrangements.</span>
  </div></ix:continuation><div>
  </div><div>&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-3858"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">10.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">SEGMENTS</span>
    </div>
  </div>
  <div style="margin-left: 18pt; clear: both;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company&#8217;s ADMA BioManufacturing operating segment reflects the Company&#8217;s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL.&#160;&#160;The Plasma Collection Centers operating segment consists of <ix:nonFraction contextRef="c0" decimals="INF" format="ixt-sec:numwordsen" name="adma:NumberOfFDALicensedPlasmaCollectionFacilities" scale="0" unitRef="Facility" id="ixv-9953">ten</ix:nonFraction></span><span style="color: rgb(0, 0, 0);">&#160;plasma collection facilities located throughout the United States, all of which are operational, collecting plasma and currently hold FDA licenses</span><span>. The Company defines its operating segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;) to analyze performance and allocate resources. While not considered an operating segment, the Corporate information included in the tables below consists of certain unallocated general and administrative overhead expenses and interest expense on the Company&#8217;s senior debt (see Note 7). The Company&#8217;s CODM is its President and Chief Executive Officer. For the Company&#8217;s <ix:nonFraction contextRef="c0" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="Segment" id="ixv-9954">two</ix:nonFraction> operating segments, the CODM uses income/loss before taxes as the measure of segment profit to determine the allocation of resources for each segment. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="ixv-9955">Summarized financial information concerning reportable segments is shown in the following tables:</ix:nonNumeric></span> </div></ix:nonNumeric><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">14</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span>
  </div><div>


  </div><ix:continuation continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_2" id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1"><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_2" id="_SegmentReportingDisclosureTextBlock-c0_cont_1"><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;" width="100%">
 <tr><td style="width: 65%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes">
  <td colspan="12" style="text-align: center; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Three Months Ended March
  31, 2025</b></div>
  </td>
 </tr>
 <tr style="mso-yfti-irow:1">
  <td style="text-align: center; vertical-align: bottom;" valign="top">
  <div style="margin: 0in;"><i style="mso-bidi-font-style:normal">(in thousands)</i></div>
  </td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">ADMA </b></div>
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">BioManufacturing</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center;" valign="top">&#160;</td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Plasma Collection </b></div>
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Centers</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center;" valign="top">&#160;</td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Total</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Revenues</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-9956">113,716</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-9957">1,050</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-9958">114,766</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:3">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Cost of product revenue</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-9959">53,057</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-9960">648</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-9961">53,705</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:5">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Research and development</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-9962">826</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-9963"> &#160;-&#160;&#160; </ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-9964">826</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:7">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Plasma center operating expenses</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherCostAndExpenseOperating" scale="3" unitRef="usd" id="ixv-9965"> &#160;-&#160;&#160; </ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCostAndExpenseOperating" scale="3" unitRef="usd" id="ixv-9966">1,286</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCostAndExpenseOperating" scale="3" unitRef="usd" id="ixv-9967">1,286</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:9">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Selling, marketing and distribution</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-9968">6,044</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:fixed-zero" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-9969"> &#160;-&#160;&#160; </ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-9970">6,044</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:11">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Depreciation and amortization expense</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-9971">25</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-9972"> &#160;-&#160;&#160; </ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-9973">25</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:13">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>General and administrative expense</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-9974">8,495</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:fixed-zero" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-9975"> &#160;-&#160;&#160; </ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-9976">8,495</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:15">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Other expense, net</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(<ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-9977">64</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-9978"> &#160;-&#160;&#160; </ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(<ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-9979">64</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:17">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Income (loss) before taxes</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-9980">45,205</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(<ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-9981">884</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-9982">44,321</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:19">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Expenditures for additions to long-lived assets</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" scale="3" unitRef="usd" id="ixv-9983">4,699</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" scale="3" unitRef="usd" id="ixv-9984">21</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" scale="3" unitRef="usd" id="ixv-9985">4,720</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:21">
  <td valign="top">
  <div>Total assets</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-9986">330,091</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c119" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-9987">27,644</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c120" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-9988">357,735</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:23">
  <td valign="top">
  <div><i>Reconciliation of revenues:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment
  revenue</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-9989">114,766</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:25">
  <td style="padding-left: 10px;" valign="top">
  <div>License revenue</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-9990">36</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated
  revenues</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-9991">114,802</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:27">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation
  of selling, general and administrative expense:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:29">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment
  selling, marketing and distribution expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-9992">6,044</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment
  general and administrative expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-9993">8,495</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:31">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate
  general and administrative expense (a)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">9,540</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated
  selling, general and administrative expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-9995">24,079</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:33">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation
  of income (loss) before taxes:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:35">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment
  income before taxes</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-9996">44,321</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>License
  revenue </div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-9997">36</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:37">
  <td style="padding-left: 10px;" valign="top">
  <div>Unallocated
  interest expense, primarily related to interest on senior debt (see Note 6)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(<ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" sign="-" unitRef="usd" id="ixv-9998">1,975</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Unallocated
  interest income</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-9999">608</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:39">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate
  general and administrative expense (a)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">(<ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">9,540</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">)&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated
  income before taxes</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-10001">33,450</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:41">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation
  of total assets:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:43">
  <td style="padding-left: 10px;" valign="top">
  <div>Total
  segment assets</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c120" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-10002">357,735</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate
  (b)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"><ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:Assets" scale="3" unitRef="usd">152,834</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:45;mso-yfti-lastrow:yes">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated
  total assets</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-10004">510,569</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-right: none;" valign="top">&#160;</td>
 </tr>
</table><div>&#160;
  </div>
  <div style="text-indent: -30.6pt; padding-left: 36pt;"> <div style="float: left; width: 30.6pt; white-space: nowrap;"> <span>(a) - </span> </div> <div> <ix:footnote id="ix_0_footnote" xml:lang="en-US"><span>Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.</span></ix:footnote> </div> </div>
  <div style="margin-left: 5.4pt; clear: both;">
   <span>&#160;</span>
  </div>
  <div style="text-indent: -30.6pt; padding-left: 36pt;"> <div style="float: left; width: 30.6pt; white-space: nowrap;"> <span>(b) -</span> </div> <div> <ix:footnote id="ix_1_footnote" xml:lang="en-US"><span>Primarily consists of cash and deferred tax assets.</span></ix:footnote> </div> </div></ix:continuation></ix:continuation><div>
  </div><div style="margin-left: 36pt; clear: both;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">15</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span>
  </div><div>


  </div><ix:continuation id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_2"><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_3" id="_SegmentReportingDisclosureTextBlock-c0_cont_2"><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;" width="100%">
 <tr><td style="width: 65%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes">
  <td colspan="12" style="text-align: center; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Three Months Ended March
  31, 2024</b></div>
  </td>
 </tr>
 <tr style="mso-yfti-irow:1">
  <td style="text-align: center; padding-left: 10px; vertical-align: bottom;" valign="top">
  <div style="margin: 0in;"><i style="mso-bidi-font-style:normal">(in thousands)</i></div>
  </td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">ADMA </b></div>
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">BioManufacturing</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center;" valign="top">&#160;</td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Plasma Collection </b></div>
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Centers</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center;" valign="top">&#160;</td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Total</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Revenues</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10005">80,113</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10006">1,726</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10007">81,839</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:3">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Cost of product revenue</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-10008">40,991</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-10009">1,776</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-10010">42,767</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:5">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Research and development</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-10011">451</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-10012"> &#160;-&#160;&#160; </ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-10013">451</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:7">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Plasma center operating expenses</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherCostAndExpenseOperating" scale="3" unitRef="usd" id="ixv-10014"> &#160;-&#160;&#160; </ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCostAndExpenseOperating" scale="3" unitRef="usd" id="ixv-10015">1,005</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCostAndExpenseOperating" scale="3" unitRef="usd" id="ixv-10016">1,005</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:9">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Selling, marketing and distribution</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-10017">4,431</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:fixed-zero" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-10018"> &#160;-&#160;&#160; </ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-10019">4,431</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:11">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Depreciation and amortization expense</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-10020">193</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-10021"> &#160;-&#160;&#160; </ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-10022">193</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:13">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>General and administrative expense</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-10023">5,351</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:fixed-zero" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-10024"> &#160;-&#160;&#160; </ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-10025">5,351</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:15">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Other expense, net</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(<ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-10026">30</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(<ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-10027">1</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(<ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-10028">31</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:17">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Income (loss) before taxes</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-10029">28,666</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(<ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-10030">1,056</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-10031">27,610</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:19">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Expenditures for additions to long-lived assets</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" scale="3" unitRef="usd" id="ixv-10032">2,330</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" scale="3" unitRef="usd" id="ixv-10033">17</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" scale="3" unitRef="usd" id="ixv-10034">2,347</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:21">
  <td valign="top">
  <div>Total assets</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-10035">278,331</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c128" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-10036">33,990</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-10037">312,321</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:23">
  <td valign="top">
  <div><i>Reconciliation of revenues:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment revenue</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10038">81,839</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:25">
  <td style="padding-left: 10px;" valign="top">
  <div>License revenue</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10039">36</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated revenues</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10040">81,875</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:27">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation of selling,
  general and administrative expense:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:29">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment selling, marketing and distribution expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-10041">4,431</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment general and administrative expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-10042">5,351</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:31">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate general and administrative expense (a)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"><ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">5,857</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated selling, general and administrative expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-10044">15,639</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:33">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation of income
  (loss) before taxes:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:35">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment income before taxes</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-10045">27,610</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>License revenue </div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-10046">36</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:37">
  <td style="padding-left: 10px;" valign="top">
  <div>Unallocated interest expense, primarily related to interest
  on senior debt (see Note 6)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(<ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" sign="-" unitRef="usd" id="ixv-10047">3,769</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Unallocated interest income</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-10048">381</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:39">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate general and administrative expense (a)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">(<ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">5,857</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">)&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated income before taxes</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-10050">18,401</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:41">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation of total
  assets:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:43">
  <td style="padding-left: 10px;" valign="top">
  <div>Total segment assets</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"><ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-10051">312,321</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate (b)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"><ix:nonFraction contextRef="c132" decimals="-3" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:Assets" scale="3" unitRef="usd">38,554</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:45">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated total assets</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-10053">350,875</ix:nonFraction></td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-right: none;" valign="top">&#160;</td>
 </tr>

</table><div>&#160;
  </div>
  <div style="text-indent: -30.6pt; padding-left: 36pt;">
    <div style="float: left; width: 30.6pt; white-space: nowrap;">
     <span>(a) - </span>
    </div>
    <div>
     <span>Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.</span>
    </div>
  </div>
  <div style="margin-left: 36pt; clear: both;">&#160;
  </div>
  <div style="text-indent: -30.6pt; padding-left: 36pt;">
    <div style="float: left; width: 30.6pt; white-space: nowrap;">
     <span>(b) - </span>
    </div>
    <div>
     <span>Primarily consists of cash and deferred tax assets.</span>
    </div>
  </div></ix:continuation></ix:continuation><div>
  </div><div style="margin-left: 36pt; clear: both;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">16</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="ixv-5251"><ix:continuation id="_SegmentReportingDisclosureTextBlock-c0_cont_3"><div> <span>Net revenues according to geographic area, based on the location of where the product is shipped, were as follows:</span> </div>


  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 45%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="19" style="text-align: center; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">Three&#160;&#160;Months Ended March 31, 2025</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">ADMA

      BioManufacturing</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">



      <span style="font-weight: bold;">Plasma

      Centers</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">



      <span style="font-weight: bold;">Total Segment <br/>

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">License

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">Consolidated

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      United States
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c133" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10054">110,609</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10055">85</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10056">110,694</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10057">36</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10058">110,730</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      International
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10059">3,107</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10060">965</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10061">4,072</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c141" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10062"> -&#160;&#160;&#160; </ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10063">4,072</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Total revenues
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10064">113,716</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10065">1,050</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10066">114,766</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10067">36</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10068">114,802</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 45%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="19" style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">Three&#160;&#160;Months Ended March 31, 2024</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">ADMA

      BioManufacturing</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">



      <span style="font-weight: bold;">Plasma

      Centers</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">



      <span style="font-weight: bold;">Total Segment <br/>

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">License

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">Consolidated

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      United States
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10069">76,460</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10070">1,495</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10071">77,955</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10072">36</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10073">77,991</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      International
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c148" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10074">3,653</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c149" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10075">231</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c150" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10076">3,884</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c151" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10077"> -&#160;&#160;&#160; </ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10078">3,884</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Total revenues
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10079">80,113</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10080">1,726</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10081">81,839</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10082">36</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-10083">81,875</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table></ix:continuation></ix:nonNumeric><div>&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-5537"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">11.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">LEASE OBLIGATIONS</span>
    </div>
  </div>
  <div style="margin-left: 18pt; clear: both;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>The Company leases certain properties and equipment for its ADMA BioCenters and ADMA BioManufacturing subsidiaries, which leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2033. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span>
  </div>
  <div style="text-align: justify; margin-left: 18pt;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>The Company determines if an arrangement is an operating lease at inception. Leases with an initial term of 12 months or less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities representing the obligation to make lease payments arising from the lease. Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include options to extend or terminate the lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#8217;s incremental borrowing rate. The Company&#8217;s lease expense is recognized on a straight-line basis over the lease term and is reflected in Plasma center operating expenses and selling, general and administrative expenses. Aggregate lease expense for the Company&#8217;s leases for the three months ended March 31, 2025 and 2024 was approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" unitRef="usd" id="ixv-10084"><ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" unitRef="usd" id="ixv-10085">0.6</ix:nonFraction></ix:nonFraction> million during each such period. Cash paid for the Company&#8217;s leases for the three months ended March 31, 2025 and 2024 was also approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="6" unitRef="usd" id="ixv-10086"><ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="6" unitRef="usd" id="ixv-10087">0.6</ix:nonFraction></ix:nonFraction> million during each such period.</span> </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>&#160; </span>
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>The Company has aggregate lease liabilities of $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="adma:OperatingAndFinancingLeaseLiability" scale="6" unitRef="usd" id="ixv-10088">9.5</ix:nonFraction> million and $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="adma:OperatingAndFinancingLeaseLiability" scale="6" unitRef="usd" id="ixv-10089">9.8</ix:nonFraction> million as of March 31, 2025 and December 31, 2024, respectively, which are comprised primarily of the leases for the Company&#8217;s plasma collection centers and a warehouse lease for raw material storage related to the Company&#8217;s immunoglobulin manufacturing operations. <ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-10090">As of March 31, 2025, the Company&#8217;s operating leases have a weighted-average remaining term of <ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-10091">6.6</ix:nonNumeric> years. Scheduled payments under the Company&#8217;s lease obligations are as follows (</ix:nonNumeric></span><ix:continuation continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_2" id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><span style="font-style: italic;">in thousands</span><span>):</span></ix:continuation> </div></ix:nonNumeric><div>
  </div><div style="margin-left: 18pt;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">17</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span>
  </div><div>
  </div><div style="text-align: center;">&#160;
  </div><div>


  </div><ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_2"><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; width: 60%; margin-left: auto; margin-right: auto;" width="100%">
 <tr><td style="width: 58%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right; vertical-align: bottom;" valign="top">
  <div>Remainder of 2025</div>
  </td>
  <td valign="top">&#160;</td>
  <td style="border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;" valign="top">
  <div>$</div>
  </td>
  <td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;" valign="top"> <div><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd" id="ixv-10092">1,812</ix:nonFraction> </div> </td>
  <td style="border-width: initial; border-style: none; border-color: initial;" valign="top">&#160;</td>
 </tr>
 <tr>
  <td style="text-align: right;" valign="top">
  <div>Year ended December 31, 2026</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-10093">2,157</ix:nonFraction> </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right;" valign="top">
  <div>2027</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-10094">2,041</ix:nonFraction> </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr>
  <td style="text-align: right;" valign="top">
  <div>2028</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd" id="ixv-10095">2,088</ix:nonFraction> </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right;" valign="top">
  <div>2029</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" unitRef="usd" id="ixv-10096">2,109</ix:nonFraction> </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr>
  <td style="text-align: right;" valign="top">
  <div>2030</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" unitRef="usd" id="ixv-10097">1,836</ix:nonFraction> </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right;" valign="top">
  <div>Thereafter</div>
  </td>
  <td valign="top">&#160;</td>
  <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
  <td style="text-align: right; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"> <div>&#160;<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" unitRef="usd" id="ixv-10098">2,205</ix:nonFraction> </div> </td>
  <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr>
  <td style="text-align: right;" valign="top">
  <div>Total payments</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-10099">14,248</ix:nonFraction> </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right;" valign="top">
  <div>Less: imputed interest</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-10100">4,762</ix:nonFraction>)</div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr>
  <td style="text-align: right;" valign="top">
  <div>Current portion</div>
  </td>
  <td valign="top">&#160;</td>
  <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
  <td style="text-align: right; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"> <div>&#160;(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-10101">1,188</ix:nonFraction>)</div> </td>
  <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right;" valign="top">
  <div>Balance at March 31, 2025</div>
  </td>
  <td valign="top">&#160;</td>
  <td style="border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div>$</div>
  </td>
  <td style="text-align: right; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;" valign="top"> <div>&#160;<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-10102">8,298</ix:nonFraction> </div> </td>
  <td style="border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
 </tr>
</table></ix:continuation></ix:continuation><div>&#160;</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-5673"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">12.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">INCOME TAXES</span>
    </div>
  </div>
  <div style="clear: both;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-5680"><div style="text-indent: 36pt; text-align: justify;"> <span>The Company uses the estimated annual effective tax rate approach as prescribed by ASC 740-270, Interim Reporting, to calculate its interim provision for income taxes. </span> </div>
  <div style="text-align: justify;">&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 79%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align : center; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; ">


      <span style="font-weight: bold;">Three Months Ended March 31,</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center; padding-left: 10px;">


      <span style="font-style: italic;">(In thousands, except percentages)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Provision for income taxes
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-10103">6,546</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-10104">595</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Effective tax rate
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-10105">19.6</ix:nonFraction></td><td style="text-align: left; width: 1%;">%</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-10106">3.2</ix:nonFraction></td><td style="text-align: left; width: 1%;">%</td>
   </tr>
  </table></ix:nonNumeric><div style="text-align: justify;">&#160;
  </div>
  <div style="text-align: justify;"> <span>The effective tax rate for the three months ended March 31, 2025 of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-10107">19.6</ix:nonFraction>%, differed from the federal statutory rate primarily due to the excess tax benefits on stock-based compensation. The effective tax rate for the three months ended March 31, 2024 of <ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-10108">3.2</ix:nonFraction>%, differed from the federal statutory tax rate primarily due to the valuation allowance maintained on the Company's federal and state net deferred tax assets until December 31, 2024.</span> </div></ix:nonNumeric><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="ixv-5748"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">13.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</span>
    </div>
  </div>
  <div style="margin-left: 18pt; clear: both;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="ixv-5755"><div style="text-indent: 36pt;"> <span>Supplemental cash flow information for the three months ended March 31, 2025 and 2024 is as follows: </span> </div>
  <div>&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 57%;">&#160;</td><td style="width: 20%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center;">
     <div>
      <span style="font-style: italic;">(In thousands)</span>
     </div>
    </td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">SUPPLEMENTAL CASH FLOW INFORMATION:</span>
     </div>
    </td>
    <td style="padding-left: 10px;">&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Cash paid for interest
     </div>
    </td>
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-10109">2,750</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-10110">584</ix:nonFraction></td><td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">Noncash Financing and Investing Activities:</span>
     </div>
    </td>
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Equipment acquired reflected in accounts payable and accrued liabilities
     </div>
    </td>
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd" id="ixv-10111">985</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd" id="ixv-10112">1,351</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">18</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span>
  </div><div>
  </div><div style="text-align: center;">&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-5857"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">14.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">SUBSEQUENT EVENTS</span>
    </div>
  </div>
  <div style="margin-left: -27pt; clear: both;">&#160;
  </div>
  <div style="text-align: justify;">
   <span style="font-style: italic;"><span style="text-decoration:underline">FDA Approval</span></span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-align: justify;">
   <span>In April 2025, the FDA approved the Company&#8217;s Prior Approval Supplement (the &#8220;PAS&#8221;) for its innovative yield enhancement production process benefiting both ASCENIV and BIVIGAM.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-align: justify;">
   <span style="font-style: italic;"><span style="text-decoration:underline">Share Repurchase Program</span></span><span>&#160;</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-align: justify;"> <span>In May 2025, the Company's Board of Directors authorized a share repurchase program of up to $<ix:nonFraction contextRef="c153" decimals="-5" format="ixt:num-dot-decimal" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="6" unitRef="usd" id="ixv-10113">500.0</ix:nonFraction> million of the Company&#8217;s outstanding shares of common stock. Repurchases under the program may be made from time to time through open market purchases or through privately negotiated transactions subject to market conditions, applicable legal requirements, and other relevant factors. Open market repurchases will be structured to occur in accordance with the requirements of Rule 10b-18. The Company may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of shares under this authorization. The timing and number of shares repurchased under the program will depend on a variety of factors, including stock price, trading volume, and general business and market conditions. The program does not obligate the Company to acquire any particular amount of its common stock, and may be modified, suspended, or terminated at any time at the Company&#8217;s discretion. The program has no expiration date.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-align: justify;">
   <span style="font-style: italic;"><span style="text-decoration:underline">Debt Reorganization</span></span></div>
  <div>&#160;
  </div>
  <div style="text-align: justify;"> <span>On May 5, 2025, the Company borrowed $<ix:nonFraction contextRef="c67" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" unitRef="usd" id="ixv-10114">30.0</ix:nonFraction> million under its revolving credit facility with Ares, which the Company used to repay an additional $<ix:nonFraction contextRef="c66" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" unitRef="usd" id="ixv-10115">30.0</ix:nonFraction> million against the Company&#8217;s term loan facility with Ares on May 6, 2025. Following such transactions, the Company had $<ix:nonFraction contextRef="c69" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-10116">72.5</ix:nonFraction> million outstanding under its revolving credit facility and $<ix:nonFraction contextRef="c68" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-10117">2.5</ix:nonFraction> million outstanding under its term loan facility. It is anticipated that the Company&#8217;s cost of current outstanding debt will be reduced from these transactions.&#160;&#160;</span> </div></ix:nonNumeric><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">19</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-indent: -72pt; padding-left: 72pt; font-weight: bold;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <span>Item 2.</span>
    </div>
    <div>
     <a id="Managements_Discussion_and_Analysis_of_Financial_Condition_and_Results_of_Operations" title="Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations."></a><span>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic;">The following discussion of our financial condition and results of operations, which refers to our historical results, should be read in conjunction with the other sections of this Quarterly Report on Form 10-Q, including &#8220;Risk Factors&#8221; and our unaudited consolidated financial statements and the notes thereto appearing elsewhere herein, and in conjunction with the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations set forth in our Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 18, 2025 (the &#8220;2024 10-K&#8221;). The various sections of this discussion contain a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risk factors described throughout or referenced within this Quarterly Report on Form 10-Q. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;&#160;&#160;Our actual results may differ materially from our current expectations.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: center; font-weight: bold;">
   <span style="text-decoration: underline;">OVERVIEW</span>
  </div><div>
  </div><div>
   <span style="font-weight: bold;">Our Business</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>ADMA Biologics, Inc. (the &#8220;Company,&#8221; &#8220;ADMA,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Through our ADMA BioManufacturing business segment, we currently have three products with U.S. Food and Drug Administration (the &#8220;FDA&#8221;) approval, all of which are currently marketed and commercially available: (i) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an Intravenous Immune Globulin (&#8220;IVIG&#8221;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;) or Inborn Errors of immunity in adults and adolescents, for which we received FDA approval in April 2019 and commenced first commercial sales in October 2019; (ii) BIVIGAM (Immune Globulin Intravenous, Human), an IVIG product indicated for the treatment of PI, and for which we received FDA approval in May 2019 and commenced commercial sales in August 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing HBsAg and other listed exposures to Hepatitis B. We seek to develop a pipeline of plasma-derived therapeutics, including a product based on our most recently approved patent application under U.S. Patent Nos. 10,259,865 and 11,084,870 related to methods of treatment and prevention of </span><span style="font-style: italic;">S. pneumonia</span><span> infection for an immunoglobulin manufactured to contain standardized antibodies to numerous serotypes of </span><span style="font-style: italic;">S. pneumoniae</span><span>. We have successfully completed production of a pilot-scale batch and are conducting animal studies for our </span><span style="font-style: italic;">S. pneumoniae</span><span> hyperimmune globulin program, SG-001. Our products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We manufacture these products at our FDA-licensed, plasma fractionation and purification facility located in Boca Raton, Florida with a peak annual processing capability of up to 600,000 liters (the &#8220;Boca Facility&#8221;). Based on current production yields, our completed and ongoing supply chain enhancements and capacity expansion initiatives, we believe this facility has the potential to produce sufficient quantities of our immune globulin (&#8220;IG&#8221;) products.</span></div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Through our ADMA BioCenters subsidiary, we currently operate ten source plasma collection facilities in the U.S., all of which hold FDA licenses. This business unit, which we refer to as our Plasma Collection Centers business segment, provides us with the blood plasma required for the manufacture of our products, and also allows us to sell certain quantities of source and hyperimmune plasma to third-party customers for further manufacturing. In addition, three of our FDA-approved plasma collection centers also have approvals from the Korean Ministry of Food and Drug Safety (&#8220;MFDS&#8221;), as well as FDA approval to operate a Hepatitis B immunization program. A typical plasma collection center, such as those operated by ADMA BioCenters, can collect approximately 30,000 to 50,000 liters of source plasma annually, which may be sold for different prices depending upon the type of plasma, quantity of purchase and market conditions at the time of sale. Plasma collected from ADMA BioCenters&#8217; facilities that is not used to manufacture our products is sold to third-party customers in the U.S. and in other locations outside the U.S. where we are approved under supply agreements or in the open &#8220;spot&#8221; market. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">20</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>From time to time, we may provide contract manufacturing services for certain third-party clients. We also provide laboratory contracting services to certain customers and may provide contract filling, labeling and packing services utilizing our FDA-approved in-house fill-finish capabilities. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>For the year ended December 31, 2024, we achieved net income of $197.7 million, the first time in our history that we achieved net income on a GAAP basis, and we generated positive cash flow from operations of $118.7 million, the full details of which can be found in our 2024 Form 10-K for the year ended December 31, 2024, filed on March 18, 2025. Our improved operating results are primarily the result of the substantial revenue growth driven by the continued physician, patient and payer acceptance of ASCENIV.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>In April 2025, the FDA approved our Prior Approval Supplement (the &#8220;PAS&#8221;) for our innovative yield enhancement production process (the &#8220;Yield Enhancement&#8221;) benefiting both ASCENIV and BIVIGAM. Such approval is expected to result in meaningful revenue and earnings accretion beginning in the second half of 2025 and accelerating further into 2026 and beyond. This innovative process has demonstrated an ability to increase ASCENIV and BIVIGAM production yields by approximately 20% from the same starting plasma volume.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold;">Our Products</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">ASCENIV </span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div>
  </div><div style="text-indent: 36pt; text-align: justify;"><span>ASCENIV is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies, which are proteins that are used by the body&#8217;s immune system to neutralize microbes, such as bacteria and viruses, and prevent against infection and disease. We manufacture ASCENIV under HHS License No. 2019 using a process known as fractionation. The Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) has issued a permanent, product-specific-J-code for ASCENIV. Under the Healthcare Common Procedure Coding System (&#8220;HCPCS&#8221;), the J-code (J1554) became effective in April 2021. As part of our proprietary manufacturing process for ASCENIV, we leverage our unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and plasma from donors tested to have high levels of neutralizing antibody titers to Respiratory Syncytial Virus (&#8220;RSV&#8221;) using our proprietary microneutralization testing assay. With our patented testing methods and assay, we are able to identify the high-titer or &#8220;hyperimmune&#8221; plasma that meets our internal and required specifications for ASCENIV. This type of high-titer plasma is typically found in less than 10% of the total donor collection samples we test. </span>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">ASCENIV is approved for the treatment of PIDD or PI, a class of inherited genetic disorders that causes a deficient or absent immune system in adults and adolescents (12 to 17 years of age). Our pivotal Phase III clinical trial in 59 PIDD patients met the primary endpoint of no Serious Bacterial Infections (&#8220;SBI&#8221;) reported during 12 months of treatment. Secondary efficacy endpoints further demonstrated the benefits of ASCENIV in the low incidence of infection, therapeutic antibiotic use, days missed from work, school and daycare and unscheduled medical visits and hospitalizations. We believe this clinical data together with the FDA approval for the treatment of PIDD better positions ADMA to potentially further evaluate ASCENIV in immune-compromised patients infected with or at-risk for RSV infection or potentially other respiratory viral pathogens at an appropriate time. In the future, we may elect to work with the FDA and the immunology and infectious disease community to design an appropriate clinical trial to evaluate the use of ASCENIV in this patient population. Following FDA approval in April 2019, commercial sales of ASCENIV commenced in October of 2019 and in</span><span> 2023 we commenced manufacturing ASCENIV at the 4,400 Liter production scale. This expansion has improved the product&#8217;s margin profile and increased plant production capacity as fewer batches are needed to support our revenue goals. ASCENIV&#8217;s prescriber and patient base continued to expand during 2024, which drove record utilization and pull-through for this product. These elevated demand trends have sustained into 2025, and we currently expect that this product&#8217;s rapid growth will continue throughout 2025 and beyond.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">21</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span>We anticipate filing our supplemental Biologics License Application (&#8220;sBLA&#8221;) in mid-2025, with potential FDA approval in the first half of 2026, for the expansion of ASCENIV&#8217;s label to include the pediatric setting for patients who are two years and older.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">BIVIGAM</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>BIVIGAM is a plasma-derived IVIG that contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are directed against bacteria and viruses and help to protect PI patients against serious infections. BIVIGAM is a purified, sterile, ready-to-use preparation of concentrated human Immunoglobulin G antibodies indicated for the treatment of PI, a group of genetic disorders. This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiency. These PIs are a group of genetic disorders. Based on recent estimates, these disorders are no longer considered to be very rare, with as many as one in every 1,200 people in the United States having some form of PI. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>In May 2019, the FDA approved the PAS for the use of our IVIG manufacturing process, thereby enabling us to re-launch and commercialize this product in the United States. We resumed production of BIVIGAM during the fourth quarter of 2017 and commercial production is ongoing, using our FDA-approved IVIG manufacturing process under U.S. Department of Health and Human Services (&#8220;HHS&#8221;) License No. 2019. The commercial re-launch and first commercial sales for this product commenced in August 2019. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>In April 2021, we announced that the FDA granted approval for our expanded plasma pool production scale process, allowing for a 4,400-liter plasma pool for the manufacture of our BIVIGAM IVIG product. This increased IVIG plasma pool scale, which allows us to produce BIVIGAM at an expanded capacity utilizing the same equipment, release testing assays and labor force, has had a favorable impact on our gross margins, manufacturing efficiencies and operating results.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>In December 2023, we announced that the FDA approved the expansion of BIVIGAM&#8217;s label in the United States to now include the pediatric setting for those two years of age and older. </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">Nabi-HB</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Nabi-HB is a hyperimmune globulin that is rich in antibodies to the Hepatitis B virus. Nabi-HB is a purified human polyclonal antibody product collected from plasma donors who have been previously vaccinated with a Hepatitis B vaccine. Nabi-HB is indicated for the treatment of acute exposure to blood containing HBsAg, prenatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute Hepatitis B virus infection in specific, listed settings. Hepatitis B is a potentially life-threatening liver infection caused by the Hepatitis B virus, which is a major global health problem. The Hepatitis B virus can cause chronic infection and places people at high risk of death from cirrhosis and liver cancer. Nabi-HB has a well-documented record of long-term safety and effectiveness since its initial market introduction. The FDA approved Nabi-HB in March 1999. Production of Nabi-HB at the Boca Facility has continued under our leadership since the third quarter of 2017. In early 2018, we received authorization from the FDA for the release of our first commercial batch of Nabi-HB for commercial distribution in the United States and we continue to manufacture Nabi-HB under HHS License No. 2019.</span>
  </div><div>
  </div><div style="text-align: center; font-weight: bold;">&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-weight: bold; text-decoration: underline;">RESULTS OF OPERATIONS</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold;">Critical Accounting Policies and Estimates</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based on our condensed consolidated financial statements, which have been prepared in accordance with Accounting Principles Generally Accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate these estimates and assumptions, including those described below. We base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results and experiences may differ materially from these estimates. Significant estimates include rebates and chargebacks deducted from gross revenues and estimates related to the Company&#8217;s effective tax rate.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">22</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Some of the estimates and assumptions we are required to make under U.S. GAAP require difficult, subjective and/or complex judgments about matters that are inherently uncertain and, as a result, actual results could differ from those estimates. Due to the estimation processes involved, the following summary of accounting estimates and their application are considered to be critical to understanding our business operations, financial condition and results of operations. For a description of our significant accounting policies, see Note 2 to the Consolidated Financial Statements included in our 2024 10-K. Estimates and assumptions used in projecting future liquidity and capital requirements are described in Note 1 to the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">Revenue Deductions for Rebates and Chargebacks </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our gross product revenues are subject to a variety of deductions which are estimated and recorded in the same period that the revenues are recognized. These deductions primarily consist of rebates, distribution fees, chargebacks and sales allowances. These deductions represent estimates of the related obligations, some of which are contractual in nature and do not require extensive judgment to be exercised by management, while other estimates require complex or subjective matters of knowledge and judgment when estimating the impact of these revenue deductions on net revenues for a reporting period. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">Effective Tax Rate </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our provision for income taxes and the determination of our effective tax rate are subject to significant judgment and complexity. We estimate our income tax expense based on enacted tax laws and statutory tax rates in the jurisdictions in which we operate, as well as our interpretation of relevant tax regulations. The effective tax rate includes the impact of various estimates and judgments. Changes in these estimates or in tax laws could significantly affect our effective tax rate and results of operations. Due to the complexity of tax regulations and the potential for differing interpretations, it is reasonably possible that the ultimate resolution of these matters could result in material adjustments to our effective tax rate in future periods.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">23</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify; font-weight: bold; font-style: italic;">
   <span style="font-style: normal;">Three Months Ended March 31, 2025 Compared to Three Months Ended March 31, 2024</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>The following table presents a summary of the changes in our results of operations for the three months ended March 31, 2025, our first fiscal quarter, compared to the three months ended March 31, 2024:</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; margin-left: auto; margin-right: auto; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="text-align: center;">
     <div><br/></div>
    </td>
    <td colspan="11" style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">Three Months Ended March 31,</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="text-align: center; vertical-align: bottom;"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-style: italic; float: none; display: inline !important;">(in thousands)</span><br/></td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">


      <span style="font-weight: bold;">2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">


      <span style="font-weight: bold;">2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">


      <span style="font-weight: bold;">Increase <br/>(Decrease)</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Revenues
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">114,802</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">81,875</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">32,927</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Cost of product revenue
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">53,705</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">42,767</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">10,938</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Gross profit
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">61,097</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">39,108</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">21,989</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Research and development expenses
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">826</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">450</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">376</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Plasma center operating expenses
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">1,286</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">1,005</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">281</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Amortization of intangibles
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">25</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">193</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(168</td><td style="text-align: left; width: 1%;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Selling, general and administrative expenses
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">24,079</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">15,639</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">8,440</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Income from operations
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">34,881</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">21,821</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">13,060</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Interest expense
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(1,975</td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(3,769</td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">1,794</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Other income, net
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">544</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">349</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">195</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Income before taxes
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">33,450</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">18,401</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">15,049</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr><tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Provision for income taxes
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">6,546</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">595</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">5,951</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: right; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Net income
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">26,904</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">17,806</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">9,098</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Adjusted EBITDA *
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">47,939</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">26,425</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">21,514</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Adjusted Net Income*
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">33,299</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">17,806</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">15,493</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><div>&#160;
  </div><div>
  </div><div style="text-indent: -30.6pt; padding-left: 36pt; font-size: 12pt;">
    <div style="float: left; width: 30.6pt; white-space: nowrap;">
     * -
    </div>
    <div style="font-size: 10pt;">
     See Non-GAAP Financial Measures appearing at the end of this discussion
    </div>
  </div><div>
  </div><div style="clear: both;">&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">Revenues</span></div><div>
  </div><div>&#160;</div><div style="text-indent: 36pt; text-align: justify;">
   <span>We recorded total revenues of $114.8 million for the three months ended March 31, 2025, as compared to $81.9 million for the three months ended March 31, 2024, an increase of $32.9 million, or approximately 40%. The increase is primarily related to increased sales of ASCENIV, as we experience increased physician, payer and patient acceptance and utilization of ASCENIV. During the three months ended March 31, 2025, as a precautionary measure, we voluntarily withdrew three lots of BIVIGAM (such a withdrawal, hereinafter referred to as the &#8220;Voluntary Withdrawal&#8221;). During the same period, the Company recorded a reduction to revenue of $3.8 million for credits issued to customers for the related product returns, which partially offset the increase driven by increased sales of ASCENIV.</span>
  </div><div>
  </div><div>
   <span>&#160;  </span>
  </div><div>
  </div><div style="font-style: italic;">
   <span style="font-weight: bold;">Cost of Product Revenue and Gross Profit</span>
  </div><div>
  </div><div style="font-style: italic;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify; font-style: italic;">
   <span style="font-style: normal;">Cost of product revenue was $53.7 million for the three months ended March 31, 2025, as compared to $42.8 million for the three months ended March 31, 2024. This increase is primarily attributable to volume-driven increases in product revenue costs related to the increased sales of our IG products of $12.4 million, partially offset by $1.1 million of lower product revenue costs related to plasma sales.  </span>
  </div><div>
  </div><div style="text-align: justify; font-style: italic;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify; font-style: italic;">
   <span style="font-style: normal;">For the three months ended March 31, 2025, we had gross profit of $61.1 million, as compared to $39.1 million for the same period of a year ago, which represents a gross margin in the first quarter of 2025 of 53.2%, as compared to 47.8% in the first quarter of 2024. This improvement in gross margin is primarily driven by a significantly more favorable mix of higher margin IG sales in 2025 as compared to 2024, along with the operational efficiencies achieved resulting in a reduction in other manufacturing costs.</span>
  </div><div>
  </div><div style="font-style: italic;">&#160;
  </div><div>
  </div><div style="font-style: italic;">
   <span style="font-weight: bold;">Research and Development Expenses</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Research and development (&#8220;R&amp;D&#8221;) expenses totaled $0.8 million for the first quarter of 2025, as compared to $0.5 million for the first quarter of 2024. The increase is primarily due to expenses incurred during the first quarter of 2025 related to the ASCENIV pediatric study.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="font-style: italic;">
   <span style="font-weight: bold;">Plasma Center Operating Expenses</span>
  </div><div>
  </div><div style="font-style: italic;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Plasma Center Operating Expenses increased from $1.0 million for the three months ended March 31, 2024 to $1.3 million for the three months ended March 31, 2025. The increase is primarily due to an increase in donor fees of $0.8 million and wages and benefits of $0.5 million, largely offset by a decrease of $1.0 million in donor testing expenses. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">24</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="font-style: italic;">
   <span style="font-weight: bold;">Amortization of Intangibles</span>
  </div><div>
  </div><div style="font-style: italic;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Amortization expense mainly pertains to the amortization of internally developed software and was less than $0.1 million and $0.2 million for the three months ended March 31, 2025 and 2024 respectively. </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="font-style: italic;">
   <span style="font-weight: bold;">Selling, General and Administrative Expenses</span>
  </div><div>
  </div><div style="font-style: italic;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses were $24.1 million for the three months ended March 31, 2025, an increase of $8.4 million from the three months ended March 31, 2024. The increase is primarily driven by higher employee-related costs of $4.2 million due to increase in headcount to support revenue growth, and higher share-based compensation expense related to the increase in the fair value of the Company&#8217;s common stock, an increase in audit fees of $1.8 million, legal and other professional services of $1.3 million, software maintenance expense of $0.5 million, and other costs of $0.7 million. SG&amp;A expenses as a percentage of net revenues increased from 19.1% in the first quarter of 2024 to 21.0% in the first quarter of 2025.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="font-style: italic;">
   <span style="font-weight: bold;">Interest Expense</span>
  </div><div>
  </div><div style="font-style: italic;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Interest expense for the three months ended March 31, 2025 was $2.0 million, as compared to $3.8 million for the three months ended March 31, 2024, primarily driven by the decrease in debt balances due to principal repayments made throughout 2024.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="font-style: italic;">
   <span style="font-weight: bold;">Other Income, Net</span>
  </div><div>
  </div><div style="font-style: italic;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Other income, net, for the three months ended March 31, 2025 was $0.5 million, as compared to $0.3 million for the three months ended March 31, 2024. </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="font-style: italic;">
   <span style="font-weight: bold;">Provision for Income Taxes</span>
  </div><div>
  </div><div style="font-style: italic;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>The provision for income taxes of $6.5 million for the three months ended March 31, 2025 represented an effective tax rate of 19.6%, as compared to the provision of $0.6 million for the three months ended March 31, 2024, with an effective tax rate of 3.2%. As of March 31, 2024, the Company had a full valuation allowance for its net deferred tax assets, and the effective tax rate for the three months ended March 31, 2024 differed from the federal statutory tax rate of 21% primarily due to the recognition of deferred tax assets for the net operating losses. The Company released its valuation allowance in December 2024, and the effective tax rate for the three months ended March 31, 2025 differed from the federal statutory rate primarily due to the excess tax benefits on stock-based compensation. </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">Non-GAAP Financial Measures </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">Earnings Before Interest, Taxes, Depreciation and Amortization (&#8220;EBITDA&#8221;), Adjusted EBITDA and Adjusted Net Income</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>EBITDA, Adjusted EBITDA and Adjusted net income are important non-GAAP financial measures used by our management and Board of Directors to assess our operating performance. We use EBITDA, Adjusted EBITDA and Adjusted net income as key performance measures because we believe that they facilitate operating performance comparisons from period to period that exclude, in the case of Adjusted net income, items that are expected to be non-recurring, and in the case of EBITDA and Adjusted EBITDA, potential differences driven by the impact of variations of non-cash items such as depreciation and amortization, as well as, in the case of Adjusted EBITDA, stock-based compensation or certain one-time and non-recurring items. In addition, we believe that EBITDA, Adjusted EBITDA and Adjusted net income and similar measures are widely used by investors, securities analysts, ratings agencies and other parties in evaluating companies in our industry as a measure of financial performance and debt-service capabilities. See below for a reconciliation of our EBITDA, Adjusted EBITDA and Adjusted net income to net income, the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP.&#160;&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">25</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span>Because EBITDA, Adjusted EBITDA and Adjusted net income are measures not deemed to be in accordance with U.S. GAAP and are susceptible to varying calculations, our EBITDA, Adjusted EBITDA and Adjusted net income may not be comparable to similarly titled measures of other companies, including companies in our industry, because other companies may calculate EBITDA, Adjusted EBITDA and Adjusted net income in a different manner than we calculate these measurements. </span><span style="color: rgb(0, 0, 0);">Although the Company uses Adjusted EBITDA as one of several financial measures to assess its operating performance, its use is limited as it excludes certain significant operating expenses. EBITDA, Adjusted EBITDA and Adjusted net income are not intended to represent cash flows for the periods presented, nor have they been presented as an alternative to operating income, net income or as an indicator of operating performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with U.S. GAAP. The following table presents the reconciliation of net income to EBITDA and Adjusted EBITDA for the three months ended March 31, 2025 and 2024:</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align : center; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; ">


      <span style="font-weight: bold;">Three Months Ended March 31,</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2025</span>
     </td><td style="text-align: center; width: 1%;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2024</span>
     </td><td style="text-align: center; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center; padding-left: 10px;">


      <span style="font-style: italic;">(In thousands)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      <span style="font-weight: bold;">Net income</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">26,904</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">17,806</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Depreciation
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">1,944</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">1,921</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Amortization
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">25</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">193</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Income taxes
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">6,546</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">595</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Interest expense
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">1,975</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">3,769</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">EBITDA</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">37,393</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">24,284</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Stock-based compensation
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">4,624</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">2,141</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Customer credits related to the Voluntary Withdrawal
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">3,837</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">          -&#160;&#160;&#160;      </td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Yield Enhancement
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">902</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">          -&#160;&#160;&#160;      </td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Non-recurring professional fees <sup>(a)
     </sup></div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">1,182</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">          -&#160;&#160;&#160;      </td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Adjusted EBITDA
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">47,939</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">26,425</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
  </table><div>&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 18pt; font-size: 12pt;">
    <div style="float: left; width: 18pt; white-space: nowrap; font-size: 10pt;"><sup>
     (a)
    </sup></div>
    <div style="font-size: 10pt;">
     Non-recurring professional fees represent incremental costs associated with a vendor change that we do not expect to incur in future periods.
    </div>
  </div><div>
  </div><div style="text-align: justify; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Adjusted EBITDA increased by $21.5 million for the three months ended March 31, 2025, as compared to the same period of a year ago. The improvement is primarily due to the substantial increase in operating income. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">The following table presents the reconciliation of Net income to Adjusted net income for the three months ended March 31, 2025 and 2024:</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="padding-left : 10px; text-align : center; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; ">
     <div style="text-indent: -7.2pt;">
      <span style="font-weight: bold;">Three months ended March 31,</span>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">
     <div style="text-indent: -7.2pt;">
      <span style="font-weight: bold;">2025</span>
     </div>
    </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">
     <div style="text-indent: -7.2pt;">
      <span style="font-weight: bold;">2024</span>
     </div>
    </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center; padding-left: 10px;">
     <div style="text-indent: -7.2pt;">
      <span style="font-style: italic;">(In thousands)</span>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      <span style="font-weight: bold;">Net income</span>
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; vertical-align: bottom;">26,904</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; vertical-align: bottom;">17,806</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Stock-based compensation modifications (pre-tax)
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;">474</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;">

       -&#160;&#160;&#160;

    </td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Customer credits related to the Voluntary Withdrawal (pre-tax)
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;">3,837</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;">

       -&#160;&#160;&#160;

    </td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Yield Enhancement (pre-tax)
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;">902</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px;">

       -&#160;&#160;&#160;

    </td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Non-recurring professional fees (pre-tax) <sup>(a)
     </sup></div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">1,182</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">

       -&#160;&#160;&#160;

    </td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">Adjusted net income </span><span><sup>(b)</sup></span></div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">33,299</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; text-indent: -7.2pt; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">17,806</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><div style="margin: 0in; font-size: 11pt;">&#160;</div><div style="margin: 0in 0in 0in 18.75pt; font-size: 11pt; text-indent: -0.25in;"><span style="font-size: 10pt;"><span style="mso-list:Ignore"><sup>(a)</sup><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-size-adjust: none; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-variant-emoji: normal; font-stretch: normal; font-size: 7pt; line-height: normal;">&#160; &#160; &#160;&#160;</span></span><span style="mso-spacerun:yes">&#160;</span>Non-recurring professional fees represent
incremental costs associated with a vendor change that we do not expect to
incur in future periods.</span></div><div style="margin: 0in 0in 0in 18.75pt; font-size: 11pt; text-indent: -0.25in;">&#160;</div><div>



  </div><div>&#160;<span style="letter-spacing: normal; text-indent: -24px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><sup>(b)</sup><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-size-adjust: none; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-variant-emoji: normal; font-stretch: normal; font-size: 7pt; line-height: normal;">&#160;&#160;&#160;&#160;&#160;</span>&#160;Excludes estimated tax effect of the add-backs of $1.3 million.</span></div><div>&#160;</div><div style="text-align: center; font-weight: bold;">
   <span style="text-decoration: underline;">LIQUIDITY AND CAPITAL RESOURCES</span>
  </div><div>
  </div><div style="text-align: center; font-weight: bold;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>At March 31, 2025, we had working capital of $298.3 million, primarily consisting of $172.2 million of inventory, cash and cash equivalents of $71.6 million and $99.4 million of accounts receivable, partially offset by current liabilities of $53.5 million, as compared to working capital at December 31, 2024 of $275.9 million, primarily consisting of $170.2 million of inventory, cash and cash equivalents of $103.1 million and accounts receivable of $50.0 million, partially offset by current liabilities of $55.5 million. Our material cash requirements are primarily comprised of: </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">26</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 72pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>The collection and procurement of raw material source plasma, which includes plasma donor fees and plasma center supplies, and other raw materials necessary to maintain and scale up our manufacturing operations;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 72pt; clear: both;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Employee compensation and benefits;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 72pt; clear: both;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Capital expenditures for equipment upgrades and capacity expansion at the Boca Facility and to maintain our plasma collection facilities;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 72pt; clear: both;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Interest on our debt;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 72pt; clear: both;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Marketing programs, medical education and continued commercialization efforts;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 72pt; clear: both;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Boca Facility maintenance, improvements, repairs and supplies; </span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 72pt; clear: both;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Conducting required post-marketing clinical trials for ASCENIV; and </span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 72pt; clear: both;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Continuous improvements and updates to our IT infrastructure, laboratory equipment and assays, and facilities and engineering equipment.&#160;&#160;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>As we continue to onboard new staff and expand production at the Boca Facility, we may also decide to use cash on hand, in whole or in part, to purchase additional real estate to add redundancies, expand operations and prepare for future growth opportunities. In addition, our end-to-end production cycle time from procurement of raw materials to commercial release of finished product can take between seven and 12 months or potentially longer, requiring substantial inventories of raw material plasma and other manufacturing and laboratory testing materials and single use disposables.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We currently anticipate, based upon our projected revenue and expenditures, that our current cash, cash equivalents and accounts receivable, along with our projected future operating cash flow, will be sufficient to fund our operations, as currently conducted, through the end of 2025 and beyond. Based on current operations and assuming continued market acceptance and utilization of our finished drug products, we do not anticipate the need to raise additional capital at this time. However, should the market for our products or political, economic or inflationary conditions change, we may need to seek additional capital which may not be available due to a variety of potential factors beyond our control (see &#8220;Risk Factors&#8221; appearing elsewhere in this report).</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>&#160;&#160;ADMA continues to evaluate a variety of strategic alternatives, and the exploration of value-creating opportunities remains a top corporate priority. </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">On December 18, 2023 (the &#8220;Ares Closing Date&#8221;), we and all of our subsidiaries entered into a senior secured credit facility (the &#8220;Ares Credit Agreement&#8221;) with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation (collectively, &#8220;Ares&#8221;). The Ares Credit Agreement provided for a total of $135.0 million in senior secured credit facilities (the &#8220;Ares Credit Facility&#8221;) consisting of (i) a term loan in the aggregate principal amount of $62.5 million and (ii) a revolving credit facility in the aggregate principal amount of $72.5 million (collectively, the &#8220;Ares Loans&#8221;), both of which were fully drawn on the Ares Closing Date. The Ares Credit Facility has a maturity date of December 20, 2027.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">On August 14, 2024, we repaid $30.0 million against the revolving credit facility and the outstanding balance on the revolving credit facility as of March 31, 2025 was $42.5 million. On December 19, 2024 we repaid $30.0 million against the term loan facility and the outstanding balance on the term loan facility as of March 31, 2025 was $32.5 million. On May 5, 2025, we borrowed $30.0 million under our revolving credit facility, which we used to concurrently repay an additional $30.0 million against the term loan facility on May 6, 2025. Following such transactions, we had $72.5 million outstanding under our revolving credit facility and $2.5 million outstanding under our term loan facility. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Borrowings under the term loan bear interest at the adjusted Term SOFR for a three&#8209;month tenor in effect on the day that is two business days prior to the first day of the applicable calendar quarter plus 6.50% (the &#8220;Initial SOFR Term Loan Applicable Margin&#8221;). Borrowings under the revolving facility initially bear interest at the adjusted Term SOFR for a three&#8209;month tenor in effect on the day that is two business days prior to the first day of the applicable calendar quarter</span><span style="color: rgb(0, 0, 0); font-style: italic;">&#160;</span><span style="color: rgb(0, 0, 0);">plus</span><span style="color: rgb(0, 0, 0); font-style: italic;">&#160;</span><span style="color: rgb(0, 0, 0);">3.75% (the &#8220;SOFR Revolving Facility Applicable Margin&#8221;). As of March 31, 2025 and December 31, 2024, the interest rate on the term loan was approximately 10.80% and 10.85%, respectively, and the interest rate on the revolving facility was approximately 8.05% and 8.34%, respectively.&#160;&#160; </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">27</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">On the Ares Maturity Date, we are required to pay Ares the entire outstanding principal amount underlying the Ares Loans and any accrued and unpaid interest thereon. Prior to the Ares Maturity Date, there are no scheduled principal payments on the Ares Credit Facility, and we are required to make quarterly interest payments during the term of Ares Credit Facility. We may prepay the outstanding principal under the revolving facility, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon three business days&#8217; prior written notice with no prepayment premium. However, in the event that we prepay an amount under the revolving facility that is greater than 50% of the current $72.5 million outstanding balance, we will still be required to pay interest on 50% of this balance, or $36.3 million, through the term of Ares Credit Facility. We may prepay the outstanding principal on the term loan, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon three business days&#8217; prior written notice, subject to the payment to Ares of a prepayment premium equal to (i) the present value as of such date of all remaining required interest payments on the principal amount being repaid plus 1.5% of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Ares Closing Date, (ii) 1.5% of the prepaid principal amount, if prepaid after the first anniversary of the Ares Closing Date and on or prior to the second anniversary of the Ares Closing Date, or (iii) 1.0% of the prepaid principal amount, if prepaid on or prior to the third anniversary of the Ares Closing Date.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">All of our obligations under the Ares Credit Agreement are secured by a first-priority lien and security interest in substantially all of our tangible and intangible assets, including intellectual property and all of the equity interests in our subsidiaries. The Ares Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings. The negative covenants include certain financial covenants, including maximum total leverage ratios and a $15.0 million liquidity covenant, and also restrict or limit our ability and the ability of our subsidiaries to, among other things and subject to certain exceptions contained in the Ares Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to our or our subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Ares Credit Agreement); engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting our ability to make loan repayments under the Ares Credit Agreement. As of March 31, 2025, we were in compliance with all of the covenants contained in the Ares Credit Agreement.</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify; color: rgb(0, 0, 0);">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify; color: rgb(0, 0, 0);">
   <span>Events of default on the Ares Loans include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. If there is an event of default, we will incur an increase in the rate of interest on the Ares Loans of 2% per annum.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="font-weight: bold;">
   <span>Cash Flows</span>
  </div><div>
  </div><div style="font-weight: bold;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; line-height: 1.76; font-weight: bold;">
   <span style="font-weight: normal;">The following table sets forth a summary of our cash flow for the periods indicated: </span>
  </div><div>
  </div><div style="line-height: 1.76; font-weight: bold;">&#160;
  </div><div>

  </div><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align : center; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; ">
     <div style="font-weight: bold;">
      Three Months Ended March 31,
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="text-align: center;">
     <div style="font-weight: bold;">
      <span style="font-weight: normal; font-style: italic;">(in thousands)</span>
     </div>
    </td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">
     <div style="font-weight: bold;">
      2025
     </div>
    </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">
     <div style="font-weight: bold;">
      2024
     </div>
    </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div style="font-weight: bold;">
      <span style="font-weight: normal;">Net cash used in operating activities</span>
     </div>
    </td>
    <td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; font-weight: normal; margin-left: 7.2pt; width: 9%; padding-left: 10px; vertical-align: bottom;">(19,675</td><td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%; vertical-align: bottom;">)&#160;</td><td style="text-align: left; font-weight: normal; margin-left: 7.2pt;">&#160;</td>
    <td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; font-weight: normal; margin-left: 7.2pt; width: 9%; padding-left: 10px; vertical-align: bottom;">(2,218</td><td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%; vertical-align: bottom;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div style="font-weight: bold;">
      <span style="font-weight: normal;">Net cash used in investing activities</span>
     </div>
    </td>
    <td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%;">&#160;</td><td style="text-align: right; font-weight: normal; margin-left: 7.2pt; width: 9%; padding-left: 10px;">(4,720</td><td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%;">)&#160;</td><td style="text-align: left; font-weight: normal; margin-left: 7.2pt;">&#160;</td>
    <td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%;">&#160;</td><td style="text-align: right; font-weight: normal; margin-left: 7.2pt; width: 9%; padding-left: 10px;">(2,362</td><td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div style="font-weight: bold;">
      <span style="font-weight: normal;">Net cash used in financing activities</span>
     </div>
    </td>
    <td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; font-weight: normal; margin-left: 7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(7,127</td><td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left; font-weight: normal; margin-left: 7.2pt;">&#160;</td>
    <td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; font-weight: normal; margin-left: 7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(1,447</td><td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div style="font-weight: bold;">
      <span style="font-weight: normal;">Net change in cash and cash equivalents</span>
     </div>
    </td>
    <td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%;">&#160;</td><td style="text-align: right; font-weight: normal; margin-left: 7.2pt; width: 9%; padding-left: 10px;">(31,522</td><td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%;">)&#160;</td><td style="text-align: left; font-weight: normal; margin-left: 7.2pt;">&#160;</td>
    <td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%;">&#160;</td><td style="text-align: right; font-weight: normal; margin-left: 7.2pt; width: 9%; padding-left: 10px;">(6,027</td><td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div style="font-weight: bold;">
      <span style="font-weight: normal;">Cash and cash equivalents - beginning of period</span>
     </div>
    </td>
    <td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; font-weight: normal; margin-left: 7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">103,147</td><td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left; font-weight: normal; margin-left: 7.2pt;">&#160;</td>
    <td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; font-weight: normal; margin-left: 7.2pt; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">51,352</td><td style="text-align: left; font-weight: normal; margin-left: 7.2pt; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div style="font-weight: bold;">
      <span style="font-weight: normal;">Cash and cash equivalents - end of period</span>
     </div>
    </td>
    <td style="font-weight: normal; margin-left: 7.2pt; width: 1%; text-align: left; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="font-weight: normal; margin-left: 7.2pt; width: 9%; padding-left: 10px; text-align: right; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">71,625</td><td style="font-weight: normal; margin-left: 7.2pt; width: 1%; text-align: left; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="font-weight: normal; margin-left: 7.2pt; text-align: left;">&#160;</td>
    <td style="font-weight: normal; margin-left: 7.2pt; width: 1%; text-align: left; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="font-weight: normal; margin-left: 7.2pt; width: 9%; padding-left: 10px; text-align: right; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">45,325</td><td style="font-weight: normal; margin-left: 7.2pt; width: 1%; text-align: left; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><div style="line-height: 1.76; font-weight: bold;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">28</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="font-weight: bold;">
   <span style="font-style: italic;">Net Cash Used in Operating Activities</span></div><div style="font-weight : bold; font-size : 10pt; ">&#160;</div><div style="text-indent: 36pt; text-align: justify; font-weight: bold;">
   <span style="font-weight: normal;">Cash used in operations for the three months ended March 31, 2025, was $19.7 million, an increase of $17.5 million from the same period of a year ago, primarily due to the unfavorable impact of the timing of sales, partially offset by higher net income. The following table illustrates the primary components of our cash flows from operations:</span>
  </div><div>
  </div><div style="font-weight: bold;">&#160;
  </div><div>

  </div><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align : center; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; ">
     <div style="font-weight: bold;">
      Three Months Ended March 31,
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="text-align: center;">
     <div style="font-weight: bold;">
      <span style="font-weight: normal; font-style: italic;">(in thousands)</span>
     </div>
    </td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">
     <div style="font-weight: bold;">
      2025
     </div>
    </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">
     <div style="font-weight: bold;">
      2024
     </div>
    </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div style="font-weight: bold;">
      <span style="font-weight: normal;">Net income</span>
     </div>
    </td>
    <td style="text-align: left; font-weight: normal; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px; vertical-align: bottom;">26,904</td><td style="text-align: left; font-weight: normal; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; font-weight: normal;">&#160;</td>
    <td style="text-align: left; font-weight: normal; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px; vertical-align: bottom;">17,806</td><td style="text-align: left; font-weight: normal; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div style="font-weight: bold;">
      <span style="font-weight: normal;">Non-cash expenses, gains and losses</span>
     </div>
    </td>
    <td style="text-align: left; font-weight: normal; width: 1%;">&#160;</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px;">10,172</td><td style="text-align: left; font-weight: normal; width: 1%;">&#160;</td><td style="text-align: left; font-weight: normal;">&#160;</td>
    <td style="text-align: left; font-weight: normal; width: 1%;">&#160;</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px;">4,495</td><td style="text-align: left; font-weight: normal; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div style="font-weight: bold;">
      <span style="font-weight: normal;">Changes in accounts receivable</span>
     </div>
    </td>
    <td style="text-align: left; font-weight: normal; width: 1%;">&#160;</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px;">(49,413</td><td style="text-align: left; font-weight: normal; width: 1%;">)&#160;</td><td style="text-align: left; font-weight: normal;">&#160;</td>
    <td style="text-align: left; font-weight: normal; width: 1%;">&#160;</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px;">(22,200</td><td style="text-align: left; font-weight: normal; width: 1%;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div style="font-weight: bold;">
      <span style="font-weight: normal;">Changes in inventories</span>
     </div>
    </td>
    <td style="text-align: left; font-weight: normal; width: 1%;">&#160;</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px;">(1,953</td><td style="text-align: left; font-weight: normal; width: 1%;">)&#160;</td><td style="text-align: left; font-weight: normal;">&#160;</td>
    <td style="text-align: left; font-weight: normal; width: 1%;">&#160;</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px;">(4,826</td><td style="text-align: left; font-weight: normal; width: 1%;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div style="font-weight: bold;">
      <span style="font-weight: normal;">Change in prepaid expenses and other current assets</span>
     </div>
    </td>
    <td style="text-align: left; font-weight: normal; width: 1%;">&#160;</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px;">(2,476</td><td style="text-align: left; font-weight: normal; width: 1%;">)&#160;</td><td style="text-align: left; font-weight: normal;">&#160;</td>
    <td style="text-align: left; font-weight: normal; width: 1%;">&#160;</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px;">1,593</td><td style="text-align: left; font-weight: normal; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div style="font-weight: bold;">
      <span style="font-weight: normal;">Changes in accounts payable and accrued expenses</span>
     </div>
    </td>
    <td style="text-align: left; font-weight: normal; width: 1%;">&#160;</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px;">(2,259</td><td style="text-align: left; font-weight: normal; width: 1%;">)&#160;</td><td style="text-align: left; font-weight: normal;">&#160;</td>
    <td style="text-align: left; font-weight: normal; width: 1%;">&#160;</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px;">1,219</td><td style="text-align: left; font-weight: normal; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div style="font-weight: bold;">
      <span style="font-weight: normal;">Other</span>
     </div>
    </td>
    <td style="text-align: left; font-weight: normal; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(650</td><td style="text-align: left; font-weight: normal; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left; font-weight: normal;">&#160;</td>
    <td style="text-align: left; font-weight: normal; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(305</td><td style="text-align: left; font-weight: normal; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div style="font-weight: bold;">
      <span style="font-weight: normal;">Cash used in operations</span>
     </div>
    </td>
    <td style="text-align: left; font-weight: normal; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">(19,675</td><td style="text-align: left; font-weight: normal; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left; font-weight: normal;">&#160;</td>
    <td style="text-align: left; font-weight: normal; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; font-weight: normal; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">(2,218</td><td style="text-align: left; font-weight: normal; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
  </table><div>&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">Net Cash Used in Investing Activities</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Net cash used in investing activities for the three months ended March 31, 2025 and 2024 was $4.7 million and $2.4 million, respectively. The increase is primarily related to the roof replacement at the Boca Facility in the amount of $1.3 million and due to capital expenditures associated with the Yield Enhancement project. While we currently have no firm commitments for capital expenditures, we expect our total capital expenditures will be between $7.3 million and $13.3 million for the remainder of fiscal 2025, mainly for additional upgrades to the Boca Facility manufacturing operations and related operational systems.</span>
  </div><div>
  </div><div style="font-weight: bold;">&#160;
  </div><div>
  </div><div style="font-weight: bold;">
   <span style="font-style: italic;">Net Cash Used in Financing Activities</span>
  </div><div>
  </div><div style="font-weight: bold;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Net cash used in financing activities was $7.1 million and $1.4 million for the three months ended March 31, 2025 and 2024, respectively. The increase is due to additional taxes paid in connection with shares that were withheld from RSUs that vested during the period, partially offset by $1.0 million in proceeds from the exercise of stock options in 2024.  </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="color: rgb(0, 0, 0); font-weight: bold;">Effect of Inflation</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Inflation impacted a number of facets of our business during the three months ended March 31, 2025 and 2024 at each of our business segments. Disruptions in the global economy have impeded global supply chains, resulted in longer lead times and delays in procuring certain raw materials, and resulted in inflationary cost increases in certain raw materials, labor and transportation. We also experienced price increases for, among other items, consumable supplies, services for repairs and maintenance of our facilities, utilities, shipping and freight charges, fuel surcharges and labor costs, among other expenses. Based upon the macroeconomic environment, publicly available information and reports from the U.S. government, we expect this trend to continue in 2025. Although we cannot predict the extent to which future domestic and global economic conditions, including, but not limited to, supply chain constraints, tariffs or trade wars, changes in federal regulatory policies or priorities, general economic and geopolitical conditions, or the continuing conflicts in Europe, the Middle East and surrounding areas will impact us, such factors could have a significant impact on our future results of operations. In addition, some of our third-party inventory purchase agreements provide for scheduled price increases that are tied to various consumer price indices, which have resulted in higher than historical percentage price increases and could result in higher source plasma and other raw material and supplies costs in 2025 and beyond. Also, in a higher inflationary environment, we may not be able to raise the prices of our products to maintain the rate of inflation and this may affect our product margins.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold;">Off-Balance Sheet Arrangements </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt;">
   <span style="color: rgb(0, 0, 0);">None. </span>
  </div><div>
  </div><div style="margin-left: 72pt; font-weight: bold;">&#160;
  </div><div>
  </div><div style="text-indent: -72pt; padding-left: 72pt; font-weight: bold;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <span>Item 3.</span>
    </div>
    <div>
     <a id="Quantitative_and_Qualitative_Disclosures_About_Market_Risk" title="Quantitative and Qualitative Disclosures About Market Risk."></a><span>Quantitative and Qualitative Disclosures About Market Risk.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We are exposed to market risk as the result of changes in interest rates. Our senior credit facility with Ares requires quarterly payments of interest based on the adjusted Term SOFR plus the Applicable Margin. We currently do not utilize any derivative financial instruments, such as interest rate swaps or caps, to mitigate this risk. As of March 31, 2025, we had $75.0 million outstanding under our senior credit facility that is subject to a variable interest rate. As a result, the effect of a hypothetical, instantaneous and unfavorable change of 100 basis points in the interest rate would have an approximate $0.8 million annualized negative impact on our earnings and cash flows. As further discussed in Note 14 &#8211; Subsequent Events, on May 6, 2025, the Company repaid $30.0 million against the term loan using a draw of $30.0 million against the revolving credit facility made on May 5, 2025; accordingly, the outstanding balance of the term loan as of May 6, 2025 was $2.5 million and the outstanding balance of the revolving credit facility as of May 6, 2025 was $72.5 million.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">29</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-indent: -72pt; padding-left: 72pt; font-weight: bold;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <span>Item 4.</span>
    </div>
    <div>
     <a id="Controls_and_Procedures" title="Controls and Procedures."></a><span>Controls and Procedures.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; clear: both;">&#160;
  </div><div>
  </div><div style="font-weight: bold;">
   <span>Evaluation of Disclosure Controls and Procedures</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We designed our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), to provide reasonable assurance that information required to be disclosed by us in reports we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Under the supervision of and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures as of March 31, 2025. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of March 31, 2025 were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding disclosures.&#160;&#160;&#160;&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">A control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.</span><span>&#160;We do not expect that our disclosure controls and procedures or our internal control over financial reporting are able to prevent with certainty all errors and all fraud.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="font-weight: bold;">
   <span>Changes in Internal Control Over Financial Reporting</span>
  </div><div>
  </div><div style="font-weight: bold;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">30</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center; font-weight: bold;">
   <a id="PART_II" title="PART II"></a><span>PART II</span>
  </div><div>
  </div><div style="text-align: center; font-weight: bold;">
   <span>OTHER INFORMATION</span>
  </div><div>
  </div><div style="text-indent: -72pt; padding-left: 72pt; font-weight: bold;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <span>Item 1.</span>
    </div>
    <div>
     <a id="Legal_Proceedings" title="Legal Proceedings."></a><span>Legal Proceedings.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We may become subject to certain legal proceedings and claims arising in connection with the normal course of our business. In the opinion of management, there are currently no material pending legal proceedings that would have a material adverse effect on our consolidated financial position, results of operations or cash flows.</span>
  </div><div>
  </div><div style="margin-left: 72pt; font-weight: bold;">&#160;
  </div><div>
  </div><div style="text-indent: -72pt; padding-left: 72pt;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">Item 1A.</span>
    </div>
    <div>
     <a id="Risk_Factors" title="Risk Factors"></a><span style="font-weight: bold;">Risk Factors</span>
    </div>
  </div><div>
  </div><div style="clear: both;">
   <span style="font-weight: bold;">&#160;</span>
  </div><div>
  </div><div>
   <span style="font-weight: bold;">Summary of Risk Factors</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="font-style: italic;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q, the 2024 10-K and our other filings with the SEC, before making an investment decision regarding our common stock.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Although we achieved net income on a GAAP basis for the year ended December 31, 2024 for the first time, we may not be able to maintain profitability and continue to generate positive cashflows in the future. </span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>We contract with third parties for the filling, packaging, testing and labeling of the drug substance we manufacture, and we also obtain source plasma from certain third parties. This reliance on third parties carries the risk that the services and raw materials upon which we rely may not be performed in a timely manner, in sufficient quantities or according to our specifications, which could delay the availability of our finished drug product and could adversely affect our commercialization efforts and our revenues.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>The estimates of market opportunity and forecasts of market and revenue growth included in our filings may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business could fail to grow at similar rates, if at all.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Both of our business segments and our facilities, as well as our suppliers and contractors, are subject to periodic inspections by the FDA and other regulatory authorities, which, depending on the outcome of such inspections, could result in certain regulatory actions, including the issuance of observations, notices, citations, warning letters or other enforcement actions.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Business interruptions could adversely affect our business. </span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, our ability to market or seek approval for ASCENIV for alternative indications could be limited unless additional clinical trials are conducted successfully and the FDA approves a Biologics License Application (&#8220;BLA&#8221;) or other required submission for review.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>With the approval of ASCENIV, there can be no assurance that we will be successful in further developing and expanding commercial operations, collecting and procuring an adequate supply of high-titer antibody RSV plasma or balancing our research and development activities with our commercialization activities.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>We depend on third-party researchers, developers and vendors to develop, manufacture, supply materials for or test our products and product candidates, as well as for other pre-and post-approval services, and such parties&#8217; performance is, to some extent, outside of our control.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>We may be unable to successfully expand our manufacturing processes to fulfill demand for our products or increase our production capabilities through the addition of new equipment, including if we do not obtain requisite approval from the FDA.</span></div>
  <div>&#160;</div></div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions or withdrawal from the market and we could be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products following approval.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">31</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify; margin-left: 36pt;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Historically, a few customers have accounted for a significant amount of our total revenue and accounts receivable and the loss of any of these customers could have a material adverse effect on our business, results of operations and financial condition.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Issues with product quality and compliance could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>If physicians, payers and patients do not accept and use our current products or our future product candidates, our ability to generate revenue from these products will be materially impaired.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Our accruals for U.S. Medicaid rebates and other liabilities related to the sale of our immunoglobulin products are estimates based on historical experience and other assumptions. These estimates are subject to change based on actual results and other factors. Any such change could have a material effect on our business, financial position and operating results.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Our long-term success may depend on our ability to supplement our existing product portfolio through new product development or the in-license or acquisition of other new products, product candidates and label expansion of existing products, and if our business development efforts are not successful, our ability to maintain profitability may be adversely impacted. </span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Our ADMA BioCenters operations collect information from donors in the United States that subjects us to consumer and health privacy laws, which could create enforcement and litigation exposure if we fail to meet their requirements.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Our senior secured credit facility with Ares Capital Corporation and certain of its affiliates (&#8220;Ares&#8221;) is subject to acceleration in specified circumstances, which may result in Ares taking possession and disposing of any collateral.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>If we are unable to protect our patents, trade secrets or other proprietary rights, if our patents are challenged or if our provisional patent applications do not get approved, our competitiveness and business prospects may be materially damaged.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Cyberattacks and other security breaches could compromise our proprietary and confidential information or otherwise penetrate our network, which could harm our business and reputation.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Our ability to continue to produce safe and effective products depends on the safety of our plasma supply, testing by third parties and the timing of receiving the testing results, and the manufacturing processes we have in place to counter transmittable diseases.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>We could become supply-constrained and our financial performance would suffer if we cannot obtain adequate quantities of FDA-approved source and high-titer plasma with proper specifications or other necessary raw materials.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Our ability to use our net operating loss carryforwards (&#8220;NOLs&#8221;) may be limited.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>Fluctuations in our tax obligations and effective tax rate and realization of our net deferred tax assets may result in volatility of our operating results and materially impact our financial condition or financial results.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>The market price of our common stock may be volatile and may fluctuate in a way that is disproportionate to our operating performance.</span>
    </div>
  </div><div>
  </div><div style="clear: both;">&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold;">Risk Factors</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-style: italic;">Described below are various risks and uncertainties that may affect our business. These risks and uncertainties are not the only ones we face. You should recognize that other significant risks and uncertainties may arise in the future, which we cannot foresee at this time. Also, the risks that we now foresee might affect us to a greater or different degree than expected. Certain risks and uncertainties, including ones that we currently deem immaterial or that are similar to those faced by other companies in our industry or business in general, may also affect our business. If any of the risks described below actually occur, our business, financial condition or results of operations could be materially and adversely affected. You should carefully consider the following risk factors and the section entitled &#8220;Special Note Regarding Forward-Looking Statements&#8221; before you decide to invest in our securities.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">32</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div>
   <span style="font-weight: bold;">Risks Relating to our Business</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">Although we achieved net income on a GAAP basis for the year ended December 31, 2024, for the first time, we may not be able to maintain profitability and continue to generate positive cash flows in the future.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Although we achieved net income of $197.7 million for the year ended December 31, 2024, for the years ended December 31, 2023 and 2022, we incurred net losses of $28.2 million and $65.9 million, respectively. From our inception in 2004 through December 31, 2024, we have incurred an accumulated deficit of $308.6 million. We may not be able to maintain profitability in 2025 or beyond, and if we are unable to continue to consistently achieve positive cash flows we may need to finance our operations through additional equity or debt financings or corporate collaboration and licensing agreements. If, in the future, our operating or financial results for a particular period do not meet our guidance, analyst estimates or the expectations of investors, or if we reduce our guidance for future periods, our stock price may decline. Any sustained or increased profitability or financial performance may contribute to increased scrutiny from the investment community and applicable federal, state and foreign regulatory authorities and government bodies. We also expect to continue to incur significant operating and capital expenditures and anticipate that as our business continues to grow our operating expenses will increase accordingly as we:</span>
  </div><div>
  </div><div>
   <span>&#160;&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>expand commercialization and marketing efforts;</span>
    </div>
  </div><div>
  </div><div style="margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>expand our research and development programs;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>implement additional internal systems, controls and infrastructure;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>hire additional personnel; and</span>
    </div>
  </div><div>
  </div><div style="margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>expand production capacity at the Boca Facility.</span>
    </div>
  </div><div>
  </div><div style="clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt;">
   <span>As a result, we will need to continue to generate significant revenues in order to maintain profitability. We may not be able to generate these revenues or maintain profitability in the future. </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Our business may be adversely affected by a pandemic, epidemic, or outbreak of an unknown or emerging infections disease. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Our business could be adversely affected by health epidemics in regions where we have concentrations of business activities and such epidemics could cause significant disruption in the operations of third-party service providers upon whom we rely. A resurgence of a global pandemic or health epidemic could adversely affect our business, financial condition, liquidity or results of operations. These adverse effects include, but are not limited to, the potential adverse effects on the global economy, our manufacturing processes, including our supply chain, our submissions or applications to the FDA and our employees. The ultimate impact will depend on the severity and duration of the pandemic and actions taken by governmental authorities and other third parties in response, each of which is unforeseeable and difficult to predict.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">We contract with third parties for a portion of the filling, packaging, testing and labeling of the drug substance we manufacture, and also obtain plasma from certain third parties. This reliance on third parties carries the risk that the services and raw materials upon which we rely may not be performed in a timely manner, in sufficient quantities or according to our specifications, which could delay the availability of our finished drug product and could adversely affect our commercialization efforts and our revenues.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Third parties may not perform as agreed or in accordance with FDA requirements. Any significant problem that our third-party providers experience could delay or interrupt our supply of finished drug product until the service provider cures the problem or until we locate, negotiate for, validate and receive FDA approval for an alternative provider (when necessary), if one is available. Failure to obtain the needed services, raw materials and products meeting the necessary quality standards or at all could have a material and adverse effect on our products, business, financial condition and results from operations.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">33</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Although we are utilizing our FDA-approved fill/finish suite that we built at the Boca Facility for a portion of our finished drug product and although we receive our raw material plasma from our ADMA BioCenters plasma collection facilities, we also intend to continue to utilize third parties to supplement our fill/finish process for final drug product and to supply raw material source and high-titer RSV plasma. Any failure by us, our contract fill/finishers, or other third parties involved in the process for producing our products or product candidates to comply with the applicable manufacturing and regulatory requirements, including quality requirements, could place us and them </span><span>at risk of regulatory enforcement actions, recalls and other adverse consequences, could adversely impact our products, and could adversely impact patients receiving our products, which may negatively impact our business and our ability to produce and supply products to meet commercial and clinical needs.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Our anticipated reliance on a limited number of third-party contractors exposes us to the following risks:</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -36pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 36.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>we may be unable to identify contractors on acceptable terms or at all because the number of potential service providers is limited and the FDA must inspect and qualify any contract manufacturers for current cGMP compliance as part of our marketing application;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -36pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 36.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>a new fill/finisher would have to be educated in, or develop substantially equivalent processes for, the production of our products and product candidates;</span>
    </div>
  </div><div>
  </div><div style="margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -36pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 36.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>a pandemic, or the resurgence of a pandemic such as the COVID-19 pandemic, or a cyberattack or data breach, could adversely affect our contractors&#8217; operations, supply chain or workforce;</span>
    </div>
  </div><div>
  </div><div style="margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -36pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 36.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>our contracted fill/finishers&#8217; resources and level of expertise with plasma-derived biologics may be limited, therefore they may require a significant amount of support from us in order to implement and maintain the infrastructure and processes required to deliver our finished drug product;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -36pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 36.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>our third-party contractors might be unable to timely provide finished drug product or raw material plasma in sufficient quantity or in accordance with our specifications to meet our commercial needs;</span>
    </div>
  </div><div>
  </div><div style="margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -36pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 36.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>contractors may not be able to execute our inspection procedures and required tests appropriately;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -36pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 36.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>contractors are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations, and we do not have control over third-party providers&#8217; compliance with these regulations;</span>
    </div>
  </div><div>
  </div><div style="margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -36pt; padding-left: 36pt;">
    <div style="float: left; width: 36.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>contractors may fail to comply with applicable regulatory requirements, placing them and us at risk of regulatory enforcement actions, recalls and other adverse consequences, and which place our patients at risk, which may negatively impact our business and their ability to supply products to meet our development, clinical and commercial needs;</span></div>
  <div>&#160;</div></div><div>
  </div><div style="text-indent: -36pt; text-align: justify; padding-left: 36pt; clear: both;">
    <div style="float: left; width: 36.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>our third parties could breach or terminate their agreements with us; </span>
    </div>
  </div><div>
  </div><div style="margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -36pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 36.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>we could have increased costs from tariffs, trade wars; and</span>
    </div>
  </div><div>
  </div><div style="margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -36pt; padding-left: 36pt;">
    <div style="float: left; width: 36.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>our contract fill/finishers may have unacceptable or inconsistent drug product quality success rates and yields, and we have no direct control over our contract fill/finishers&#8217; ability to maintain adequate quality control, quality assurance and qualified personnel.</span>
    </div>
  </div><div>
  </div><div style="clear: both;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Each of these risks could delay or prevent production, the completion of our finished drug product and the release of finished drug product by us or the FDA, which could result in higher costs or adversely impact our revenues. These risks could also result in the delay in obtaining clinical supplies, which would delay our development programs. In addition, our contract fill/finishers and our other third-party vendors may source their materials and supplies globally and are therefore subject to supply disruptions in the event of </span><span>fire, weather related events such as hurricanes, wind and rain, international conflicts, strikes, embargoes, trade and sanction requirements and limits, other acts of God or force majeure events or global health occurrences and emergencies. </span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">34</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">The estimates of market opportunity and forecasts of market and revenue growth included in our filings may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business could fail to grow at similar rates, if at all.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. In particular, the size and growth of the overall U.S. IVIG and source plasma markets and the potential market opportunity for an </span><span style="color: rgb(0, 0, 0); font-style: italic;">S. pneumoniae</span><span style="color: rgb(0, 0, 0);"> hyperimmune globulin are subject to significant variables that can be difficult to measure, estimate or quantify. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Our business depends on, among other things, successful manufacturing and commercialization of our existing products, market acceptance of such products and ensuring that our products are safe and effective. Further, there can be no assurance that we will be able to generate the revenue that we believe our products and plasma collection facilities are capable of generating, including but not limited to our current expectations with respect to our yield enhancement production process, which received FDA approval in April 2025. As a result, we may not be able to accurately forecast or predict revenue. For these reasons, the estimates and forecasts in our filings relating to revenue generation and growth may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and forecasted growth, our business could fail to grow at similar rates, if at all.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">Geopolitical and economic conditions, war, terrorism or other military actions may have a material adverse effect on our business.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Geopolitical conflicts, war or other military action or international acts of terrorism may cause significant disruption to commerce throughout the world. To the extent that such disruptions result in disruptions to our supply chain, delays or cancellations of customer orders, a general decrease in consumer spending, our inability to effectively market and distribute our products and/or our inability to access the capital markets, our business and results of operations could be materially and adversely affected. For example, in response to the ongoing conflict between Russia and Ukraine, the United States has imposed and may further impose, and other countries may additionally impose, broad sanctions or other restrictive actions against governmental and other entities in Russia. Additionally, further escalation of geopolitical tensions, such as ongoing conflicts in the Middle East and the surrounding areas could have a broader impact that extends into other markets where we do business. Additionally, rapid changes in U.S. trade policy, such as the imposition of additional tariffs and trade barriers, as well as potential retaliatory measures taken by other governments, could materially increase the price of and/or affect the availability of imported raw materials used in the production of our products. We are unable to predict whether geopolitical or economic conditions, acts of international terrorism or the involvement in a war or other military actions will result in any long-term commercial disruptions or if such involvement or responses will have any long-term material adverse effect on our business, results of operations, or financial condition.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">Both of our business segments and our facilities, as well as our suppliers and contractors, are subject to periodic inspections by the FDA and other regulatory authorities, which, depending on the outcome of such inspections, could result in certain regulatory actions, including the issuance of observations, notices, citations, warning letters or other enforcement actions.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">We and our suppliers and contractors may be unable to comply with our specifications, cGMP requirements and with other FDA, state, and foreign regulatory requirements for commercial and clinical supply. </span><span>The FDA and other regulatory authorities are authorized to perform inspections and remote regulatory assessments of our and our suppliers&#8217; facilities, including the Boca Facility. The FDA and other regulatory authorities also may inspect and approve our and our third-parties&#8217; facilities before they may be used for commercial production. If we or our suppliers are not able to comply with the applicable regulatory requirements, we or they may be subject to regulatory enforcement actions, which can materially impact our business. For instance, at the end of such an inspection, the FDA could issue a Form 483 Notice of Inspectional Observations, which could cause the FDA to not approve the use of the facility and cause us to modify certain activities identified during the inspection. Following such inspections, the FDA may issue an untitled letter as an initial correspondence that cites violations that do not meet the threshold of regulatory significance of a warning letter. FDA guidelines also provide for the issuance of warning letters for violations of &#8220;regulatory significance&#8221; for which the failure to adequately and promptly achieve correction may be expected to result in an enforcement action. FDA also may issue warning letters and untitled letters in connection with events or circumstances unrelated to an FDA inspection. Depending on the seriousness of any findings, we or our suppliers may be subject to additional significant enforcement actions which could have a material impact on our business.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">35</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>In the event of any enforcement actions, we and our third-party contractors would need to implement remedial actions which may be time-intensive or costly. We may not be able to timely resolve concerns raised by the applicable regulator as a result of an inspection or without expending significant resources. We are unable to control the timing of inspections, communications and actions, and will be required to respond to the regulator and make certain submissions within certain timeframes. We also do not know whether or not the regulator will change its requirements, guidance or expectations. If the regulator determines that we have not remediated the issues identified in a warning letter or any other inspection issues and deficiencies, any failure of ours to address or provide requested documentation of corrections for these issues could disrupt our business operations and the timing of our commercialization efforts and could have a material adverse effect on our financial condition and operating results.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our commercial manufacturing and any research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption to our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized internally and by our third-party manufacturers and service providers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our commercial manufacturing, research and development, or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties, or other sanctions.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">Business interruptions could adversely affect our business</span><span style="font-weight: bold;">.</span><span>&#160;</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our operations, including our headquarters located in Ramsey, NJ, the Boca Facility and our plasma collection facilities, are vulnerable to interruption by fire, weather related events such as hurricanes, wind and rain, other acts of God or force majeure events, electric power loss, telecommunications failure, equipment failure and breakdown, cyberattacks on our operations and information technology systems as well as the systems of our customers, suppliers and related entities, human error, employee issues, global health occurrences such as a pandemic, global and economic uncertainty, war, terrorism, geopolitical conditions and emergencies, product liability claims and events beyond our control. While we maintain several insurance policies with reputable carriers that provide partial coverage for a variety of these risks, including replacing or rebuilding a part of our facilities, these policies are subject to the insurance carriers&#8217; final determination of compensation to us and we may not have adequate coverage if we need to rebuild or replace our inventory, infrastructure, business income or our entire facility.&#160;&#160;In addition, our disaster recovery plans for our facilities may not be adequate and we do not have an alternative manufacturing facility or contractual arrangements with other manufacturers in the event of a casualty to or destruction of any of our facilities. If we are required to rebuild or relocate any of our facilities, a substantial investment in improvements and equipment would be necessary. We carry only a limited amount of business interruption insurance, which may not sufficiently compensate us for losses that may occur. As a result, any significant business interruption could adversely affect our business and results of operations. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">36</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">If we are unsuccessful in obtaining regulatory approval for any of our product candidates or if any of our product candidates do not provide positive results, we may be required to delay or abandon development of such product, which would have a material adverse impact on our business.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Product candidates require extensive clinical data analysis and regulatory review and may require additional testing. Clinical trials and data analysis can be very expensive, time-consuming and difficult to design and implement. The conduct of preclinical studies and clinical trials is subject to numerous risks and results of the studies and trials are highly uncertain.</span><span style="font-weight: bold; font-style: italic;">&#160;</span><span>Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time-consuming. Furthermore, delays or setbacks can occur at any stage of the process, and we could encounter problems that cause us to abandon our product development programs and related IND applications or BLAs, or to repeat clinical trials. The commencement and completion of clinical trials or ultimate product approval for any current or future development product candidate may be delayed by several factors, including:</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>unforeseen safety issues;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>determination of dosing issues;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>lack of safety or effectiveness, or other adverse study results during clinical trials;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>slower than expected rates of patient recruitment or noncompliance with clinical trial requirements;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>inability to monitor patients adequately during or after treatment; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>inability or unwillingness of medical investigators to follow our clinical protocols.</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We cannot be certain as to what type and how many clinical trials the FDA, or equivalent foreign regulatory agencies, will require us to conduct before we may successfully gain approval to market any of our product candidates that still require FDA approval. Prior to approving a new drug or biologic, the FDA generally requires that the effectiveness of the product candidate (which is not typically fully investigated until Phase III) be demonstrated in two adequate and well-controlled clinical trials. However, if the FDA or an equivalent foreign regulatory authority determines that our Phase III clinical trial results do not demonstrate a statistically significant, clinically meaningful benefit with an acceptable safety profile, or if a relevant regulator requires us to conduct additional Phase III clinical trials in order to gain approval, we will incur significant additional development costs and commercialization of these products would be prevented or delayed and our business could be adversely affected.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>In addition, the FDA or an IRB may not permit us to commence a clinical trial, may require amendments to our clinical trial protocols, or may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or if the FDA or IRB finds deficiencies in our IND submissions or the conduct of these trials. Regulatory authorities may also not accept data from clinical trials if the trials are not conducted in accordance with the applicable regulatory requirements. Failure to comply with the applicable regulatory requirements may also result in enforcement actions. Therefore, we cannot provide any assurance or predict with certainty the schedule for future clinical trials. In the event we do not ultimately receive regulatory approval for our product candidates, we may be required to terminate development of such product candidates. If we fail to obtain regulatory approval to market and sell our product candidates, or if approval is delayed, we will be unable to generate revenue from the sale of these products, our potential for generating positive cash flow will be diminished and the capital necessary to fund our operations will increase. </span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">37</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">If the results of our clinical trials do not support our product candidate claims, completing the development of such product candidate may be significantly delayed or we may be forced to abandon development of such product candidate altogether.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We cannot be certain that the clinical trial results of our product candidates will support our product candidates&#8217; claims. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>The clinical trial process may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. This failure would cause us to abandon a product candidate and may delay the development of other product candidates. Any delay in, or termination of, our clinical trials will delay our ability to commercialize our product candidates and generate product revenues. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Other issues that may impact our clinical trials and that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, include:</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>Delays in reaching, or failure to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and our contract research organizations (&#8220;CROs&#8221;);</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>Regulators requiring us to perform additional or unanticipated clinical trials to obtain approval or becoming subject to additional post-marketing testing, surveillance, or Risk Evaluation and Mitigation Strategies requirements to maintain regulatory approval;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>Failure by our third-party contractors to comply with regulatory requirements or the clinical trial protocol, or meet their contractual obligations to us in a timely manner, or at all, or our being required to engage in additional clinical trial site monitoring;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>The cost of clinical trials of our product candidates being greater than we anticipate;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>Insufficient supply or inadequate quality of our product candidates or other materials necessary to conduct clinical trials;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>Inability to achieve sufficient study enrollment, subjects dropping out or withdrawing from our studies, delays in adding new investigators or clinical trial sites or a withdrawal of clinical trial sites;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>Flaws in our clinical trial design that are not discoverable until the clinical trial has progressed;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>Disagreement by the FDA or comparable foreign regulatory authorities with our intended indications or study design, including endpoints, or our interpretation of data from preclinical studies and clinical trials, finding that a product candidate&#8217;s benefits do not outweigh its safety risks or requiring that we conduct additional development or study work;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>The need to make changes to our product candidates that require additional testing or that cause our product candidates to perform differently than expected;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>Global trade policies that may impact our ability to obtain raw materials and/or finished product for commercialization;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>FDA or comparable regulatory authorities taking longer than we anticipate to make decisions on our products or product candidates; and</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>Potential inability to demonstrate that a product or product candidate provides an advantage over current standards of care or current or future competitive therapies in development.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>In addition, our clinical trials involve a relatively small patient population. Because of the small sample size, the results of these clinical trials may not be indicative of future results. In addition, certain portions of our clinical trials and product testing for our product candidates may be performed outside of the United States, and therefore, may not be performed in accordance with standards normally required by the FDA and other regulatory agencies.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">38</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">If we do not obtain and maintain the necessary U.S. or international regulatory approvals to commercialize a product candidate, we will not be able to sell that product candidate, which would make it difficult for us to recover the costs of researching and developing such product candidate.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>If we are not able to generate revenue from our products and product candidates, our sources of revenue may continue to be from a product mix consisting only of plasma collection and sales revenues, revenues generated from sales of our FDA-approved commercial products and revenues generated from new contract manufacturing arrangements with third parties. We cannot assure you that we will receive the approvals necessary to commercialize any product candidate we may acquire or develop in the future or that we will be able to maintain our current approvals. In order to obtain FDA approval of any product candidate requiring FDA approval, our clinical development must demonstrate that the product candidate is safe for humans and effective for its intended use, and we must successfully complete an FDA BLA review. Obtaining FDA approval of a product candidate generally requires significant research and testing, referred to as preclinical studies, as well as human tests, referred to as clinical trials. Satisfaction of the FDA&#8217;s regulatory requirements typically takes many years, depends upon the type, complexity and novelty of the product candidate and requires substantial resources for research, development and testing. We cannot predict whether our research and clinical approaches will result in products that the FDA considers safe for humans and effective for indicated uses. The FDA has substantial discretion in the product approval process and may require us to conduct additional preclinical and clinical testing or to perform post-marketing studies or may require additional CMC or other data and information, and the development and provision of this data and information may be time-consuming and expensive. The approval process may also be delayed by changes in government regulation, future legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may:</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>delay commercialization of, and our ability to derive revenues from, our product candidates;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>impose costly procedures on us; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#8226;</span>
    </div>
    <div>
     <span>diminish any competitive advantages that we may otherwise enjoy.</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Even if we comply with all FDA requests, the FDA may ultimately reject our product candidate&#8217;s BLA. In addition, the FDA could determine that we must test additional subjects and/or require that we conduct further studies with more subjects. We may never obtain regulatory approval for any future potential product candidate or label expansion activity. Failure to obtain FDA approval for any of our product candidates will severely undermine our business by leaving us without the ability to generate additional accretive revenues. There is no guarantee that we will ever be able to develop or acquire other product candidates. In foreign jurisdictions, we must receive approval from the appropriate regulatory authorities before we can commercialize any products or product candidates outside the U.S. Foreign regulatory approval processes generally include all of the risks and uncertainties associated with the FDA review, inspection and approval procedures described above. We cannot assure you that we will receive the approvals necessary to commercialize any product candidate for sale outside the United States.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, our ability to market or seek approval for ASCENIV for alternative indications could be limited, unless additional clinical trials are conducted successfully and the FDA approves a BLA or other required submission for review.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>The FDA and other governmental authorities strictly regulate and monitor marketing, labeling and the advertising and promotion of prescription drugs. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the Internet and off-label promotion. The FDA does not allow drugs to be promoted for &#8220;off-label&#8221; uses&#8201;-&#8201;that is, uses that are not described in the product&#8217;s labeling and that differ from those that were approved by the FDA. The FDA limits approved uses to those studied by a company in its clinical trials. In addition to the FDA approval required for new formulations, any new indication for an approved product also requires FDA approval. Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, we cannot be sure whether we will be able to obtain FDA approval for any desired future indications for ASCENIV.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">39</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>While physicians in the United States may choose, and are generally permitted, to prescribe drugs for uses that are not described in the product&#8217;s labeling, and for uses that differ from those tested in clinical studies and approved by the regulatory authorities, our ability to promote our products is narrowly limited to those indications that are specifically approved by the FDA. &#8220;Off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the United States generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on the subject of off-label use. If the FDA determines that our promotional activities fail to comply with the FDA&#8217;s regulations or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition, our failure to follow FDA rules and guidelines related to promotion and advertising may cause the FDA to issue warning letters or untitled letters, bring an enforcement action against us, suspend or withdraw an approved product from the market, require a recall, require payment of civil fines or could result in disgorgement of money, operating restrictions, injunctions or criminal prosecution, among other consequences, any of which could harm our reputation and our business.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">With the approval of ASCENIV, there can be no assurance that we will be successful in further developing and expanding commercial operations, collecting and procuring an adequate supply of high-titer antibody RSV plasma or balancing our research and development activities with our commercialization activities.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Since receiving FDA approval for ASCENIV, we have been commercializing this product while also continuing our research and development activities. There can be no assurance that we will be able to successfully manage the balance of our research and development operations with our commercialization activities. Potential investors and stockholders should be aware of the problems, delays, expenses and difficulties frequently encountered by companies balancing development of product candidates, which can include problems such as unanticipated issues related to clinical trials and receipt of approvals from the FDA and foreign regulatory bodies, with commercialization efforts, which can include problems related to managing manufacturing and supply, including supply chain constraints, reimbursement, marketing challenges, development of a comprehensive compliance program, and other related and additional costs. For example, the raw material plasma we collect and procure to manufacture ASCENIV using our patented proprietary microneutralization assay is comprised of plasma collected from donors which contains high-titer antibodies to RSV. This high-titer plasma </span><span style="color: rgb(0, 0, 0);">which meets our internal specifications for the manufacture of ASCENIV that we are able to identify with our patented testing assay </span><span>amounts to less than 10% of the total donor collection samples we test. As a result, we may experience an insufficient supply of this plasma. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our product candidates will require significant additional research and clinical trials, and we will need to overcome significant regulatory burdens prior to commercialization in the United States and other countries. In addition, we may be required to spend significant funds on building out our commercial operations. There can be no assurance that after the expenditure of substantial funds and efforts, we will successfully develop and commercialize any of our product candidates, generate any significant revenues or ever achieve and maintain a substantial level of sales of our products.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">We depend on third-party researchers, developers and vendors to develop, manufacture, supply materials for or test our products and product candidates, as well as for other pre and post-approval services, and such parties&#8217; performance is, to some extent, outside of our control.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We depend on independent investigators and collaborators, such as universities and medical institutions, contract laboratories, CROs, contract manufacturers, contract fill/finishers, third-party plasma centers and consultants to conduct our preclinical activities, clinical trials, CMC testing and other activities under agreements with us. These collaborators are not our employees and we cannot control the amount or timing of resources that they devote to our programs. These third parties may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves. If outside collaborators fail to devote sufficient time and resources to our products and/or development programs, or if their performance is substandard or does not comply with the applicable regulatory standards, our trials may be repeated, extended, delayed, or terminated, the approval of our FDA application(s), if any, and our introduction of new products, if any, will be delayed, and we may not be able to maintain existing approvals or meet our regulatory requirements or we may not be able to produce forecasted amounts of product. We or they may also be subject to regulatory enforcement actions, may need to take corrective actions, including initiating recalls, and we may not be able to meet commercial demand. These collaborators may also have relationships with other commercial entities, some of whom may compete with us. If our collaborators assist our competitors at our expense, our competitive position would be harmed. We also depend on third-party suppliers for materials used in our operations. Certain of our third-party suppliers may be single-sourced, subject to tariff risk, or may not be able to supply sufficient materials for our operations, and it may be time-consuming, expensive or otherwise not feasible to locate an alternative supplier. In the event a single-source supplier is unable to provide us with a sufficient amount of materials, such shortage could have a material adverse effect on our business, results of operations and financial condition. Additionally, any change in the regulatory compliance status of any of our vendors may impede our ability to receive and maintain approval for our product candidates.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">40</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">We may be unable to successfully expand our manufacturing processes to fulfill demand for our products or</span><span>&#160;</span><span style="font-weight: bold; font-style: italic;">increase our production capabilities through the addition of new equipment, including if we do not obtain requisite approval from the FDA.</span>
  </div><div>

  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We currently anticipate expanding the manufacturing capacity and product output capability of our Boca Facility. Following the expansion of any of our manufacturing processes or the addition of new equipment, we will need to validate the expanded facility and equipment, make the necessary submissions to FDA, obtain any FDA-required approvals and have it inspected by the FDA. Given the significant delays that may result during the validation process, we may experience a supply shortage of our products or our production capabilities may be limited until completion of and validation of our facility expansion and new manufacturing equipment.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions or withdrawal from the market and we could be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products following approval.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions, new FDA guidance, or other regulatory actions, such as withdrawal from the market. Such products, as well as the manufacturing processes, post-marketing studies and measures, labeling and advertising and promotional activities for such products, among other things, are subject to ongoing regulatory compliance requirements, and oversight, review, and inspection by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, adherence with labeling and promotional requirements and restrictions, requirements related to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding safeguarding the drug supply chain as well as the distribution of samples to physicians and recordkeeping. For example, the FDA&#8217;s approval of our application supplement to allow for the commercial relaunch of BIVIGAM, as well as the FDA&#8217;s approval of our BLA for ASCENIV, required us to conduct specified post-marketing studies, including pediatric and safety studies. If, during the post-marketing period (after marketing approval) previously unknown adverse events emerge, there is the discovery that the product is less effective than previously thought, or other potential concerns regarding our products or their manufacturing processes emerge, or we are observed in any way to fail to comply with the numerous regulatory requirements to which we are subject, those circumstances may yield various results, including:</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;</div><div>
  </div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;<span style="mso-tab-count:1">&#160;&#160;&#160;&#160;&#160;</span>restrictions on such products or manufacturing
processes;</span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-align: justify; text-indent: -0.25in;"><span style="font-size: 10pt;"><span style="mso-spacerun:yes">&#160;</span></span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt; mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;</span><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;"><span style="mso-tab-count:1">&#160;&#160;&#160;&#160; </span>restrictions on the labeling or marketing
of a product;</span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-align: justify; text-indent: -0.25in;"><span style="font-size: 10pt;"><span style="mso-spacerun:yes">&#160;</span></span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt; mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;</span><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;"><span style="mso-tab-count:1">&#160;&#160;&#160;&#160; </span>restrictions on product distribution or
use;</span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-align: justify; text-indent: -0.25in;"><span style="font-size: 10pt;">&#160;</span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt; mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;</span><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;"><span style="mso-tab-count:1">&#160;&#160;&#160;&#160; </span>clinical holds or termination of clinical
trials;</span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;">&#160;</div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;<span style="mso-tab-count:1">&#160;&#160;&#160;&#160;&#160;</span>requirements to conduct further
post-marketing studies or clinical trials, implement risk mitigation
strategies, or to issue corrective information;</span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-align: justify; text-indent: -0.25in;"><span style="font-size: 10pt;"><span style="mso-spacerun:yes">&#160;</span></span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt; mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;</span><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;"><span style="mso-tab-count:1">&#160;&#160;&#160;&#160; </span>warning letters or untitled letters;</span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-align: justify; text-indent: -0.25in;"><span style="font-size: 10pt;"><span style="mso-spacerun:yes">&#160;</span></span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt; mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;</span><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;"><span style="mso-tab-count:1">&#160;&#160;&#160;&#160; </span>withdrawal of the products from the market;</span></div><div>














  </div><div style="text-indent: -18pt; padding-left: 54pt;">


  &#160;</div><div>


  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">41</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>


  </div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in; text-align: justify;"><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;<span style="mso-tab-count:1">&#160;&#160;&#160;&#160;&#160;</span>refusal to approve pending applications or
supplements to approved applications that we submit;</span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:&quot;Times New Roman&quot;"> </span>&#160;</div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;<span style="mso-tab-count:1">&#160;&#160;&#160;&#160;&#160;</span>recall of products;</span></div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; clear: both;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;<span style="mso-tab-count:1">&#160;&#160;&#160;&#160;&#160;</span>restrictions on coverage by third-party
payers;</span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-align: justify; text-indent: -0.25in;"><span style="font-size: 10pt;"><span style="mso-spacerun:yes">&#160;</span></span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt; mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;</span><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;"><span style="mso-tab-count:1">&#160;&#160;&#160;&#160; </span>fines, restitution or disgorgement of
profits or revenues;</span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-align: justify; text-indent: -0.25in;"><span style="font-size: 10pt;"><span style="mso-spacerun:yes">&#160;</span></span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt; mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;</span><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;"><span style="mso-tab-count:1">&#160;&#160;&#160;&#160; </span>suspension or withdrawal of marketing
approvals;</span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-align: justify; text-indent: -0.25in;"><span style="font-size: 10pt;"><span style="mso-spacerun:yes">&#160;</span></span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt; mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;</span><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;"><span style="mso-tab-count:1">&#160;&#160;&#160;&#160; </span>refusal to permit the import or export of
products;</span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-align: justify; text-indent: -0.25in;"><span style="font-size: 10pt;">&#160;</span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in; text-align: justify;"><span style="font-size:10.0pt; mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;</span><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;"><span style="mso-tab-count:1">&#160; &#160;</span>FDA debarment, suspension and debarment
from government programs, refusal of orders under existing government
contracts, exclusion from participation in federal healthcare programs, consent
decrees, deferred or non-prosecution agreements or corporate integrity
agreements;</span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-align: justify; text-indent: -0.25in;"><span style="font-size: 10pt;"><span style="mso-spacerun:yes">&#160;</span></span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt; mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;</span><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;"><span style="mso-tab-count:1">&#160;&#160;&#160;&#160; </span>product seizure or detention; or</span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-align: justify; text-indent: -0.25in;"><span style="font-size: 10pt;"><span style="mso-spacerun:yes">&#160;</span></span></div><div style="margin: 0in 0in 0in 0.75in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt; mso-fareast-font-family:&quot;Times New Roman&quot;">&#9679;</span><span style="font-size:10.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;"><span style="mso-tab-count:1">&#160;&#160;&#160;&#160; </span>injunctions or the imposition of civil
penalties or criminal fines.</span></div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; clear: both;">&#160;</div><div>












  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; clear: both;">&#160;</div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Historically, a few customers have accounted for a significant amount of our total revenue and accounts receivable and the loss of any of these customers could have a material adverse effect on our business, results of operations and financial condition.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>For the three months ended March 31, 2025 and 2024, two customers, BioCARE, Inc. (&#8220;BioCare&#8221;) and Priority Healthcare Distribution, Inc. d/b/a CuraScript SD Specialty Distribution (&#8220;Curascript&#8221;), represented an aggregate of approximately 64% and 70%, respectively, of our consolidated revenues. </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>As of March 31, 2025, and December 31, 2024, three customers, BioCare, Curascript and Healix Infusion Therapy, LLC (&#8220;Healix&#8221;), represented an aggregate of approximately 85% and 87%, respectively, of our consolidated accounts receivable. </span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>The loss of any key customers or a material change in the revenue generated by any of these customers,&#160;&#160;could have a material adverse effect on our business, results of operations and financial condition. Moreover, we anticipate deriving increased revenue from some of these customers over the next few years. Factors that could influence our relationships with our customers include, among other things:</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our ability to sell our products at competitive prices;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our ability to maintain features and quality standards for our products sufficient to meet the expectations of our customers;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>our ability to produce and deliver a sufficient quantity of our products in a timely manner to meet our customers&#8217; requirements; </span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>the impact of a pandemic, or the resurgence of a pandemic, and government responses thereto on our customers and their businesses, operations and financial condition;&#160;&#160;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>the impact of a cyberattack or data breach on our customers or related entities; and</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>widespread economic conditions or geopolitical conditions, including the exacerbated conflicts in Europe, the Middle East and the surrounding areas.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; clear: both;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   Additionally, an adverse change in the financial condition of any of our key customers could negatively affect revenue derived from such customer, which in turn could have a material adverse effect on our business and results of operations.
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">42</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
   <span style="font-weight: bold; font-style: italic;">Issues with product quality and compliance could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our success depends upon the quality of our products. Quality management plays an essential role in meeting customer requirements, preventing defects, improving our products and services and assuring the safety and efficacy of our products. Our future success depends on our ability to maintain and continuously improve our quality management program. A quality or safety issue may result in failure to obtain product approval, adverse inspection reports, warning letters, product recalls or seizures, withdrawals, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, patient injury, refusal of a government to grant approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses. The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products. We may elect, in the interest of public safety, to voluntarily withdraw our products from the market for labeled adverse events or for other reasons. &#160;Recalls or withdrawals of any of our products could divert managerial and financial resources which could have an adverse effect on our financial condition and results of operations.&#160;&#160;An inability to address a quality or safety issue by us or by a third-party vendor in an effective and timely manner may also cause negative publicity or a loss of customer confidence in us or our current or future products, which may result in the loss of prior or future sales and difficulty in successfully commercializing our current products and launching new products.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>In addition, as a manufacturer of biological products, we are subject to the risks inherent in biological production, which could include normal course losses and failures inherent in the manufacturing process. As our biologics production levels increase, there may be normal course inventory losses or write-downs as we ensure product quality and compliance with cGMP, FDA and state and local regulations, or due to testing results not meeting specifications. As a result, our operating results are subject to potentially significant variability from one reporting period to the next should such losses or write-downs occur in any given period. Additionally, because our products and product candidates are plasma-based products, not only are we subject to the FDA&#8217;s drug and biologic cGMP requirements, but we are also subject to special requirements for the collection, testing, handling, storage, and use of blood products.&#160;&#160;This adds an extra level of compliance and complexity to our operations, which we may not be able to successfully meet.&#160;&#160;Failure to meet any regulatory quality standards could have an adverse impact on our business. </span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">If physicians, payers and patients do not accept and use our current products or our future product candidates, our ability to generate revenue from these products will be materially impaired.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Even if the FDA approves a product made by us, physicians, payers and patients may not accept and use it. Acceptance and use of our products depends on a number of factors including, but not limited to:</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our products;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>cost-effectiveness of our products relative to competing products;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>availability of reimbursement for our products from government or other healthcare payers; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>the effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>The failure of our current or future products to find market acceptance would harm our business and could require us to seek additional financing or make such financing difficult to obtain on favorable terms, if at all.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">43</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Our accruals for U.S. Medicaid rebates and other liabilities related to the sale of our immunoglobulin products are estimates based on historical experience and other assumptions.&#160;&#160;These estimates are subject to change based on actual results and other factors. Any such change could have a material effect on our business, financial position, and operating results.</span>
  </div><div>
  </div><div style="margin-left: 36pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our gross product revenues are subject to a variety of deductions which are estimated and recorded in the same period that the revenues are recognized. These deductions primarily consist of rebates, distribution fees, chargebacks and sales allowances. These deductions represent estimates of the related obligations, some of which are contractual in nature and do not require extensive judgment to be exercised by management, while other estimates require complex or subjective matters of knowledge and judgment when estimating the impact of these revenue deductions on net revenues for a reporting period. Significant estimates include, among other things, accruals for U.S. Medicaid rebates related to the sale of our immunoglobulin products. We accrue these rebates at the time of sale based on our estimates of the sales mix of our products and the portion of the products we sell that will be prescribed to Medicaid beneficiaries. These estimates are based on historical experience and certain other assumptions, and while we believe that such estimates are reasonable, they are subject to change based on future experience, Medicaid utilization trends and other factors.&#160;&#160;If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate estimates of our future experience, our results could be materially affected. Estimates that are most at risk for material adjustment include those associated with U.S. Medicaid rebates because of the extensive time delay between the recording of the accrual and its ultimate settlement, an interval that can generally take up to several years or more. These estimates may change from time to time based on changes in utilization, payer and channel mixes or the ultimate settlement or resolution of payor claims. For example, during 2024 we engaged a third-party specialist to assist in the evaluation of our accrual for U.S. Medicaid rebates related to the sale of our immunoglobulin products. As a result of this evaluation, we recognized a reduction in this accrual and a corresponding increase to net revenues of $12.6 million for the year ended December 31, 2024. We considered several qualitative factors when evaluating our rebate accrual, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid programs and general uncertainty that pharmaceutical manufacturers have historically seen with government payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. There was additional new information that arose during June 2024 that suggested our liabilities for certain payor claims were successfully resolved, which resulted in the $12.6 million adjustment to the accrual for U.S. Medicaid rebates in June 2024. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>In addition, the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) included a significant expansion of state Medicaid programs. As more individuals become eligible for coverage under these programs, Medicaid utilization of our products could increase, resulting in a corresponding increase in our rebate payments. Such rebate payments may exceed what we have accrued for during the applicable period.&#160;&#160;Increases in Medicaid rebate payments could decrease our net revenues from product sales, which in turn could adversely affect our business, financial position, and operating results.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Our long-term success may depend on our ability to supplement our existing product portfolio through new product development or the in-license or acquisition of other new products, product candidates and label expansion of existing products, and if our business development efforts are not successful, our ability to maintain profitability may be adversely impacted. </span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our current product development portfolio consists primarily of label expansion activities for ASCENIV, as well as expanding our IP estate with patents issued for </span><span style="font-style: italic;">S. pneumoniae</span><span> hyperimmune IG. We have initiated small-scale preclinical activities to potentially expand our current portfolio through new product development efforts. If we are not successful in developing or acquiring additional products and product candidates, we will have to depend on our ability to continue to generate revenues from ASCENIV, BIVIGAM, Nabi-HB, intermediates, contract manufacturing and plasma attributable to the operations of ADMA BioCenters to support our operations.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Our ADMA BioCenters operations collect information from donors in the United States that subjects us to consumer and health privacy laws, which could create enforcement and litigation exposure if we fail to meet their requirements.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Consumer privacy is highly protected by federal and state law. The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations, impose requirements with respect to safeguarding the privacy, security and transmission of protected health information (&#8220;PHI&#8221;) held by covered entities and business associates. HIPAA &#8220;covered entities&#8221; include health plans/insurers, healthcare providers engaging in HIPAA standard electronic transactions and healthcare clearinghouses. A &#8220;business associate&#8221; provides services to covered entities (directly or as subcontractors to other business associates) involving arranging, creating, receiving, maintaining, or transmitting PHI on a covered entity&#8217;s behalf.&#160;&#160;In order to legally provide access to PHI to service providers, covered entities and business associates must enter into a &#8220;business associate agreement&#8221; with the service provider that receives PHI on behalf of the entity. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">44</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span>While we are not a covered entity or business associate subject to HIPAA, personal information that we obtain pursuant to a clinical trial may be subject to U.S. Federal Trade Commission (the &#8220;FTC&#8221;) privacy regulation. Failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute an unfair act or practice violating Section 5(a) of the Federal Trade Commission Act, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to, but less prescriptive than, what is required by the HIPAA Security Rule. In addition, states impose a variety of laws protecting consumer information, with certain sensitive information such as HIV/Sexually Transmitted Disease status subject to heightened standards.&#160;&#160;In addition, federal and state privacy, data security, and breach notification laws, rules and regulations, and other laws apply to the collection, use and security of personal information, including social security numbers, driver&#8217;s license numbers, government identifiers, credit card and financial account numbers. For example, the CCPA was amended by the CPRA, effective January 1, 2023. The CCPA, among other things, imposes data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. We could be subject to enforcement action and litigation exposure if we fail to adhere to these data privacy and security laws. Virginia, Colorado, Connecticut and Utah have also enacted privacy laws that became effective in 2023 and are similar in many respects to the CCPA. Several other states have also enacted privacy laws similar to the CCPA that will become effective in the coming years, adding to potential privacy compliance obligations.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">The Ares Credit Facility is subject to acceleration in specified circumstances, which may result in Ares taking possession and disposing of any collateral.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>On December 18, 2023 (the &#8220;Ares Closing Date&#8221;), we entered into a credit agreement with Ares (the &#8220;Ares Credit Agreement&#8221;) (see &#8220;Liquidity and Capital Resources&#8221;). The Ares Credit Agreement provided for a total of $135 million in senior secured credit facilities (the &#8220;Ares Credit Facility&#8221;) consisting of (i) a term loan in the aggregate principal amount of $62.5 million and (ii) a revolving credit facility in the aggregate principal amount of $72.5 million (collectively, the &#8220;Ares Loans&#8221;), both of which were fully drawn on the Ares Closing Date. The Ares Credit Facility has a maturity date of December 20, 2027 (the &#8220;Ares Maturity Date&#8221;). On August 14, 2024, we repaid $30.0 million against the revolving credit facility and on December 19, 2024, we repaid $30.0 million against the term loan. As of March 31, 2025, we had $42.5 million and $32.5 million of borrowings outstanding under the revolving credit facility and the term loan, respectively. As discussed in Note 14 &#8211; Subsequent Events, on May 5, 2025, we borrowed $30.0 million under our revolving credit facility with Ares, which we used to concurrently repay an additional $30.0 million against our term loan facility with Ares on May 6, 2025. Following such transactions, we had $72.5 million outstanding under our revolving credit facility and $2.5 million outstanding under our term loan facility. The Ares Loans are secured by substantially all of our assets, including our intellectual property. Events of default include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. If there is an event of default, we would incur an increase in the rate of interest on the Ares Loans of 2% per annum. The occurrence of an event of default could result in, among other things, the termination of commitments under the Ares Credit Facility, the declaration that all outstanding loans are immediately due and payable in whole or in part, and Ares taking immediate possession of, and selling, any collateral securing the Ares Loans.</span>
  </div><div>
  </div><div>
   <span>&#160; </span>
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">Developments by competitors may render our products or technologies obsolete or non-competitive.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our current products and any future product we may develop will have to compete with other marketed therapies. In addition, other companies may pursue the development of pharmaceuticals that target the same diseases and conditions that we are targeting. We face competition from pharmaceutical and biotechnology companies in the United States and abroad. In addition, companies pursuing different but related fields represent substantial competition. Many of these organizations competing with us have substantially greater financial resources, larger research and development staffs and facilities, longer product development history in obtaining regulatory approvals and greater manufacturing and marketing capabilities than we do. These organizations also compete with us to attract qualified personnel and parties for acquisitions, joint ventures or other collaborations.</span>
  </div><div>

  </div><div><br/></div><div>


  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">45</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-align: justify;"><i><b>If we are unable to protect our patents, trade secrets or other proprietary rights, if our patents are challenged or if our provisional patent applications do not get approved, our competitiveness and business prospects may be materially damaged.</b></i></div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;"><span>As we move forward in clinical development, we continue to discover novel technologies related to our products and we may draft patent applications directed to these technologies. We rely on a combination of patent rights, trade secrets, intellectual property assignment agreements and nondisclosure and non-competition agreements to protect our proprietary intellectual property, and we will continue to do so. There can be no assurance that our patents, trade secret policies and practices or other agreements will adequately protect our intellectual property. Our issued patents may be challenged, found to be over-broad or otherwise invalidated in subsequent proceedings before courts, the U.S. Patent and Trademark Office or foreign patent offices. Even if enforceable, we cannot provide any assurances that they will provide significant protection from competition. The processes, systems, and/or security measures we use to preserve the integrity and confidentiality of our data and trade secrets may be breached, and we may not have adequate remedies as a result of any such breaches. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. There can be no assurance that the confidentiality, invention assignment, nondisclosure and non-competition agreements with employees, consultants and other parties with access to our proprietary information to protect our trade secrets, proprietary technology, processes and other proprietary rights, or any other security measures relating to such trade secrets, proprietary technology, processes and proprietary rights, will be adequate, will not be breached, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets or proprietary knowledge. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">We could lose market exclusivity of a product earlier than expected.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>In the pharmaceutical and biotechnology industries, the majority of an innovative product&#8217;s commercial value is realized during its market exclusivity period. In the United States and in some other countries, when market exclusivity expires and generic or biosimilar versions are approved and marketed or when biosimilars are introduced (even if only for a competing product), there are usually very substantial and rapid declines in a product&#8217;s revenues.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Market exclusivity for our products is based upon patent rights and certain regulatory forms of exclusivity. The scope of our patent rights may vary from country to country and may also be dependent on the availability of meaningful legal remedies in a country. The failure to obtain patent and other intellectual property rights, limitations on the use or loss of such rights could be material to us. In some countries, basic patent protections for our products may not exist because certain countries did not historically offer the right to obtain specific types of patents and/or we (or our licensors) did not file in those markets. In addition, the patent environment can be unpredictable and the validity and enforceability of patents cannot be predicted with certainty. Absent relevant patent protection for a product, once the data exclusivity period expires, generic versions can be approved and marketed.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Patent rights covering our products may become subject to patent litigation. In some cases, manufacturers may seek regulatory approval by submitting their own clinical trial data to obtain marketing approval or choose to launch a generic product &#8220;at risk&#8221; before the expiration of our patent rights/or before the final resolution of related patent litigation. Enforcement of claims in patent litigation can be very costly, time-consuming and no assurance can be given that we will prevail. In addition, any such litigation may divert our management's attention from our core business and reduce the resources available for our clinical development, manufacturing and marketing activities, and consequently have a material and adverse effect on our business and prospects, regardless of the outcome.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>There is no assurance that ASCENIV, or any other of our products for which we are issued a patent, will enjoy market exclusivity for the full time period of the respective patent. </span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">46</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Third parties could obtain patents that may require us to negotiate licenses to conduct our business, and there can be no assurance that the required licenses would be available on reasonable terms or at all.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We may not be able to operate our business without infringing third-party patents. Numerous U.S. and foreign patents and pending patent applications owned by third parties exist in fields that relate to the development and commercialization of IG. In addition, many companies have employed intellectual property litigation as a way to gain a competitive advantage. It is possible that infringement claims may occur as the number of products and competitors in our market increases. In addition, to the extent that we gain greater visibility and market exposure as a public company, we face a greater risk of being the subject of intellectual property infringement claims. We cannot be certain that the conduct of our business does not and will not infringe intellectual property or other proprietary rights of others in the United States and in foreign jurisdictions. If our products, methods, processes and other technologies are found to infringe third-party patent rights, we could be prohibited from manufacturing and commercializing the infringing technology, process or product unless we obtain a license under the applicable third-party patent and pay royalties or are able to design around such patent. We may be unable to obtain a license on terms acceptable to us, or at all, and we may not be able to redesign our products or processes to avoid infringement. Even if we are able to redesign our products or processes to avoid an infringement claim, our efforts to design around the patent could require significant time, effort and expense and ultimately may lead to an inferior or more costly product and/or process. Any claim of infringement by a third party, even those without merit, could cause us to incur substantial costs defending against the claim and could distract our management from our business. Furthermore, if any such claim is successful, a court could order us to pay substantial damages, including compensatory damages for any infringement, plus prejudgment interest and could, in certain circumstances, treble the compensatory damages and award attorney fees. These damages could be substantial and could harm our reputation, business, financial condition and operating results. A court also could enter orders that temporarily, preliminarily or permanently prohibit us, our licensees, if any, or our customers from making, using, selling, offering to sell or importing one or more of our products or practicing our proprietary technologies or processes, or could enter an order mandating that we undertake certain remedial activities. Any of these events could seriously harm our business, operating results and financial condition.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">If we are unable to successfully manage our growth, our business may be harmed.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our success will depend on the expansion of our commercial and manufacturing activities, supply of raw material plasma and overall operations and the effective management of our growth, which will place a significant strain on our management and on our administrative, operational and financial resources. To manage this growth, we must expand our operational, financial and management systems and hire and train additional qualified personnel. If we are unable to manage our growth effectively, our business could be harmed.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">The loss of one or more key members of our management team could adversely affect our business.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our performance is substantially dependent on the continued service and performance of our management team, who have extensive experience and specialized expertise in our business. In particular, the loss of Adam S. Grossman, our President and Chief Executive Officer, could adversely affect our business and operating results. We do not have &#8220;key person&#8221; life insurance policies for any members of our management team. We have employment agreements with each of our executive officers; however, the existence of an employment agreement does not guarantee retention of members of our management team and we may not be able to retain those individuals for the duration of or beyond the end of their respective terms. The loss of services of key personnel, or the inability to attract and retain additional qualified personnel, could result in delays in development or approval of our product candidates and diversion of management resources. </span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">47</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Cyberattacks and other security breaches could compromise our proprietary and confidential information or otherwise penetrate our network, which could harm our business and reputation.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>In the ordinary course of our business, we generate, collect and store proprietary information, including intellectual property and business information. The secure storage, maintenance, and transmission of and access to this information is important to our operations and reputation. Computer hackers may attempt to penetrate our computer systems and, if successful, misappropriate our proprietary and confidential information including e-mails and other electronic communications. Cybersecurity vulnerabilities can also arise from human error, fraud or malice on the part of our employees, other insiders or third parties, or from technology or product enhancements or the migration of information and data to new technology platforms, systems or applications. Hackers may impersonate our vendors, suppliers or other third parties with whom we do business, which may result in financial harm to our business. Further, while many of our employees and certain suppliers with whom we do business operate in a remote working environment, the risk of cybersecurity attacks and data breaches, particularly through phishing attempts, may be increased as we and third parties with whom we interact leverage our IT infrastructure in unanticipated ways. In addition, an employee, contractor, or other third party with whom we do business may attempt to obtain such information and may purposefully or inadvertently cause a breach involving such information. While we have certain safeguards in place to reduce the risk of and detect cyberattacks, including a Company-wide cybersecurity policy, our information technology networks and infrastructure may be vulnerable to unpermitted access by hackers or other breaches, such as the IT disruption described elsewhere in this report, or employee error or malfeasance. Any such compromise of our data security and access to, or public disclosure or loss of, confidential business or proprietary information could disrupt our operations, damage our reputation, provide our competitors with valuable information and subject us to additional costs which could adversely affect our business.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">If we are unable to hire and retain a substantial number of qualified personnel, our ability to sustain and grow our business may be harmed.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our success depends in part on our ability to attract, motivate, and retain a sufficient number of qualified employees across various areas of our operations, such as research and development, manufacturing operations and sales, who understand and appreciate our strategy and culture and are able to contribute to our mission. We will need to hire additional qualified personnel with expertise in commercialization, sales, marketing, medical affairs, reimbursement, government regulation, formulation, quality control, manufacturing, finance, general and operational management and plasma collections. In particular, over the next 12-24 months, we expect to hire several new employees devoted to our plasma collection centers, commercialization, sales, marketing, medical and scientific affairs, regulatory affairs, quality control, information technology, finance and general and operational management. Qualified individuals of the requisite caliber and number needed to fill these positions may be in short supply in some areas. We compete for qualified individuals with numerous biopharmaceutical companies, universities and other research institutions. Competition for such individuals is intense, and we cannot assure you that our search for such personnel will be successful. If we are unable to hire and retain personnel capable of consistently performing at a high level, our business and operations could be materially adversely affected. Additionally, any material increases in existing employee turnover rates or increases in labor costs could have a material adverse effect on our business, financial condition or operating results.</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">We currently collect human blood plasma at our ADMA BioCenters facilities, and if we cannot maintain FDA licensure for these facilities or obtain FDA licensure for additional facilities that we may construct or acquire rights to, we may be adversely affected and may not be able to sell or use this human blood plasma for future commercial purposes.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We intend to maintain FDA licensure of our current and future ADMA BioCenters collection facilities for the collection of human blood plasma and we may seek other governmental and regulatory approvals for these facilities. Collection facilities are subject to FDA and potentially other governmental and regulatory inspections and extensive regulation, including compliance with current cGMP and blood standards and FDA licensure and other governmental approvals, as applicable. Failure to comply with applicable governmental regulations or to receive applicable approvals for our current or future facilities may result in enforcement actions, such as adverse inspection reports, warning or untitled letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of regulatory authority approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses, any of which may significantly delay or suspend our operations for these locations, potentially having a material adverse effect on our ability to manufacture our products or offer for sale plasma collected at the affected sites. Failure to comply with applicable governmental regulations may also impact the ultimate quality and compliance of our finished biologic products, which may have a material adverse effect on our business.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">48</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">We manufacture our current marketed products, pipeline products, and products for third parties in our manufacturing and testing facilities, and if we or our vendors cannot maintain appropriate FDA status for these facilities, we may be adversely affected, and may not be able to sell, manufacture or commercialize these products.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>There are no assurances we will be able to maintain compliance with all FDA or other regulations. There is also no guarantee that we will be able to fulfill our contractual requirements to our customers. Moreover, to the extent that we use third-party vendors to fulfill our regulatory or contractual requirements, these third-party vendors may perform activities for themselves or other clients and we may not be privy to all regulatory findings or issues discovered by the FDA or other regulatory agencies. Such findings, which are out of our control, may adversely affect our ability to continue to work with these vendors, or our ability to release commercial drug product or perform necessary testing or other actions for us or our clients, which may be required in order to remain FDA compliant or to commercialize our products. If we are not able to maintain manufacturing compliance at our facilities or our vendors&#8217; facilities for our products and product candidates, we may not be able to successfully develop and commercialize our products and product candidates and we may face potential contractual or regulatory actions, which would have an adverse impact on our business.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>The testing and marketing of medical products entail an inherent risk of product liability. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Product liability claims may also result in recalls and/or regulatory enforcement actions. Even successful defense, however, could impair our results of operations. Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of pharmaceutical products we develop, either alone or with collaborators.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Many of our business practices are subject to scrutiny by federal and state regulatory authorities, as well as to lawsuits brought by private citizens under federal and state laws. Failure to comply with applicable law or an adverse decision in lawsuits may result in adverse consequences to us.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>The laws governing our conduct in the United States are enforceable on the federal, state and local levels by criminal, civil and administrative sanctions. Violations of laws such as the FDCA, the Social Security Act (including the Anti-Kickback Statute), the Public Health Service Act, the civil and criminal federal False Claims Act, the civil monetary penalty statute, requirements regarding the reporting and repayment of overpayments, other fraud and abuse laws and any regulations promulgated under the authority of the preceding, may result in significant criminal and/or civil sanctions, including jail sentences, fines or exclusion from participation in or debarment from federal and state healthcare or government procurement programs, pursuant to enforcement actions by DOJ, Medicare, Medicaid, OIG and other regulatory authorities. Similarly, the violation of applicable laws, rules and regulations of states, including the State of Florida, with respect to the manufacture and marketing of our products and product candidates may result in significant criminal and/or civil sanctions, including jail sentences, fines or exclusion from participation in applicable state healthcare programs. There can be no assurance that our activities will not come under the scrutiny of federal and/or state regulators and other government authorities or that our practices will not be found to violate applicable laws, rules and regulations or prompt lawsuits by private citizen &#8220;relators&#8221; under federal or state false claims laws.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>For example, under the Anti-Kickback Statute and similar state laws and regulations, the offer or payment of anything of value to induce or reward patient referrals, or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease, or ordering of any item or service reimbursable in whole or in part by a federal healthcare program is prohibited.&#160;&#160;This places constraints on the marketing and promotion of products and on common business arrangements, such as discounted terms and volume incentives for customers in a position to recommend or choose products for patients, such as physicians and hospitals, and these practices can result in substantial legal penalties, including, among others, exclusion from participation in the Medicare and Medicaid programs. Arrangements with referral sources such as purchasers, group purchasing organizations, healthcare organizations, physicians and pharmacists must be structured with care to comply with applicable requirements. Legislators and regulators may seek to further restrict the scope of financial relationships that are considered appropriate. For example, HHS recently promulgated a regulation that is effective in two phases.&#160;&#160;First, the regulation excludes from the definition of &#8220;remuneration&#8221; limited categories of (a) PBM rebates or other reductions in price to a plan sponsor under Medicare Part D or a Medicaid Managed Care Organization plan reflected in point-of-sale reductions in price and (b) PBM service fees paid by a manufacturer to a PBM.&#160;&#160;Second, effective January 1, 2023, the regulation expressly provides that rebates to plan sponsors under Medicare Part D either directly to the plan sponsor under Medicare Part D, or indirectly through a pharmacy benefit manager, will not be protected under the Anti-Kickback Statute discounts safe harbor. Recent legislation and a final rule promulgated on December 29, 2023 delayed implementation of this portion of the rule until January 1, 2032.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">49</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span>Also, certain business practices, such as payments of consulting fees to healthcare professionals, sponsorship of educational or research grants, charitable donations, interactions with healthcare professionals who prescribe products for uses not approved by the FDA and financial support for continuing medical education programs, must be conducted within narrowly prescribed and controlled limits to avoid any possibility of wrongfully influencing healthcare professionals to prescribe or purchase particular products or as a reward for past prescribing. Under the Healthcare Reform Law, payments and transfers of value by pharmaceutical manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to or at the request of covered recipients, such as, but limited to, U.S.-licensed physicians, physician assistants, nurse practitioners, clinical nurse specialists and certified registered nurse anesthetists and U.S. teaching hospitals, must be tracked and reported to CMS, and are publicly disclosed. Such &#8220;applicable manufacturers&#8221; are also required to report certain ownership interests held by physicians and their immediate family members. A number of states have similar laws in place. Additional and stricter prohibitions could be implemented by federal and state authorities. Where such practices have been found to be improper incentives to use such products, government investigations and sanctions against manufacturers have resulted in substantial fines, penalties and damages. Many manufacturers have been required to enter into consent decrees or orders that prescribe allowable corporate conduct and/or Corporate Integrity Agreements that impose ongoing compliance requirements on a manufacturer.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Failure to satisfy requirements under the FDCA can also result in penalties, as well as requirements to enter into consent decrees or orders that prescribe allowable corporate conduct. In addition, while regulatory authorities generally do not regulate physicians&#8217; discretion in their choice of treatments for their patients, they do restrict communications by manufacturers on unapproved uses of approved products or on the potential safety and efficacy of unapproved products in development. Companies in the United States, Canada and the European Union cannot promote approved products for other indications that are not specifically approved by the competent regulatory authorities such as the FDA in the United States, nor can companies promote unapproved products. In limited circumstances, companies may disseminate to physicians information regarding unapproved uses of approved products or results of studies involving investigational products. If such activities fail to comply with applicable regulations and guidelines of the various regulatory authorities, we may be subject to warnings from, or enforcement action by, these authorities. Furthermore, if such activities are prohibited, it may harm demand for our products. Promotion of unapproved drugs or devices or unapproved indications for a drug or device is a violation of the FDCA and subjects us to civil and criminal sanctions. Furthermore, sanctions under the federal False Claims Act have been brought against companies accused of promoting off-label uses of drugs, because such promotion induces unapproved use and subsequent claims for reimbursement under Medicare and other federal programs. Similar actions for off-label promotion have been initiated by several states for Medicaid fraud. The Healthcare Reform Law significantly strengthened provisions of the federal False Claims Act, the federal Anti-Kickback Statute that applies to government healthcare programs, and other healthcare fraud provisions, leading to the possibility of greatly increased lawsuits by whistleblowers for perceived violations. Violations or allegations of violations of the foregoing restrictions could materially and adversely affect our business.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We are required to report detailed pricing information, net of included discounts, rebates and other concessions, to CMS for the purpose of calculating national reimbursement levels, certain federal prices and certain federal and state rebate obligations. Inaccurate or incomplete reporting of pricing information could result in criminal and/or civil liability under the federal False Claims Act, the federal Anti-Kickback Statute and various other laws, rules and regulations.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We have established systems for collecting and reporting this data accurately to CMS and have instituted a compliance program to assure that the information collected is complete in all respects. If we report pricing information that is not accurate to the federal government, we could be subject to fines and other sanctions that could adversely affect our business. If we choose to pursue clinical development and commercialization in the European Union or otherwise market and sell our products outside of the United States, we must obtain and maintain regulatory approvals and comply with regulatory requirements in such jurisdictions. The approval procedures vary among countries in complexity and timing. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all, which would preclude us from commercializing products in those markets.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">50</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>In addition, some countries, particularly the countries of the European Union, regulate the pricing of prescription pharmaceuticals. In these countries, pricing discussions with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. Such trials may be time-consuming and expensive and may not show an advantage in efficacy for our products. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, in either the U.S. or the European Union, we could be adversely affected.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Also, under the U.S. Foreign Corrupt Practices Act, the United States has increasingly focused on regulating the conduct by U.S. businesses occurring outside of the United States, generally prohibiting remuneration to foreign officials for the purpose of obtaining or retaining business. To enhance compliance with applicable healthcare laws, and mitigate potential liability in the event of noncompliance, regulatory authorities such as the HHS Office of Inspector General (the &#8220;OIG&#8221;) have recommended the adoption and implementation of a comprehensive healthcare compliance program that generally contains the elements of an effective compliance and ethics program described in Section 8B2.1 of the U.S. Sentencing Commission Guidelines Manual. Most U.S.-based pharmaceutical companies have such programs. We will need to adopt healthcare compliance and ethics programs that would incorporate the OIG&#8217;s recommendations and voluntary industry guidelines and train our employees. Such a program may be expensive and may not provide assurance that we will avoid compliance issues.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We are also required to comply with the applicable laws, rules, regulations and permit requirements of the various states and localities in which our business operates, including the State of Florida where our manufacturing facility is located.  These regulations and permit requirements are not always in concert with applicable federal laws, rules and regulations regulating our business.  Although compliant with applicable federal requirements, we may be required to comply with additional state and local laws, rules, regulations and permits.  Failure to appropriately comply with such state and local requirements could result in temporary or long-term cessation of our manufacturing operations, as well as fines and other sanctions.  Any such penalties may have a material adverse effect on our business and results of operations.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">We are subject to extensive and rigorous governmental regulation, including the requirement of FDA and other federal, state and local business regulatory</span><span style="color: rgb(0, 0, 255); font-weight: bold; font-style: italic;">&#160;</span><span style="font-weight: bold; font-style: italic;">approvals before our products and product candidates may be lawfully marketed, and our ability to obtain regulatory approval of our products and product candidates from the FDA in a timely manner, access the public markets and obtain necessary capital in order to properly capitalize and continue our operations may be hindered by inadequate funding for the FDA, the SEC and other state and local government agencies.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Both before and after the approval of our products, our products, operations, facilities, suppliers and CROs are subject to extensive regulation by federal, state and local governmental authorities in the United States and other countries, with regulations differing from country to country. In the United States, the FDA regulates, among other things, the pre-clinical and nonclinical testing, clinical trials, manufacturing, safety, efficacy, potency, labeling, storage, record keeping, quality systems, advertising, promotion, sale and distribution of therapeutic products. Failure to comply with applicable requirements could result in, among other things, one or more of the following actions: notices of violation, untitled letters, warning letters, CRLs, fines and other monetary penalties, unanticipated expenditures, delays in approval or refusal to approve a product or product candidate, product recall or seizure, interruption of manufacturing or clinical trials, operating restrictions, injunctions and criminal prosecution. Our products and product candidates cannot be lawfully marketed in the United States without FDA and other federal, state and local business regulatory approvals. Any failure to receive the marketing approvals necessary to commercialize our products or product candidates could harm our business.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">51</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span>Additionally, the ability of the FDA and other federal, state and local business regulatory agencies to review and approve products and product candidates can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and to accept the payment of user fees, as well as statutory, regulatory, and policy changes. Average review times at the FDA and other federal, state and local business regulatory agencies have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for products and product candidate submissions to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including in December 2018 and January 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections at domestic and foreign manufacturing facilities from March 2020 until July 2021. More recently, in April 2025, at least 15% of the FDA&#8217;s staff was terminated as part of the new U.S. presidential administration&#8217;s efforts to reduce the size of the federal government and cut costs. If a prolonged government shutdown or regulatory agency disruption reoccurs, or in the event the FDA has an insufficient amount of staff, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, conduct evaluations and inspections and other reporting requirements which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain capital that may be necessary in order to properly capitalize and continue our operations.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">The manufacturing processes for plasma-based biologics are complex and involve biological intermediates that are susceptible to contamination and impurities.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Plasma is a raw material that is susceptible to damage and contamination and may contain human pathogens, any of which would render the plasma unsuitable as raw material for further manufacturing. For instance, improper storage of plasma, by us or third-party suppliers, may require us to destroy some of our raw material. If unsuitable plasma is not identified and discarded prior to the release of the plasma to the manufacturing process, it may be necessary to discard intermediate or finished product made from that plasma or to recall any finished product released to the market, resulting in a charge to cost of product revenue. The manufacture of our plasma products is an extremely complex process of fractionation, purification, testing, filling and finishing. Our products can become non-releasable or otherwise fail to meet our stringent specifications or regulatory agencies&#8217; specifications through a failure in one or more of these process steps. We may detect instances in which an unreleased product was produced without adherence to our manufacturing procedures or plasma used in our production process was not collected or stored in a compliant manner consistent with cGMP or other regulations. Such an event of noncompliance would likely result in our determination that the implicated products should not be released or maybe replaced or withdrawn from the market and therefore should be destroyed. Once manufactured, our plasma-derived products must be handled carefully and kept at appropriate temperatures. Our failure, or the failure of third parties that supply, test, ship or distribute our products or product components to properly care for our products, may require that those products be destroyed. Even if handled properly, biologics may form or contain particulates or have other issues or problems after storage which may require products to be destroyed or recalled. While we expect to write off certain amounts of raw materials and work-in-process inventory in the ordinary course of business due to the complex nature of plasma, our processes and our products, unanticipated events may lead to write-offs and other costs materially in excess of our expectations and the reserves we have established for these purposes. Such write-offs or losses and other costs could cause material fluctuations in our results of operations. Product or component quality issues may also result in regulatory enforcement actions, liability, corrective actions and recalls, among other actions, as described elsewhere in our 2024 10-K.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Furthermore, contamination of our products could cause investors, consumers, or other third parties with whom we conduct business to lose confidence in the reliability of our manufacturing procedures, which could adversely affect our revenues. In addition, faulty or contaminated products that are unknowingly distributed could result in patient harm, threaten the reputation of our products and expose us to product liability damages and claims from companies for whom we do contract manufacturing.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">52</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Our ability to continue to produce safe and effective products depends on the safety of our plasma supply, testing by third parties and the timing of receiving the testing results, and manufacturing processes we have in place to counter transmittable diseases.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Despite overlapping safeguards, including the screening of donors and other steps to remove or inactivate viruses and other infectious disease-causing agents, the risk of transmissible disease through blood plasma products cannot be entirely eliminated. For example, since plasma-derived therapeutics involves the use and purification of human plasma, there has been concern raised about the risk of transmitting HIV, prions, West Nile virus, H1N1 virus or &#8220;swine flu&#8221; and other blood-borne pathogens through plasma-derived products. There are also concerns about the future transmission of H5N1 virus, or &#8220;bird flu.&#8221; In the 1980s, thousands of hemophiliacs worldwide were infected with HIV through the use of contaminated Factor VIII. Other producers of Factor VIII, though not us, were defendants in numerous lawsuits resulting from these infections. New infectious diseases emerge in the human population from time to time. If a new infectious disease has a period during which time the causative agent is present in the bloodstream but symptoms are not present, it is possible that plasma donations could be contaminated by that infectious agent. Typically, early in an outbreak of a new disease, tests for the causative agent do not exist. During this early phase, we must rely on screening of donors for behavioral risk factors or physical symptoms to reduce the risk of plasma contamination. Screening methods are generally less sensitive and specific than a direct test as a means of identifying potentially contaminated plasma units. During the early phase of an outbreak of a new infectious disease, our ability to manufacture safe products would depend on the manufacturing process&#8217; capacity to inactivate or remove the infectious agent. To the extent our manufacturing processes are inadequate to inactivate or remove an infectious agent, our ability to manufacture and distribute our products would be impaired. If a new infectious disease were to emerge in the human population or if there were a reemergence of an infectious disease, the regulatory and public health authorities could impose precautions to limit the transmission of the disease that would impair our ability to procure plasma, manufacture our products or both. Such precautionary measures could be taken before there is conclusive medical or scientific evidence that a disease poses a risk for plasma-derived products. In recent years, new testing and viral inactivation methods have been developed that more effectively detect and inactivate infectious viruses in collected plasma. There can be no assurance, however, that such new testing and inactivation methods will adequately screen for, and inactivate, infectious agents in the plasma used in the production of our products.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">We could become supply-constrained and our financial performance would suffer if we cannot obtain adequate quantities of FDA-approved source and high-titer plasma with proper specifications or other necessary raw materials.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>In order for plasma to be used in the manufacturing of our products, the individual centers at which the plasma is collected must generally be licensed by the FDA and approved by the regulatory authorities of any country in which we may wish to commercialize our products. When we open a new plasma center, and on an ongoing basis after licensure, it must be inspected by the FDA for compliance with cGMP and other regulatory requirements. Therefore, even if we are able to construct new plasma collection centers to complement our current plasma collection facilities, an unsatisfactory inspection could prevent a new center from being licensed or risk the suspension or revocation of an existing license, among other enforcement actions. Additionally, although we achieved normal source plasma supply self-sufficiency with the approval of our tenth plasma collection center in November 2023, we remain reliant on the purchase of RSV plasma from third parties and the collection of RSV and normal source plasma from our FDA-licensed plasma collection centers to manufacture our products. We can give no assurances that appropriate plasma will be available to us through our own plasma collection facilities or on commercially reasonable terms, or at all, to manufacture our products, or that third parties will be able to supply plasma to us in accordance with plasma purchase agreements. Further, the COVID-19 pandemic resulted in significant constraints in raw material supply across various different industries, including the supply of plasma. It is possible that in the future, pandemics and government responses thereto will have an adverse effect on our ability to source plasma from donors in quantity and quality sufficient for our manufacturing processes. In order to maintain a plasma center&#8217;s license, its operations must continue to conform to cGMP and other regulatory requirements. In the event that we determine that plasma was not collected in compliance with cGMP and other applicable regulatory requirements, we may be unable to use and may ultimately destroy plasma collected from that center, which would be recorded as a charge to cost of product revenue. Additionally, if non-compliance in the plasma collection process is identified after the impacted plasma has been pooled with compliant plasma from other sources, entire plasma pools, in-process intermediate materials and final products could be impacted. Consequently, we could experience significant inventory impairment provisions and write-offs which could adversely affect our business and financial results. We plan to increase our supplies of plasma for use in the manufacturing processes through increased purchases of plasma from third-party suppliers as well as collections from our existing ADMA BioCenters plasma collection facilities. This strategy is dependent upon our ability to maintain a cGMP compliant environment at our plasma collection facilities and to expand production and attract donors to our facilities. There is no assurance that the FDA will inspect and license any of our current or future unlicensed plasma collection facilities in a timely manner consistent with our production plans. If we misjudge the readiness of a center for an FDA inspection, we may lose credibility with the FDA and cause the FDA to more closely examine all of our operations. Such additional scrutiny could materially hamper our operations and our ability to increase plasma collections. Our ability to expand production and increase our plasma collection facilities to more efficient production levels may be affected by changes in the economic environment and population in selected regions where ADMA BioCenters operates its current or future plasma facilities, by the entry of competitive plasma centers into regions where ADMA BioCenters operates such centers, by misjudging the demographic potential of individual regions where ADMA BioCenters expects to expand production and attract new donors, by unexpected facility related challenges, or by unexpected management challenges at selected plasma facilities held by us from time to time.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">53</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Our ability to commercialize our products, alone or with collaborators, will depend in part upon the extent to which reimbursement will be available from governmental agencies, health administration authorities, private health maintenance organizations and health insurers and other healthcare payers, and also depends upon the approval, timing and representations by the FDA or other governmental authorities for our product candidates. </span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our ability to generate product revenues will be diminished if our products sell for inadequate prices or patients are unable to obtain adequate levels of insurance coverage. Significant uncertainty exists as to the reimbursement status of newly approved healthcare products, as well as to the timing, language, specifications and other details pertaining to the approval of such products. Healthcare payers, including Medicare, are challenging the prices charged for medical products and services. Government and other healthcare payers increasingly attempt to contain healthcare costs by limiting both coverage and the level of reimbursement for products. Even if one of our product candidates is approved by the FDA, insurance coverage may not be available, and reimbursement levels may be inadequate, to cover such product. If government and other healthcare payers do not provide adequate coverage and reimbursement levels for one of our products, once approved, market acceptance of such product could be reduced. Prices in many countries, including many in Europe, are subject to local regulation and certain pharmaceutical products, such as plasma-derived products, are subject to price controls in several of the world&#8217;s principal markets, including many countries within the European Union. In the United States, where pricing levels for our products are substantially established by third-party payers, including Medicare, if payers reduce the amount of reimbursement for a product, it may cause groups or individuals dispensing the product to discontinue administration of the product, to administer lower doses, to substitute lower cost products or to seek additional price-related concessions. These actions could have a negative effect on our financial results, particularly in cases where our products command a premium price in the marketplace, or where changes in reimbursement induce a shift in the site of treatment. The existence of direct and indirect price controls and pressures over our products could materially adversely affect our financial prospects and performance.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">The biosimilar pathway established as part of healthcare reform may make it easier for competitors to market biosimilar products.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>The ACA and the companion Healthcare and Education Reconciliation Act (which together are referred to as the &#8220;Healthcare Reform Law&#8221;) introduced an abbreviated licensure pathway for biological products that are demonstrated to be biosimilar to an FDA-licensed biological product.  A biological product may be demonstrated to be &#8220;biosimilar&#8221; if data shows that, among other things, the product is &#8220;highly similar&#8221; to an already-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product. The law provides that a biosimilar application may be submitted as soon as four years after the reference product is first licensed, and that the FDA may not make approval of an application effective until 12 years after the reference product was first licensed.  Since the enactment of the law, the FDA has issued several guidance documents to assist sponsors of biosimilar products in preparing their approval applications. Moreover, in an effort to increase competition in the biologic product marketplace, Congress, the executive branch, and the FDA have taken certain legislative and regulatory steps. For example, in 2020 the FDA finalized a guidance to facilitate biologic product importation. The 2020 Further Consolidated Appropriations Act included provisions requiring that sponsors of approved biologic products provide samples of the approved products to persons developing biosimilar products within specified timeframes, in sufficient quantities, and on commercially reasonable market-based terms. The FDA approved the first biosimilar product in 2015 and has since approved a number of biosimilars.  As a result of the biosimilar pathway in the United States, we expect in the future to face greater competition from biosimilar products, including a possible increase in patent challenges.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">54</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
   <span style="font-weight: bold; font-style: italic;">The implementation of the Healthcare Reform Law in the United States may adversely affect our business.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Through the March 2010 adoption of the Healthcare Reform Law in the United States, substantial changes are being made to the current system for paying for healthcare in the United States, including programs to extend medical benefits to millions of individuals who currently lack insurance coverage. This reform establishes significant cost-saving measures with respect to several government healthcare programs, including Medicaid and Medicare Parts B and D, that may cover the cost of our future products, and these efforts could have a material adverse impact on our future financial prospects and performance. For example, in order for a manufacturer&#8217;s products to be reimbursed by federal funding under Medicaid, the manufacturer must enter into a Medicaid rebate agreement with the Secretary of HHS and pay certain rebates to the states based on utilization data provided by each state to the manufacturer and to CMS and pricing data provided by the manufacturer to the federal government. The states share these savings with the federal government, and sometimes implement their own additional supplemental rebate programs. Under the Medicaid drug rebate program, the rebate amount for most branded drug products was previously equal to a minimum of 15.1% of the Average Manufacturer Price (&#8220;AMP&#8221;) or the AMP less Best Price, whichever is greater, plus the inflation penalty if applicable. Effective January 1, 2010, the Healthcare Reform Law generally increased the size of the Medicaid rebates paid by manufacturers for single source and innovator multiple source (brand name) drug products from a minimum of 15.1% to a minimum of 23.1% of AMP, subject to certain exceptions, plus the inflation penalty if applicable. For non-innovator multiple source (generic) products, the rebate percentage was increased from a minimum of 11.0% to a minimum of 13.0% of AMP, and the Bipartisan Budget Act of 2015 established a new inflation penalty for these drugs.&#160;&#160;In 2010, the Healthcare Reform Law also newly extended the Medicaid drug rebate obligation to prescription drugs covered by Medicaid managed care organizations. These increases in required rebates may adversely affect our future financial prospects and performance. In order for a pharmaceutical product to receive federal reimbursement under the Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program.&#160;&#160;The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer.&#160;&#160;As the 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase, and recent regulations have established a civil monetary penalty for failure to refund these overcharges.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Effective in 2011, the Healthcare Reform Law imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs. These fees may adversely affect our future financial prospects and performance. </span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>The Healthcare Reform Law also created new rebate obligations for our products under Medicare Part D, a partial, voluntary prescription drug benefit created by the U.S. federal government primarily for persons 65 years old and over. The Part D drug program is administered through private insurers that contract with CMS. Beginning in 2011, the Healthcare Reform Law generally requires that in order for a drug manufacturer&#8217;s products to be reimbursed under Medicare Part D, the manufacturer must enter into a Medicare Coverage Gap Discount Program agreement with the Secretary of HHS, and reimburse each Medicare Part D plan sponsor an amount now equal to 70% savings for the manufacturer&#8217;s brand name drugs and biologics which the Part D plan sponsor has provided to its Medicare Part D beneficiaries who are in the &#8220;donut hole&#8221; (or a gap in Medicare Part D coverage for beneficiaries who have expended certain amounts for drugs). The Part D plan sponsor is responsible for calculating and providing the discount directly to its beneficiaries and for reporting these amounts paid to CMS&#8217;s contractor, which notifies drug manufacturers of the rebate amounts it must pay to each Part D plan sponsor. The rebate requirement could adversely affect our future financial performance, particularly if contracts with Part D plans cannot be favorably renegotiated or the Part D plan sponsors fail to accurately calculate payments due in a manner that overstates our rebate obligation. Regarding access to our products, the Healthcare Reform Law established and provided significant funding for a Patient-Centered Outcomes Research Institute to coordinate and fund Comparative Effectiveness Research (&#8220;CER&#8221;). While the stated intent of CER is to develop information to guide providers to the most efficacious therapies, outcomes of CER could influence the reimbursement or coverage for therapies that are determined to be less cost-effective than others. Should any of our products be determined to be less cost effective than alternative therapies, the levels of reimbursement for these products, or the willingness to reimburse at all, could be impacted, which could materially impact our future financial prospects and results.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">55</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span>There have been repeated legal challenges and attempts by Congress to repeal or change the Healthcare Reform Law and the possibility of future challenges or legislative changes contribute to the uncertainty of the ongoing implementation and impact of the law and also underscores the potential for additional reform going forward. We cannot assure that the law, as currently enacted or as amended in the future, will not adversely affect our business and financial results and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.&#160;&#160;Certain provisions of enacted or proposed legislative changes may negatively impact coverage and reimbursement of, or rebates paid by manufacturers for, healthcare items and services. We will continue to evaluate the effect that the Healthcare Reform Law and any potential changes may have on our business. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">Corporate responsibility, specifically related to Environmental, Social and Governance (&#8220;ESG&#8221;) matters, may impose additional costs and expose us to new risks.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Public ESG and sustainability reporting is becoming more broadly expected by investors, stockholders and other third parties. Certain organizations that provide corporate governance and other corporate risk information to investors and stockholders have developed, and others may in the future develop, scores and ratings to evaluate companies and investment funds based upon ESG or &#8220;sustainability&#8221; metrics. Many investment funds focus on positive ESG business practices and sustainability scores when making investments and may consider a company&#8217;s ESG or sustainability scores as a reputational or other factor in making an investment decision. In addition, investors, particularly institutional investors, use these scores to benchmark companies against their peers and if a company is perceived as lagging, these investors may engage with such company to improve ESG disclosure or performance and may also make voting decisions, or take other actions, to hold these companies and their boards of directors accountable.  We may face reputational damage in the event our corporate responsibility initiatives or objectives do not meet the standards set by our investors, stockholders, lawmakers, listing exchanges or other constituencies, or if we are unable to achieve an acceptable ESG or sustainability rating from third-party rating</span><span style="color: rgb(255, 0, 0);">&#160;</span><span style="color: rgb(0, 0, 0);">services. A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our common stock from consideration by certain investors who may elect to invest with our competition instead. Ongoing focus on corporate responsibility matters by investors and other parties as described above may impose additional costs or expose us to new risks.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold;">Risks Relating to our Finances, Capital Requirements and Other Financial Matters</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: rgb(0, 0, 0); font-weight: bold; font-style: italic;">We may not have cash available to us in amounts sufficient to enable us to make interest or principal payments on our indebtedness when due.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>The Ares Credit Facility provided for total senior secured loans in an aggregate principal amount of $135.0 million, of which $75.0 million is currently outstanding. Borrowings under the Ares Credit Facility currently bear interest at a weighted-average rate of approximately 9.4% per annum, which reflects the three-month term SOFR rate; provided, however, that upon, and during the continuance of, an event of default, the interest rate will automatically increase by an additional 200 basis points. We are currently required to make quarterly payments of interest during the remaining term of the Ares Credit Facility of approximately $1.8 million, with all principal and unpaid interest due at maturity. In addition, our monthly interest rate obligation is subject to rising interest rates. The Ares Credit Facility has a maturity date of December 20, 2027, subject to acceleration pursuant to the Ares Credit Agreement, including upon an event of default. All of our obligations under the Ares Credit Facility are secured by a first-priority lien and security interest in substantially all of our and our subsidiaries&#8217; tangible and intangible assets, including intellectual property, and all of the equity interests in our subsidiaries.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our current and projected cash, cash equivalents and accounts receivable may not be sufficient to repay all of our current outstanding debt obligations as they mature. If we are unable to maintain sufficient positive cash flow to repay our outstanding debt obligations as they mature, we would need to obtain additional financing in the amounts necessary to repay our outstanding debt obligations when due. If we are unable to repay our outstanding debt obligations when they mature, our creditors would be able to accelerate all of the amounts due and, in the case of the Ares Credit Facility, seek to enforce their security interests, which could lead to our creditors taking immediate possession of and selling substantially all of our assets with no return provided to our stockholders.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">56</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Raising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>To the extent that we raise additional capital by issuing equity securities, the share ownership of existing stockholders will be diluted. Any future debt financing may involve covenants that, among other restrictions, limit our ability to incur liens or additional debt, pay dividends, redeem or repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. In addition, if we raise additional funds through licensing arrangements or the disposition of any of our assets, it may be necessary to relinquish potentially valuable rights to our product candidates or grant licenses on terms that are not favorable to us.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We regularly maintain cash balances at third-party financial institutions in excess of the Federal Deposit Insurance Corporation insurance limit. While we monitor the cash balances in our operating accounts on a daily basis and adjust the balances as appropriate, these balances could be impacted, and there could be a material adverse effect on our business, if one or more of the financial institutions with which we deposit cash fails or is subject to other adverse conditions in the financial or credit markets. To date, we have experienced no loss or lack of access to our invested cash or cash equivalents; however, we can provide no assurance that access to our invested cash and cash equivalents will not be impacted by adverse conditions in the financial and credit markets.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">If we fail to maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could result in investors losing confidence in the accuracy and completeness of our financial statements, harm our operating results and negatively affect the market price of our common stock.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 and related rules (the &#8220;Sarbanes-Oxley Act&#8221;), we are required to maintain internal control over financial reporting and our management is required to report on the effectiveness of our internal control over financial reporting, including any material weaknesses in such internal controls. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we have been required to upgrade, and will need to implement further upgrades, to our financial, information and operating systems, implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Because we became a large accelerated filer effective December 31, 2023, the Sarbanes-Oxley Act requires our </span><span style="color: rgb(0, 0, 0);">independent registered public accounting firm to attest to the effectiveness of our internal control over financial reporting. Our transition to large accelerated filer status and becoming subject to additional requirements of the Sarbanes-Oxley Act has been and will continue to be time-consuming, and there is a risk of noncompliance. In addition, as a large accelerated filer, we anticipate incurring additional fees due to the increased complexity of our financial statements and the additional efforts required by our status, including, but not limited to, higher accounting and auditor costs. Further, the costs associated with the compliance with and implementation of procedures under these and future laws and related rules could have a material impact on our results of operations. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Consequently, we have incurred increased costs related to our compliance with Section 404 of the Sarbanes-Oxley Act and will continue to do so. Our Audit Committee has retained the services of BDO, a Sarbanes-Oxley advisor, to assist with our internal control over financial reporting and information technology related to the Sarbanes-Oxley Act. Moreover, i</span><span style="color: rgb(0, 0, 0);">f we have a material weakness in our internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. If we identify material weaknesses in our internal control over financial reporting, if we are unable to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely </span><span>manner</span><span style="color: rgb(0, 0, 0);">, if we are unable to assert that our internal control over financial reporting is effective or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, and the market price of our common stock could be negatively affected. In addition, we could become subject to investigations by any stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources, which could have an adverse impact on our business.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">57</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Our ability to use our net operating loss carryforwards (&#8220;NOLs&#8221;) may be limited.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We have incurred substantial losses during our history. As of December 31, 2024, we had federal and state NOLs of $265.6 million and $203.4 million, respectively. Federal and state NOLs of approximately $33.4 million and $62.0 million, respectively, will begin to expire at various dates beginning in 2028, if not limited by triggering events prior to such time. Under the provisions of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), changes in our ownership, in certain circumstances, will limit the amount of federal NOLs that can be utilized annually in the future to offset taxable income. In particular, Section 382 of the Code ("Section 382") imposes limitations on a company&#8217;s ability to use NOLs upon certain changes in such ownership. If we are limited in our ability to use our NOLs in future years in which we have taxable income, we will pay more taxes than if we were able to fully utilize our NOLs. The acquisition transaction that we completed on June 6, 2017, resulted in a change in ownership of ADMA under Section 382 and, as a result, we were required to write off $57.6 million of federal NOLs. On October 25, 2021, we completed a public offering of our common stock whereby we issued 57,500,000 shares of our common stock resulting in another change of ownership for ADMA under section 382 of the Code, resulting in an additional write-off of $3.0 million of federal NOLs, $28.1 million of state NOLs and $1.0 million of research and development credits. Although we did not experience any ownership changes for the years ended December 31, 2024 and 2023, we may experience ownership changes in the future as a result of subsequent changes in our stock ownership that we cannot predict or control that could result in further limitations being placed on our ability to utilize our federal NOLs.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Fluctuations in our tax obligations and effective tax rate and realization of our net deferred tax assets may result in volatility of our operating results and materially impact our financial condition or financial results.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We are subject to taxes by the U.S. federal, state, and local tax authorities. We record income tax expense based on our estimates of future payments, which may include the recording of, or adjustments to, liabilities for uncertain tax positions, and the determination of a need for a valuation allowance related to our net deferred tax assets. In addition, at any one time multiple tax years may be subject to audit by various tax authorities. The results of these audits and negotiations with taxing authorities may affect the ultimate settlement of these issues and impact our results of operations. For fiscal year 2025 and beyond there could be ongoing variability in our effective tax rate as events occur and exposures are evaluated. The volatility of our future effective tax rate could be materially impacted by a number of factors, including:</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>changes in our assessment of the lack of a need for a valuation allowance on our deferred tax assets; or</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>changes in U.S. federal, state and local tax rates, tax laws, regulations, or interpretations thereof.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>In addition, our effective tax rate in a given financial statement period may be materially impacted by a variety of other factors including, but not limited to, changes in the mix and level of earnings, changes in the states and other jurisdictions in which we operate, and deductible expenses and limitations on the use of NOLs resulting from ownership changes. Further, tax legislation may be enacted or amended, as applicable, in the future which could materially impact our current or future tax structure and effective tax rates. We may be subject to audits of our income, sales, and other transaction taxes by U.S. federal, state, and local taxing authorities. Outcomes from these audits could have a material effect on our financial condition or financial results.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold;">Risks Associated with our Common Stock</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">The market price of our common stock may be volatile and may fluctuate in a way that is disproportionate to our operating performance.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our stock price may experience substantial volatility as a result of a number of factors, including:</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>sales or potential sales of substantial amounts of our common stock;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>delay or failure in initiating or completing preclinical or clinical trials or unsatisfactory results of these trials;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>delay in a decision by federal, state or local business regulatory authority;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>the timing of acceptance, third-party reimbursement and sales of BIVIGAM and ASCENIV;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">58</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>announcements about us or about our competitors, including clinical trial results, regulatory approvals or new product introductions;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>developments concerning our licensors or third-party vendors;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>litigation and other developments relating to our patents or other proprietary rights or those of our competitors;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>conditions in the pharmaceutical or biotechnology industries;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>governmental regulation and legislation;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>overall market volatility;</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>global and economic uncertainty;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>variations in our anticipated or actual operating results; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>change in securities analysts&#8217; estimates of our performance, or our failure to meet analysts&#8217; expectations.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>Many of these factors are beyond our control. The stock markets in general, and the market for pharmaceutical and biotechnology companies in particular, have historically experienced extreme price and volume fluctuations. These fluctuations often have been unrelated or disproportionate to the operating performance of these companies. These broad market and industry factors could reduce the market price of our common stock, regardless of our actual operating performance.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div>
   <span style="font-weight: bold; font-style: italic;">Sales of a substantial number of shares of our common stock, or the perception that such sales may occur, may adversely affect the market price of our common stock.</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>As of May 2, 2025, most of our 238,734,246 outstanding shares of common stock, were available for sale in the public market, subject to certain restrictions with respect to sales of our common stock by our affiliates, either pursuant to Rule 144 under the Securities Act, or under effective registration statements. Sales of a substantial number of shares of our common stock, or the perception that such sales may occur, could cause the market price of our common stock to decline or adversely affect demand for our common stock.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Our affiliates control a substantial amount of our shares of common stock. Provisions in our Second Amended and Restated Certificate of Incorporation, as amended (the &#8220;Certificate of Incorporation&#8221;), our Amended and Restated Bylaws (the &#8220;Bylaws&#8221;) and Delaware law might discourage, delay or prevent a change in control of our Company or changes in our management and, therefore, depress the trading price of our common stock.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>As of March 31, 2025, BlackRock, Inc., The Vanguard Group, Inc., State Street Corporation, and our directors and executive officers and their affiliates owned approximately 32% of the outstanding shares of our common stock. Provisions of our Certificate of Incorporation, our Bylaws and Delaware law may have the effect of deterring unsolicited takeovers or delaying or preventing a change in control of our Company or changes in our management, including transactions in which our stockholders might otherwise receive a premium for their shares over then current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem to be in their best interests. These provisions include:</span>
  </div><div>
  </div><div>
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>the inability of stockholders to call special meetings; </span>
    </div>
  </div><div>
  </div><div style="margin-left: 36pt; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>classification of our Board and limitation on filling of vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our Company; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt; clear: both;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>&#9679;</span>
    </div>
    <div>
     <span>authorization of the issuance of &#8220;blank check&#8221; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board, without any need for action by stockholders.</span>
    </div>
  </div><div>
  </div><div style="clear: both;">
   <span>&#160;</span>
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">59</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span>In addition, Section 203 of the Delaware General Corporation Law prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years, has owned 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.&#160;&#160;The existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock. They could also deter potential acquirers of our Company, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition. In addition, as a result of the concentration of ownership of our shares of common stock, our stockholders may, from time to time, observe instances where there may be less liquidity in the public markets for our securities. </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">We have never paid cash dividends and do not intend to pay cash dividends in the foreseeable future. As a result, capital appreciation, if any, will be your sole source of gain.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We have never paid cash dividends on any of our capital stock, and we currently intend to retain future earnings, if any, to fund the development and growth of our business. In addition, the terms of existing and future debt agreements may preclude us from paying dividends. For example, the Ares Credit Agreement prohibits us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">If we fail to adhere to the strict listing requirements of the Nasdaq Global Market (&#8220;Nasdaq&#8221;), we may be subject to delisting. As a result, our stock price may decline and our common stock may be delisted.&#160;&#160;If our stock were no longer listed on Nasdaq, the liquidity of our securities likely would be impaired.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our Common Stock currently trades on the Nasdaq Global Market under the symbol &#8220;ADMA.&#8221; If we fail to adhere to Nasdaq&#8217;s strict listing criteria, including with respect to stock price, market capitalization and stockholders&#8217; equity, our stock may be delisted. This could potentially impair the liquidity of our securities not only in the number of shares that could be bought and sold at a given price, which may be depressed by the relative illiquidity, but also through delays in the timing of transactions and the potential reduction in media coverage. As a result, an investor might find it more difficult to dispose of our common stock. We believe that current and prospective investors would view an investment in our common stock more favorably if it continues to be listed on Nasdaq. Any failure at any time to meet the Nasdaq continued listing requirements could have an adverse impact on the value and trading activity of our common stock. Although we currently satisfy the listing criteria for Nasdaq, if our stock price declines dramatically, we could be at risk of failing to meet the Nasdaq continued listing criteria.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Our Board may, without stockholder approval, issue and fix the terms of shares of preferred stock and issue additional shares of common stock adversely affecting the rights of holders of our common stock.</span>
  </div><div>
  </div><div style="text-align: justify;">
   <span>&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our Certificate of Incorporation authorizes the issuance of up to 10,000,000 shares of &#8220;blank check&#8221; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board. Currently, our Certificate of Incorporation authorizes the issuance of up to 300,000,000 shares of common stock. As of March 31, 2025, there were 36,622,488 shares remaining available for issuance, after giving effect to 11,639,969 shares of our common stock that were subject to outstanding stock options, RSUs and warrants as of March 31, 2025 that may be issued by us without stockholder approval, as well as an additional 13,205,291 shares reserved for the future issuance of awards under our equity compensation plans.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: -72pt; padding-left: 72pt; font-weight: bold;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <span>Item 2.</span>
    </div>
    <div>
     <a id="Unregistered_Sales_of_Equity_Securities_and_Use_of_Proceeds" title="Unregistered Sales of Equity Securities and Use of Proceeds."></a><span>Unregistered Sales of Equity Securities and Use of Proceeds.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; margin-left: 36pt; font-weight: bold;">
   <span style="font-weight: normal;">None.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -72pt; padding-left: 72pt; font-weight: bold;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <span>Item 3.</span>
    </div>
    <div>
     <a id="Defaults_Upon_Senior_Securities" title="Defaults Upon Senior Securities."></a><span>Defaults Upon Senior Securities.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; margin-left: 36pt;">
   <span>None.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">60</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: -72pt; padding-left: 72pt; font-weight: bold;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <span>Item 4.</span>
    </div>
    <div>
     <a id="Mine_Safety_Disclosures" title="Mine Safety Disclosures."></a><span>Mine Safety Disclosures.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; margin-left: 36pt;">
   <span>Not applicable.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: -72pt; padding-left: 72pt; font-weight: bold;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <span>Item 5.</span>
    </div>
    <div>
     <a id="Other_Information" title="Other Information."></a><span>Other Information.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; clear: both;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="font-weight: bold;">Insider Trading Arrangements</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;"> <span>Our directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or may represent a non-Rule 10b5-1 trading arrangement under the Exchange Act. During the quarter ended March 31, 2025, <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-10118"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-10119"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-10120"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-10121">no</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> such plans or other arrangements were adopted or terminated. </span> </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div>
    <div style="float: left; width: 36.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">Item 6.</span>
    </div>
    <div style="float: left; width: 36.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">&#160;</span>
    </div>
    <div>
     <a id="Exhibits" title="Exhibits"></a><span style="font-weight: bold;">Exhibits</span>
    </div>
  </div><div>
  </div><div style="clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt;">
   <span>See the Exhibit Index immediately preceding the signature page of this Quarterly Report on Form 10-Q.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">61</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="font-weight: bold;">EXHIBIT INDEX</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><table style="font-size: 10pt; width: 100%;">
   <tr><td style="width: 12%;">&#160;</td><td style="width: 88%;">&#160;</td></tr><tr><td>&#160;</td><td>&#160;</td></tr><tr>
    <td>
     <div>
      <span style="text-decoration:underline">Exhibit Number</span>
     </div>
    </td>
    <td>
     <div>
      <span style="text-decoration:underline">Description</span>
     </div>
    </td>
   </tr><tr>
    <td>&#160;</td>
    <td>&#160;</td>
   </tr>
   <tr style="background-color: rgb(204, 238, 255);">
    <td>
     <div>
      <a href="ef20047548_ex31-1.htm" style="-sec-extract:exhibit">31.1*</a>
     </div>
    </td>
    <td>


      Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     </td>
   </tr>
   <tr>
    <td>
     <div>
      <a href="ef20047548_ex31-2.htm" style="-sec-extract:exhibit">31.2*</a>
     </div>
    </td>
    <td>


      Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     </td>
   </tr>
   <tr style="background-color: rgb(204, 238, 255);">
    <td>
     <div>
      <a href="ef20047548_ex32-1.htm" style="-sec-extract:exhibit">32.1**</a>
     </div>
    </td>
    <td>


      Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     </td>
   </tr>
   <tr>
    <td>
     <div>
      <a href="ef20047548_ex32-2.htm" style="-sec-extract:exhibit">32.2**</a>
     </div>
    </td>
    <td>


      Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     </td>
   </tr>
   <tr style="background-color: rgb(204, 238, 255);">
    <td>
     <div>
      101
     </div>
    </td>
    <td>
     <div>
      The following materials from ADMA Biologics, Inc.&#8217;s Form 10-Q for the quarter ended March 31, 2025, formatted in Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets as of March 31, 2025 (Unaudited) and December 31, 2024, (ii) Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2025 and 2024, (iii) Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity for the three months ended March 31, 2025 and 2024, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and 2024, and (v) Notes to (Unaudited) Condensed Consolidated Financial Statements.
     </div>
    </td>
   </tr>
   <tr>
    <td>
     <div>
      104
     </div>
    </td>
    <td>
     <div>
      Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
     </div>
    </td>
   </tr>
  </table><div>
  </div><div>&#160;
  </div><hr style="border-top: 2px solid black; border-bottom: none; border-left: none; border-right: none; height: 0px; margin: 6px auto 6px 0px; width: 20%;"/><div>

  </div><div style="text-indent: -18pt; padding-left: 36pt;">


  &#160;</div><div>
  </div><div style="margin: 0in 0in 0in 0.5in; font-size: 11pt; text-indent: -0.5in;"><span style="font-size: 10.0pt;mso-bidi-font-size:11.0pt">*<span style="mso-tab-count:1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Filed
herewith.</span></div><div style="margin: 0in 0in 0in 0.5in; font-size: 11pt; text-indent: -0.25in;"><span style="font-size:10.0pt;mso-bidi-font-size:11.0pt">&#160;</span></div><div style="font-size: 11pt; margin: 0in 0in 0in 0.5in; text-align: left; text-indent: -0.5in;"><span style="font-size:10.0pt">**<span style="mso-tab-count:1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span>In
accordance with SEC Release 33-8238, Exhibit 32.1 and Exhibit 32.2 are being
furnished and not filed.</span></div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 8pt; margin-top: 10px; margin-bottom: 10px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">62</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header override" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-align: center; font-weight: bold;">
   <a id="SIGNATURES" title="SIGNATURES"></a><span>SIGNATURES</span></div><div>
  </div><div style="text-align: center; font-weight: bold;">&#160;</div><div>
  </div><div style="text-indent: 36pt;">
   <span>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span>
  </div><div>


  </div><table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse; width: 100%;">
   <tr><td style="width: 50%;">&#160;</td><td style="width: 3%;">&#160;</td><td style="width: 5%;">&#160;</td><td style="width: 42%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">&#160;</td>
    <td colspan="3" style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">


      <span style="font-weight: bold;">ADMA Biologics, Inc.</span></td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">&#160;</td>
    <td colspan="3" style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">&#160;</td>
   </tr>

   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">


       <div style="float: left; width: 36.0pt; white-space: nowrap;">
        Date:
       </div>
       <div>
        May 7, 2025
       </div>
     </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; clear: both; text-align: justify;">


      By:
     </td>
    <td colspan="2" style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">
     <div>
      /s/ Adam S. Grossman
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top; clear: both;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">&#160;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">&#160;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify; border-width: initial; border-style: none; border-color: initial;">


      Name:
     </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify; border-width: initial; border-style: none; border-color: initial;">


      Adam S. Grossman
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">&#160;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">&#160;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">


      Title:
     </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">


      President and Chief Executive Officer
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">&#160;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">&#160;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">&#160;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">


       <div style="float: left; width: 36.0pt; white-space: nowrap;">
        Date:
       </div>
       <div>
        May 7, 2025
       </div>
     </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; clear: both; text-align: justify;">


      By:
     </td>
    <td colspan="2" style="padding-top: 0px; padding-bottom: 0px; border-bottom: 2px solid black; padding-right: 5.4pt; text-align: justify; border-top: none; border-left: none; border-right: none;">


      /s/ Brad Tade
     </td>
   </tr>
   <tr style="vertical-align: top; clear: both;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">&#160;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">&#160;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; border-top: 1pt solid black; padding-right: 5.4pt; text-align: justify;">


      Name:
     </td>
    <td style="padding-top: 0px; padding-bottom: 0px; border-top: 1pt solid black; padding-right: 5.4pt; text-align: justify;">


      Brad Tade
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">&#160;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">&#160;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">


      Title:
     </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.4pt; text-align: justify;">


      Chief Financial Officer
     </td>
   </tr>
  </table><div style="clear: both;">&#160;</div><div>
 </div><div style="clear: both; text-align: center; font-size: 8pt;">63</div><hr style="border-top: 2px solid black; border-bottom: none; border-left: none; border-right: none; height: 0px; margin: 6px auto 6px 0px; width: 100%;"/><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c2" id="hidden-fact-0" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c50" id="hidden-fact-2" name="adma:DebtInstrumentTermOfVariableRate">P3M</ix:nonNumeric>
<ix:nonNumeric contextRef="c52" id="hidden-fact-3" name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</ix:nonNumeric>
<ix:nonNumeric contextRef="c53" id="hidden-fact-4" name="adma:DebtInstrumentTermOfVariableRate">P3M</ix:nonNumeric>
<ix:nonNumeric contextRef="c108" id="hidden-fact-5" name="adma:AgreementWithTermExpirationDate">2039-09-30</ix:nonNumeric>
<ix:nonNumeric contextRef="c109" id="hidden-fact-6" name="adma:AgreementWithTermExpirationDate">2031-07-31</ix:nonNumeric>
<ix:nonNumeric contextRef="c109" id="hidden-fact-7" name="adma:PlasmaPurchaseAgreementRenewalPeriod">P5Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-10132">0001368514</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-10133">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-10134">Q1</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate" id="ixv-10135">--12-31</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="adma-20250331.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_4_fact ix_5_fact" toRefs="ix_1_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-05-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:TwoCustomersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-18</xbrli:startDate>
    <xbrli:endDate>2023-12-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-18</xbrli:startDate>
    <xbrli:endDate>2023-12-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-18</xbrli:startDate>
    <xbrli:endDate>2023-12-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-18</xbrli:startDate>
    <xbrli:endDate>2023-12-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-18</xbrli:startDate>
    <xbrli:endDate>2023-12-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToFirstAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-18</xbrli:startDate>
    <xbrli:endDate>2023-12-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidAfterTheFirstAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-18</xbrli:startDate>
    <xbrli:endDate>2023-12-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToThirdAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-18</xbrli:startDate>
    <xbrli:endDate>2023-12-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-05-06</xbrli:startDate>
    <xbrli:endDate>2025-05-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-05-05</xbrli:startDate>
    <xbrli:endDate>2025-05-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-05-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-05-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:EmployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uqgO9qQHmt9BQ98lPQIyw9cjUtWqGRthAHbCpPWJm+ZBnUANbVsFup3oAMJaWvFS/k3ezQjgEaFZJvCq0OWEaVRhBMH4wstjV4pDB+cYAEkKIlZ4nwn5o7i0ti/NOF+bcutUP8C4CXNiPP5su4uqzFkgaDLt3IeykvMgrNxbz1zlEBFkcWhdBcut2hb2b7lGcY9pI+D9MeK/5zybfw/v3KnrZo32yWITlcc0KRPcZ6zOPZmYvhb/tEniiceTZ24RBRac1FqiAwvFDAjQn4JwB] CSR-->
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:GenesisBPSMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:GenesisBPSMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:GrifolsAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:KEDPlasmaAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:GrifolsAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:KEDPlasmaAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-04-01</xbrli:startDate>
    <xbrli:endDate>2019-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-05-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="Facility">
  <xbrli:measure>adma:Facility</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="Product">
  <xbrli:measure>adma:Product</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="Customer">
  <xbrli:measure>adma:Customer</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="Term">
  <xbrli:measure>adma:Term</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="L">
  <xbrli:measure>adma:L</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="Segment">
  <xbrli:measure>adma:Segment</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>adma-20250331.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION - SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 07 19:58:08 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://admabiologics.com/20250331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:adma="http://admabiologics.com/20250331" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20250331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20250331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20250331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20250331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://admabiologics.com/role/ConsolidatedBalanceSheet" id="adma_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ConsolidatedBalanceSheet_Parentheticals" id="adma_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ConsolidatedIncomeStatement" id="adma_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ShareholdersEquityType2or3" id="adma_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ConsolidatedCashFlow" id="adma_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ORGANIZATIONANDBUSINESS" id="adma_r_ORGANIZATIONANDBUSINESS">
        <link:definition>995306 - Disclosure - ORGANIZATION AND BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" id="adma_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>995307 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/INVENTORIES" id="adma_r_INVENTORIES">
        <link:definition>995308 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PROPERTYANDEQUIPMENT" id="adma_r_PROPERTYANDEQUIPMENT">
        <link:definition>995309 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" id="adma_r_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES">
        <link:definition>995310 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/DEBT" id="adma_r_DEBT">
        <link:definition>995311 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITY" id="adma_r_STOCKHOLDERSEQUITY">
        <link:definition>995312 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/RELATEDPARTYTRANSACTIONS" id="adma_r_RELATEDPARTYTRANSACTIONS">
        <link:definition>995313 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIES" id="adma_r_COMMITMENTSANDCONTINGENCIES">
        <link:definition>995314 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SEGMENTS" id="adma_r_SEGMENTS">
        <link:definition>995315 - Disclosure - SEGMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LEASEOBLIGATIONS" id="adma_r_LEASEOBLIGATIONS">
        <link:definition>995316 - Disclosure - LEASE OBLIGATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/INCOMETAXES" id="adma_r_INCOMETAXES">
        <link:definition>995317 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATION" id="adma_r_SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATION">
        <link:definition>995318 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SUBSEQUENTEVENTS" id="adma_r_SUBSEQUENTEVENTS">
        <link:definition>995319 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/AccountingPoliciesByPolicy" id="adma_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" id="adma_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>996001 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/INVENTORIESTables" id="adma_r_INVENTORIESTables">
        <link:definition>996002 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PROPERTYANDEQUIPMENTTables" id="adma_r_PROPERTYANDEQUIPMENTTables">
        <link:definition>996003 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" id="adma_r_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables">
        <link:definition>996004 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/DEBTTables" id="adma_r_DEBTTables">
        <link:definition>996005 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITYTables" id="adma_r_STOCKHOLDERSEQUITYTables">
        <link:definition>996006 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SEGMENTSTables" id="adma_r_SEGMENTSTables">
        <link:definition>996007 - Disclosure - SEGMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LEASEOBLIGATIONSTables" id="adma_r_LEASEOBLIGATIONSTables">
        <link:definition>996008 - Disclosure - LEASE OBLIGATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/INCOMETAXESTables" id="adma_r_INCOMETAXESTables">
        <link:definition>996009 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATIONTables" id="adma_r_SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATIONTables">
        <link:definition>996010 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ORGANIZATIONANDBUSINESSDetails" id="adma_r_ORGANIZATIONANDBUSINESSDetails">
        <link:definition>996011 - Disclosure - ORGANIZATION AND BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable" id="adma_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable">
        <link:definition>996012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill" id="adma_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill">
        <link:definition>996013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition" id="adma_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition">
        <link:definition>996014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable" id="adma_r_CalculationofBasicandDilutedEarningsPerShareTable">
        <link:definition>996015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of Basic and Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ComponentsofInventoryTable" id="adma_r_ComponentsofInventoryTable">
        <link:definition>996016 - Disclosure - INVENTORIES - Components of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PROPERTYANDEQUIPMENTDetails" id="adma_r_PROPERTYANDEQUIPMENTDetails">
        <link:definition>996017 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyandEquipmentTable" id="adma_r_PropertyandEquipmentTable">
        <link:definition>996018 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uqgO9qQHmt9BQ98lPQIyw9cjUtWqGRthAHbCpPWJm+ZBnUANbVsFup3oAMJaWvFS/k3ezQjgEaFZJvCq0OWEaVRhBMH4wstjV4pDB+cYAEkKIlZ4nwn5o7i0ti/NOF+bcutUP8C4CXNiPP5su4uqzFkgaDLt3IeykvMgrNxbz1zlEBFkcWhdBcut2hb2b7lGcY9pI+D9MeK/5zybfw/v3KnrZo32yWITlcc0KRPcZ6zOPZmYvhb/tEniiceTZ24QrpwwccSy6RhrAkR972JvA] CSR-->
      <link:roleType roleURI="http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable" id="adma_r_AccruedExpensesandOtherCurrentLiabilitiesTable">
        <link:definition>996019 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/DEBTDetails" id="adma_r_DEBTDetails">
        <link:definition>996020 - Disclosure - DEBT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable" id="adma_r_SummaryofOutstandingSeniorNotesPayableTable">
        <link:definition>996021 - Disclosure - DEBT - Summary of Outstanding Senior Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsPreferredStock" id="adma_r_STOCKHOLDERSEQUITYDetailsPreferredStock">
        <link:definition>996022 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsCommonStock" id="adma_r_STOCKHOLDERSEQUITYDetailsCommonStock">
        <link:definition>996023 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants" id="adma_r_STOCKHOLDERSEQUITYDetailsWarrants">
        <link:definition>996024 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans" id="adma_r_STOCKHOLDERSEQUITYDetailsEquityIncentivePlans">
        <link:definition>996025 - Disclosure - STOCKHOLDERS' EQUITY - Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ScheduleofAssumptionsTable" id="adma_r_ScheduleofAssumptionsTable">
        <link:definition>996026 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ScheduleofOptionActivityTable" id="adma_r_ScheduleofOptionActivityTable">
        <link:definition>996027 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable" id="adma_r_ScheduleofUnvestedRSUActivityTable">
        <link:definition>996028 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Unvested RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable" id="adma_r_ScheduleofStockBasedCompensationExpenseTable">
        <link:definition>996029 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails" id="adma_r_RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>996030 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails" id="adma_r_COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>996031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SEGMENTSDetails" id="adma_r_SEGMENTSDetails">
        <link:definition>996032 - Disclosure - SEGMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable" id="adma_r_SummarizedFinancialInformationbySegmentTable">
        <link:definition>996033 - Disclosure - SEGMENTS - Summarized Financial Information by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable" id="adma_r_NetRevenuesAccordingtoGeographicAreaTable">
        <link:definition>996034 - Disclosure - SEGMENTS - Net Revenues According to Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LEASEOBLIGATIONSDetails" id="adma_r_LEASEOBLIGATIONSDetails">
        <link:definition>996035 - Disclosure - LEASE OBLIGATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable" id="adma_r_PaymentsUnderLeaseObligationsTable">
        <link:definition>996036 - Disclosure - LEASE OBLIGATIONS - Payments Under Lease Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/INCOMETAXESDetails" id="adma_r_INCOMETAXESDetails">
        <link:definition>996037 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/EstimatedAnnualEffectiveTaxRateTable" id="adma_r_EstimatedAnnualEffectiveTaxRateTable">
        <link:definition>996038 - Disclosure - INCOME TAXES - Estimated Annual Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalCashFlowInformationTable" id="adma_r_SupplementalCashFlowInformationTable">
        <link:definition>996039 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SUBSEQUENTEVENTSDetails" id="adma_r_SUBSEQUENTEVENTSDetails">
        <link:definition>996040 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:element name="CalculationOfBasicAndDilutedEarningsPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_CalculationOfBasicAndDilutedEarningsPerShareAbstract"/>
  <xs:element name="PropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_PropertyAndEquipmentAbstract"/>
  <xs:element name="SummaryOfOutstandingSeniorNotesPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_SummaryOfOutstandingSeniorNotesPayableAbstract"/>
  <xs:element name="ScheduleOfAssumptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ScheduleOfAssumptionsAbstract"/>
  <xs:element name="ScheduleOfOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ScheduleOfOptionActivityAbstract"/>
  <xs:element name="ScheduleOfUnvestedRsuActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ScheduleOfUnvestedRsuActivityAbstract"/>
  <xs:element name="ScheduleOfStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ScheduleOfStockBasedCompensationExpenseAbstract"/>
  <xs:element name="SummarizedFinancialInformationBySegmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_SummarizedFinancialInformationBySegmentAbstract"/>
  <xs:element name="NetRevenuesAccordingToGeographicAreaAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_NetRevenuesAccordingToGeographicAreaAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_UnlabeledAbstract3"/>
  <xs:element name="ReconciliationOfRevenuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ReconciliationOfRevenuesAbstract"/>
  <xs:element name="ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract"/>
  <xs:element name="ReconciliationOfIncomeLossBeforeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract"/>
  <xs:element name="ReconciliationOfTotalAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ReconciliationOfTotalAssetsAbstract"/>
  <xs:element name="ReconciliationOfRevenuesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ReconciliationOfRevenuesAbstract0"/>
  <xs:element name="ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract0"/>
  <xs:element name="ReconciliationOfIncomeLossBeforeTaxesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract0"/>
  <xs:element name="ReconciliationOfTotalAssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ReconciliationOfTotalAssetsAbstract0"/>
  <xs:element name="DepositsAndOtherNoncurrentAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adma_DepositsAndOtherNoncurrentAssets"/>
  <xs:element name="LongTermLiabilityEndOfTermFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adma_LongTermLiabilityEndOfTermFeePayable"/>
  <xs:element name="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants"/>
  <xs:element name="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants"/>
  <xs:element name="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares"/>
  <xs:element name="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount"/>
  <xs:element name="AmortizationOfLicenseRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adma_AmortizationOfLicenseRevenue"/>
  <xs:element name="IncreaseDecreaseInDepositsAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adma_IncreaseDecreaseInDepositsAndOtherAssets"/>
  <xs:element name="TaxesPaidOnVestedRestrictedStockUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adma_TaxesPaidOnVestedRestrictedStockUnits"/>
  <xs:element name="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adma_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable"/>
  <xs:element name="AccruedRebatesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adma_AccruedRebatesCurrent"/>
  <xs:element name="AccruedTestingCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adma_AccruedTestingCurrent"/>
  <xs:element name="DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adma_DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable"/>
  <xs:element name="SeniorNotesPayableBeforeDebtDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adma_SeniorNotesPayableBeforeDebtDiscount"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice"/>
  <xs:element name="SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adma_SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable"/>
  <xs:element name="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities"/>
  <xs:element name="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment"/>
  <xs:element name="NumberOfFDAApprovedProduct" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_NumberOfFDAApprovedProduct"/>
  <xs:element name="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts"/>
  <xs:element name="NumberOfCustomers" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_NumberOfCustomers"/>
  <xs:element name="DeferredRevenueRemainingAmortizationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_DeferredRevenueRemainingAmortizationPeriod"/>
  <xs:element name="DEBTDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adma_DEBTDetailsTable"/>
  <xs:element name="DebtInstrumentTermOfVariableRate" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_DebtInstrumentTermOfVariableRate"/>
  <xs:element name="NumberOfBusinessDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_NumberOfBusinessDays"/>
  <xs:element name="DebtInstrumentApplicableMargin" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_DebtInstrumentApplicableMargin"/>
  <xs:element name="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal"/>
  <xs:element name="MinimumLiquidityCovenantsCreditFacilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adma_MinimumLiquidityCovenantsCreditFacilities"/>
  <xs:element name="COMMITMENTSANDCONTINGENCIESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adma_COMMITMENTSANDCONTINGENCIESDetailsTable"/>
  <xs:element name="NumberOfPlasmaCollectionFacilities" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_NumberOfPlasmaCollectionFacilities"/>
  <xs:element name="AgreementWithTermExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_AgreementWithTermExpirationDate"/>
  <xs:element name="NumberOfRenewalTerms" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_NumberOfRenewalTerms"/>
  <xs:element name="QuantityOfRespiratorySyncytialVirusPlasmaUsed" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed"/>
  <xs:element name="RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod"/>
  <xs:element name="IncreaseInMinimumAnnualPriceTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_IncreaseInMinimumAnnualPriceTerm"/>
  <xs:element name="PlasmaPurchaseAgreementRenewalPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_PlasmaPurchaseAgreementRenewalPeriod"/>
  <xs:element name="PlasmaSupplyAgreementTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_PlasmaSupplyAgreementTerm"/>
  <xs:element name="NumberOfFDALicensedPlasmaCollectionFacilities" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities"/>
  <xs:element name="OperatingAndFinancingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adma_OperatingAndFinancingLeaseLiability"/>
  <xs:element name="SUBSEQUENTEVENTSDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adma_SUBSEQUENTEVENTSDetailsTable"/>
  <xs:element name="ADMABioManufacturingSegmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ADMABioManufacturingSegmentMember"/>
  <xs:element name="ASCENIVMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ASCENIVMember"/>
  <xs:element name="AresCreditAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_AresCreditAgreementMember"/>
  <xs:element name="AresCreditFacilityMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_AresCreditFacilityMember"/>
  <xs:element name="ArethLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ArethLLCMember"/>
  <xs:element name="EmployeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_EmployeesMember"/>
  <xs:element name="EquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_EquityIncentivePlanMember"/>
  <xs:element name="GenesisBPSMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_GenesisBPSMember"/>
  <xs:element name="GrifolsAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_GrifolsAgreementMember"/>
  <xs:element name="KEDPlasmaAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_KEDPlasmaAgreementMember"/>
  <xs:element name="PlasmaCollectionCentersSegmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_PlasmaCollectionCentersSegmentMember"/>
  <xs:element name="PlasmaPurchaseAgreementOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_PlasmaPurchaseAgreementOneMember"/>
  <xs:element name="PrepaidAfterTheFirstAnniversaryMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_PrepaidAfterTheFirstAnniversaryMember"/>
  <xs:element name="PrepaidOnOrPriorToFirstAnniversaryMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_PrepaidOnOrPriorToFirstAnniversaryMember"/>
  <xs:element name="PrepaidOnOrPriorToThirdAnniversaryMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_PrepaidOnOrPriorToThirdAnniversaryMember"/>
  <xs:element name="TermLoanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_TermLoanMember"/>
  <xs:element name="ThreeCustomersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_ThreeCustomersMember"/>
  <xs:element name="TwoCustomersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_TwoCustomersMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adma_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>adma-20250331_def.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION - DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 07 19:58:08 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ConsolidatedBalanceSheet" roleURI="http://admabiologics.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://admabiologics.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ConsolidatedIncomeStatement" roleURI="http://admabiologics.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ShareholdersEquityType2or3" roleURI="http://admabiologics.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ConsolidatedCashFlow" roleURI="http://admabiologics.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ORGANIZATIONANDBUSINESS" roleURI="http://admabiologics.com/role/ORGANIZATIONANDBUSINESS"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_INVENTORIES" roleURI="http://admabiologics.com/role/INVENTORIES"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_PROPERTYANDEQUIPMENT" roleURI="http://admabiologics.com/role/PROPERTYANDEQUIPMENT"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" roleURI="http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_DEBT" roleURI="http://admabiologics.com/role/DEBT"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_STOCKHOLDERSEQUITY" roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_RELATEDPARTYTRANSACTIONS" roleURI="http://admabiologics.com/role/RELATEDPARTYTRANSACTIONS"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_COMMITMENTSANDCONTINGENCIES" roleURI="http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIES"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SEGMENTS" roleURI="http://admabiologics.com/role/SEGMENTS"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_LEASEOBLIGATIONS" roleURI="http://admabiologics.com/role/LEASEOBLIGATIONS"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_INCOMETAXES" roleURI="http://admabiologics.com/role/INCOMETAXES"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATION" roleURI="http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATION"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUBSEQUENTEVENTS" roleURI="http://admabiologics.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_AccountingPoliciesByPolicy" roleURI="http://admabiologics.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_INVENTORIESTables" roleURI="http://admabiologics.com/role/INVENTORIESTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_PROPERTYANDEQUIPMENTTables" roleURI="http://admabiologics.com/role/PROPERTYANDEQUIPMENTTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" roleURI="http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_DEBTTables" roleURI="http://admabiologics.com/role/DEBTTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_STOCKHOLDERSEQUITYTables" roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITYTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SEGMENTSTables" roleURI="http://admabiologics.com/role/SEGMENTSTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_LEASEOBLIGATIONSTables" roleURI="http://admabiologics.com/role/LEASEOBLIGATIONSTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_INCOMETAXESTables" roleURI="http://admabiologics.com/role/INCOMETAXESTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATIONTables" roleURI="http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_CalculationofBasicandDilutedEarningsPerShareTable" roleURI="http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ComponentsofInventoryTable" roleURI="http://admabiologics.com/role/ComponentsofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_PropertyandEquipmentTable" roleURI="http://admabiologics.com/role/PropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_AccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SummaryofOutstandingSeniorNotesPayableTable" roleURI="http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ScheduleofAssumptionsTable" roleURI="http://admabiologics.com/role/ScheduleofAssumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ScheduleofOptionActivityTable" roleURI="http://admabiologics.com/role/ScheduleofOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ScheduleofUnvestedRSUActivityTable" roleURI="http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ScheduleofStockBasedCompensationExpenseTable" roleURI="http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SummarizedFinancialInformationbySegmentTable" roleURI="http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_NetRevenuesAccordingtoGeographicAreaTable" roleURI="http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_PaymentsUnderLeaseObligationsTable" roleURI="http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_EstimatedAnnualEffectiveTaxRateTable" roleURI="http://admabiologics.com/role/EstimatedAnnualEffectiveTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SupplementalCashFlowInformationTable" roleURI="http://admabiologics.com/role/SupplementalCashFlowInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ORGANIZATIONANDBUSINESSDetails" roleURI="http://admabiologics.com/role/ORGANIZATIONANDBUSINESSDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable" roleURI="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill" roleURI="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition" roleURI="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_PROPERTYANDEQUIPMENTDetails" roleURI="http://admabiologics.com/role/PROPERTYANDEQUIPMENTDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_DEBTDetails" roleURI="http://admabiologics.com/role/DEBTDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_STOCKHOLDERSEQUITYDetailsPreferredStock" roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsPreferredStock"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_STOCKHOLDERSEQUITYDetailsCommonStock" roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsCommonStock"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_STOCKHOLDERSEQUITYDetailsWarrants" roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_STOCKHOLDERSEQUITYDetailsEquityIncentivePlans" roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_RELATEDPARTYTRANSACTIONSDetails" roleURI="http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SEGMENTSDetails" roleURI="http://admabiologics.com/role/SEGMENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_LEASEOBLIGATIONSDetails" roleURI="http://admabiologics.com/role/LEASEOBLIGATIONSDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_INCOMETAXESDetails" roleURI="http://admabiologics.com/role/INCOMETAXESDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUBSEQUENTEVENTSDetails" roleURI="http://admabiologics.com/role/SUBSEQUENTEVENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://admabiologics.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Goodwill" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_DepositsAndOtherNoncurrentAssets" xlink:href="adma-20250331.xsd#adma_DepositsAndOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="adma_DepositsAndOtherNoncurrentAssets" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeniorLongTermNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_SeniorLongTermNotes" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_LongTermLiabilityEndOfTermFeePayable" xlink:href="adma-20250331.xsd#adma_LongTermLiabilityEndOfTermFeePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="adma_LongTermLiabilityEndOfTermFeePayable" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockValue" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="29" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherCostAndExpenseOperating" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:href="adma-20250331.xsd#adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:href="adma-20250331.xsd#adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:href="adma-20250331.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:href="adma-20250331.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_AmortizationOfLicenseRevenue" xlink:href="adma-20250331.xsd#adma_AmortizationOfLicenseRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="adma_AmortizationOfLicenseRevenue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:href="adma-20250331.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:href="adma-20250331.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/ORGANIZATIONANDBUSINESS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/INVENTORIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/DEBT" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/SEGMENTS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/LEASEOBLIGATIONS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/INCOMETAXES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATION" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/INVENTORIESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/DEBTTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/SEGMENTSTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/LEASEOBLIGATIONSTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/INCOMETAXESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATIONTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <loc xlink:type="locator" xlink:label="adma_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable" xlink:href="adma-20250331.xsd#adma_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="adma_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/ComponentsofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/PropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetUnderConstructionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetUnderConstructionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AssetUnderConstructionMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="adma_AccruedRebatesCurrent" xlink:href="adma-20250331.xsd#adma_AccruedRebatesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="adma_AccruedRebatesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_AccruedTestingCurrent" xlink:href="adma-20250331.xsd#adma_AccruedTestingCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="adma_AccruedTestingCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="adma_DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable" xlink:href="adma-20250331.xsd#adma_DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="adma_DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable" xlink:to="us-gaap_CreditFacilityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_TermLoanMember" xlink:href="adma-20250331.xsd#adma_TermLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="adma_TermLoanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount" xlink:href="adma-20250331.xsd#adma_SeniorNotesPayableBeforeDebtDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeniorLongTermNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SeniorLongTermNotes" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/ScheduleofAssumptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/ScheduleofOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uqgO9qQHmt9BQ98lPQIyw9cjUtWqGRthAHbCpPWJm+ZBnUANbVsFup3oAMJaWvFS/k3ezQjgEaFZJvCq0OWEaVRhBMH4wstjV4pDB+cYAEkKIlZ4nwn5o7i0ti/NOF+bcutUP8C4CXNiPP5su4uqzFkgaDLt3IeykvMgrNxbz1zlEBFkcWhdBcut2hb2b7lGcY9pI+D9MeK/5zybfw/v3KnrZo32yWITlcc0KRPcZ6zOPZmYvhb/tEniiceTZ24QNhvNqELDZ9kPshIJ7QV6r] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_ADMABioManufacturingSegmentMember" xlink:href="adma-20250331.xsd#adma_ADMABioManufacturingSegmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="adma_ADMABioManufacturingSegmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_PlasmaCollectionCentersSegmentMember" xlink:href="adma-20250331.xsd#adma_PlasmaCollectionCentersSegmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="adma_PlasmaCollectionCentersSegmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_MaterialReconcilingItemsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_CorporateNonSegmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_OtherCostAndExpenseOperating" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_Assets" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="adma_SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable" xlink:href="adma-20250331.xsd#adma_SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="adma_SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable" xlink:to="srt_ConsolidationItemsAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_MaterialReconcilingItemsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_ADMABioManufacturingSegmentMember" xlink:href="adma-20250331.xsd#adma_ADMABioManufacturingSegmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="adma_ADMABioManufacturingSegmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_PlasmaCollectionCentersSegmentMember" xlink:href="adma-20250331.xsd#adma_PlasmaCollectionCentersSegmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="adma_PlasmaCollectionCentersSegmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/EstimatedAnnualEffectiveTaxRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/SupplementalCashFlowInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:href="adma-20250331.xsd#adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/ORGANIZATIONANDBUSINESSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:href="adma-20250331.xsd#adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfFDAApprovedProduct" xlink:href="adma-20250331.xsd#adma_NumberOfFDAApprovedProduct"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="adma_NumberOfFDAApprovedProduct" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ScheduleOfChangeInAccountingEstimateTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="srt_MajorCustomersAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_ThreeCustomersMember" xlink:href="adma-20250331.xsd#adma_ThreeCustomersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adma_ThreeCustomersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:href="adma-20250331.xsd#adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfCustomers" xlink:href="adma-20250331.xsd#adma_NumberOfCustomers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="adma_NumberOfCustomers" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ScheduleOfChangeInAccountingEstimateTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_Goodwill" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ScheduleOfChangeInAccountingEstimateTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="srt_MajorCustomersAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_ThreeCustomersMember" xlink:href="adma-20250331.xsd#adma_ThreeCustomersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adma_ThreeCustomersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_TwoCustomersMember" xlink:href="adma-20250331.xsd#adma_TwoCustomersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adma_TwoCustomersMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_DeferredRevenueRemainingAmortizationPeriod" xlink:href="adma-20250331.xsd#adma_DeferredRevenueRemainingAmortizationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="adma_DeferredRevenueRemainingAmortizationPeriod" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfCustomers" xlink:href="adma-20250331.xsd#adma_NumberOfCustomers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="adma_NumberOfCustomers" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/DEBTDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="adma_DEBTDetailsTable" xlink:href="adma-20250331.xsd#adma_DEBTDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="adma_DEBTDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_DEBTDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_DEBTDetailsTable" xlink:to="us-gaap_CreditFacilityAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_DEBTDetailsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_DEBTDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_DEBTDetailsTable" xlink:to="srt_RangeAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_DEBTDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_AresCreditAgreementMember" xlink:href="adma-20250331.xsd#adma_AresCreditAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="adma_AresCreditAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_TermLoanMember" xlink:href="adma-20250331.xsd#adma_TermLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="adma_TermLoanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:href="adma-20250331.xsd#adma_PrepaidOnOrPriorToFirstAnniversaryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="adma_PrepaidOnOrPriorToFirstAnniversaryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_PrepaidAfterTheFirstAnniversaryMember" xlink:href="adma-20250331.xsd#adma_PrepaidAfterTheFirstAnniversaryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="adma_PrepaidAfterTheFirstAnniversaryMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_PrepaidOnOrPriorToThirdAnniversaryMember" xlink:href="adma-20250331.xsd#adma_PrepaidOnOrPriorToThirdAnniversaryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="adma_PrepaidOnOrPriorToThirdAnniversaryMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_AresCreditFacilityMember" xlink:href="adma-20250331.xsd#adma_AresCreditFacilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adma_AresCreditFacilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount" xlink:href="adma-20250331.xsd#adma_SeniorNotesPayableBeforeDebtDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_DebtInstrumentTermOfVariableRate" xlink:href="adma-20250331.xsd#adma_DebtInstrumentTermOfVariableRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="adma_DebtInstrumentTermOfVariableRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfBusinessDays" xlink:href="adma-20250331.xsd#adma_NumberOfBusinessDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="adma_NumberOfBusinessDays" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_DebtInstrumentApplicableMargin" xlink:href="adma-20250331.xsd#adma_DebtInstrumentApplicableMargin"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="adma_DebtInstrumentApplicableMargin" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:href="adma-20250331.xsd#adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_MinimumLiquidityCovenantsCreditFacilities" xlink:href="adma-20250331.xsd#adma_MinimumLiquidityCovenantsCreditFacilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="adma_MinimumLiquidityCovenantsCreditFacilities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsPreferredStock" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsCommonStock" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_EquityIncentivePlanMember" xlink:href="adma-20250331.xsd#adma_EquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adma_EquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_EmployeesMember" xlink:href="adma-20250331.xsd#adma_EmployeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="adma_EmployeesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_ArethLLCMember" xlink:href="adma-20250331.xsd#adma_ArethLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="adma_ArethLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_GenesisBPSMember" xlink:href="adma-20250331.xsd#adma_GenesisBPSMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="adma_GenesisBPSMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:label="adma_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:href="adma-20250331.xsd#adma_COMMITMENTSANDCONTINGENCIESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="adma_COMMITMENTSANDCONTINGENCIESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_ASCENIVMember" xlink:href="adma-20250331.xsd#adma_ASCENIVMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adma_ASCENIVMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_PlasmaPurchaseAgreementOneMember" xlink:href="adma-20250331.xsd#adma_PlasmaPurchaseAgreementOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_GrifolsAgreementMember" xlink:href="adma-20250331.xsd#adma_GrifolsAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adma_GrifolsAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_KEDPlasmaAgreementMember" xlink:href="adma-20250331.xsd#adma_KEDPlasmaAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adma_KEDPlasmaAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfPlasmaCollectionFacilities" xlink:href="adma-20250331.xsd#adma_NumberOfPlasmaCollectionFacilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="adma_NumberOfPlasmaCollectionFacilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_AgreementWithTermExpirationDate" xlink:href="adma-20250331.xsd#adma_AgreementWithTermExpirationDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="adma_AgreementWithTermExpirationDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfRenewalTerms" xlink:href="adma-20250331.xsd#adma_NumberOfRenewalTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="adma_NumberOfRenewalTerms" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:href="adma-20250331.xsd#adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:href="adma-20250331.xsd#adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_IncreaseInMinimumAnnualPriceTerm" xlink:href="adma-20250331.xsd#adma_IncreaseInMinimumAnnualPriceTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="adma_IncreaseInMinimumAnnualPriceTerm" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:href="adma-20250331.xsd#adma_PlasmaPurchaseAgreementRenewalPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_PlasmaSupplyAgreementTerm" xlink:href="adma-20250331.xsd#adma_PlasmaSupplyAgreementTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="adma_PlasmaSupplyAgreementTerm" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/SEGMENTSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:href="adma-20250331.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/LEASEOBLIGATIONSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_OperatingAndFinancingLeaseLiability" xlink:href="adma-20250331.xsd#adma_OperatingAndFinancingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="adma_OperatingAndFinancingLeaseLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/INCOMETAXESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://admabiologics.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="adma_SUBSEQUENTEVENTSDetailsTable" xlink:href="adma-20250331.xsd#adma_SUBSEQUENTEVENTSDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="adma_SUBSEQUENTEVENTSDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adma_SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_CreditFacilityAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adma_TermLoanMember" xlink:href="adma-20250331.xsd#adma_TermLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="adma_TermLoanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCredit" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrMember" order="0" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>adma-20250331_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 07 19:58:08 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">INCOME FROM OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">INCOME BEFORE INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (loss) before taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net income available to common stockholders (numerator) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash used in financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents - beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents - end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">ORGANIZATION AND BUSINESS [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Total property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Total accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">DEBT [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&apos; EQUITY [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, vested and expected to vest, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Options outstanding, vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options outstanding, vested and expected to vest, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Options outstanding, vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">SEGMENTS [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsAxis_lbl" xml:lang="en-US">Consolidation Items [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">LEASE OBLIGATIONS [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Payments Under Lease Obligations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">INCOME TAXES [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-to-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_DepositsAndOtherNoncurrentAssets" xlink:href="adma-20250331.xsd#adma_DepositsAndOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_DepositsAndOtherNoncurrentAssets_lbl" xml:lang="en-US">Deposits and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DepositsAndOtherNoncurrentAssets" xlink:to="adma_DepositsAndOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Current portion of deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeniorLongTermNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeniorLongTermNotes_lbl" xml:lang="en-US">Senior notes payable, net of discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeniorLongTermNotes_lbl0" xml:lang="en-US">Senior notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenue, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_LongTermLiabilityEndOfTermFeePayable" xlink:href="adma-20250331.xsd#adma_LongTermLiabilityEndOfTermFeePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_LongTermLiabilityEndOfTermFeePayable_lbl" xml:lang="en-US">End of term fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_LongTermLiabilityEndOfTermFeePayable" xlink:to="adma_LongTermLiabilityEndOfTermFeePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease obligations, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Balance at March 31, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred stock, outstanding (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 238,532,252 and 236,620,545 shares issued and outstanding at March 31, 2025 and December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of product revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US">Plasma center operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Consolidated selling, general and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSE):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Unallocated interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">BASIC EARNINGS PER COMMON SHARE (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Basic earnings per common shares (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">DILUTED EARNINGS PER COMMON SHARE (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Diluted earnings per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted-average number of common shares (denominator)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted-average number of common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Total shares - diluted (denominator)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:href="adma-20250331.xsd#adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl" xml:lang="en-US">Cashless exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:href="adma-20250331.xsd#adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl" xml:lang="en-US">Cashless exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:href="adma-20250331.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl" xml:lang="en-US">Vesting of restricted stock units, net of shares withheld for taxes (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:href="adma-20250331.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl" xml:lang="en-US">Vesting of restricted stock units, net of shares withheld for taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net income to net cash provided used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_AmortizationOfLicenseRevenue" xlink:href="adma-20250331.xsd#adma_AmortizationOfLicenseRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_AmortizationOfLicenseRevenue_lbl" xml:lang="en-US">Amortization of license revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Other current and non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Net proceeds from the exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl0" xml:lang="en-US">Unallocated interest expense, primarily related to interest on senior debt (see Note 6)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Loss on disposal of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:href="adma-20250331.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" xml:lang="en-US">Deposits and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Acquisition of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:href="adma-20250331.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" xml:lang="en-US">Taxes paid on vested restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND BUSINESS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Calculation of Basic and Diluted Earnings Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US">Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Components of Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work-in-process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_AccruedRebatesCurrent" xlink:href="adma-20250331.xsd#adma_AccruedRebatesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_AccruedRebatesCurrent_lbl" xml:lang="en-US">Accrued rebates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AccruedRebatesCurrent" xlink:to="adma_AccruedRebatesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued distribution fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued incentives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_AccruedTestingCurrent" xlink:href="adma-20250331.xsd#adma_AccruedTestingCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_AccruedTestingCurrent_lbl" xml:lang="en-US">Accrued testing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AccruedTestingCurrent" xlink:to="adma_AccruedTestingCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll and other compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Income taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Summary of Outstanding Senior Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount" xlink:href="adma-20250331.xsd#adma_SeniorNotesPayableBeforeDebtDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount_lbl" xml:lang="en-US">Senior notes payable before debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_SeniorNotesPayableBeforeDebtDiscount" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" xml:lang="en-US">Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" xml:lang="en-US">Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" xml:lang="en-US">Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" xml:lang="en-US">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" xml:lang="en-US">Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Unvested RSU Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Summarized Financial Information Concerning Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_UnlabeledAbstract" xlink:href="adma-20250331.xsd#adma_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_UnlabeledAbstract" xlink:to="adma_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_UnlabeledAbstract0" xlink:href="adma-20250331.xsd#adma_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_UnlabeledAbstract0" xlink:to="adma_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_UnlabeledAbstract1" xlink:href="adma-20250331.xsd#adma_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_UnlabeledAbstract1" xlink:to="adma_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_UnlabeledAbstract2" xlink:href="adma-20250331.xsd#adma_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_UnlabeledAbstract2" xlink:to="adma_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Selling, marketing and distribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_UnlabeledAbstract3" xlink:href="adma-20250331.xsd#adma_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_UnlabeledAbstract3" xlink:to="adma_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets_lbl" xml:lang="en-US">Expenditures for additions to long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:to="us-gaap_SegmentExpenditureAdditionToLongLivedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ReconciliationOfRevenuesAbstract" xlink:href="adma-20250331.xsd#adma_ReconciliationOfRevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ReconciliationOfRevenuesAbstract_lbl" xml:lang="en-US">Reconciliation of revenues:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfRevenuesAbstract" xlink:to="adma_ReconciliationOfRevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract" xlink:href="adma-20250331.xsd#adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">Reconciliation of selling, general and administrative expense:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract" xlink:to="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract" xlink:href="adma-20250331.xsd#adma_ReconciliationOfIncomeLossBeforeTaxesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract_lbl" xml:lang="en-US">Reconciliation of income (loss) before taxes:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract" xlink:to="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ReconciliationOfTotalAssetsAbstract" xlink:href="adma-20250331.xsd#adma_ReconciliationOfTotalAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ReconciliationOfTotalAssetsAbstract_lbl" xml:lang="en-US">Reconciliation of total assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfTotalAssetsAbstract" xlink:to="adma_ReconciliationOfTotalAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ReconciliationOfRevenuesAbstract0" xlink:href="adma-20250331.xsd#adma_ReconciliationOfRevenuesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ReconciliationOfRevenuesAbstract0_lbl" xml:lang="en-US">Reconciliation of revenues:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfRevenuesAbstract0" xlink:to="adma_ReconciliationOfRevenuesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract0" xlink:href="adma-20250331.xsd#adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract0_lbl" xml:lang="en-US">Reconciliation of selling, general and administrative expense:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract0" xlink:to="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract0" xlink:href="adma-20250331.xsd#adma_ReconciliationOfIncomeLossBeforeTaxesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract0_lbl" xml:lang="en-US">Reconciliation of income (loss) before taxes:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract0" xlink:to="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ReconciliationOfTotalAssetsAbstract0" xlink:href="adma-20250331.xsd#adma_ReconciliationOfTotalAssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ReconciliationOfTotalAssetsAbstract0_lbl" xml:lang="en-US">Reconciliation of total assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfTotalAssetsAbstract0" xlink:to="adma_ReconciliationOfTotalAssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Net Revenues According to Geographic Area</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASE OBLIGATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Payments Under Lease Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Remainder of 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Year ended December 31, 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2030</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Estimated Annual Effective Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Supplemental Cash Flow Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Financing and Investing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:href="adma-20250331.xsd#adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Equipment acquired reflected in accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xml:lang="en-US">Manufacturing and Laboratory Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment and Computer Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetUnderConstructionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetUnderConstructionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetUnderConstructionMember_lbl" xml:lang="en-US">Construction in Process [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetUnderConstructionMember" xlink:to="us-gaap_AssetUnderConstructionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xml:lang="en-US">Buildings and Building Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_TermLoanMember" xlink:href="adma-20250331.xsd#adma_TermLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_TermLoanMember_lbl" xml:lang="en-US">Term Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_TermLoanMember" xlink:to="adma_TermLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving Credit Facility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenseMember_lbl" xml:lang="en-US">Plasma Center Operating Expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Product Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US">Operating Segments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaterialReconcilingItemsMember_lbl" xml:lang="en-US">Reconciling Item [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaterialReconcilingItemsMember" xlink:to="us-gaap_MaterialReconcilingItemsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateNonSegmentMember_lbl" xml:lang="en-US">Corporate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateNonSegmentMember" xlink:to="us-gaap_CorporateNonSegmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ADMABioManufacturingSegmentMember" xlink:href="adma-20250331.xsd#adma_ADMABioManufacturingSegmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ADMABioManufacturingSegmentMember_lbl" xml:lang="en-US">ADMA BioManufacturing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ADMABioManufacturingSegmentMember" xlink:to="adma_ADMABioManufacturingSegmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_PlasmaCollectionCentersSegmentMember" xlink:href="adma-20250331.xsd#adma_PlasmaCollectionCentersSegmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_PlasmaCollectionCentersSegmentMember_lbl" xml:lang="en-US">Plasma Collection Centers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PlasmaCollectionCentersSegmentMember" xlink:to="adma_PlasmaCollectionCentersSegmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonUsMember_lbl" xml:lang="en-US">International [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:href="adma-20250331.xsd#adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" xml:lang="en-US">Number of FDA-licensed plasma collection facilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfFDAApprovedProduct" xlink:href="adma-20250331.xsd#adma_NumberOfFDAApprovedProduct"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_NumberOfFDAApprovedProduct_lbl" xml:lang="en-US">Number of FDA approved product</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfFDAApprovedProduct" xlink:to="adma_NumberOfFDAApprovedProduct_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:href="adma-20250331.xsd#adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" xml:lang="en-US">Accounts receivable, allowances for contractual credits and credit losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfCustomers" xlink:href="adma-20250331.xsd#adma_NumberOfCustomers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_NumberOfCustomers_lbl" xml:lang="en-US">Number of customers (in Customer)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Percentage of consolidated revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Impairment charges related to goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_DeferredRevenueRemainingAmortizationPeriod" xlink:href="adma-20250331.xsd#adma_DeferredRevenueRemainingAmortizationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_DeferredRevenueRemainingAmortizationPeriod_lbl" xml:lang="en-US">Amortization period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DeferredRevenueRemainingAmortizationPeriod" xlink:to="adma_DeferredRevenueRemainingAmortizationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potentially dilutive securities (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_DebtInstrumentTermOfVariableRate" xlink:href="adma-20250331.xsd#adma_DebtInstrumentTermOfVariableRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_DebtInstrumentTermOfVariableRate_lbl" xml:lang="en-US">Term of variable rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DebtInstrumentTermOfVariableRate" xlink:to="adma_DebtInstrumentTermOfVariableRate_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfBusinessDays" xlink:href="adma-20250331.xsd#adma_NumberOfBusinessDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_NumberOfBusinessDays_lbl" xml:lang="en-US">Number of business days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfBusinessDays" xlink:to="adma_NumberOfBusinessDays_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_DebtInstrumentApplicableMargin" xlink:href="adma-20250331.xsd#adma_DebtInstrumentApplicableMargin"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_DebtInstrumentApplicableMargin_lbl" xml:lang="en-US">Applicable margin</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DebtInstrumentApplicableMargin" xlink:to="adma_DebtInstrumentApplicableMargin_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl" xml:lang="en-US">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Scheduled principal payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xml:lang="en-US">Frequency of periodic payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" xml:lang="en-US">Interest payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:href="adma-20250331.xsd#adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl" xml:lang="en-US">Number of business days for prior written notice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:to="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xml:lang="en-US">Revolving facility percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Aggregate principal amount revolving credit facility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xml:lang="en-US">Percentage of prepaid principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Amount of loan repaid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Amount drew from the credit facility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Line of credit outstanding balance amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_MinimumLiquidityCovenantsCreditFacilities" xlink:href="adma-20250331.xsd#adma_MinimumLiquidityCovenantsCreditFacilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_MinimumLiquidityCovenantsCreditFacilities_lbl" xml:lang="en-US">Minimum liquidity covenant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_MinimumLiquidityCovenantsCreditFacilities" xlink:to="adma_MinimumLiquidityCovenantsCreditFacilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US">Increase applicable margin</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Preferred stock, shares authorized (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrant to purchase shares of common stock (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense, stock options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Unrecognized compensation expense recognition period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Equity incentive plans, vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized compensation expense, non option (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Purchased materials amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfPlasmaCollectionFacilities" xlink:href="adma-20250331.xsd#adma_NumberOfPlasmaCollectionFacilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_NumberOfPlasmaCollectionFacilities_lbl" xml:lang="en-US">Number of plasma collection facilities (in Facility)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfPlasmaCollectionFacilities" xlink:to="adma_NumberOfPlasmaCollectionFacilities_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_AgreementWithTermExpirationDate" xlink:href="adma-20250331.xsd#adma_AgreementWithTermExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_AgreementWithTermExpirationDate_lbl" xml:lang="en-US">Agreement term expiring date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AgreementWithTermExpirationDate" xlink:to="adma_AgreementWithTermExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfRenewalTerms" xlink:href="adma-20250331.xsd#adma_NumberOfRenewalTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_NumberOfRenewalTerms_lbl" xml:lang="en-US">Number of renewal terms (in Term)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfRenewalTerms" xlink:to="adma_NumberOfRenewalTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:href="adma-20250331.xsd#adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl" xml:lang="en-US">Quantity of RSV plasma used (in L)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:to="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:href="adma-20250331.xsd#adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl" xml:lang="en-US">Volume supplied period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:to="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_IncreaseInMinimumAnnualPriceTerm" xlink:href="adma-20250331.xsd#adma_IncreaseInMinimumAnnualPriceTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_IncreaseInMinimumAnnualPriceTerm_lbl" xml:lang="en-US">Increase in minimum annual price, term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_IncreaseInMinimumAnnualPriceTerm" xlink:to="adma_IncreaseInMinimumAnnualPriceTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:href="adma-20250331.xsd#adma_PlasmaPurchaseAgreementRenewalPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" xml:lang="en-US">Plasma purchase agreement renewal period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_PlasmaSupplyAgreementTerm" xlink:href="adma-20250331.xsd#adma_PlasmaSupplyAgreementTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_PlasmaSupplyAgreementTerm_lbl" xml:lang="en-US">Plasma supply agreement term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:href="adma-20250331.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" xml:lang="en-US">Number of FDA-licensed plasma collection facilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Aggregate lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash payments for lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_OperatingAndFinancingLeaseLiability" xlink:href="adma-20250331.xsd#adma_OperatingAndFinancingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_OperatingAndFinancingLeaseLiability_lbl" xml:lang="en-US">Operating and financing lease liabilities</label>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uqgO9qQHmt9BQ98lPQIyw9cjUtWqGRthAHbCpPWJm+ZBnUANbVsFup3oAMJaWvFS/k3ezQjgEaFZJvCq0OWEaVRhBMH4wstjV4pDB+cYAEkKIlZ4nwn5o7i0ti/NOF+bcutUP8C4CXNiPP5su4uqzFkgaDLt3IeykvMgrNxbz1zlEBFkcWhdBcut2hb2b7lGcY9pI+D9MeK/5zybfw/v3KnrZo32yWITlcc0KRPcZ6zOPZmYvhb/tEniiceTZ24TPAKN8pt187rKlRiJe0DYa] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_OperatingAndFinancingLeaseLiability" xlink:to="adma_OperatingAndFinancingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1_lbl" xml:lang="en-US">Share repurchase program authorized amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation and basis of presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Product Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings/loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ThreeCustomersMember" xlink:href="adma-20250331.xsd#adma_ThreeCustomersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ThreeCustomersMember_lbl" xml:lang="en-US">Three Customers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ThreeCustomersMember" xlink:to="adma_ThreeCustomersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Consolidated Revenues [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_TwoCustomersMember" xlink:href="adma-20250331.xsd#adma_TwoCustomersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_TwoCustomersMember_lbl" xml:lang="en-US">Two Customers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_TwoCustomersMember" xlink:to="adma_TwoCustomersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_AresCreditAgreementMember" xlink:href="adma-20250331.xsd#adma_AresCreditAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_AresCreditAgreementMember_lbl" xml:lang="en-US">Ares Credit Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AresCreditAgreementMember" xlink:to="adma_AresCreditAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_AresCreditFacilityMember" xlink:href="adma-20250331.xsd#adma_AresCreditFacilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_AresCreditFacilityMember_lbl" xml:lang="en-US">Ares Credit Facility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AresCreditFacilityMember" xlink:to="adma_AresCreditFacilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:href="adma-20250331.xsd#adma_PrepaidOnOrPriorToFirstAnniversaryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl" xml:lang="en-US">Prepaid on or Prior to First Anniversary [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_PrepaidAfterTheFirstAnniversaryMember" xlink:href="adma-20250331.xsd#adma_PrepaidAfterTheFirstAnniversaryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_PrepaidAfterTheFirstAnniversaryMember_lbl" xml:lang="en-US">Prepaid after the First Anniversary [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PrepaidAfterTheFirstAnniversaryMember" xlink:to="adma_PrepaidAfterTheFirstAnniversaryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_PrepaidOnOrPriorToThirdAnniversaryMember" xlink:href="adma-20250331.xsd#adma_PrepaidOnOrPriorToThirdAnniversaryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl" xml:lang="en-US">Prepaid on or Prior to Third Anniversary [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PrepaidOnOrPriorToThirdAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_EquityIncentivePlanMember" xlink:href="adma-20250331.xsd#adma_EquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_EquityIncentivePlanMember_lbl" xml:lang="en-US">Equity Incentive Plans [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_EquityIncentivePlanMember" xlink:to="adma_EquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_EmployeesMember" xlink:href="adma-20250331.xsd#adma_EmployeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_EmployeesMember" xlink:to="adma_EmployeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ArethLLCMember" xlink:href="adma-20250331.xsd#adma_ArethLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ArethLLCMember_lbl" xml:lang="en-US">Areth, LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ArethLLCMember" xlink:to="adma_ArethLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_GenesisBPSMember" xlink:href="adma-20250331.xsd#adma_GenesisBPSMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_GenesisBPSMember_lbl" xml:lang="en-US">Genesis [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_GenesisBPSMember" xlink:to="adma_GenesisBPSMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_PlasmaPurchaseAgreementOneMember" xlink:href="adma-20250331.xsd#adma_PlasmaPurchaseAgreementOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_PlasmaPurchaseAgreementOneMember_lbl" xml:lang="en-US">2011 Plasma Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PlasmaPurchaseAgreementOneMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_GrifolsAgreementMember" xlink:href="adma-20250331.xsd#adma_GrifolsAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_GrifolsAgreementMember_lbl" xml:lang="en-US">A&amp;R Grifols Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_GrifolsAgreementMember" xlink:to="adma_GrifolsAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_KEDPlasmaAgreementMember" xlink:href="adma-20250331.xsd#adma_KEDPlasmaAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_KEDPlasmaAgreementMember_lbl" xml:lang="en-US">A&amp;R Grifols Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_KEDPlasmaAgreementMember" xlink:to="adma_KEDPlasmaAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_ASCENIVMember" xlink:href="adma-20250331.xsd#adma_ASCENIVMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adma_ASCENIVMember_lbl" xml:lang="en-US">ASCENIV [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ASCENIVMember" xlink:to="adma_ASCENIVMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable" xlink:href="adma-20250331.xsd#adma_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of Basic and Diluted Earnings Per Share (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable" xlink:to="adma_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_lbl" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDilutedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US">Credit Facility [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable" xlink:href="adma-20250331.xsd#adma_DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable_lbl" xml:lang="en-US">DEBT - Summary of Outstanding Senior Notes Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable" xlink:to="adma_DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsDomain_lbl" xml:lang="en-US">Consolidation Items [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable" xlink:href="adma-20250331.xsd#adma_SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable_lbl" xml:lang="en-US">SEGMENTS - Net Revenues According to Geographic Area (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable" xlink:to="adma_SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfChangeInAccountingEstimateTable_lbl" xml:lang="en-US">Change in Accounting Estimate [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="us-gaap_ScheduleOfChangeInAccountingEstimateTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems_lbl" xml:lang="en-US">Change in Accounting Estimate [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_DEBTDetailsTable" xlink:href="adma-20250331.xsd#adma_DEBTDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_DEBTDetailsTable_lbl" xml:lang="en-US">DEBT (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DEBTDetailsTable" xlink:to="adma_DEBTDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:href="adma-20250331.xsd#adma_COMMITMENTSANDCONTINGENCIESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_COMMITMENTSANDCONTINGENCIESDetailsTable_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="adma_COMMITMENTSANDCONTINGENCIESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_SUBSEQUENTEVENTSDetailsTable" xlink:href="adma-20250331.xsd#adma_SUBSEQUENTEVENTSDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_SUBSEQUENTEVENTSDetailsTable_lbl" xml:lang="en-US">SUBSEQUENT EVENTS (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_SUBSEQUENTEVENTSDetailsTable" xlink:to="adma_SUBSEQUENTEVENTSDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">SUBSEQUENT EVENTS [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl0" xml:lang="en-US">Amount of allowance for contractual credits and doubtful accounts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_AccruedRebatesCurrent_lbl0" xml:lang="en-US">Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AccruedRebatesCurrent" xlink:to="adma_AccruedRebatesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_AccruedTestingCurrent_lbl0" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for testing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AccruedTestingCurrent" xlink:to="adma_AccruedTestingCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_AgreementWithTermExpirationDate_lbl0" xml:lang="en-US">Date the agreement with term expired, in YYYY-MM-DD format.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AgreementWithTermExpirationDate" xlink:to="adma_AgreementWithTermExpirationDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_AmortizationOfLicenseRevenue_lbl0" xml:lang="en-US">Amount of noncash revenue related to amortization of license revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_DebtInstrumentApplicableMargin_lbl0" xml:lang="en-US">Percentage points added to the reference rate to compute the margin rate on the debt instrument.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DebtInstrumentApplicableMargin" xlink:to="adma_DebtInstrumentApplicableMargin_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_DebtInstrumentTermOfVariableRate_lbl0" xml:lang="en-US">Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index, in PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DebtInstrumentTermOfVariableRate" xlink:to="adma_DebtInstrumentTermOfVariableRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_DeferredRevenueRemainingAmortizationPeriod_lbl0" xml:lang="en-US">Remaining amortization period of deferred revenue, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DeferredRevenueRemainingAmortizationPeriod" xlink:to="adma_DeferredRevenueRemainingAmortizationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_DepositsAndOtherNoncurrentAssets_lbl0" xml:lang="en-US">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DepositsAndOtherNoncurrentAssets" xlink:to="adma_DepositsAndOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl0" xml:lang="en-US">Amount of increase (decrease) in deposits and operating assets classified as other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_IncreaseInMinimumAnnualPriceTerm_lbl0" xml:lang="en-US">Increase in annual price term period on usage of RSV Plasma, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_IncreaseInMinimumAnnualPriceTerm" xlink:to="adma_IncreaseInMinimumAnnualPriceTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_LongTermLiabilityEndOfTermFeePayable_lbl0" xml:lang="en-US">Principal balance of the loans and any other obligations advanced or otherwise owed.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_LongTermLiabilityEndOfTermFeePayable" xlink:to="adma_LongTermLiabilityEndOfTermFeePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_MinimumLiquidityCovenantsCreditFacilities_lbl0" xml:lang="en-US">The carrying amount of minimum liquidity requirements required to be maintained by the borrower per the Company&apos;s credit facilities covenants under the loan agreement that are not restricted as to withdrawal or usage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_MinimumLiquidityCovenantsCreditFacilities" xlink:to="adma_MinimumLiquidityCovenantsCreditFacilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_NumberOfBusinessDays_lbl0" xml:lang="en-US">Number of business days, in PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfBusinessDays" xlink:to="adma_NumberOfBusinessDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl0" xml:lang="en-US">Number of business days for prior written notice to pay outstanding principal loans, Number of business days, in PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:to="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_NumberOfCustomers_lbl0" xml:lang="en-US">Number of major customers of the organization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_NumberOfFDAApprovedProduct_lbl0" xml:lang="en-US">Number of products approved by FDA.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfFDAApprovedProduct" xlink:to="adma_NumberOfFDAApprovedProduct_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl0" xml:lang="en-US">Number of plasma collection facilities having FDA license.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_NumberOfPlasmaCollectionFacilities_lbl0" xml:lang="en-US">Number of wholly-owned plasma collection facilities of the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfPlasmaCollectionFacilities" xlink:to="adma_NumberOfPlasmaCollectionFacilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl0" xml:lang="en-US">Number of plasma collection facilities under various stages of development.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_NumberOfRenewalTerms_lbl0" xml:lang="en-US">Number of renewal terms to extend purchase agreement, if agreed to by the parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfRenewalTerms" xlink:to="adma_NumberOfRenewalTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_OperatingAndFinancingLeaseLiability_lbl0" xml:lang="en-US">Present value of lessee&apos;s discounted obligation for lease payments from operating and finance leases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_OperatingAndFinancingLeaseLiability" xlink:to="adma_OperatingAndFinancingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl0" xml:lang="en-US">Plasma purchase agreement renewal period, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_PlasmaSupplyAgreementTerm_lbl0" xml:lang="en-US">Plasma supply agreement term period, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl0" xml:lang="en-US">Respiratory Syncytial Virus (RSV) Converted human plasma used by company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:to="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl0" xml:lang="en-US">Supplied period on usage of RSV plasma in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:to="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount_lbl0" xml:lang="en-US">Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_SeniorNotesPayableBeforeDebtDiscount" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl0" xml:lang="en-US">Number of shares under fully vested and expected to vest options that were exercised during the current period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl0" xml:lang="en-US">Number of shares under fully vested and expected to vest options for which rights to exercise lapsed.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted-average exercise price, for fully vested and expected to vest that were expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl0" xml:lang="en-US">Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl0" xml:lang="en-US">Number of shares under fully vested and expected to vest options that were granted during the current period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl0" xml:lang="en-US">Number of shares issued during the period as a result of the cashless exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl0" xml:lang="en-US">Aggregate change in value for stock issued during the period as a result of the cashless exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl0" xml:lang="en-US">Amount of cash outflow related to taxes on vested Restricted Stock Units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl0" xml:lang="en-US">Value of stock related to restricted stock awards issued during the period, net of shares withheld to cover grantees&apos; income tax liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl0" xml:lang="en-US">Number of shares issued during the period related to restricted stock awards, net of shares withheld to cover grantees&apos; income tax liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_ADMABioManufacturingSegmentMember_lbl0" xml:lang="en-US">Component of ADMA BioManufacturing that usually provides financial, operational and administrative support and is considered an operating segment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ADMABioManufacturingSegmentMember" xlink:to="adma_ADMABioManufacturingSegmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_ASCENIVMember_lbl0" xml:lang="en-US">ASCENIV an Intravenous Immune Globulin (&quot;IVIG&quot;) product indicated for the treatment of Primary Humoral Immunodeficiency (&quot;PI&quot;), also known as Primary Immunodeficiency Disease (&quot;PIDD&quot;).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ASCENIVMember" xlink:to="adma_ASCENIVMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_AresCreditAgreementMember_lbl0" xml:lang="en-US">Ares credit agreement is a legally-binding contract documenting the terms of a loan agreement; it is made between a person or party borrowing money and a lender.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AresCreditAgreementMember" xlink:to="adma_AresCreditAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_AresCreditFacilityMember_lbl0" xml:lang="en-US">Arrangement in which facility proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AresCreditFacilityMember" xlink:to="adma_AresCreditFacilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_ArethLLCMember_lbl0" xml:lang="en-US">Name of the entity associated with related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ArethLLCMember" xlink:to="adma_ArethLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_EmployeesMember_lbl0" xml:lang="en-US">A group of person working with the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_EmployeesMember" xlink:to="adma_EmployeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_EquityIncentivePlanMember_lbl0" xml:lang="en-US">Equity compensation is often a significant portion of the total compensation paid to employees and other service providers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_EquityIncentivePlanMember" xlink:to="adma_EquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_GenesisBPSMember_lbl0" xml:lang="en-US">Name of the entity associated with related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_GenesisBPSMember" xlink:to="adma_GenesisBPSMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_GrifolsAgreementMember_lbl0" xml:lang="en-US">Restated Plasma Purchase Agreement with Grifols used in the manufacture of ASCENIV.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_GrifolsAgreementMember" xlink:to="adma_GrifolsAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_KEDPlasmaAgreementMember_lbl0" xml:lang="en-US">Plasma Purchase Agreement with KEDPlasma LLC for usage of RSV Plasma.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_KEDPlasmaAgreementMember" xlink:to="adma_KEDPlasmaAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_PlasmaCollectionCentersSegmentMember_lbl0" xml:lang="en-US">Component of Plasma Collection Centers segment that usually provides financial, operational and administrative support and is considered an operating segment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PlasmaCollectionCentersSegmentMember" xlink:to="adma_PlasmaCollectionCentersSegmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_PlasmaPurchaseAgreementOneMember_lbl0" xml:lang="en-US">Plasma purchase agreement to purchase plasma containing antibodies to RSV to be used in the manufacture of ASCENIV.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PlasmaPurchaseAgreementOneMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_PrepaidAfterTheFirstAnniversaryMember_lbl0" xml:lang="en-US">The first anniversary representing most prepaid of after period of debt redemption features under terms of the debt agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PrepaidAfterTheFirstAnniversaryMember" xlink:to="adma_PrepaidAfterTheFirstAnniversaryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl0" xml:lang="en-US">The first anniversary representing most current period of debt redemption features under terms of the debt agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl0" xml:lang="en-US">The third anniversary representing most current period of debt redemption features under terms of the debt agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PrepaidOnOrPriorToThirdAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_TermLoanMember_lbl0" xml:lang="en-US">A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_TermLoanMember" xlink:to="adma_TermLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_ThreeCustomersMember_lbl0" xml:lang="en-US">Information about number of customers accounting for a percentage of consolidated revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ThreeCustomersMember" xlink:to="adma_ThreeCustomersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adma_TwoCustomersMember_lbl0" xml:lang="en-US">Information about number of customers accounting for a percentage of consolidated revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_TwoCustomersMember" xlink:to="adma_TwoCustomersMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrMember_lbl" xml:lang="en-US">SOFR</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets_lbl0" xml:lang="en-US">Segment, Expenditure, Addition to Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:to="us-gaap_SegmentExpenditureAdditionToLongLivedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl1" xml:lang="en-US">Stock Issued During Period Shares Cashless Exercise Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl0" xml:lang="en-US">Debt Instrument, Frequency of Periodic Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl2" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_AmortizationOfLicenseRevenue_lbl1" xml:lang="en-US">Amortization Of License Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Expired Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl1" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenseMember_lbl0" xml:lang="en-US">Operating Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_IncreaseInMinimumAnnualPriceTerm_lbl1" xml:lang="en-US">Increase In Minimum Annual Price Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_IncreaseInMinimumAnnualPriceTerm" xlink:to="adma_IncreaseInMinimumAnnualPriceTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaterialReconcilingItemsMember_lbl0" xml:lang="en-US">Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaterialReconcilingItemsMember" xlink:to="us-gaap_MaterialReconcilingItemsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl1" xml:lang="en-US">Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_NumberOfRenewalTerms_lbl1" xml:lang="en-US">Number Of Renewal Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfRenewalTerms" xlink:to="adma_NumberOfRenewalTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Forfeited Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl1" xml:lang="en-US">Quantity Of Respiratory Syncytial Virus Plasma Used</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:to="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl0" xml:lang="en-US">Goodwill, Impairment Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_OperatingAndFinancingLeaseLiability_lbl1" xml:lang="en-US">Operating And Financing Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_OperatingAndFinancingLeaseLiability" xlink:to="adma_OperatingAndFinancingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PlasmaPurchaseAgreementOneMember_lbl1" xml:lang="en-US">Plasma Purchase Agreement One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PlasmaPurchaseAgreementOneMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl0" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetUnderConstructionMember_lbl0" xml:lang="en-US">Asset under Construction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetUnderConstructionMember" xlink:to="us-gaap_AssetUnderConstructionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl0" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl0" xml:lang="en-US">Accrued Salaries, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Granted Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="adma_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:href="adma-20250331.xsd#adma_ScheduleOfStockBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ScheduleOfStockBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Stock Based Compensation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="adma_ScheduleOfStockBasedCompensationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl0" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl1" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl0" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_AccruedTestingCurrent_lbl1" xml:lang="en-US">Accrued Testing Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AccruedTestingCurrent" xlink:to="adma_AccruedTestingCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl0" xml:lang="en-US">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_UnlabeledAbstract3" xlink:to="adma_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_UnlabeledAbstract2" xlink:to="adma_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1" xml:lang="en-US">Number Of Business Days For Prior Written Notice To Prepay Outstanding Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:to="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_AresCreditAgreementMember_lbl1" xml:lang="en-US">Ares Credit Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AresCreditAgreementMember" xlink:to="adma_AresCreditAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_UnlabeledAbstract1" xlink:to="adma_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_UnlabeledAbstract0" xlink:to="adma_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_GenesisBPSMember_lbl1" xml:lang="en-US">Genesis BPSMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_GenesisBPSMember" xlink:to="adma_GenesisBPSMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_AccruedRebatesCurrent_lbl1" xml:lang="en-US">Accrued Rebates Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AccruedRebatesCurrent" xlink:to="adma_AccruedRebatesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Preferred Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_NumberOfPlasmaCollectionFacilities_lbl1" xml:lang="en-US">Number Of Plasma Collection Facilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfPlasmaCollectionFacilities" xlink:to="adma_NumberOfPlasmaCollectionFacilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl0" xml:lang="en-US">Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_DebtInstrumentApplicableMargin_lbl1" xml:lang="en-US">Debt Instrument Applicable Margin</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DebtInstrumentApplicableMargin" xlink:to="adma_DebtInstrumentApplicableMargin_lbl1"/>
    <loc xlink:type="locator" xlink:label="adma_SummarizedFinancialInformationBySegmentAbstract" xlink:href="adma-20250331.xsd#adma_SummarizedFinancialInformationBySegmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_SummarizedFinancialInformationBySegmentAbstract_lbl" xml:lang="en-US">Summarized Financial Information By Segment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_SummarizedFinancialInformationBySegmentAbstract" xlink:to="adma_SummarizedFinancialInformationBySegmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_TermLoanMember_lbl1" xml:lang="en-US">Term Loan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_TermLoanMember" xlink:to="adma_TermLoanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="adma_ScheduleOfAssumptionsAbstract" xlink:href="adma-20250331.xsd#adma_ScheduleOfAssumptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ScheduleOfAssumptionsAbstract_lbl" xml:lang="en-US">Schedule Of Assumptions Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ScheduleOfAssumptionsAbstract" xlink:to="adma_ScheduleOfAssumptionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonUsMember_lbl0" xml:lang="en-US">Non-US [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl0" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" xml:lang="en-US">Plasma Purchase Agreement Renewal Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1"/>
    <loc xlink:type="locator" xlink:label="adma_CalculationOfBasicAndDilutedEarningsPerShareAbstract" xlink:href="adma-20250331.xsd#adma_CalculationOfBasicAndDilutedEarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_CalculationOfBasicAndDilutedEarningsPerShareAbstract_lbl" xml:lang="en-US">Calculation Of Basic And Diluted Earnings Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_CalculationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="adma_CalculationOfBasicAndDilutedEarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adma_PropertyAndEquipmentAbstract" xlink:href="adma-20250331.xsd#adma_PropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PropertyAndEquipmentAbstract" xlink:to="adma_PropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_UnlabeledAbstract" xlink:to="adma_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl0" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract0_lbl0" xml:lang="en-US">Reconciliation Of Income Loss Before Taxes Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract0" xlink:to="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract0_lbl0"/>
    <loc xlink:type="locator" xlink:label="adma_ScheduleOfOptionActivityAbstract" xlink:href="adma-20250331.xsd#adma_ScheduleOfOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ScheduleOfOptionActivityAbstract_lbl" xml:lang="en-US">Schedule Of Option Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ScheduleOfOptionActivityAbstract" xlink:to="adma_ScheduleOfOptionActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercised Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_DebtInstrumentTermOfVariableRate_lbl1" xml:lang="en-US">Debt Instrument Term Of Variable Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DebtInstrumentTermOfVariableRate" xlink:to="adma_DebtInstrumentTermOfVariableRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ReconciliationOfTotalAssetsAbstract0_lbl0" xml:lang="en-US">Reconciliation Of Total Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfTotalAssetsAbstract0" xlink:to="adma_ReconciliationOfTotalAssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" xml:lang="en-US">Number Of Plasma Collection Facilities Under Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl0" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract_lbl0" xml:lang="en-US">Reconciliation Of Income Loss Before Taxes Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract" xlink:to="adma_ReconciliationOfIncomeLossBeforeTaxesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" xml:lang="en-US">Increase Decrease In Deposits And Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl1" xml:lang="en-US">Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ReconciliationOfTotalAssetsAbstract_lbl0" xml:lang="en-US">Reconciliation Of Total Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfTotalAssetsAbstract" xlink:to="adma_ReconciliationOfTotalAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeniorLongTermNotes_lbl1" xml:lang="en-US">Senior Notes, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ADMABioManufacturingSegmentMember_lbl1" xml:lang="en-US">ADMABio Manufacturing Segment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ADMABioManufacturingSegmentMember" xlink:to="adma_ADMABioManufacturingSegmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl0" xml:lang="en-US">Revolving Credit Facility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1_lbl0" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ArethLLCMember_lbl1" xml:lang="en-US">Areth LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ArethLLCMember" xlink:to="adma_ArethLLCMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_AresCreditFacilityMember_lbl1" xml:lang="en-US">Ares Credit Facility Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AresCreditFacilityMember" xlink:to="adma_AresCreditFacilityMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl1" xml:lang="en-US">Stock Issued During Period Value Cashless Exercise Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" xml:lang="en-US">Taxes Paid On Vested Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_TwoCustomersMember_lbl1" xml:lang="en-US">Two Customers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_TwoCustomersMember" xlink:to="adma_TwoCustomersMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ReconciliationOfRevenuesAbstract0_lbl0" xml:lang="en-US">Reconciliation Of Revenues Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfRevenuesAbstract0" xlink:to="adma_ReconciliationOfRevenuesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract0_lbl0" xml:lang="en-US">Reconciliation Of Selling General And Administrative Expense Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract0" xlink:to="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" xml:lang="en-US">Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManufacturingFacilityMember_lbl0" xml:lang="en-US">Manufacturing Facility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateNonSegmentMember_lbl0" xml:lang="en-US">Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateNonSegmentMember" xlink:to="us-gaap_CorporateNonSegmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_NumberOfFDAApprovedProduct_lbl1" xml:lang="en-US">Number Of FDAApproved Product</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfFDAApprovedProduct" xlink:to="adma_NumberOfFDAApprovedProduct_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1" xml:lang="en-US">Prepaid On Or Prior To First Anniversary Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl1" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" xml:lang="en-US">Number Of FDALicensed Plasma Collection Facilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_AgreementWithTermExpirationDate_lbl1" xml:lang="en-US">Agreement With Term Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AgreementWithTermExpirationDate" xlink:to="adma_AgreementWithTermExpirationDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" xml:lang="en-US">Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl0" xml:lang="en-US">Proceeds from Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl0" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Granted Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_DepositsAndOtherNoncurrentAssets_lbl1" xml:lang="en-US">Deposits And Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DepositsAndOtherNoncurrentAssets" xlink:to="adma_DepositsAndOtherNoncurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Forfeited Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl1" xml:lang="en-US">Respiratory Syncytial Virus Plasma Volume Supplied Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:to="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl1" xml:lang="en-US">Interest Expense, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl0" xml:lang="en-US">Cost of Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_GrifolsAgreementMember_lbl1" xml:lang="en-US">Grifols Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_GrifolsAgreementMember" xlink:to="adma_GrifolsAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl0" xml:lang="en-US">Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl0" xml:lang="en-US">Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl1" xml:lang="en-US">Prepaid On Or Prior To Third Anniversary Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PrepaidOnOrPriorToThirdAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="adma_NetRevenuesAccordingToGeographicAreaAbstract" xlink:href="adma-20250331.xsd#adma_NetRevenuesAccordingToGeographicAreaAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_NetRevenuesAccordingToGeographicAreaAbstract_lbl" xml:lang="en-US">Net Revenues According To Geographic Area Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NetRevenuesAccordingToGeographicAreaAbstract" xlink:to="adma_NetRevenuesAccordingToGeographicAreaAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercised Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl0" xml:lang="en-US">Taxes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl0" xml:lang="en-US">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl0" xml:lang="en-US">Repayments of Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Expired Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl0" xml:lang="en-US">Other Cost and Expense, Operating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ASCENIVMember_lbl1" xml:lang="en-US">ASCENIVMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ASCENIVMember" xlink:to="adma_ASCENIVMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl0" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl0" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract_lbl0" xml:lang="en-US">Reconciliation Of Selling General And Administrative Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract" xlink:to="adma_ReconciliationOfSellingGeneralAndAdministrativeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" xml:lang="en-US">Deferred Revenue Remaining Amortization Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DeferredRevenueRemainingAmortizationPeriod" xlink:to="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_NumberOfBusinessDays_lbl1" xml:lang="en-US">Number Of Business Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfBusinessDays" xlink:to="adma_NumberOfBusinessDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl0" xml:lang="en-US">Long-Term Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl0" xml:lang="en-US">Interest Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_EquityIncentivePlanMember_lbl1" xml:lang="en-US">Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_EquityIncentivePlanMember" xlink:to="adma_EquityIncentivePlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PlasmaSupplyAgreementTerm_lbl1" xml:lang="en-US">Plasma Supply Agreement Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ThreeCustomersMember_lbl1" xml:lang="en-US">Three Customers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ThreeCustomersMember" xlink:to="adma_ThreeCustomersMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl0" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl0" xml:lang="en-US">Operating Costs and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl0" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl0" xml:lang="en-US">Accrued Bonuses, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PrepaidAfterTheFirstAnniversaryMember_lbl1" xml:lang="en-US">Prepaid After The First Anniversary Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PrepaidAfterTheFirstAnniversaryMember" xlink:to="adma_PrepaidAfterTheFirstAnniversaryMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" xml:lang="en-US">Senior Notes Payable Before Debt Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_SeniorNotesPayableBeforeDebtDiscount" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ReconciliationOfRevenuesAbstract_lbl0" xml:lang="en-US">Reconciliation Of Revenues Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ReconciliationOfRevenuesAbstract" xlink:to="adma_ReconciliationOfRevenuesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl0" xml:lang="en-US">Inventory, Work in Process, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_LongTermLiabilityEndOfTermFeePayable_lbl1" xml:lang="en-US">Long Term Liability End Of Term Fee Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_LongTermLiabilityEndOfTermFeePayable" xlink:to="adma_LongTermLiabilityEndOfTermFeePayable_lbl1"/>
    <loc xlink:type="locator" xlink:label="adma_SummaryOfOutstandingSeniorNotesPayableAbstract" xlink:href="adma-20250331.xsd#adma_SummaryOfOutstandingSeniorNotesPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_SummaryOfOutstandingSeniorNotesPayableAbstract_lbl" xml:lang="en-US">Summary Of Outstanding Senior Notes Payable Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_SummaryOfOutstandingSeniorNotesPayableAbstract" xlink:to="adma_SummaryOfOutstandingSeniorNotesPayableAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl0" xml:lang="en-US">Building and Building Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_NumberOfCustomers_lbl1" xml:lang="en-US">Number Of Customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="adma_ScheduleOfUnvestedRsuActivityAbstract" xlink:href="adma-20250331.xsd#adma_ScheduleOfUnvestedRsuActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ScheduleOfUnvestedRsuActivityAbstract_lbl" xml:lang="en-US">Schedule Of Unvested Rsu Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ScheduleOfUnvestedRsuActivityAbstract" xlink:to="adma_ScheduleOfUnvestedRsuActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_MinimumLiquidityCovenantsCreditFacilities_lbl1" xml:lang="en-US">Minimum Liquidity Covenants Credit Facilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_MinimumLiquidityCovenantsCreditFacilities" xlink:to="adma_MinimumLiquidityCovenantsCreditFacilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_EmployeesMember_lbl1" xml:lang="en-US">Employees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_EmployeesMember" xlink:to="adma_EmployeesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingSegmentsMember_lbl0" xml:lang="en-US">Operating Segments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_KEDPlasmaAgreementMember_lbl1" xml:lang="en-US">KEDPlasma Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_KEDPlasmaAgreementMember" xlink:to="adma_KEDPlasmaAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PlasmaCollectionCentersSegmentMember_lbl1" xml:lang="en-US">Plasma Collection Centers Segment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PlasmaCollectionCentersSegmentMember" xlink:to="adma_PlasmaCollectionCentersSegmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>adma-20250331_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 07 19:58:08 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ConsolidatedBalanceSheet" roleURI="http://admabiologics.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://admabiologics.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ConsolidatedIncomeStatement" roleURI="http://admabiologics.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ShareholdersEquityType2or3" roleURI="http://admabiologics.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ConsolidatedCashFlow" roleURI="http://admabiologics.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ORGANIZATIONANDBUSINESS" roleURI="http://admabiologics.com/role/ORGANIZATIONANDBUSINESS"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_INVENTORIES" roleURI="http://admabiologics.com/role/INVENTORIES"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_PROPERTYANDEQUIPMENT" roleURI="http://admabiologics.com/role/PROPERTYANDEQUIPMENT"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" roleURI="http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_DEBT" roleURI="http://admabiologics.com/role/DEBT"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_STOCKHOLDERSEQUITY" roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_RELATEDPARTYTRANSACTIONS" roleURI="http://admabiologics.com/role/RELATEDPARTYTRANSACTIONS"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_COMMITMENTSANDCONTINGENCIES" roleURI="http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIES"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SEGMENTS" roleURI="http://admabiologics.com/role/SEGMENTS"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_LEASEOBLIGATIONS" roleURI="http://admabiologics.com/role/LEASEOBLIGATIONS"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_INCOMETAXES" roleURI="http://admabiologics.com/role/INCOMETAXES"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATION" roleURI="http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATION"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUBSEQUENTEVENTS" roleURI="http://admabiologics.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_AccountingPoliciesByPolicy" roleURI="http://admabiologics.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_INVENTORIESTables" roleURI="http://admabiologics.com/role/INVENTORIESTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_PROPERTYANDEQUIPMENTTables" roleURI="http://admabiologics.com/role/PROPERTYANDEQUIPMENTTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" roleURI="http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_DEBTTables" roleURI="http://admabiologics.com/role/DEBTTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_STOCKHOLDERSEQUITYTables" roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITYTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SEGMENTSTables" roleURI="http://admabiologics.com/role/SEGMENTSTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_LEASEOBLIGATIONSTables" roleURI="http://admabiologics.com/role/LEASEOBLIGATIONSTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_INCOMETAXESTables" roleURI="http://admabiologics.com/role/INCOMETAXESTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATIONTables" roleURI="http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_CalculationofBasicandDilutedEarningsPerShareTable" roleURI="http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ComponentsofInventoryTable" roleURI="http://admabiologics.com/role/ComponentsofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_PropertyandEquipmentTable" roleURI="http://admabiologics.com/role/PropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_AccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SummaryofOutstandingSeniorNotesPayableTable" roleURI="http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ScheduleofAssumptionsTable" roleURI="http://admabiologics.com/role/ScheduleofAssumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ScheduleofOptionActivityTable" roleURI="http://admabiologics.com/role/ScheduleofOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ScheduleofUnvestedRSUActivityTable" roleURI="http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ScheduleofStockBasedCompensationExpenseTable" roleURI="http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SummarizedFinancialInformationbySegmentTable" roleURI="http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_NetRevenuesAccordingtoGeographicAreaTable" roleURI="http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_PaymentsUnderLeaseObligationsTable" roleURI="http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_EstimatedAnnualEffectiveTaxRateTable" roleURI="http://admabiologics.com/role/EstimatedAnnualEffectiveTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SupplementalCashFlowInformationTable" roleURI="http://admabiologics.com/role/SupplementalCashFlowInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ORGANIZATIONANDBUSINESSDetails" roleURI="http://admabiologics.com/role/ORGANIZATIONANDBUSINESSDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable" roleURI="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill" roleURI="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition" roleURI="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_PROPERTYANDEQUIPMENTDetails" roleURI="http://admabiologics.com/role/PROPERTYANDEQUIPMENTDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_DEBTDetails" roleURI="http://admabiologics.com/role/DEBTDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_STOCKHOLDERSEQUITYDetailsPreferredStock" roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsPreferredStock"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_STOCKHOLDERSEQUITYDetailsCommonStock" roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsCommonStock"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_STOCKHOLDERSEQUITYDetailsWarrants" roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_STOCKHOLDERSEQUITYDetailsEquityIncentivePlans" roleURI="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_RELATEDPARTYTRANSACTIONSDetails" roleURI="http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SEGMENTSDetails" roleURI="http://admabiologics.com/role/SEGMENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_LEASEOBLIGATIONSDetails" roleURI="http://admabiologics.com/role/LEASEOBLIGATIONSDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_INCOMETAXESDetails" roleURI="http://admabiologics.com/role/INCOMETAXESDetails"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_SUBSEQUENTEVENTSDetails" roleURI="http://admabiologics.com/role/SUBSEQUENTEVENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://admabiologics.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DepositsAndOtherNoncurrentAssets" xlink:href="adma-20250331.xsd#adma_DepositsAndOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="DepositsAndOtherNoncurrentAssets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeniorLongTermNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_SeniorLongTermNotes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermLiabilityEndOfTermFeePayable" xlink:href="adma-20250331.xsd#adma_LongTermLiabilityEndOfTermFeePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="LongTermLiabilityEndOfTermFeePayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherCostAndExpenseOperating" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:href="adma-20250331.xsd#adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:href="adma-20250331.xsd#adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:href="adma-20250331.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:href="adma-20250331.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmortizationOfLicenseRevenue" xlink:href="adma-20250331.xsd#adma_AmortizationOfLicenseRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfLicenseRevenue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInDepositsAndOtherAssets" xlink:href="adma-20250331.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInDepositsAndOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxesPaidOnVestedRestrictedStockUnits" xlink:href="adma-20250331.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="TaxesPaidOnVestedRestrictedStockUnits" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/ORGANIZATIONANDBUSINESS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/INVENTORIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/DEBT" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/SEGMENTS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/LEASEOBLIGATIONS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/INCOMETAXES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATION" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/INVENTORIESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/DEBTTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/SEGMENTSTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/LEASEOBLIGATIONSTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/INCOMETAXESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATIONTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CalculationOfBasicAndDilutedEarningsPerShareAbstract" xlink:href="adma-20250331.xsd#adma_CalculationOfBasicAndDilutedEarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable" xlink:href="adma-20250331.xsd#adma_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CalculationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable" xlink:to="us-gaap_EarningsPerShareDilutedLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/ComponentsofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/PropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="PropertyAndEquipmentAbstract" xlink:href="adma-20250331.xsd#adma_PropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ManufacturingFacilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetUnderConstructionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetUnderConstructionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_AssetUnderConstructionMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedRebatesCurrent" xlink:href="adma-20250331.xsd#adma_AccruedRebatesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedRebatesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedTestingCurrent" xlink:href="adma-20250331.xsd#adma_AccruedTestingCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedTestingCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="SummaryOfOutstandingSeniorNotesPayableAbstract" xlink:href="adma-20250331.xsd#adma_SummaryOfOutstandingSeniorNotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable" xlink:href="adma-20250331.xsd#adma_DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryOfOutstandingSeniorNotesPayableAbstract" xlink:to="DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable" xlink:to="us-gaap_CreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TermLoanMember" xlink:href="adma-20250331.xsd#adma_TermLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="TermLoanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:href="adma-20250331.xsd#adma_SeniorNotesPayableBeforeDebtDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="SeniorNotesPayableBeforeDebtDiscount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeniorLongTermNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SeniorLongTermNotes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/ScheduleofAssumptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssumptionsAbstract" xlink:href="adma-20250331.xsd#adma_ScheduleOfAssumptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssumptionsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/ScheduleofOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionActivityAbstract" xlink:href="adma-20250331.xsd#adma_ScheduleOfOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uqgO9qQHmt9BQ98lPQIyw9cjUtWqGRthAHbCpPWJm+ZBnUANbVsFup3oAMJaWvFS/k3ezQjgEaFZJvCq0OWEaVRhBMH4wstjV4pDB+cYAEkKIlZ4nwn5o7i0ti/NOF+bcutUP8C4CXNiPP5su4uqzFkgaDLt3IeykvMgrNxbz1zlEBFkcWhdBcut2hb2b7lGcY9pI+D9MeK/5zybfw/v3KnrZo32yWITlcc0KRPcZ6zOPZmYvhb/tEniiceTZ24R8hzITQ0cjNIyo6hSm3MX5] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionActivityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:href="adma-20250331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfUnvestedRsuActivityAbstract" xlink:href="adma-20250331.xsd#adma_ScheduleOfUnvestedRsuActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnvestedRsuActivityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockBasedCompensationExpenseAbstract" xlink:href="adma-20250331.xsd#adma_ScheduleOfStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_OperatingExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_CostOfSalesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="SummarizedFinancialInformationBySegmentAbstract" xlink:href="adma-20250331.xsd#adma_SummarizedFinancialInformationBySegmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummarizedFinancialInformationBySegmentAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ADMABioManufacturingSegmentMember" xlink:href="adma-20250331.xsd#adma_ADMABioManufacturingSegmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="ADMABioManufacturingSegmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:href="adma-20250331.xsd#adma_PlasmaCollectionCentersSegmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="PlasmaCollectionCentersSegmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="us-gaap_OperatingSegmentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="us-gaap_MaterialReconcilingItemsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="us-gaap_CorporateNonSegmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_OtherCostAndExpenseOperating" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_Assets" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="NetRevenuesAccordingToGeographicAreaAbstract" xlink:href="adma-20250331.xsd#adma_NetRevenuesAccordingToGeographicAreaAbstract"/>
    <loc xlink:type="locator" xlink:label="SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable" xlink:href="adma-20250331.xsd#adma_SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetRevenuesAccordingToGeographicAreaAbstract" xlink:to="SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ADMABioManufacturingSegmentMember" xlink:href="adma-20250331.xsd#adma_ADMABioManufacturingSegmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="ADMABioManufacturingSegmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:href="adma-20250331.xsd#adma_PlasmaCollectionCentersSegmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="PlasmaCollectionCentersSegmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="us-gaap_NonUsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable" xlink:to="srt_ConsolidationItemsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="us-gaap_OperatingSegmentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="us-gaap_MaterialReconcilingItemsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/EstimatedAnnualEffectiveTaxRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/SupplementalCashFlowInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:href="adma-20250331.xsd#adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/ORGANIZATIONANDBUSINESSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:href="adma-20250331.xsd#adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfFDAApprovedProduct" xlink:href="adma-20250331.xsd#adma_NumberOfFDAApprovedProduct"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NumberOfFDAApprovedProduct" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfChangeInAccountingEstimateTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="srt_MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ThreeCustomersMember" xlink:href="adma-20250331.xsd#adma_ThreeCustomersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="ThreeCustomersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:href="adma-20250331.xsd#adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfCustomers" xlink:href="adma-20250331.xsd#adma_NumberOfCustomers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="NumberOfCustomers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfChangeInAccountingEstimateTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_Goodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfChangeInAccountingEstimateTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="srt_MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ThreeCustomersMember" xlink:href="adma-20250331.xsd#adma_ThreeCustomersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="ThreeCustomersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoCustomersMember" xlink:href="adma-20250331.xsd#adma_TwoCustomersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="TwoCustomersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:href="adma-20250331.xsd#adma_DeferredRevenueRemainingAmortizationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="DeferredRevenueRemainingAmortizationPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfCustomers" xlink:href="adma-20250331.xsd#adma_NumberOfCustomers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="NumberOfCustomers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/DEBTDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="DEBTDetailsTable" xlink:href="adma-20250331.xsd#adma_DEBTDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="DEBTDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DEBTDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DEBTDetailsTable" xlink:to="us-gaap_CreditFacilityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TermLoanMember" xlink:href="adma-20250331.xsd#adma_TermLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="TermLoanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DEBTDetailsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:href="adma-20250331.xsd#adma_PrepaidOnOrPriorToFirstAnniversaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="PrepaidOnOrPriorToFirstAnniversaryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidAfterTheFirstAnniversaryMember" xlink:href="adma-20250331.xsd#adma_PrepaidAfterTheFirstAnniversaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="PrepaidAfterTheFirstAnniversaryMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:href="adma-20250331.xsd#adma_PrepaidOnOrPriorToThirdAnniversaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="PrepaidOnOrPriorToThirdAnniversaryMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DEBTDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AresCreditAgreementMember" xlink:href="adma-20250331.xsd#adma_AresCreditAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="AresCreditAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DEBTDetailsTable" xlink:to="srt_RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DEBTDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AresCreditFacilityMember" xlink:href="adma-20250331.xsd#adma_AresCreditFacilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="AresCreditFacilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DEBTDetailsTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:href="adma-20250331.xsd#adma_SeniorNotesPayableBeforeDebtDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="SeniorNotesPayableBeforeDebtDiscount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentTermOfVariableRate" xlink:href="adma-20250331.xsd#adma_DebtInstrumentTermOfVariableRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentTermOfVariableRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfBusinessDays" xlink:href="adma-20250331.xsd#adma_NumberOfBusinessDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="NumberOfBusinessDays" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentApplicableMargin" xlink:href="adma-20250331.xsd#adma_DebtInstrumentApplicableMargin"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentApplicableMargin" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:href="adma-20250331.xsd#adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumLiquidityCovenantsCreditFacilities" xlink:href="adma-20250331.xsd#adma_MinimumLiquidityCovenantsCreditFacilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="MinimumLiquidityCovenantsCreditFacilities" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsPreferredStock" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsCommonStock" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EquityIncentivePlanMember" xlink:href="adma-20250331.xsd#adma_EquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="EquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeesMember" xlink:href="adma-20250331.xsd#adma_EmployeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="EmployeesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ArethLLCMember" xlink:href="adma-20250331.xsd#adma_ArethLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="ArethLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenesisBPSMember" xlink:href="adma-20250331.xsd#adma_GenesisBPSMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="GenesisBPSMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:href="adma-20250331.xsd#adma_COMMITMENTSANDCONTINGENCIESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="COMMITMENTSANDCONTINGENCIESDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PlasmaPurchaseAgreementOneMember" xlink:href="adma-20250331.xsd#adma_PlasmaPurchaseAgreementOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="PlasmaPurchaseAgreementOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrifolsAgreementMember" xlink:href="adma-20250331.xsd#adma_GrifolsAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="GrifolsAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KEDPlasmaAgreementMember" xlink:href="adma-20250331.xsd#adma_KEDPlasmaAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="KEDPlasmaAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ASCENIVMember" xlink:href="adma-20250331.xsd#adma_ASCENIVMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ASCENIVMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_LossContingenciesLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfPlasmaCollectionFacilities" xlink:href="adma-20250331.xsd#adma_NumberOfPlasmaCollectionFacilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="NumberOfPlasmaCollectionFacilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementWithTermExpirationDate" xlink:href="adma-20250331.xsd#adma_AgreementWithTermExpirationDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="AgreementWithTermExpirationDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfRenewalTerms" xlink:href="adma-20250331.xsd#adma_NumberOfRenewalTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="NumberOfRenewalTerms" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:href="adma-20250331.xsd#adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="QuantityOfRespiratorySyncytialVirusPlasmaUsed" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:href="adma-20250331.xsd#adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseInMinimumAnnualPriceTerm" xlink:href="adma-20250331.xsd#adma_IncreaseInMinimumAnnualPriceTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="IncreaseInMinimumAnnualPriceTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlasmaPurchaseAgreementRenewalPeriod" xlink:href="adma-20250331.xsd#adma_PlasmaPurchaseAgreementRenewalPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="PlasmaPurchaseAgreementRenewalPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlasmaSupplyAgreementTerm" xlink:href="adma-20250331.xsd#adma_PlasmaSupplyAgreementTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="PlasmaSupplyAgreementTerm" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/SEGMENTSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:href="adma-20250331.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="NumberOfFDALicensedPlasmaCollectionFacilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/LEASEOBLIGATIONSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingAndFinancingLeaseLiability" xlink:href="adma-20250331.xsd#adma_OperatingAndFinancingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="OperatingAndFinancingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/INCOMETAXESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://admabiologics.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SUBSEQUENTEVENTSDetailsTable" xlink:href="adma-20250331.xsd#adma_SUBSEQUENTEVENTSDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SUBSEQUENTEVENTSDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_CreditFacilityAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TermLoanMember" xlink:href="adma-20250331.xsd#adma_TermLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="TermLoanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCredit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended"/>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>adma-20250331_cal.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION - CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 07 19:58:08 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ConsolidatedBalanceSheet" roleURI="http://admabiologics.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ConsolidatedIncomeStatement" roleURI="http://admabiologics.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ConsolidatedCashFlow" roleURI="http://admabiologics.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_ComponentsofInventoryTable" roleURI="http://admabiologics.com/role/ComponentsofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_PropertyandEquipmentTable" roleURI="http://admabiologics.com/role/PropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_AccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="adma-20250331.xsd#adma_r_PaymentsUnderLeaseObligationsTable" roleURI="http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable"/>
  <calculationLink xlink:role="http://admabiologics.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="adma_DepositsAndOtherNoncurrentAssets" xlink:href="adma-20250331.xsd#adma_DepositsAndOtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="adma_DepositsAndOtherNoncurrentAssets" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeniorLongTermNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_SeniorLongTermNotes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="adma_LongTermLiabilityEndOfTermFeePayable" xlink:href="adma-20250331.xsd#adma_LongTermLiabilityEndOfTermFeePayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="adma_LongTermLiabilityEndOfTermFeePayable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://admabiologics.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OtherCostAndExpenseOperating" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uqgO9qQHmt9BQ98lPQIyw9cjUtWqGRthAHbCpPWJm+ZBnUANbVsFup3oAMJaWvFS/k3ezQjgEaFZJvCq0OWEaVRhBMH4wstjV4pDB+cYAEkKIlZ4nwn5o7i0ti/NOF+bcutUP8C4CXNiPP5su4uqzFkgaDLt3IeykvMgrNxbz1zlEBFkcWhdBcut2hb2b7lGcY9pI+D9MeK/5zybfw/v3KnrZo32yWITlcc0KRPcZ6zOPZmYvhb/tEniiceTZ24RIYl5I+B05eXFy83aTZiFN] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://admabiologics.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="adma_AmortizationOfLicenseRevenue" xlink:href="adma-20250331.xsd#adma_AmortizationOfLicenseRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adma_AmortizationOfLicenseRevenue" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:href="adma-20250331.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:href="adma-20250331.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://admabiologics.com/role/ComponentsofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://admabiologics.com/role/PropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <loc xlink:type="locator" xlink:label="adma_AccruedRebatesCurrent" xlink:href="adma-20250331.xsd#adma_AccruedRebatesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="adma_AccruedRebatesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedBonusesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_InterestPayableCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="adma_AccruedTestingCurrent" xlink:href="adma-20250331.xsd#adma_AccruedTestingCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="adma_AccruedTestingCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedSalariesCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_TaxesPayableCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="8" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="7" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ef20047548_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!-- Created by CompSci Resources, LLC on Sat May 03 23:24:57 UTC 2025 --><!doctype html><html>
 <head><meta content="text/html; charset=ASCII">
  <title></title>
 </head>
 <body style="font-family: Times New Roman; font-size: 11pt;">

  <hr style="border-top: 4px solid black; border-bottom: none; border-left: none; border-right: none; height: 0px; margin: 6px auto; width: 100%;"><div style="text-indent: 36pt; margin-bottom: 12pt; text-align: right; font-size: 10pt;"><font style="font-weight: bold;">Exhibit 31.1</font>
  </div><div style="margin-bottom: 12pt; text-align: center; font-size: 10pt;">
   <font style="font-weight: bold;">CERTIFICATIONS</font>
  </div>
  <div style="text-align: justify;">
   <font style="font-size: 10.0pt;">I, Adam S. Grossman, certify that:</font>
  </div>
  <div style="text-align: justify; font-size: 10pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">1.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">I have reviewed this Quarterly Report on Form 10-Q of ADMA Biologics, Inc. (the &#x201c;registrant&#x201d;);</font>
    </div>
  </div>
  <div style="text-align: justify; margin-left: 18pt; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">2.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font>
    </div>
  </div>
  <div style="text-align: justify; margin-left: 18pt; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">3.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font>
    </div>
  </div>
  <div style="text-align: justify; margin-left: 18pt; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">4.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font>
    </div>
  </div>
  <div style="text-align: justify; margin-left: 18pt; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">a)</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font>
    </div>
  </div>
  <div style="text-align: justify; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">b)</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
    </div>
  </div>
  <div style="text-align: justify; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">c)</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
    </div>
  </div>
  <div style="text-align: justify; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">d)</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font>
    </div>
  </div>
  <div style="text-align: justify; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">5.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font>
    </div>
  </div>
  <div style="text-align: justify; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">a)</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
    </div>
  </div>
  <div style="text-align: justify; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">b)</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
    </div>
  </div>



  <table style="border-spacing: 0px; border-collapse: collapse; width: 100%; font-size: 10pt;">
   <tr><td style="width: 50%;">&#xa0;</td><td style="width: 5%;">&#xa0;</td><td style="width: 45%;">&#xa0;</td></tr><tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Date: May 7, 2025
     </div>
    </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      By:
     </div>
    </td>
    <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">
     <div>
      /s/ Adam S. Grossman
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">&#xa0;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Name:
     </div>
    </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Adam S. Grossman
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">&#xa0;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Title:
     </div>
    </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      President and Chief Executive Officer
     </div>
     <div>
      (Principal Executive Officer)
     </div>
    </td>
   </tr>
  </table><div>&#xa0;</div>
 <div>&#xa0;</div><hr style="border-top: 2px solid black; border-bottom: none; border-left: none; border-right: none; height: 0px; margin: 6px auto; width: 100%;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ef20047548_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!-- Created by CompSci Resources, LLC on Sat May 03 23:24:57 UTC 2025 --><!doctype html><html>
 <head><meta content="text/html; charset=ASCII">
  <title></title>
 </head>
 <body style="font-family: Times New Roman; font-size: 11pt;">

  <hr style="border-top: 4px solid black; border-bottom: none; border-left: none; border-right: none; height: 0px; margin: 6px auto; width: 100%;"><div style="text-indent: 36pt; margin-bottom: 12pt; text-align: right; font-size: 10pt;"><font style="font-weight: bold;">Exhibit 31.2</font>
  </div><div style="text-align: center; font-size: 10pt;">
   <font style="font-weight: bold;">CERTIFICATIONS</font>
  </div>
  <div style="text-align: justify;">
   <font style="font-size: 10.0pt;">I, Brad Tade, certify that:</font>
  </div>
  <div style="text-align: justify; font-size: 10pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">1.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">I have reviewed this Quarterly Report on Form 10-Q of ADMA Biologics, Inc. (the &#x201c;registrant&#x201d;);</font>
    </div>
  </div>
  <div style="text-align: justify; margin-left: 18pt; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">2.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font>
    </div>
  </div>
  <div style="text-align: justify; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">3.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font>
    </div>
  </div>
  <div style="text-align: justify; margin-left: 18pt; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">4.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font>
    </div>
  </div>
  <div style="margin-left: 36pt; font-size: 10pt; clear: both;">&#xa0;
  </div>

  <div style="text-indent: -20.5pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 20.5pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">a)</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font>
    </div>
  </div>
  <div style="text-align: justify; margin-left: 2.5pt; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -20.5pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 20.5pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">b)</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
    </div>
  </div>
  <div style="margin-left: 36pt; font-size: 10pt; clear: both;">&#xa0;
  </div>

  <div style="text-indent: -20.5pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 20.5pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">c)</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
    </div>
  </div>
  <div style="text-align: justify; margin-left: 2.5pt; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -20.5pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 20.5pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">d)</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font>
    </div>
  </div>
  <div style="text-align: justify; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">5.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font>
    </div>
  </div>
  <div style="text-align: justify; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">a.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
    </div>
  </div>
  <div style="text-align: justify; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">b.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
    </div>
  </div>



  <table style="border-spacing: 0px; border-collapse: collapse; width: 100%; font-size: 10pt;">
   <tr><td style="width: 50%;">&#xa0;</td><td style="width: 5pt;">&#xa0;</td><td style="width: 45%;">&#xa0;</td></tr><tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Date: May 7, 2025
     </div>
    </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      By:
     </div>
    </td>
    <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">
     <div>
      /s/ Brad Tade
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">&#xa0;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Name:
     </div>
    </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Brad Tade
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">&#xa0;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Title:
     </div>
    </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Chief Financial Officer
     </div>
     <div>
      (Principal Financial Officer)
     </div>
    </td>
   </tr>
  </table><div>&#xa0;</div>
 <div>&#xa0;</div><hr style="border-top: 2px solid black; border-bottom: none; border-left: none; border-right: none; height: 0px; margin: 6px auto; width: 100%;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ef20047548_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!-- Created by CompSci Resources, LLC on Sat May 03 23:24:57 UTC 2025 --><!doctype html><html>
 <head><meta content="text/html; charset=ASCII">
  <title></title>
 </head>
 <body style="font-family: 'Times New Roman'; font-size: 11pt;">

  <hr style="border-top: 4px solid black; border-bottom: none; border-left: none; border-right: none; height: 0px; margin: 6px auto; width: 100%;"><div style="text-indent: 36pt; margin-bottom: 12pt; text-align: right; font-size: 10pt;"><font style="font-weight: bold;">Exhibit 32.1</font>
  </div><div style="margin-bottom: 12pt; text-align: center; font-size: 10pt;">
   <font style="font-weight: bold;">CERTIFICATIONS</font>
  </div>
  <div style="text-align: justify;">
   <font style="font-size: 10.0pt;">In connection with the Quarterly Report of ADMA Biologics, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), on Form 10-Q for the quarter ended March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Adam S. Grossman, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#xa7; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font>
  </div>
  <div style="font-size: 10pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">1.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font>
    </div>
  </div>
  <div style="margin-left: 36pt; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">2.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font>
    </div>
  </div>




  <table style="border-spacing: 0px; border-collapse: collapse; font-size: 10pt; width: 100%;">
   <tr><td style="width: 50%;">&#xa0;</td><td style="width: 5%;">&#xa0;</td><td style="width: 45%;">&#xa0;</td></tr><tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Date: May 7, 2025
     </div>
    </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      By:
     </div>
    </td>
    <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">
     <div>
      /s/ Adam S. Grossman
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">&#xa0;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Name:
     </div>
    </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Adam S. Grossman
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">&#xa0;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Title:
     </div>
    </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      President and Chief Executive Officer
     </div>
     <div>
      (Principal Executive Officer)
     </div>
    </td>
   </tr>
  </table><div>&#xa0;</div>
 <div>&#xa0;</div><hr style="border-top: 2px solid black; border-bottom: none; border-left: none; border-right: none; height: 0px; margin: 6px auto; width: 100%;"><div>&#xa0;</div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>ef20047548_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!-- Created by CompSci Resources, LLC on Sat May 03 23:24:57 UTC 2025 --><!doctype html><html>
 <head><meta content="text/html; charset=ASCII">
  <title></title>
 </head>
 <body style="font-family: 'Times New Roman'; font-size: 11pt;">

  <hr style="border-top: 4px solid black; border-bottom: none; border-left: none; border-right: none; height: 0px; margin: 6px auto; width: 100%;"><div style="text-indent: 36pt; margin-bottom: 12pt; text-align: right; font-size: 10pt;"><font style="font-weight: bold;">Exhibit 32.2</font>
  </div><div style="margin-bottom: 12pt; text-align: center; font-size: 10pt;">
   <font style="font-weight: bold;">CERTIFICATIONS</font>
  </div>
  <div style="text-align: justify;">
   <font style="font-size: 10.0pt;">In connection with the Quarterly Report of ADMA Biologics, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), on Form 10-Q for the quarter ended March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Brad Tade, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#xa7; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font>
  </div>
  <div style="font-size: 10pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">1.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font>
    </div>
  </div>
  <div style="margin-left: 36pt; font-size: 10pt; clear: both;">&#xa0;
  </div>
  <div style="text-indent: -18pt; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font style="font-size: 10.0pt;">2.</font>
    </div>
    <div>
     <font style="font-size: 10.0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font>
    </div>
  </div>




  <table style="border-spacing: 0px; border-collapse: collapse; font-size: 10pt; width: 100%;">
   <tr><td style="width: 50%;">&#xa0;</td><td style="width: 5%;">&#xa0;</td><td style="width: 45%;">&#xa0;</td></tr><tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Date: May 7, 2025
     </div>
    </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      By:
     </div>
    </td>
    <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">
     <div>
      /s/ Brad Tade
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">&#xa0;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Name:
     </div>
    </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Brad Tade
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">&#xa0;</td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Title:
     </div>
    </td>
    <td style="padding-top: 0px; padding-bottom: 0px; padding-right: 5.75pt;">
     <div>
      Chief Financial Officer
     </div>
     <div>
      (Principal Financial Officer)
     </div>
    </td>
   </tr>
  </table><div style="margin-bottom: 12pt; text-align: justify;">&#xa0;</div>
  <hr style="border-top: 2px solid black; border-bottom: none; border-left: none; border-right: none; height: 0px; margin: 6px auto; width: 100%;"><div>&#xa0;
  </div>
 </body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 02, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADMA BIOLOGICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001368514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2590442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">465 State Route 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ramsey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">478-5552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADMA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,734,246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 71,625<span></span>
</td>
<td class="nump">$ 103,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">99,412<span></span>
</td>
<td class="nump">49,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">172,188<span></span>
</td>
<td class="nump">170,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,589<span></span>
</td>
<td class="nump">8,029<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">351,814<span></span>
</td>
<td class="nump">331,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">57,710<span></span>
</td>
<td class="nump">54,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,530<span></span>
</td>
<td class="nump">3,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">80,855<span></span>
</td>
<td class="nump">84,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-to-use assets</a></td>
<td class="nump">8,020<span></span>
</td>
<td class="nump">8,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DepositsAndOtherNoncurrentAssets', window );">Deposits and other assets</a></td>
<td class="nump">8,188<span></span>
</td>
<td class="nump">5,657<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">510,569<span></span>
</td>
<td class="nump">488,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">20,607<span></span>
</td>
<td class="nump">20,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">31,560<span></span>
</td>
<td class="nump">33,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease obligations</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">53,498<span></span>
</td>
<td class="nump">55,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior notes payable, net of discount</a></td>
<td class="nump">72,527<span></span>
</td>
<td class="nump">72,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">1,512<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_LongTermLiabilityEndOfTermFeePayable', window );">End of term fee</a></td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease obligations, net of current portion</a></td>
<td class="nump">8,298<span></span>
</td>
<td class="nump">8,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">137,150<span></span>
</td>
<td class="nump">139,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 238,532,252 and 236,620,545 shares issued and outstanding at March 31, 2025 and December 31, 2024</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">655,074<span></span>
</td>
<td class="nump">657,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(281,679)<span></span>
</td>
<td class="num">(308,583)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' EQUITY</a></td>
<td class="nump">373,419<span></span>
</td>
<td class="nump">349,018<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 510,569<span></span>
</td>
<td class="nump">$ 488,678<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DepositsAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DepositsAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_LongTermLiabilityEndOfTermFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal balance of the loans and any other obligations advanced or otherwise owed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_LongTermLiabilityEndOfTermFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">238,532,252<span></span>
</td>
<td class="nump">236,620,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">238,532,252<span></span>
</td>
<td class="nump">236,620,545<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">REVENUES</a></td>
<td class="nump">$ 114,802<span></span>
</td>
<td class="nump">$ 81,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">53,705<span></span>
</td>
<td class="nump">42,767<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">61,097<span></span>
</td>
<td class="nump">39,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Plasma center operating expenses</a></td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">24,079<span></span>
</td>
<td class="nump">15,639<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">26,216<span></span>
</td>
<td class="nump">17,287<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">INCOME FROM OPERATIONS</a></td>
<td class="nump">34,881<span></span>
</td>
<td class="nump">21,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">608<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(1,975)<span></span>
</td>
<td class="num">(3,769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(1,431)<span></span>
</td>
<td class="num">(3,420)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME BEFORE INCOME TAXES</a></td>
<td class="nump">33,450<span></span>
</td>
<td class="nump">18,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">6,546<span></span>
</td>
<td class="nump">595<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME</a></td>
<td class="nump">$ 26,904<span></span>
</td>
<td class="nump">$ 17,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC EARNINGS PER COMMON SHARE (in Dollars per share)</a></td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED EARNINGS PER COMMON SHARE (in Dollars per share)</a></td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in Shares)</a></td>
<td class="nump">237,775,476<span></span>
</td>
<td class="nump">228,874,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in Shares)</a></td>
<td class="nump">244,676,350<span></span>
</td>
<td class="nump">236,414,374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">226,063,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 641,439<span></span>
</td>
<td class="num">$ (506,256)<span></span>
</td>
<td class="nump">$ 135,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants', window );">Cashless exercise of warrants (in Shares)</a></td>
<td class="nump">4,545,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares', window );">Vesting of restricted stock units, net of shares withheld for taxes (in Shares)</a></td>
<td class="nump">774,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount', window );">Vesting of restricted stock units, net of shares withheld for taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(2,476)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,476)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="nump">386,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,806<span></span>
</td>
<td class="nump">17,806<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">642,133<span></span>
</td>
<td class="num">(488,450)<span></span>
</td>
<td class="nump">153,706<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">231,769,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">236,620,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">657,577<span></span>
</td>
<td class="num">(308,583)<span></span>
</td>
<td class="nump">349,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,624<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants', window );">Cashless exercise of warrants (in Shares)</a></td>
<td class="nump">866,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares', window );">Vesting of restricted stock units, net of shares withheld for taxes (in Shares)</a></td>
<td class="nump">1,016,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount', window );">Vesting of restricted stock units, net of shares withheld for taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(7,228)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="nump">29,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,904<span></span>
</td>
<td class="nump">26,904<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 655,074<span></span>
</td>
<td class="num">$ (281,679)<span></span>
</td>
<td class="nump">$ 373,419<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="nump">238,532,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of the cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to restricted stock awards issued during the period, net of shares withheld to cover grantees' income tax liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to restricted stock awards, net of shares withheld to cover grantees' income tax liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 26,904<span></span>
</td>
<td class="nump">$ 17,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,969<span></span>
</td>
<td class="nump">2,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax provision</a></td>
<td class="nump">3,425<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,624<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AmortizationOfLicenseRevenue', window );">Amortization of license revenue</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(49,413)<span></span>
</td>
<td class="num">(22,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(1,953)<span></span>
</td>
<td class="num">(4,826)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,596)<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_IncreaseDecreaseInDepositsAndOtherAssets', window );">Deposits and other assets</a></td>
<td class="nump">120<span></span>
</td>
<td class="num">(982)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(2,401)<span></span>
</td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current and non-current liabilities</a></td>
<td class="num">(650)<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(19,675)<span></span>
</td>
<td class="num">(2,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(4,701)<span></span>
</td>
<td class="num">(2,347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(4,720)<span></span>
</td>
<td class="num">(2,362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_TaxesPaidOnVestedRestrictedStockUnits', window );">Taxes paid on vested restricted stock units</a></td>
<td class="num">(7,228)<span></span>
</td>
<td class="num">(2,476)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from the exercise of stock options</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(7,127)<span></span>
</td>
<td class="num">(1,447)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(31,522)<span></span>
</td>
<td class="num">(6,027)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - beginning of period</a></td>
<td class="nump">103,147<span></span>
</td>
<td class="nump">51,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - end of period</a></td>
<td class="nump">$ 71,625<span></span>
</td>
<td class="nump">$ 45,325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AmortizationOfLicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash revenue related to amortization of license revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AmortizationOfLicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_IncreaseDecreaseInDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits and operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_IncreaseDecreaseInDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_TaxesPaidOnVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow related to taxes on vested Restricted Stock Units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_TaxesPaidOnVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND BUSINESS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BUSINESS</a></td>
<td class="text"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">1.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">ORGANIZATION AND BUSINESS</span>
    </div>
  </div>
  <div style="clear: both;">&#160;
  </div>
  <div style="text-indent: 33.75pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">ADMA Biologics, Inc. (&#8220;ADMA&#8221; or the &#8220;Company&#8221;) is a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company&#8217;s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.</span>
  </div>
  <div style="text-indent: 33.75pt;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div>
  <div style="text-indent: 33.75pt; text-align: justify;"> <span style="color: rgb(0, 0, 0);">ADMA operates through its wholly owned subsidiaries ADMA BioManufacturing, LLC (&#8220;ADMA BioManufacturing&#8221;) and ADMA BioCenters Georgia Inc. (&#8220;ADMA BioCenters&#8221;). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of certain assets held by the Company&#8217;s former third-party contract manufacturer, which included the U.S. Food and Drug Administration (&#8220;FDA&#8221;)-licensed BIVIGAM and Nabi-HB immunoglobulin products, and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the &#8220;Boca Facility&#8221;). ADMA BioCenters is the Company&#8217;s source plasma collection business with ten plasma collection facilities located throughout the United States, all of which hold an approved license with the FDA.</span> </div>
  <div style="text-indent: 33.75pt;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div>
  <div style="text-indent: 33.75pt; text-align: justify;"> <span style="color: rgb(0, 0, 0);">The Company has three FDA-approved products, all of which are currently marketed and commercially available: (i) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an intravenous immune globulin (&#8220;IVIG&#8221;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;) or Inborn Errors of Immunity, for which the Company received FDA approval in April&#160;&#160;2019 and commenced first commercial sales in October 2019; (ii) BIVIGAM (Immune Globulin Intravenous, Human), an IVIG product indicated for the treatment of PI, and for which the Company received FDA approval in May 2019 and commenced commercial sales in August 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (&#8220;HBsAg&#8221;) and other listed exposures to Hepatitis B. In addition to its commercially available immunoglobulin products, the Company generates revenues from the sale of intermediates that result from the immunoglobulin production process and from time to time provides contract manufacturing and laboratory services for certain clients. The Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.</span> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">2.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span>
    </div>
  </div>
  <div style="clear: both;">&#160;
  </div>
  <div> <span style="font-style: italic; text-decoration: underline;">Principles of consolidation and basis of presentation</span></div>

  <div>&#160;</div><div style="text-indent: 36pt; text-align: justify;">
   <span>The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (the &#8220;FASB&#8221;). </span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2024 included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 18, 2025. All intercompany balances and transactions have been eliminated in consolidation. The preparation of our interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed. We have made reasonable estimates and judgments of such items within our financial statements and there may be changes to those estimates in future periods. </span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>During the three months ended March 31, 2025 and 2024, comprehensive income was equal to the net income amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year.</span>
  </div><div> <span style="font-style: italic; text-decoration: underline;">Use of Estimates</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include rebates deducted from gross revenues and estimates related to Company&#8217;s effective tax rate.</span>
  </div>
  <div>&#160;
  </div>
  <div> <span style="font-style: italic; text-decoration: underline;">Fair Value of Financial Instruments</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company&#8217;s senior credit facility (see Note 6) approximates fair value, based on a Level 3 classification under the fair value hierarchy, due to the variable interest rate on this debt.&#160;&#160;</span>
  </div>
  <div>&#160;
  </div>
  <div> <span style="font-style: italic; text-decoration: underline;">Accounts Receivable</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>Accounts receivable is reported at realizable value, net of allowances for customer credits and credit losses in the amount of $3.0 million and $0.2 million at March 31, 2025 and December 31, 2024, respectively. </span><span style="color: rgb(33, 37, 41);">The Company extends credit to its customers based upon an evaluation of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition, payment history and associated credit risk of customers are performed on an ongoing basis.</span><span> Based on these evaluations, the Company has concluded that its credit risk is minimal. At March 31, 2025 and December 31, 2024, three customers accounted for an aggregate of approximately 85% and 91%, respectively, of the Company&#8217;s total accounts receivable.</span> </div>
  <div style="margin-left: 18pt;">&#160;
  </div>
  <div> <span style="font-style: italic; text-decoration: underline;">Inventories</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 33.75pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Raw materials inventory consists of various materials purchased from suppliers, including normal source plasma and Respiratory Syncytial Virus (&#8220;RSV&#8221;) high titer plasma, used in the production of the Company&#8217;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable supplies and depreciation. The Boca Facility overhead allocation to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#8217;s FDA-approved products relative to the total square footage of the facility.</span>
  </div>
  <div style="text-indent: 33.75pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">&#160;</span>
  </div>
  <div style="text-indent: 33.75pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. </span>
  </div>
  <div>&#160;
  </div>
  <div> <span style="font-style: italic; text-decoration: underline;">Goodwill</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at March 31, 2025 and December 31, 2024 was $3.5 million. All of the Company&#8217;s goodwill is attributable to its ADMA BioManufacturing business segment.&#160;&#160;</span> </div>
  <div style="text-align: justify; margin-left: 18pt;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>The Company did not record any impairment charges related to goodwill for the three months ended March 31, 2025 and 2024.</span> </div><div> <span style="font-style: italic; text-decoration: underline;">Revenue Recognition</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>Revenues are comprised of (i) revenues from the sale of the Company&#8217;s immunoglobulin products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company&#8217;s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediates; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest AG (&#8220;Biotest&#8221;) in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years. </span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based on when the product is shipped or delivered, depending on the sales terms, and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#8217;s immunoglobulin products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, wholesaler distribution and related fees, customer incentives, including prompt pay discounts, wholesaler chargebacks, group purchasing organization fees and reimbursements for patient assistance. These estimates are based on historical experience and certain other assumptions, and while the Company believes that such estimates are reasonable, they are subject to change based on future experience and other factors. </span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company. &#160;&#160;&#160;&#160;</span>
  </div>
  <div style="text-align: justify; margin-left: 18pt;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.</span>
  </div>
  <div style="margin-left: 18pt;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>For the three months ended March 31, 2025, three customers represented an aggregate of approximately 74% of the Company&#8217;s consolidated revenues. For the three months ended March 31, 2024, two customers represented an aggregate of approximately 70% of the Company&#8217;s consolidated revenue. </span> </div>
  <div>&#160;
  </div>
  <div> <span style="font-style: italic; text-decoration: underline;">Cost of Product Revenue</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA-approved products, intermediates and the collection of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the activities of these operations are attributable to new products or processes in development, the expenses are classified as research and development expenses. </span>
  </div>
  <div>&#160;
  </div>
  <div> <span style="color: rgb(0, 0, 0); font-style: italic; text-decoration: underline;">Earnings/loss Per Common Share</span><span style="color: rgb(0, 0, 0); font-style: italic;">&#160;&#160;</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt;"> <span>For the three months ended March 31, 2025, basic and diluted earnings per share are calculated as follows:</span> </div>
  <div>&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 89%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top; height: 23.0pt;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-top: none; border-left: none; border-right: none; border-bottom: 2px solid black;">&#160;</td><td style="text-align: center; width: 9%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none; white-space: nowrap;">



      <span style="font-weight: bold;">Three Months Ended
<br/>
      March 31, 2025</span>
     </td><td style="text-align: center; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Net income available to common stockholders ($000's) (numerator)
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">26,904</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Weighted-average number of common shares (denominator)
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">237,775,476</td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Basic earnings per common shares
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">0.11</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Weighted-average number of common shares
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">237,775,476</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Potential shares of common stock arising from outstanding stock options
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">3,987,814</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Potential shares of common stock arising from outstanding warrants
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">47,536</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Potential shares of common stock arising from unvested RSUs
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">2,865,524</td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Total shares - diluted (denominator)
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">244,676,350</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-left: none; border-right: none; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Diluted earnings per common share
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">0.11</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><div style="text-indent: 36pt;"> <span>For the three months ended March 31, 2025 and 2024, there were no shares with an anti-dilutive effect that needed to be excluded from the earnings per share computation. </span> </div>
  <div>&#160;
  </div>
  <div> <span style="font-style: italic; text-decoration: underline;">Recent Accounting Pronouncements</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): </span><span style="font-style: italic;">Improvements to Income Tax Disclosures</span><span>. This Update requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid and became effective for public business entities for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that this Update may have on the Company&#8217;s consolidated financial statements.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 27pt; text-align: justify;">
   <span>In November 2024, the FASB issued ASU No. 2024-03, </span><span style="font-style: italic;">Income Statement - Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures</span><span> (Subtopic 220-40). The amendments in this Update require disclosure, in the notes to the financial statements, of specified information about certain costs and expenses, including but not limited to, purchases of inventory, employee compensation and selling expense. This Update becomes effective for fiscal years beginning after December 15, 2026. The Company is currently evaluating the impact that this Update may have on the Company&#8217;s consolidated financial statements.</span>
  </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">3.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">INVENTORIES</span>
    </div>
  </div>
  <div style="margin-left: 27pt; clear: both;">&#160;
  </div>
  <div style="text-indent: 36pt;"> <span>The following table provides the components of inventories:</span> </div>
  <div style="text-align: center;">&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width : 9%; white-space : nowrap; ">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">March 31, <br/>

      2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align : center; width : 9%; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; ">



      <span style="font-weight: bold;">December 31,<br/>

      2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center;">


      <span style="font-style: italic;">(In thousands)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Raw materials
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">75,819</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">60,473</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Work-in-process
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">49,780</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">61,641</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Finished goods
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">46,589</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">48,121</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Total inventories
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">172,188</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">170,235</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><div style="text-align: center;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>Raw materials includes plasma and other materials expected to be used in the production of ASCENIV, BIVIGAM and Nabi-HB. These materials will be consumed in the production of goods expected to be available for sale or otherwise have alternative uses that provide a probable future benefit.&#160;&#160;</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the Company&#8217;s immunoglobulin products. </span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available for commercial sale, as well as plasma collected at the Company&#8217;s plasma collection centers that is expected to be sold to third-party customers. </span>
  </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">4.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">PROPERTY AND EQUIPMENT</span>
    </div>
  </div>
  <div style="clear: both;">&#160;
  </div>
  <div style="text-indent: 36pt;"> <span>Property and equipment and related accumulated depreciation are summarized as follows:</span> </div>
  <div>&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">March 31, 2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">December 31, 2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center;">


      <span style="font-style: italic;">(In thousands)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Manufacturing and laboratory equipment
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">21,916</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">21,305</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Office equipment and computer software
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">6,142</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">5,772</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Furniture and fixtures
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">5,939</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">5,840</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Construction in process
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">11,225</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">8,149</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Leasehold improvements
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">21,103</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">21,066</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Land
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">4,339</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">4,339</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Buildings and building improvements
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">22,542</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">21,788</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">93,206</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">88,259</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Less: Accumulated depreciation
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(35,496</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(33,552</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Total property and equipment, net
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">57,710</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">54,707</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><div>&#160;
  </div>
  <div style="text-indent: 36pt;"> <span style="color: rgb(0, 0, 0);">The Company recorded depreciation expense on property and equipment for the three months ended March 31, 2025 and 2024 of $1.9 million.</span> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">5.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span>
    </div>
  </div>
  <div style="margin-left: 18pt; clear: both;">&#160;
  </div>
  <div style="text-indent: 36pt;"> <span>Accrued expenses and other current liabilities at March 31, 2025 and December 31, 2024 are as follows:</span> </div>
  <div>&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">March 31, 2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap; vertical-align: middle;">


      <span style="font-weight: bold;">December 31, 2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center;">


      <span style="font-style: italic;">(In thousands)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Accrued rebates
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;">4,847</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;">4,155</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Accrued distribution fees
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">12,115</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">11,565</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Accrued incentives
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">1,671</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">5,892</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Accrued interest
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">1,893</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">2,857</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Accrued testing
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">463</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">827</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Accrued payroll and other compensation
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">1,924</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">3,332</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Income taxes payable
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">6,601</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">3,481</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Other
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">2,046</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">1,853</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Total accrued expenses and other current liabilities
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">31,560</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">33,962</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">6.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">DEBT </span>
    </div>
  </div>
  <div style="clear: both;">&#160;
  </div>
  <div style="text-indent: 36pt;"> <span>A summary of outstanding senior notes payable is as follows:</span> </div>
  <div>&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">March 31, 2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">December 31, 2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center;">


      <span style="font-style: italic;">(In thousands)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Term loan
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">32,500</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">32,500</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Revolving credit facility
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">42,500</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">42,500</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Less:
     </div>
    </td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">
     <div>
      Debt discount
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(2,473</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(2,663</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Senior notes payable
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">72,527</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">72,337</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: rgb(0, 0, 0);">On December 18, 2023 (the &#8220;Ares Closing Date&#8221;), the Company and all of its subsidiaries entered into a new senior secured credit facility (the &#8220;Ares Credit Agreement&#8221;) with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation (collectively, &#8220;Ares&#8221;). The Ares Credit Agreement provided for a total of $135.0 million in senior secured credit facilities (the &#8220;Ares Credit Facility&#8221;) consisting of (i) a term loan in the aggregate principal amount of $62.5 million and (ii) a revolving credit facility in the aggregate principal amount of $72.5 million (collectively, the &#8220;Ares Loans&#8221;), both of which were fully drawn on the Ares Closing Date. The Ares Credit Facility has a maturity date of December 20, 2027 (the &#8220;Ares Maturity Date&#8221;).</span> </div><div style="text-indent: 36pt; text-align: justify;"> <span style="color: rgb(0, 0, 0);">Borrowings under the term loan bear interest at the adjusted Term SOFR for a <span style="-sec-ix-hidden: hidden-fact-2">three</span>&#8209;month tenor in effect on the day that is two business days prior to the first day of the applicable calendar quarter plus 6.50% (the &#8220;Initial <span style="-sec-ix-hidden: hidden-fact-3">SOFR</span> Term Loan Applicable Margin&#8221;). Borrowings under the revolving facility bear interest at the adjusted Term SOFR for a <span style="-sec-ix-hidden: hidden-fact-4">three</span>&#8209;month tenor in effect on the day that is two business days prior to the first day of the applicable calendar quarter</span><span style="color: rgb(0, 0, 0); font-style: italic;">&#160;</span><span style="color: rgb(0, 0, 0);">plus</span><span style="color: rgb(0, 0, 0); font-style: italic;">&#160;</span><span style="color: rgb(0, 0, 0);">3.75% (the &#8220;SOFR Revolving Facility Applicable Margin&#8221;). As of March 31, 2025 and December 31, 2024, the interest rate on the term loan was approximately 10.80% and 10.85%, respectively, and the interest rate on the revolving facility was approximately 8.05% and 8.34%, respectively. </span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: rgb(0, 0, 0);">On the Ares Maturity Date, the Company is required to pay Ares the entire outstanding principal amount underlying the Ares term loan and revolving loan (together, the &#8220;Ares Loans&#8221;) and any accrued and unpaid interest thereon. Prior to the Ares Maturity Date, there are no scheduled principal payments on the Ares Loans. After giving effect to the principal payments made during the year ended December 31, 2024, the Company is required to make quarterly interest payments to Ares of approximately $1.8 million. The Company may prepay the outstanding principal under the revolving facility, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon three business days&#8217; prior written notice with no prepayment premium. However, in the event the Company pays down an aggregate amount under the revolving facility that is greater than 50% of the $72.5 million commitment amount, the Company will still be required to pay interest on 50% of this amount, or $36.3 million, through the Ares Maturity Date. The Company may prepay the outstanding principal on the term loan, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon three business days&#8217; prior written notice, subject to the payment to Ares of a prepayment premium equal to (i) the present value as of such date of all remaining required interest payments on the principal amount being repaid plus 1.5% of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Ares Closing Date, (ii) 1.5% of the prepaid principal amount, if prepaid after the first anniversary of the Ares Closing Date and on or prior to the second anniversary of the Ares Closing Date, or (iii) 1.0% of the prepaid principal amount, if prepaid on or prior to the third anniversary of the Ares Closing Date. As further discussed in Note 14 &#8211; Subsequent Events, on May 6, 2025, the Company repaid $30.0 million against the term loan using a draw of $30.0 million against the revolving credit facility made on May 5, 2025; accordingly, the outstanding balance of the term loan facility as of May 6, 2025 was $2.5 million and the outstanding balance of the revolving loan facility as of May 6, 2025 was $72.5 million.&#160;&#160;</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: rgb(0, 0, 0);">All of the Company&#8217;s obligations under the Ares Credit Agreement are secured by a first-priority lien and security interest in substantially all of the Company&#8217;s tangible and intangible assets, including intellectual property and all of the equity interests in the Company&#8217;s subsidiaries. The Ares Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar debt financings. The negative covenants include certain financial covenants, including maximum total leverage ratios and a $15.0 million minimum liquidity covenant, and also restrict or limit the Company&#8217;s ability and the ability of the Company&#8217;s subsidiaries to, among other things and subject to certain exceptions contained in the Ares Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#8217;s or the Company&#8217;s subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Ares Credit Agreement); engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company&#8217;s ability to make loan repayments under the Ares Credit Agreement. As of March 31, 2025, the Company was in compliance with all of the covenants contained in the Ares Credit Agreement.</span> </div>
  <div style="text-indent: 36pt; text-align: justify; color: rgb(0, 0, 0);">
   <span>&#160;</span>
  </div>
  <div style="text-indent: 36pt; text-align: justify; color: rgb(0, 0, 0);"> <span>Events of Default on the Ares Loans include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. If there is an event of default, the Company will incur an increase in the rate of interest on the Ares Loans of 2% per annum.</span> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">7.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">STOCKHOLDERS&#8217; EQUITY </span>
    </div>
  </div>
  <div style="clear: both;">&#160;
  </div>
  <div>
   <span style="font-style: italic; text-decoration: underline;">Preferred Stock</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt;"> <span>The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001, par value per share. There were no shares of preferred stock outstanding at March 31, 2025 and December 31, 2024.</span> </div><div>
   <span style="font-style: italic; text-decoration: underline;">Common Stock</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>As of March 31, 2025 and December 31, 2024, the Company was authorized to issue 300,000,000 shares of its common stock, $0.0001 par value per share, and 238,532,252 and 236,620,545 shares of common stock were outstanding as of March 31, 2025 and December 31, 2024, respectively. After giving effect to shares reserved for the issuance of warrants and for awards issued under the Company&#8217;s equity incentive plans, 36,622,488 shares of common stock were available for issuance as of March 31, 2025. </span> </div>
  <div>&#160;
  </div>
  <div>
   <span style="font-style: italic; text-decoration: underline;">Warrants</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>On January 7, 2025, affiliates of a former noteholder of the Company exercised warrants to purchase an aggregate of 966,554 shares of common stock on a cashless basis, and the Company issued 866,302 shares of common stock to these entities. On January 10, 2024, a former noteholder of the Company exercised a warrant to purchase 4 million shares of the Company&#8217;s common stock on a cashless basis and the Company issued 1,977,514 shares of common stock to this noteholder. On March 8, 2024, affiliates of a former noteholder exercised warrants to purchase an aggregate of 3,388,681 shares of the Company&#8217;s common stock on a cashless basis and the Company issued 2,482,205 shares of common stock to such noteholders. On March 14, 2024, an entity associated with another former noteholder of the Company exercised a warrant to purchase 169,651 shares of the Company&#8217;s common stock on a cashless basis and the Company issued 85,784 shares of common stock to this entity. </span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>On February 24, 2024, a warrant to purchase 34,800 shares of the Company&#8217;s common stock held by a former noteholder of the Company expired in accordance with its terms. At March 31, 2024 and December 31, 2023, the Company had outstanding warrants to purchase an aggregate of 4,909,774 and 12,502,906 shares, respectively, of common stock, with weighted-average exercise prices of $2.51 and $2.32 per share, respectively, with expiration dates ranging between October 2024 and May 2030.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>There were no outstanding warrants as of March 31, 2025 and outstanding warrants to purchase 966,554 shares of common stock as of December 31, 2024. </span> </div>
  <div style="margin-left: 18pt;">&#160;
  </div>
  <div>
   <span style="font-style: italic; text-decoration: underline;">Equity Incentive Plans</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>The fair value of stock options granted under the Company&#8217;s equity incentive plans was determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimate. The following assumptions were used to determine the fair value of options granted during the three months ended March 31, 2025 and 2024:</span> </div>
  <div>&#160;</div>

  <table cellpadding="0" style="font-size: 9.5pt; border-collapse: collapse; border-spacing: 0px; width: 100%; margin-left: auto; margin-right: auto;">
 <tr><td style="width: 79%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td></tr><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes">
  <td valign="top">&#160;</td>
  <td colspan="3" style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b>Three Months Ended March 31,</b></div>
  </td>
 </tr>
 <tr style="mso-yfti-irow:1">
  <td valign="top">&#160;</td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; text-align: center;" valign="top">
  <div><b>2025</b></div>
  </td>
  <td style="padding: 0in 5.4pt 0in 5px; text-align: center;" valign="top">&#160;</td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; text-align: center;" valign="top">
  <div><b>2024</b></div>
  </td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="vertical-align: bottom;" valign="top">
  <div>Expected term</div>
  </td>
  <td style="padding-top : 0in; padding-right : 5.4pt; padding-bottom : 0in; text-align : center; vertical-align : bottom; white-space : nowrap; " valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">5.5 - 6.3 years</span></div> </td>
  <td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top">&#160;</td>
  <td style="padding-top : 0in; padding-right : 5.4pt; padding-bottom : 0in; text-align : center; vertical-align : bottom; white-space : nowrap; " valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">5.5 - 6.3 years</span></div> </td>
 </tr>
 <tr style="mso-yfti-irow:3">
  <td valign="top">
  <div>Volatility</div>
  </td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">66%</span></div> </td>
  <td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top">&#160;</td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">66%</span></div> </td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Dividend yield</div>
  </td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">0.0</span></div> </td>
  <td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top">&#160;</td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">0.0</span></div> </td>
 </tr>
 <tr style="mso-yfti-irow:5;mso-yfti-lastrow:yes">
  <td valign="top">
  <div>Risk-free interest rate</div>
  </td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">4.40%</span></div> </td>
  <td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top">&#160;</td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">4.29%</span></div> </td>
 </tr>
</table><div style="text-indent: 36pt;"> <span>A summary of the Company&#8217;s option activity under the Company&#8217;s equity incentive plans and related information is as follows:</span> </div>


  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">


      <span style="font-weight: bold;">Shares</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom; white-space: nowrap;">




      <span style="font-weight: bold;">Weighted <br/>

      Average <br/>

      Exercise Price</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Options outstanding, vested and expected to vest at December 31, 2024
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">5,141,516</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">3.90</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Forfeited
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(1,101</td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">1.29</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Expired
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(10,480</td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">4.89</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Granted
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">683,720</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">16.07</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Exercised
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(39,173</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">6.61</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Options outstanding, vested and expected to vest at March 31, 2025
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">5,774,482</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">5.32</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Options exercisable
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">3,086,687</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">3.21</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>As of March 31, 2025, the Company had $12.7 million of unrecognized compensation expense related to options granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average period of 3.1 years.&#160;&#160;</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>The Company&#8217;s RSUs generally vest annually over a period of four years for employees and semi-annually over a period of one year for directors. A summary of the Company&#8217;s unvested RSU activity and related information is as follows: </span> </div>


  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">Shares</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">




      <span style="font-weight: bold;">Weighted <br/>

      Average Grant <br/>

      Date Fair Value</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Balance at December 31, 2024
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">5,745,990</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">5.50</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Granted
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">1,658,458</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">16.11</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Vested
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(1,455,350</td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">4.17</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Forfeited
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(93,611</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">6.64</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Balance at March 31, 2025
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">5,855,487</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">8.82</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
  </table><div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>As of March 31, 2025, the Company had $48.3 million of unrecognized compensation expense related to unvested RSUs granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average period of 3.4 years.</span> </div>
  <div style="text-align: justify; margin-left: 9pt;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for the three months ended March 31, 2025 and 2024 was as follows:&#160;&#160;</span> </div>


  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align : center; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; ">


      <span style="font-weight: bold;">Three Months Ended March 31,</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="text-align: center;">
     <div>
      <span style="font-style: italic;">(in thousands)</span>
     </div>
    </td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Research and development
     </div>
    </td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">39</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">17</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Plasma center operating expenses
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">77</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">39</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Selling, general and administrative
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">3,873</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">1,841</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Cost of product revenue
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">635</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">244</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Total stock-based compensation expense
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">4,624</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">2,141</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">8.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">RELATED PARTY TRANSACTIONS</span>
    </div>
  </div>
  <div style="margin-left: 18pt; clear: both;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>The Company leases an office building and equipment from Areth, LLC (&#8220;Areth&#8221;) pursuant to an agreement for services effective as of January 1, 2016, as amended from time to time, and pays monthly rent on this facility in the amount of $10,000. Either party may terminate the agreement by providing the other party with one year&#8217;s prior written notice. Rent expense for the three months ended March 31, 2025 and 2024 amounted to $30,000. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Board, and Adam S. Grossman, the Company&#8217;s President and Chief Executive Officer. The Company also reimburses Areth for office, warehousing and building related (common area) expenses, equipment and certain other operational expenses, which were not material to the consolidated financial statements for the three months ended March 31, 2025 and 2024.</span> </div><div style="text-indent: 36pt; text-align: justify;"> <span>During the three months ended March 31, 2025 and 2024, the Company purchased certain specialized equipment and repair services used for the collection and processing of source plasma from GenesisBPS in the amount of $34 thousand and $0.1 million, respectively. Genesis is owned by Dr. Grossman and Adam Grossman. </span> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">9.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">COMMITMENTS AND CONTINGENCIES</span>
    </div>
  </div>
  <div style="margin-left: 18pt; clear: both;">&#160;
  </div>
  <div>
   <span style="font-style: italic; text-decoration: underline;">General Legal Matters</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>From time to time, the Company is or may become subject to certain legal proceedings and claims arising in connection with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#8217;s liquidity, results of operations or financial condition. </span>
  </div>
  <div style="margin-left: 18pt;">&#160;
  </div>
  <div>
   <span style="font-style: italic; text-decoration: underline;">Vendor Commitments</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>Pursuant to the terms of a plasma purchase agreement dated as of November 17, 2011 (the &#8220;2011 Plasma Purchase Agreement&#8221;), the Company agreed to purchase from its former contract manufacturer an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum volume from the counterparty, and under the original 2011 Plasma Purchase Agreement the Company was permitted to also collect high-titer RSV plasma from up to five wholly owned ADMA plasma collection facilities.&#160;&#160;During 2015, the Company amended the 2011 Plasma Purchase Agreement to (i) allow the Company to collect its raw material RSV high-titer plasma from any number of wholly owned ADMA plasma collection facilities and (ii) allow the Company to purchase its raw material RSV high-titer plasma from other third-party collection organizations, in each case, provided that the annual minimum volumes from the Company&#8217;s former contract manufacturer were met, thus allowing the Company to expand its reach for raw material supply as it executes its commercialization plans for ASCENIV. On December 10, 2018, the Company&#8217;s former contract manufacturer assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations Limited (&#8220;Grifols&#8221;) as its successor-in-interest, effective January 1, 2019. Effective October 1, 2024, the Company entered into an Amended and Restated Plasma Purchase Agreement with Grifols (the &#8220;A&amp;R Grifols Agreement&#8221;) with a term expiring in <span style="-sec-ix-hidden: hidden-fact-5">September 2039</span>, after which it may be renewed for two additional multi-year periods if agreed to by the parties. Pursuant to the A&amp;R Grifols Agreement, Grifols supplies, on a non-exclusive basis, to ADMA BioManufacturing a minimum of 35,000 liters of RSV plasma annually to be used in the manufacture of ASCENIV, with an escalating price per liter depending on the volume supplied in a given 12-month period, with a minimum annual price increase every 12 months. Additionally, Grifols will be entitled to receive a fixed bonus payment in the event that a specified liter amount of high-titer plasma is supplied to the Company in any 12-month period during the term of the A&amp;R Grifols Agreement.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>Effective August 6, 2024, the Company entered into a Plasma Purchase Agreement with KEDPlasma LLC (&#8220;KEDPlasma&#8221;) with a term expiring in <span style="-sec-ix-hidden: hidden-fact-6">July 2031</span>, after which it may be renewed for an additional <span style="-sec-ix-hidden: hidden-fact-7">five</span>-year period if agreed to by the parties (the &#8220;KEDPlasma Agreement&#8221;). Pursuant to the KEDPlasma Agreement, KEDPlasma supplies, on a non-exclusive basis, to ADMA BioManufacturing a minimum of 35,000 liters of RSV plasma annually commencing with the 12-month period ending July 31, 2026, with an escalating price per liter depending on the volume supplied in a given 12-month period. The price per liter of high-titer plasma supplied pursuant to the KEDPlasma Agreement is also scheduled to increase on an annual basis. Additionally, KEDPlasma will be entitled to receive a fixed bonus payment in the event that a specified liter amount of RSV plasma is supplied to the Company in any 12-month period during the term of the KEDPlasma Agreement.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>On June 6, 2017, the Company entered into a Plasma Supply Agreement with its former contract manufacturer, pursuant to which the counterparty supplies, on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a 10-year term. On July 19, 2018, the Plasma Supply Agreement was amended to provide, among other things, that in the event the counterparty elects not to supply in excess of ADMA BioManufacturing&#8217;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit percentage of the price that ADMA BioManufacturing pays to the counterparty, then the counterparty shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, the Company&#8217;s former contract manufacturer assigned its rights and obligations under the Plasma Supply Agreement to Grifols, effective January 1, 2019.</span> </div><div>
   <span style="font-style: italic; text-decoration: underline;">Post-Marketing Commitments</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>In connection with the FDA&#8217;s approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. For the three months ended March 31, 2025 and 2024, the Company incurred expenses related to this study in the amount of $0.6 million and $0.3 million, respectively. During the remainder of 2025, the Company expects to incur expenses of approximately $0.3 million to complete this study, which is required to be completed by June 2026.</span> </div>
  <div>&#160;
  </div>
  <div>
   <span style="font-style: italic; text-decoration: underline;">Other Commitments</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure under these arrangements is unknown as of March 31, 2025. The Company does not anticipate recognizing any significant losses relating to these arrangements.</span>
  </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTS</a></td>
<td class="text"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">10.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">SEGMENTS</span>
    </div>
  </div>
  <div style="margin-left: 18pt; clear: both;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company&#8217;s ADMA BioManufacturing operating segment reflects the Company&#8217;s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL.&#160;&#160;The Plasma Collection Centers operating segment consists of ten</span><span style="color: rgb(0, 0, 0);">&#160;plasma collection facilities located throughout the United States, all of which are operational, collecting plasma and currently hold FDA licenses</span><span>. The Company defines its operating segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;) to analyze performance and allocate resources. While not considered an operating segment, the Corporate information included in the tables below consists of certain unallocated general and administrative overhead expenses and interest expense on the Company&#8217;s senior debt (see Note 7). The Company&#8217;s CODM is its President and Chief Executive Officer. For the Company&#8217;s two operating segments, the CODM uses income/loss before taxes as the measure of segment profit to determine the allocation of resources for each segment. Summarized financial information concerning reportable segments is shown in the following tables:</span> </div><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;" width="100%">
 <tr><td style="width: 65%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes">
  <td colspan="12" style="text-align: center; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Three Months Ended March
  31, 2025</b></div>
  </td>
 </tr>
 <tr style="mso-yfti-irow:1">
  <td style="text-align: center; vertical-align: bottom;" valign="top">
  <div style="margin: 0in;"><i style="mso-bidi-font-style:normal">(in thousands)</i></div>
  </td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">ADMA </b></div>
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">BioManufacturing</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center;" valign="top">&#160;</td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Plasma Collection </b></div>
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Centers</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center;" valign="top">&#160;</td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Total</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Revenues</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top">113,716</td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top">1,050</td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top">114,766</td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:3">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Cost of product revenue</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">53,057</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">648</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">53,705</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:5">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Research and development</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">826</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">826</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:7">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Plasma center operating expenses</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">1,286</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">1,286</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:9">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Selling, marketing and distribution</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">6,044</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">6,044</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:11">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Depreciation and amortization expense</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">25</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">25</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:13">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>General and administrative expense</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">8,495</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">8,495</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:15">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Other expense, net</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(64</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(64</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:17">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Income (loss) before taxes</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">45,205</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(884</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">44,321</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:19">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Expenditures for additions to long-lived assets</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">4,699</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">21</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">4,720</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:21">
  <td valign="top">
  <div>Total assets</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">330,091</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">27,644</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">357,735</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:23">
  <td valign="top">
  <div><i>Reconciliation of revenues:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment
  revenue</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">114,766</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:25">
  <td style="padding-left: 10px;" valign="top">
  <div>License revenue</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">36</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated
  revenues</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">114,802</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:27">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation
  of selling, general and administrative expense:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:29">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment
  selling, marketing and distribution expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">6,044</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment
  general and administrative expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">8,495</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:31">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate
  general and administrative expense (a)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">9,540</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated
  selling, general and administrative expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">24,079</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:33">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation
  of income (loss) before taxes:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:35">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment
  income before taxes</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">44,321</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>License
  revenue </div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">36</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:37">
  <td style="padding-left: 10px;" valign="top">
  <div>Unallocated
  interest expense, primarily related to interest on senior debt (see Note 6)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(1,975</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Unallocated
  interest income</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">608</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:39">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate
  general and administrative expense (a)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">(9,540</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">)&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated
  income before taxes</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">33,450</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:41">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation
  of total assets:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:43">
  <td style="padding-left: 10px;" valign="top">
  <div>Total
  segment assets</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">357,735</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate
  (b)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">152,834</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:45;mso-yfti-lastrow:yes">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated
  total assets</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">510,569</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-right: none;" valign="top">&#160;</td>
 </tr>
</table><div>&#160;
  </div>
  <div style="text-indent: -30.6pt; padding-left: 36pt;"> <div style="float: left; width: 30.6pt; white-space: nowrap;"> <span>(a) - </span> </div> <div> <span>Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.</span> </div> </div>
  <div style="margin-left: 5.4pt; clear: both;">
   <span>&#160;</span>
  </div>
  <div style="text-indent: -30.6pt; padding-left: 36pt;"> <div style="float: left; width: 30.6pt; white-space: nowrap;"> <span>(b) -</span> </div> <div> <span>Primarily consists of cash and deferred tax assets.</span> </div> </div><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;" width="100%">
 <tr><td style="width: 65%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes">
  <td colspan="12" style="text-align: center; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Three Months Ended March
  31, 2024</b></div>
  </td>
 </tr>
 <tr style="mso-yfti-irow:1">
  <td style="text-align: center; padding-left: 10px; vertical-align: bottom;" valign="top">
  <div style="margin: 0in;"><i style="mso-bidi-font-style:normal">(in thousands)</i></div>
  </td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">ADMA </b></div>
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">BioManufacturing</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center;" valign="top">&#160;</td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Plasma Collection </b></div>
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Centers</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center;" valign="top">&#160;</td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Total</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Revenues</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top">80,113</td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top">1,726</td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top">81,839</td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:3">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Cost of product revenue</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">40,991</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">1,776</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">42,767</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:5">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Research and development</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">451</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">451</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:7">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Plasma center operating expenses</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">1,005</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">1,005</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:9">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Selling, marketing and distribution</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">4,431</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">4,431</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:11">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Depreciation and amortization expense</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">193</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">193</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:13">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>General and administrative expense</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">5,351</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">5,351</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:15">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Other expense, net</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(30</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(1</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(31</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:17">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Income (loss) before taxes</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">28,666</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(1,056</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">27,610</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:19">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Expenditures for additions to long-lived assets</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">2,330</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">17</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">2,347</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:21">
  <td valign="top">
  <div>Total assets</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">278,331</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">33,990</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">312,321</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:23">
  <td valign="top">
  <div><i>Reconciliation of revenues:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment revenue</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">81,839</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:25">
  <td style="padding-left: 10px;" valign="top">
  <div>License revenue</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">36</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated revenues</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">81,875</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:27">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation of selling,
  general and administrative expense:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:29">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment selling, marketing and distribution expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">4,431</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment general and administrative expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">5,351</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:31">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate general and administrative expense (a)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">5,857</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated selling, general and administrative expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">15,639</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:33">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation of income
  (loss) before taxes:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:35">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment income before taxes</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">27,610</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>License revenue </div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">36</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:37">
  <td style="padding-left: 10px;" valign="top">
  <div>Unallocated interest expense, primarily related to interest
  on senior debt (see Note 6)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(3,769</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Unallocated interest income</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">381</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:39">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate general and administrative expense (a)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">(5,857</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">)&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated income before taxes</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">18,401</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:41">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation of total
  assets:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:43">
  <td style="padding-left: 10px;" valign="top">
  <div>Total segment assets</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">312,321</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate (b)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">38,554</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:45">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated total assets</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">350,875</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-right: none;" valign="top">&#160;</td>
 </tr>

</table><div>&#160;
  </div>
  <div style="text-indent: -30.6pt; padding-left: 36pt;">
    <div style="float: left; width: 30.6pt; white-space: nowrap;">
     <span>(a) - </span>
    </div>
    <div>
     <span>Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.</span>
    </div>
  </div>
  <div style="margin-left: 36pt; clear: both;">&#160;
  </div>
  <div style="text-indent: -30.6pt; padding-left: 36pt;">
    <div style="float: left; width: 30.6pt; white-space: nowrap;">
     <span>(b) - </span>
    </div>
    <div>
     <span>Primarily consists of cash and deferred tax assets.</span>
    </div>
  </div><div> <span>Net revenues according to geographic area, based on the location of where the product is shipped, were as follows:</span> </div>


  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 45%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="19" style="text-align: center; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">Three&#160;&#160;Months Ended March 31, 2025</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">ADMA

      BioManufacturing</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">



      <span style="font-weight: bold;">Plasma

      Centers</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">



      <span style="font-weight: bold;">Total Segment <br/>

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">License

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">Consolidated

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      United States
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">110,609</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">85</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">110,694</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">36</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">110,730</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      International
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">3,107</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">965</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">4,072</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"> -&#160;&#160;&#160; </td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">4,072</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Total revenues
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">113,716</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">1,050</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">114,766</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">36</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">114,802</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 45%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="19" style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">Three&#160;&#160;Months Ended March 31, 2024</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">ADMA

      BioManufacturing</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">



      <span style="font-weight: bold;">Plasma

      Centers</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">



      <span style="font-weight: bold;">Total Segment <br/>

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">License

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">Consolidated

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      United States
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">76,460</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">1,495</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">77,955</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">36</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">77,991</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      International
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">3,653</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">231</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">3,884</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"> -&#160;&#160;&#160; </td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">3,884</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Total revenues
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">80,113</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">1,726</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">81,839</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">36</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">81,875</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASE OBLIGATIONS</a></td>
<td class="text"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">11.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">LEASE OBLIGATIONS</span>
    </div>
  </div>
  <div style="margin-left: 18pt; clear: both;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>The Company leases certain properties and equipment for its ADMA BioCenters and ADMA BioManufacturing subsidiaries, which leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2033. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span>
  </div>
  <div style="text-align: justify; margin-left: 18pt;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>The Company determines if an arrangement is an operating lease at inception. Leases with an initial term of 12 months or less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities representing the obligation to make lease payments arising from the lease. Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include options to extend or terminate the lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#8217;s incremental borrowing rate. The Company&#8217;s lease expense is recognized on a straight-line basis over the lease term and is reflected in Plasma center operating expenses and selling, general and administrative expenses. Aggregate lease expense for the Company&#8217;s leases for the three months ended March 31, 2025 and 2024 was approximately $0.6 million during each such period. Cash paid for the Company&#8217;s leases for the three months ended March 31, 2025 and 2024 was also approximately $0.6 million during each such period.</span> </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>&#160; </span>
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>The Company has aggregate lease liabilities of $9.5 million and $9.8 million as of March 31, 2025 and December 31, 2024, respectively, which are comprised primarily of the leases for the Company&#8217;s plasma collection centers and a warehouse lease for raw material storage related to the Company&#8217;s immunoglobulin manufacturing operations. As of March 31, 2025, the Company&#8217;s operating leases have a weighted-average remaining term of 6.6 years. Scheduled payments under the Company&#8217;s lease obligations are as follows (</span><span style="font-style: italic;">in thousands</span><span>):</span> </div><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; width: 60%; margin-left: auto; margin-right: auto;" width="100%">
 <tr><td style="width: 58%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right; vertical-align: bottom;" valign="top">
  <div>Remainder of 2025</div>
  </td>
  <td valign="top">&#160;</td>
  <td style="border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;" valign="top">
  <div>$</div>
  </td>
  <td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;" valign="top"> <div>1,812 </div> </td>
  <td style="border-width: initial; border-style: none; border-color: initial;" valign="top">&#160;</td>
 </tr>
 <tr>
  <td style="text-align: right;" valign="top">
  <div>Year ended December 31, 2026</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;2,157 </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right;" valign="top">
  <div>2027</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;2,041 </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr>
  <td style="text-align: right;" valign="top">
  <div>2028</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;2,088 </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right;" valign="top">
  <div>2029</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;2,109 </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr>
  <td style="text-align: right;" valign="top">
  <div>2030</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;1,836 </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right;" valign="top">
  <div>Thereafter</div>
  </td>
  <td valign="top">&#160;</td>
  <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
  <td style="text-align: right; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"> <div>&#160;2,205 </div> </td>
  <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr>
  <td style="text-align: right;" valign="top">
  <div>Total payments</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;14,248 </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right;" valign="top">
  <div>Less: imputed interest</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;(4,762)</div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr>
  <td style="text-align: right;" valign="top">
  <div>Current portion</div>
  </td>
  <td valign="top">&#160;</td>
  <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
  <td style="text-align: right; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"> <div>&#160;(1,188)</div> </td>
  <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right;" valign="top">
  <div>Balance at March 31, 2025</div>
  </td>
  <td valign="top">&#160;</td>
  <td style="border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div>$</div>
  </td>
  <td style="text-align: right; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;" valign="top"> <div>&#160;8,298 </div> </td>
  <td style="border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
 </tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">12.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">INCOME TAXES</span>
    </div>
  </div>
  <div style="clear: both;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>The Company uses the estimated annual effective tax rate approach as prescribed by ASC 740-270, Interim Reporting, to calculate its interim provision for income taxes. </span> </div>
  <div style="text-align: justify;">&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 79%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align : center; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; ">


      <span style="font-weight: bold;">Three Months Ended March 31,</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center; padding-left: 10px;">


      <span style="font-style: italic;">(In thousands, except percentages)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Provision for income taxes
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">6,546</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">595</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Effective tax rate
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">19.6</td><td style="text-align: left; width: 1%;">%</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">3.2</td><td style="text-align: left; width: 1%;">%</td>
   </tr>
  </table><div style="text-align: justify;">&#160;
  </div>
  <div style="text-align: justify;"> <span>The effective tax rate for the three months ended March 31, 2025 of 19.6%, differed from the federal statutory rate primarily due to the excess tax benefits on stock-based compensation. The effective tax rate for the three months ended March 31, 2024 of 3.2%, differed from the federal statutory tax rate primarily due to the valuation allowance maintained on the Company's federal and state net deferred tax assets until December 31, 2024.</span> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</a></td>
<td class="text"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">13.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</span>
    </div>
  </div>
  <div style="margin-left: 18pt; clear: both;">&#160;
  </div>
  <div style="text-indent: 36pt;"> <span>Supplemental cash flow information for the three months ended March 31, 2025 and 2024 is as follows: </span> </div>
  <div>&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 57%;">&#160;</td><td style="width: 20%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center;">
     <div>
      <span style="font-style: italic;">(In thousands)</span>
     </div>
    </td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">SUPPLEMENTAL CASH FLOW INFORMATION:</span>
     </div>
    </td>
    <td style="padding-left: 10px;">&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Cash paid for interest
     </div>
    </td>
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">2,750</td><td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">584</td><td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">Noncash Financing and Investing Activities:</span>
     </div>
    </td>
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Equipment acquired reflected in accounts payable and accrued liabilities
     </div>
    </td>
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">985</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">1,351</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/230/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="text-indent: -27pt; padding-left: 27pt;">
    <div style="float: left; width: 27.0pt; white-space: nowrap;">
     <span style="font-weight: bold;">14.</span>
    </div>
    <div>
     <span style="font-weight: bold; text-decoration: underline;">SUBSEQUENT EVENTS</span>
    </div>
  </div>
  <div style="margin-left: -27pt; clear: both;">&#160;
  </div>
  <div style="text-align: justify;">
   <span style="font-style: italic;"><span style="text-decoration:underline">FDA Approval</span></span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-align: justify;">
   <span>In April 2025, the FDA approved the Company&#8217;s Prior Approval Supplement (the &#8220;PAS&#8221;) for its innovative yield enhancement production process benefiting both ASCENIV and BIVIGAM.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-align: justify;">
   <span style="font-style: italic;"><span style="text-decoration:underline">Share Repurchase Program</span></span><span>&#160;</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-align: justify;"> <span>In May 2025, the Company's Board of Directors authorized a share repurchase program of up to $500.0 million of the Company&#8217;s outstanding shares of common stock. Repurchases under the program may be made from time to time through open market purchases or through privately negotiated transactions subject to market conditions, applicable legal requirements, and other relevant factors. Open market repurchases will be structured to occur in accordance with the requirements of Rule 10b-18. The Company may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of shares under this authorization. The timing and number of shares repurchased under the program will depend on a variety of factors, including stock price, trading volume, and general business and market conditions. The program does not obligate the Company to acquire any particular amount of its common stock, and may be modified, suspended, or terminated at any time at the Company&#8217;s discretion. The program has no expiration date.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-align: justify;">
   <span style="font-style: italic;"><span style="text-decoration:underline">Debt Reorganization</span></span></div>
  <div>&#160;
  </div>
  <div style="text-align: justify;"> <span>On May 5, 2025, the Company borrowed $30.0 million under its revolving credit facility with Ares, which the Company used to repay an additional $30.0 million against the Company&#8217;s term loan facility with Ares on May 6, 2025. Following such transactions, the Company had $72.5 million outstanding under its revolving credit facility and $2.5 million outstanding under its term loan facility. It is anticipated that the Company&#8217;s cost of current outstanding debt will be reduced from these transactions.&#160;&#160;</span> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 26,904<span></span>
</td>
<td class="nump">$ 17,806<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Principles of consolidation and basis of presentation</a></td>
<td class="text"><div> <span style="font-style: italic; text-decoration: underline;">Principles of consolidation and basis of presentation</span></div><div style="text-indent: 36pt; text-align: justify;">
   <span>The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (the &#8220;FASB&#8221;). </span>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2024 included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 18, 2025. All intercompany balances and transactions have been eliminated in consolidation. The preparation of our interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed. We have made reasonable estimates and judgments of such items within our financial statements and there may be changes to those estimates in future periods. </span>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>During the three months ended March 31, 2025 and 2024, comprehensive income was equal to the net income amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year.</span>
  </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div> <span style="font-style: italic; text-decoration: underline;">Use of Estimates</span> </div><div style="text-indent: 36pt; text-align: justify;">
   <span>The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include rebates deducted from gross revenues and estimates related to Company&#8217;s effective tax rate.</span>
  </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div> <span style="font-style: italic; text-decoration: underline;">Fair Value of Financial Instruments</span> </div><div style="text-indent: 36pt; text-align: justify;">
   <span>The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company&#8217;s senior credit facility (see Note 6) approximates fair value, based on a Level 3 classification under the fair value hierarchy, due to the variable interest rate on this debt.&#160;&#160;</span>
  </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div> <span style="font-style: italic; text-decoration: underline;">Accounts Receivable</span> </div><div style="text-indent: 36pt; text-align: justify;"> <span>Accounts receivable is reported at realizable value, net of allowances for customer credits and credit losses in the amount of $3.0 million and $0.2 million at March 31, 2025 and December 31, 2024, respectively. </span><span style="color: rgb(33, 37, 41);">The Company extends credit to its customers based upon an evaluation of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition, payment history and associated credit risk of customers are performed on an ongoing basis.</span><span> Based on these evaluations, the Company has concluded that its credit risk is minimal. At March 31, 2025 and December 31, 2024, three customers accounted for an aggregate of approximately 85% and 91%, respectively, of the Company&#8217;s total accounts receivable.</span> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div> <span style="font-style: italic; text-decoration: underline;">Inventories</span> </div><div style="text-indent: 33.75pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Raw materials inventory consists of various materials purchased from suppliers, including normal source plasma and Respiratory Syncytial Virus (&#8220;RSV&#8221;) high titer plasma, used in the production of the Company&#8217;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable supplies and depreciation. The Boca Facility overhead allocation to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#8217;s FDA-approved products relative to the total square footage of the facility.</span>
  </div><div style="text-indent: 33.75pt; text-align: justify;">
   <span style="color: rgb(0, 0, 0);">Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. </span>
  </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div> <span style="font-style: italic; text-decoration: underline;">Goodwill</span> </div><div style="text-indent: 36pt; text-align: justify;"> <span>Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at March 31, 2025 and December 31, 2024 was $3.5 million. All of the Company&#8217;s goodwill is attributable to its ADMA BioManufacturing business segment.&#160;&#160;</span> </div><div style="text-indent: 36pt; text-align: justify;"> <span>The Company did not record any impairment charges related to goodwill for the three months ended March 31, 2025 and 2024.</span> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div> <span style="font-style: italic; text-decoration: underline;">Revenue Recognition</span> </div><div style="text-indent: 36pt; text-align: justify;"> <span>Revenues are comprised of (i) revenues from the sale of the Company&#8217;s immunoglobulin products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company&#8217;s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediates; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest AG (&#8220;Biotest&#8221;) in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years. </span> </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based on when the product is shipped or delivered, depending on the sales terms, and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#8217;s immunoglobulin products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, wholesaler distribution and related fees, customer incentives, including prompt pay discounts, wholesaler chargebacks, group purchasing organization fees and reimbursements for patient assistance. These estimates are based on historical experience and certain other assumptions, and while the Company believes that such estimates are reasonable, they are subject to change based on future experience and other factors. </span>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company. &#160;&#160;&#160;&#160;</span>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.</span>
  </div><div style="text-indent: 36pt; text-align: justify;"> <span>For the three months ended March 31, 2025, three customers represented an aggregate of approximately 74% of the Company&#8217;s consolidated revenues. For the three months ended March 31, 2024, two customers represented an aggregate of approximately 70% of the Company&#8217;s consolidated revenue. </span> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Revenue</a></td>
<td class="text"><div> <span style="font-style: italic; text-decoration: underline;">Cost of Product Revenue</span> </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA-approved products, intermediates and the collection of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the activities of these operations are attributable to new products or processes in development, the expenses are classified as research and development expenses. </span>
  </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings/loss Per Common Share</a></td>
<td class="text"><div> <span style="color: rgb(0, 0, 0); font-style: italic; text-decoration: underline;">Earnings/loss Per Common Share</span><span style="color: rgb(0, 0, 0); font-style: italic;">&#160;&#160;</span> </div><div style="text-indent: 36pt;"> <span>For the three months ended March 31, 2025, basic and diluted earnings per share are calculated as follows:</span> </div><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 89%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top; height: 23.0pt;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-top: none; border-left: none; border-right: none; border-bottom: 2px solid black;">&#160;</td><td style="text-align: center; width: 9%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none; white-space: nowrap;">



      <span style="font-weight: bold;">Three Months Ended
<br/>
      March 31, 2025</span>
     </td><td style="text-align: center; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Net income available to common stockholders ($000's) (numerator)
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">26,904</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Weighted-average number of common shares (denominator)
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">237,775,476</td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Basic earnings per common shares
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">0.11</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Weighted-average number of common shares
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">237,775,476</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Potential shares of common stock arising from outstanding stock options
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">3,987,814</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Potential shares of common stock arising from outstanding warrants
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">47,536</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Potential shares of common stock arising from unvested RSUs
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">2,865,524</td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Total shares - diluted (denominator)
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">244,676,350</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-left: none; border-right: none; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Diluted earnings per common share
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">0.11</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><div style="text-indent: 36pt;"> <span>For the three months ended March 31, 2025 and 2024, there were no shares with an anti-dilutive effect that needed to be excluded from the earnings per share computation. </span> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div> <span style="font-style: italic; text-decoration: underline;">Recent Accounting Pronouncements</span> </div><div style="text-indent: 36pt; text-align: justify;">
   <span>In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): </span><span style="font-style: italic;">Improvements to Income Tax Disclosures</span><span>. This Update requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid and became effective for public business entities for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that this Update may have on the Company&#8217;s consolidated financial statements.</span>
  </div><div style="text-indent: 27pt; text-align: justify;">
   <span>In November 2024, the FASB issued ASU No. 2024-03, </span><span style="font-style: italic;">Income Statement - Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures</span><span> (Subtopic 220-40). The amendments in this Update require disclosure, in the notes to the financial statements, of specified information about certain costs and expenses, including but not limited to, purchases of inventory, employee compensation and selling expense. This Update becomes effective for fiscal years beginning after December 15, 2026. The Company is currently evaluating the impact that this Update may have on the Company&#8217;s consolidated financial statements.</span>
  </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Calculation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="text-indent: 36pt;"> <span>For the three months ended March 31, 2025, basic and diluted earnings per share are calculated as follows:</span> </div>
  <div>&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 89%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top; height: 23.0pt;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-top: none; border-left: none; border-right: none; border-bottom: 2px solid black;">&#160;</td><td style="text-align: center; width: 9%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none; white-space: nowrap;">



      <span style="font-weight: bold;">Three Months Ended
<br/>
      March 31, 2025</span>
     </td><td style="text-align: center; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Net income available to common stockholders ($000's) (numerator)
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">26,904</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Weighted-average number of common shares (denominator)
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">237,775,476</td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Basic earnings per common shares
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">0.11</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Weighted-average number of common shares
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">237,775,476</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Potential shares of common stock arising from outstanding stock options
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">3,987,814</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Potential shares of common stock arising from outstanding warrants
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">47,536</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Potential shares of common stock arising from unvested RSUs
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">2,865,524</td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Total shares - diluted (denominator)
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;">244,676,350</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-left: none; border-right: none; border-top: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Diluted earnings per common share
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">0.11</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of Inventory</a></td>
<td class="text"><div style="text-indent: 36pt;"> <span>The following table provides the components of inventories:</span> </div>
  <div style="text-align: center;">&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width : 9%; white-space : nowrap; ">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">March 31, <br/>

      2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align : center; width : 9%; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; ">



      <span style="font-weight: bold;">December 31,<br/>

      2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center;">


      <span style="font-style: italic;">(In thousands)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Raw materials
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">75,819</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">60,473</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Work-in-process
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">49,780</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">61,641</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Finished goods
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">46,589</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">48,121</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Total inventories
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">172,188</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">170,235</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="text-indent: 36pt;"> <span>Property and equipment and related accumulated depreciation are summarized as follows:</span> </div>
  <div>&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">March 31, 2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">December 31, 2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center;">


      <span style="font-style: italic;">(In thousands)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Manufacturing and laboratory equipment
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">21,916</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">21,305</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Office equipment and computer software
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">6,142</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">5,772</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Furniture and fixtures
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">5,939</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">5,840</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Construction in process
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">11,225</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">8,149</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Leasehold improvements
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">21,103</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">21,066</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Land
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">4,339</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">4,339</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Buildings and building improvements
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">22,542</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">21,788</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">93,206</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">88,259</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Less: Accumulated depreciation
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(35,496</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(33,552</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Total property and equipment, net
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">57,710</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">54,707</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="text-indent: 36pt;"> <span>Accrued expenses and other current liabilities at March 31, 2025 and December 31, 2024 are as follows:</span> </div>
  <div>&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">March 31, 2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap; vertical-align: middle;">


      <span style="font-weight: bold;">December 31, 2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center;">


      <span style="font-style: italic;">(In thousands)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Accrued rebates
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;">4,847</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;">4,155</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Accrued distribution fees
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">12,115</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">11,565</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Accrued incentives
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">1,671</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">5,892</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Accrued interest
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">1,893</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">2,857</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Accrued testing
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">463</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">827</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Accrued payroll and other compensation
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">1,924</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">3,332</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Income taxes payable
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">6,601</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">3,481</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Other
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">2,046</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">1,853</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Total accrued expenses and other current liabilities
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">31,560</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">33,962</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Outstanding Senior Notes Payable</a></td>
<td class="text"><div style="text-indent: 36pt;"> <span>A summary of outstanding senior notes payable is as follows:</span> </div>
  <div>&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">March 31, 2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">


      <span style="font-weight: bold;">December 31, 2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center;">


      <span style="font-style: italic;">(In thousands)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Term loan
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">32,500</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">32,500</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Revolving credit facility
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">42,500</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">42,500</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Less:
     </div>
    </td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">
     <div>
      Debt discount
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(2,473</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(2,663</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Senior notes payable
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">72,527</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">72,337</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions</a></td>
<td class="text">The following assumptions were used to determine the fair value of options granted during the three months ended March 31, 2025 and 2024:<table cellpadding="0" style="font-size: 9.5pt; border-collapse: collapse; border-spacing: 0px; width: 100%; margin-left: auto; margin-right: auto;">
 <tr><td style="width: 79%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td></tr><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes">
  <td valign="top">&#160;</td>
  <td colspan="3" style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b>Three Months Ended March 31,</b></div>
  </td>
 </tr>
 <tr style="mso-yfti-irow:1">
  <td valign="top">&#160;</td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; text-align: center;" valign="top">
  <div><b>2025</b></div>
  </td>
  <td style="padding: 0in 5.4pt 0in 5px; text-align: center;" valign="top">&#160;</td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; text-align: center;" valign="top">
  <div><b>2024</b></div>
  </td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="vertical-align: bottom;" valign="top">
  <div>Expected term</div>
  </td>
  <td style="padding-top : 0in; padding-right : 5.4pt; padding-bottom : 0in; text-align : center; vertical-align : bottom; white-space : nowrap; " valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">5.5 - 6.3 years</span></div> </td>
  <td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top">&#160;</td>
  <td style="padding-top : 0in; padding-right : 5.4pt; padding-bottom : 0in; text-align : center; vertical-align : bottom; white-space : nowrap; " valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">5.5 - 6.3 years</span></div> </td>
 </tr>
 <tr style="mso-yfti-irow:3">
  <td valign="top">
  <div>Volatility</div>
  </td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">66%</span></div> </td>
  <td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top">&#160;</td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">66%</span></div> </td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Dividend yield</div>
  </td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">0.0</span></div> </td>
  <td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top">&#160;</td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">0.0</span></div> </td>
 </tr>
 <tr style="mso-yfti-irow:5;mso-yfti-lastrow:yes">
  <td valign="top">
  <div>Risk-free interest rate</div>
  </td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">4.40%</span></div> </td>
  <td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top">&#160;</td>
  <td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"> <div style="margin: 0in; font-size: 11pt;"><span style="font-size:9.5pt;mso-bidi-font-size:10.0pt">4.29%</span></div> </td>
 </tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option Activity</a></td>
<td class="text"><div style="text-indent: 36pt;"> <span>A summary of the Company&#8217;s option activity under the Company&#8217;s equity incentive plans and related information is as follows:</span> </div>


  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">


      <span style="font-weight: bold;">Shares</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom; white-space: nowrap;">




      <span style="font-weight: bold;">Weighted <br/>

      Average <br/>

      Exercise Price</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Options outstanding, vested and expected to vest at December 31, 2024
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">5,141,516</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">3.90</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Forfeited
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(1,101</td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">1.29</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Expired
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(10,480</td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">4.89</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Granted
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">683,720</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">16.07</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Exercised
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(39,173</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">6.61</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Options outstanding, vested and expected to vest at March 31, 2025
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">5,774,482</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">5.32</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Options exercisable
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">3,086,687</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">3.21</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of Unvested RSU Activity</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span>The Company&#8217;s RSUs generally vest annually over a period of four years for employees and semi-annually over a period of one year for directors. A summary of the Company&#8217;s unvested RSU activity and related information is as follows: </span> </div>


  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">Shares</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">




      <span style="font-weight: bold;">Weighted <br/>

      Average Grant <br/>

      Date Fair Value</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Balance at December 31, 2024
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">5,745,990</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">5.50</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Granted
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">1,658,458</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">16.11</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Vested
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">(1,455,350</td><td style="text-align: left; width: 1%;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">4.17</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Forfeited
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">(93,611</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">)&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">6.64</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Balance at March 31, 2025
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">5,855,487</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">8.82</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span>Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for the three months ended March 31, 2025 and 2024 was as follows:&#160;&#160;</span> </div>


  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 77%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align : center; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; ">


      <span style="font-weight: bold;">Three Months Ended March 31,</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="text-align: center;">
     <div>
      <span style="font-style: italic;">(in thousands)</span>
     </div>
    </td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Research and development
     </div>
    </td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">39</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%; padding-left: 10px;">17</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Plasma center operating expenses
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">77</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">39</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Selling, general and administrative
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">3,873</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">1,841</td><td style="text-align: left; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Cost of product revenue
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">635</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">244</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Total stock-based compensation expense
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">4,624</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">2,141</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summarized Financial Information Concerning Reportable Segments</a></td>
<td class="text">Summarized financial information concerning reportable segments is shown in the following tables:<table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;" width="100%">
 <tr><td style="width: 65%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes">
  <td colspan="12" style="text-align: center; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Three Months Ended March
  31, 2025</b></div>
  </td>
 </tr>
 <tr style="mso-yfti-irow:1">
  <td style="text-align: center; vertical-align: bottom;" valign="top">
  <div style="margin: 0in;"><i style="mso-bidi-font-style:normal">(in thousands)</i></div>
  </td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">ADMA </b></div>
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">BioManufacturing</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center;" valign="top">&#160;</td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Plasma Collection </b></div>
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Centers</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center;" valign="top">&#160;</td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Total</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Revenues</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top">113,716</td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top">1,050</td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top">114,766</td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:3">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Cost of product revenue</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">53,057</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">648</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">53,705</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:5">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Research and development</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">826</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">826</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:7">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Plasma center operating expenses</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">1,286</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">1,286</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:9">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Selling, marketing and distribution</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">6,044</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">6,044</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:11">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Depreciation and amortization expense</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">25</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">25</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:13">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>General and administrative expense</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">8,495</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">8,495</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:15">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Other expense, net</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(64</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(64</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:17">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Income (loss) before taxes</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">45,205</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(884</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">44,321</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:19">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Expenditures for additions to long-lived assets</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">4,699</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">21</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">4,720</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:21">
  <td valign="top">
  <div>Total assets</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">330,091</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">27,644</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">357,735</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:23">
  <td valign="top">
  <div><i>Reconciliation of revenues:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment
  revenue</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">114,766</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:25">
  <td style="padding-left: 10px;" valign="top">
  <div>License revenue</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">36</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated
  revenues</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">114,802</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:27">
  <td valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation
  of selling, general and administrative expense:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:29">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment
  selling, marketing and distribution expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">6,044</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment
  general and administrative expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">8,495</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:31">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate
  general and administrative expense (a)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">9,540</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated
  selling, general and administrative expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">24,079</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:33">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation
  of income (loss) before taxes:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:35">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment
  income before taxes</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">44,321</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>License
  revenue </div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">36</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:37">
  <td style="padding-left: 10px;" valign="top">
  <div>Unallocated
  interest expense, primarily related to interest on senior debt (see Note 6)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(1,975</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Unallocated
  interest income</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">608</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:39">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate
  general and administrative expense (a)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">(9,540</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">)&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated
  income before taxes</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">33,450</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:41">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation
  of total assets:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:43">
  <td style="padding-left: 10px;" valign="top">
  <div>Total
  segment assets</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">357,735</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate
  (b)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">152,834</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:45;mso-yfti-lastrow:yes">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated
  total assets</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">510,569</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-right: none;" valign="top">&#160;</td>
 </tr>
</table><div>&#160;
  </div>
  <div style="text-indent: -30.6pt; padding-left: 36pt;"> <div style="float: left; width: 30.6pt; white-space: nowrap;"> <span>(a) - </span> </div> <div> <span>Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.</span> </div> </div>
  <div style="margin-left: 5.4pt; clear: both;">
   <span>&#160;</span>
  </div>
  <div style="text-indent: -30.6pt; padding-left: 36pt;"> <div style="float: left; width: 30.6pt; white-space: nowrap;"> <span>(b) -</span> </div> <div> <span>Primarily consists of cash and deferred tax assets.</span> </div> </div><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;" width="100%">
 <tr><td style="width: 65%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes">
  <td colspan="12" style="text-align: center; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Three Months Ended March
  31, 2024</b></div>
  </td>
 </tr>
 <tr style="mso-yfti-irow:1">
  <td style="text-align: center; padding-left: 10px; vertical-align: bottom;" valign="top">
  <div style="margin: 0in;"><i style="mso-bidi-font-style:normal">(in thousands)</i></div>
  </td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">ADMA </b></div>
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">BioManufacturing</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center;" valign="top">&#160;</td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Plasma Collection </b></div>
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Centers</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center;" valign="top">&#160;</td>
  <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div style="margin: 0in;"><b style="mso-bidi-font-weight:normal">Total</b></div>
  </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Revenues</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top">80,113</td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top">1,726</td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top">81,839</td><td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:3">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Cost of product revenue</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">40,991</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">1,776</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">42,767</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:5">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Research and development</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">451</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">451</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:7">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Plasma center operating expenses</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">1,005</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">1,005</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:9">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Selling, marketing and distribution</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">4,431</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">4,431</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:11">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Depreciation and amortization expense</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">193</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">193</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:13">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>General and administrative expense</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">5,351</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"> &#160;-&#160;&#160; </td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">5,351</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:15">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Other expense, net</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(30</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(1</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(31</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:17">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Income (loss) before taxes</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">28,666</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(1,056</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">27,610</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:19">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div>Expenditures for additions to long-lived assets</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">2,330</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">17</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">2,347</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:21">
  <td valign="top">
  <div>Total assets</div>
  </td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">278,331</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">33,990</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: left; margin: 0in;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">312,321</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:23">
  <td valign="top">
  <div><i>Reconciliation of revenues:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment revenue</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">81,839</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:25">
  <td style="padding-left: 10px;" valign="top">
  <div>License revenue</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">36</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated revenues</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">81,875</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:27">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation of selling,
  general and administrative expense:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:29">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment selling, marketing and distribution expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">4,431</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment general and administrative expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">5,351</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:31">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate general and administrative expense (a)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">5,857</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated selling, general and administrative expense</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">15,639</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:33">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation of income
  (loss) before taxes:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:35">
  <td style="padding-left: 10px;" valign="top">
  <div>Segment income before taxes</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">27,610</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>License revenue </div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">36</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:37">
  <td style="padding-left: 10px;" valign="top">
  <div>Unallocated interest expense, primarily related to interest
  on senior debt (see Note 6)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">(3,769</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">)&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Unallocated interest income</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">381</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:39">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate general and administrative expense (a)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">(5,857</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">)&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated income before taxes</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">18,401</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:41">
  <td style="padding-left: 10px;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td valign="top">
  <div><i>Reconciliation of total
  assets:</i></div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:43">
  <td style="padding-left: 10px;" valign="top">
  <div>Total segment assets</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top">312,321</td><td style="text-align: left; margin: 0in; width: 1%;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="padding-left: 10px;" valign="top">
  <div>Corporate (b)</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top">&#160;</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top">38,554</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr style="mso-yfti-irow:45">
  <td style="padding-left: 20px;" valign="top">
  <div>Consolidated total assets</div>
  </td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;" valign="top">&#160;</td><td style="text-align: right; width: 1%;" valign="top">&#160;</td><td style="text-align: right;" valign="top">&#160;</td>
  <td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top">$</td><td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top">350,875</td><td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-right: none;" valign="top">&#160;</td>
 </tr>

</table><div>&#160;
  </div>
  <div style="text-indent: -30.6pt; padding-left: 36pt;">
    <div style="float: left; width: 30.6pt; white-space: nowrap;">
     <span>(a) - </span>
    </div>
    <div>
     <span>Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.</span>
    </div>
  </div>
  <div style="margin-left: 36pt; clear: both;">&#160;
  </div>
  <div style="text-indent: -30.6pt; padding-left: 36pt;">
    <div style="float: left; width: 30.6pt; white-space: nowrap;">
     <span>(b) - </span>
    </div>
    <div>
     <span>Primarily consists of cash and deferred tax assets.</span>
    </div>
  </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Net Revenues According to Geographic Area</a></td>
<td class="text"><div> <span>Net revenues according to geographic area, based on the location of where the product is shipped, were as follows:</span> </div>


  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 45%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="19" style="text-align: center; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">Three&#160;&#160;Months Ended March 31, 2025</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">ADMA

      BioManufacturing</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">



      <span style="font-weight: bold;">Plasma

      Centers</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">



      <span style="font-weight: bold;">Total Segment <br/>

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">License

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">Consolidated

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      United States
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">110,609</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">85</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">110,694</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">36</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">110,730</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      International
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">3,107</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">965</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">4,072</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"> -&#160;&#160;&#160; </td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">4,072</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Total revenues
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">113,716</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">1,050</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">114,766</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">36</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">114,802</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 45%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="19" style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">Three&#160;&#160;Months Ended March 31, 2024</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">ADMA

      BioManufacturing</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">



      <span style="font-weight: bold;">Plasma

      Centers</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;">



      <span style="font-weight: bold;">Total Segment <br/>

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">License

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">



      <span style="font-weight: bold;">Consolidated

      Revenue</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      United States
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">76,460</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">1,495</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">77,955</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">36</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">77,991</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      International
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">3,653</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">231</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">3,884</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"> -&#160;&#160;&#160; </td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">3,884</td><td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Total revenues
     </div>
    </td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">80,113</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">1,726</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">81,839</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">36</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">81,875</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Payments Under Lease Obligations</a></td>
<td class="text">As of March 31, 2025, the Company&#8217;s operating leases have a weighted-average remaining term of 6.6 years. Scheduled payments under the Company&#8217;s lease obligations are as follows (<span style="font-style: italic;">in thousands</span><span>):</span><table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; width: 60%; margin-left: auto; margin-right: auto;" width="100%">
 <tr><td style="width: 58%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right; vertical-align: bottom;" valign="top">
  <div>Remainder of 2025</div>
  </td>
  <td valign="top">&#160;</td>
  <td style="border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;" valign="top">
  <div>$</div>
  </td>
  <td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;" valign="top"> <div>1,812 </div> </td>
  <td style="border-width: initial; border-style: none; border-color: initial;" valign="top">&#160;</td>
 </tr>
 <tr>
  <td style="text-align: right;" valign="top">
  <div>Year ended December 31, 2026</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;2,157 </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right;" valign="top">
  <div>2027</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;2,041 </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr>
  <td style="text-align: right;" valign="top">
  <div>2028</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;2,088 </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right;" valign="top">
  <div>2029</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;2,109 </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr>
  <td style="text-align: right;" valign="top">
  <div>2030</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;1,836 </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right;" valign="top">
  <div>Thereafter</div>
  </td>
  <td valign="top">&#160;</td>
  <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
  <td style="text-align: right; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"> <div>&#160;2,205 </div> </td>
  <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr>
  <td style="text-align: right;" valign="top">
  <div>Total payments</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;14,248 </div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right;" valign="top">
  <div>Less: imputed interest</div>
  </td>
  <td valign="top">&#160;</td>
  <td valign="top">&#160;</td>
  <td style="text-align: right;" valign="top"> <div>&#160;(4,762)</div> </td>
  <td valign="top">&#160;</td>
 </tr>
 <tr>
  <td style="text-align: right;" valign="top">
  <div>Current portion</div>
  </td>
  <td valign="top">&#160;</td>
  <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
  <td style="text-align: right; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"> <div>&#160;(1,188)</div> </td>
  <td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
 </tr>
 <tr style="background-color: rgb(204, 238, 255);">
  <td style="text-align: right;" valign="top">
  <div>Balance at March 31, 2025</div>
  </td>
  <td valign="top">&#160;</td>
  <td style="border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;" valign="top">
  <div>$</div>
  </td>
  <td style="text-align: right; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;" valign="top"> <div>&#160;8,298 </div> </td>
  <td style="border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;" valign="top">&#160;</td>
 </tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Estimated Annual Effective Tax Rate</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span>The Company uses the estimated annual effective tax rate approach as prescribed by ASC 740-270, Interim Reporting, to calculate its interim provision for income taxes. </span> </div>
  <div style="text-align: justify;">&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 79%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="height: 0px; font-size: 0px;">
    <td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align : center; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; ">


      <span style="font-weight: bold;">Three Months Ended March 31,</span>
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td colspan="7" style="text-align: center; padding-left: 10px;">


      <span style="font-style: italic;">(In thousands, except percentages)</span>
     </td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td>
     <div>
      Provision for income taxes
     </div>
    </td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">6,546</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td style="text-align: left; vertical-align: bottom;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;">595</td><td style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      Effective tax rate
     </div>
    </td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">19.6</td><td style="text-align: left; width: 1%;">%</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">3.2</td><td style="text-align: left; width: 1%;">%</td>
   </tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text"><div style="text-indent: 36pt;"> <span>Supplemental cash flow information for the three months ended March 31, 2025 and 2024 is as follows: </span> </div>
  <div>&#160;
  </div>

  <table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;">
   <tr><td style="width: 57%;">&#160;</td><td style="width: 20%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 1%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2025</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center;">&#160;</td>
    <td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">


      <span style="font-weight: bold;">2024</span>
     </td><td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: center;">
     <div>
      <span style="font-style: italic;">(In thousands)</span>
     </div>
    </td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">SUPPLEMENTAL CASH FLOW INFORMATION:</span>
     </div>
    </td>
    <td style="padding-left: 10px;">&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td><td>&#160;</td>
    <td style="width: 1%;">&#160;</td><td style="width: 9%; padding-left: 10px;">&#160;</td><td style="width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Cash paid for interest
     </div>
    </td>
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">2,750</td><td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">584</td><td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td>
     <div>
      <span style="font-weight: bold;">Noncash Financing and Investing Activities:</span>
     </div>
    </td>
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right;">&#160;</td>
    <td style="text-align: right; width: 1%;">&#160;</td><td style="text-align: right; width: 9%; padding-left: 10px;">&#160;</td><td style="text-align: right; width: 1%;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding-left: 10px;">
     <div>
      Equipment acquired reflected in accounts payable and accrued liabilities
     </div>
    </td>
    <td style="padding-left: 10px;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">985</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td><td style="text-align: left;">&#160;</td>
    <td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">$</td><td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">1,351</td><td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;">&#160;</td>
   </tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>Facility </div>
<div>Product</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND BUSINESS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment', window );">Number of FDA-licensed plasma collection facilities | Facility</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfFDAApprovedProduct', window );">Number of FDA approved product | Product</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfFDAApprovedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of products approved by FDA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfFDAApprovedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection facilities under various stages of development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>Customer</div>
</th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts', window );">Accounts receivable, allowances for contractual credits and credit losses | $</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Three Customers [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers (in Customer) | Customer</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of consolidated revenues</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for contractual credits and doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of major customers of the organization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,530,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges related to goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>Customer </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>Customer </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DeferredRevenueRemainingAmortizationPeriod', window );">Amortization period</a></td>
<td class="text">22 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in Shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Three Customers [Member] | Consolidated Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers (in Customer)</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of consolidated revenues</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Two Customers [Member] | Consolidated Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers (in Customer)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of consolidated revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DeferredRevenueRemainingAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DeferredRevenueRemainingAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of major customers of the organization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_TwoCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_TwoCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of Basic and Diluted Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income available to common stockholders (numerator) (in Dollars)</a></td>
<td class="nump">$ 26,904<span></span>
</td>
<td class="nump">$ 17,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares (denominator)</a></td>
<td class="nump">237,775,476<span></span>
</td>
<td class="nump">228,874,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per common shares (in Dollars per share)</a></td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares</a></td>
<td class="nump">237,775,476<span></span>
</td>
<td class="nump">228,874,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Total shares - diluted (denominator)</a></td>
<td class="nump">244,676,350<span></span>
</td>
<td class="nump">236,414,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per common share (in Dollars per share)</a></td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs</a></td>
<td class="nump">3,987,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs</a></td>
<td class="nump">47,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs</a></td>
<td class="nump">2,865,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Components of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 75,819<span></span>
</td>
<td class="nump">$ 60,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">49,780<span></span>
</td>
<td class="nump">61,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">46,589<span></span>
</td>
<td class="nump">48,121<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 172,188<span></span>
</td>
<td class="nump">$ 170,235<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY, PLANT AND EQUIPMENT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 93,206<span></span>
</td>
<td class="nump">$ 88,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(35,496)<span></span>
</td>
<td class="num">(33,552)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">57,710<span></span>
</td>
<td class="nump">54,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing and Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY, PLANT AND EQUIPMENT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">21,916<span></span>
</td>
<td class="nump">21,305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment and Computer Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY, PLANT AND EQUIPMENT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,142<span></span>
</td>
<td class="nump">5,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY, PLANT AND EQUIPMENT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,939<span></span>
</td>
<td class="nump">5,840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Construction in Process [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY, PLANT AND EQUIPMENT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">11,225<span></span>
</td>
<td class="nump">8,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY, PLANT AND EQUIPMENT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">21,103<span></span>
</td>
<td class="nump">21,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY, PLANT AND EQUIPMENT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">4,339<span></span>
</td>
<td class="nump">4,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY, PLANT AND EQUIPMENT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 22,542<span></span>
</td>
<td class="nump">$ 21,788<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AccruedRebatesCurrent', window );">Accrued rebates</a></td>
<td class="nump">$ 4,847<span></span>
</td>
<td class="nump">$ 4,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued distribution fees</a></td>
<td class="nump">12,115<span></span>
</td>
<td class="nump">11,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued incentives</a></td>
<td class="nump">1,671<span></span>
</td>
<td class="nump">5,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">2,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AccruedTestingCurrent', window );">Accrued testing</a></td>
<td class="nump">463<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and other compensation</a></td>
<td class="nump">1,924<span></span>
</td>
<td class="nump">3,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">6,601<span></span>
</td>
<td class="nump">3,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">1,853<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 31,560<span></span>
</td>
<td class="nump">$ 33,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AccruedRebatesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AccruedRebatesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AccruedTestingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for testing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AccruedTestingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 06, 2025</div></th>
<th class="th"><div>May 05, 2025</div></th>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Senior notes payable before debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration', window );">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">SOFR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember', window );">Ares Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_MinimumLiquidityCovenantsCreditFacilities', window );">Minimum liquidity covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Increase applicable margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember', window );">Ares Credit Agreement [Member] | Ares Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 20,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Scheduled principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Frequency of periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">quarterly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Interest payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal', window );">Number of business days for prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember', window );">Ares Credit Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Revolving facility percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToFirstAnniversaryMember', window );">Prepaid on or Prior to First Anniversary [Member] | Ares Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidAfterTheFirstAnniversaryMember', window );">Prepaid after the First Anniversary [Member] | Ares Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToThirdAnniversaryMember', window );">Prepaid on or Prior to Third Anniversary [Member] | Ares Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=adma_TermLoanMember', window );">Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Senior notes payable before debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.5<span></span>
</td>
<td class="nump">$ 32.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentTermOfVariableRate', window );">Term of variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfBusinessDays', window );">Number of business days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentApplicableMargin', window );">Applicable margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.80%<span></span>
</td>
<td class="nump">10.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Senior notes payable before debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.5<span></span>
</td>
<td class="nump">$ 42.5<span></span>
</td>
<td class="nump">$ 72.5<span></span>
</td>
<td class="nump">$ 72.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentTermOfVariableRate', window );">Term of variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfBusinessDays', window );">Number of business days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentApplicableMargin', window );">Applicable margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.05%<span></span>
</td>
<td class="nump">8.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Amount of loan repaid</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit outstanding balance amount</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Amount drew from the credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit outstanding balance amount</a></td>
<td class="nump">$ 72.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentApplicableMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the margin rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentApplicableMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentTermOfVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentTermOfVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_MinimumLiquidityCovenantsCreditFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of minimum liquidity requirements required to be maintained by the borrower per the Company's credit facilities covenants under the loan agreement that are not restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_MinimumLiquidityCovenantsCreditFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of business days for prior written notice to pay outstanding principal loans, Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_SeniorNotesPayableBeforeDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_SeniorNotesPayableBeforeDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of variable interest rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_AresCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adma_AresCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adma_AresCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidAfterTheFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidAfterTheFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToThirdAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToThirdAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=adma_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=adma_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Summary of Outstanding Senior Notes Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 18, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Senior notes payable before debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="num">$ (2,473)<span></span>
</td>
<td class="num">$ (2,663)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior notes payable</a></td>
<td class="nump">72,527<span></span>
</td>
<td class="nump">72,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=adma_TermLoanMember', window );">Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Senior notes payable before debt discount</a></td>
<td class="nump">32,500<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Senior notes payable before debt discount</a></td>
<td class="nump">$ 42,500<span></span>
</td>
<td class="nump">$ 42,500<span></span>
</td>
<td class="nump">$ 72,500<span></span>
</td>
<td class="nump">$ 72,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_SeniorNotesPayableBeforeDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_SeniorNotesPayableBeforeDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=adma_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=adma_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of nonredeemable preferred shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">238,532,252<span></span>
</td>
<td class="nump">236,620,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">36,622,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jan. 07, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 14, 2024</div></th>
<th class="th"><div>Mar. 08, 2024</div></th>
<th class="th"><div>Feb. 24, 2024</div></th>
<th class="th"><div>Jan. 10, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares of common stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">966,554<span></span>
</td>
<td class="nump">966,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,651<span></span>
</td>
<td class="nump">3,388,681<span></span>
</td>
<td class="nump">34,800<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">238,532,252<span></span>
</td>
<td class="nump">866,302<span></span>
</td>
<td class="nump">236,620,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,784<span></span>
</td>
<td class="nump">2,482,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,977,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">36,622,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,909,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,502,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Equity Incentive Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=adma_EmployeesMember', window );">Employees [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Equity incentive plans, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Directors [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Equity incentive plans, vesting period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember', window );">Equity Incentive Plans [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense, stock options (in Dollars)</a></td>
<td class="nump">$ 12.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember', window );">Equity Incentive Plans [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense, non option (in Dollars)</a></td>
<td class="nump">$ 48.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adma_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adma_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Schedule of Assumptions (Details) - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.29%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Schedule of Option Activity (Details) - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options outstanding, vested and expected to vest, beginning balance | shares</a></td>
<td class="nump">5,141,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options outstanding, vested and expected to vest, beginning balance | $ / shares</a></td>
<td class="nump">$ 3.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber', window );">Forfeited | shares</a></td>
<td class="num">(1,101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice', window );">Forfeited | $ / shares</a></td>
<td class="nump">$ 1.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber', window );">Expired | shares</a></td>
<td class="num">(10,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice', window );">Expired | $ / shares</a></td>
<td class="nump">$ 4.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber', window );">Granted | shares</a></td>
<td class="nump">683,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">$ 16.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber', window );">Exercised | shares</a></td>
<td class="num">(39,173)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice', window );">Exercised | $ / shares</a></td>
<td class="nump">$ 6.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options outstanding, vested and expected to vest, ending balance | shares</a></td>
<td class="nump">5,774,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options outstanding, vested and expected to vest, ending balance | $ / shares</a></td>
<td class="nump">$ 5.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable | shares</a></td>
<td class="nump">3,086,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable | $ / shares</a></td>
<td class="nump">$ 3.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options that were exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, for fully vested and expected to vest that were expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options that were granted during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Schedule of Unvested RSU Activity (Details) - RSUs [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance | shares</a></td>
<td class="nump">5,745,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance | $ / shares</a></td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">1,658,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">$ 16.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(1,455,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">$ 4.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(93,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited | $ / shares</a></td>
<td class="nump">$ 6.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance | shares</a></td>
<td class="nump">5,855,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance | $ / shares</a></td>
<td class="nump">$ 8.82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 4,624<span></span>
</td>
<td class="nump">$ 2,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Plasma Center Operating Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,873<span></span>
</td>
<td class="nump">1,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 635<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_ArethLLCMember', window );">Areth, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Rent expense</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Areth, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Rent expense</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Genesis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchased materials amount</a></td>
<td class="nump">$ 34,000,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_ArethLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_ArethLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_GenesisBPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_GenesisBPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>Facility </div>
<div>Term </div>
<div>L</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PlasmaSupplyAgreementTerm', window );">Plasma supply agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (in Dollars) | $</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adma_ASCENIVMember', window );">ASCENIV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_GrifolsAgreementMember', window );">A&amp;R Grifols Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AgreementWithTermExpirationDate', window );">Agreement term expiring date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod', window );">Volume supplied period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_IncreaseInMinimumAnnualPriceTerm', window );">Increase in minimum annual price, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_KEDPlasmaAgreementMember', window );">A&amp;R Grifols Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AgreementWithTermExpirationDate', window );">Agreement term expiring date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfRenewalTerms', window );">Number of renewal terms (in Term) | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod', window );">Volume supplied period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PlasmaPurchaseAgreementRenewalPeriod', window );">Plasma purchase agreement renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2011 Plasma Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfPlasmaCollectionFacilities', window );">Number of plasma collection facilities (in Facility) | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | A&amp;R Grifols Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed', window );">Quantity of RSV plasma used (in L) | L</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | A&amp;R Grifols Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed', window );">Quantity of RSV plasma used (in L) | L</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AgreementWithTermExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the agreement with term expired, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AgreementWithTermExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_IncreaseInMinimumAnnualPriceTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in annual price term period on usage of RSV Plasma, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_IncreaseInMinimumAnnualPriceTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfPlasmaCollectionFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of wholly-owned plasma collection facilities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfPlasmaCollectionFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of renewal terms to extend purchase agreement, if agreed to by the parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PlasmaPurchaseAgreementRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Plasma purchase agreement renewal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PlasmaPurchaseAgreementRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PlasmaSupplyAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Plasma supply agreement term period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PlasmaSupplyAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Respiratory Syncytial Virus (RSV) Converted human plasma used by company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplied period on usage of RSV plasma in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adma_ASCENIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adma_ASCENIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_GrifolsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_GrifolsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_KEDPlasmaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_KEDPlasmaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>Facility </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfFDALicensedPlasmaCollectionFacilities', window );">Number of FDA-licensed plasma collection facilities | Facility</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfFDALicensedPlasmaCollectionFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection facilities having FDA license.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfFDALicensedPlasmaCollectionFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS - Summarized Financial Information by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2019</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,802<span></span>
</td>
<td class="nump">$ 81,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,705<span></span>
</td>
<td class="nump">42,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">826<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Plasma center operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,969<span></span>
</td>
<td class="nump">2,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Consolidated selling, general and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,079<span></span>
</td>
<td class="nump">15,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,431)<span></span>
</td>
<td class="num">(3,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,450<span></span>
</td>
<td class="nump">18,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Unallocated interest expense, primarily related to interest on senior debt (see Note 6)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Unallocated interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,569<span></span>
</td>
<td class="nump">350,875<span></span>
</td>
<td class="nump">$ 488,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,766<span></span>
</td>
<td class="nump">81,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,705<span></span>
</td>
<td class="nump">42,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Plasma center operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling, marketing and distribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,044<span></span>
</td>
<td class="nump">4,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,495<span></span>
</td>
<td class="nump">5,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,321<span></span>
</td>
<td class="nump">27,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Expenditures for additions to long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,720<span></span>
</td>
<td class="nump">2,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,735<span></span>
</td>
<td class="nump">312,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Reconciling Item [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Unallocated interest expense, primarily related to interest on senior debt (see Note 6)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,975)<span></span>
</td>
<td class="num">(3,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Unallocated interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,540<span></span>
</td>
<td class="nump">5,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,540)<span></span>
</td>
<td class="num">(5,857)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,834<span></span>
</td>
<td class="nump">38,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember', window );">ADMA BioManufacturing [Member] | Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,716<span></span>
</td>
<td class="nump">80,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,057<span></span>
</td>
<td class="nump">40,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Plasma center operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling, marketing and distribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,044<span></span>
</td>
<td class="nump">4,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,495<span></span>
</td>
<td class="nump">5,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,205<span></span>
</td>
<td class="nump">28,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Expenditures for additions to long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,699<span></span>
</td>
<td class="nump">2,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,091<span></span>
</td>
<td class="nump">278,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember', window );">Plasma Collection Centers [Member] | Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="nump">1,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Plasma center operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling, marketing and distribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(884)<span></span>
</td>
<td class="num">(1,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Expenditures for additions to long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,644<span></span>
</td>
<td class="nump">$ 33,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span>Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span>Primarily consists of cash and deferred tax assets.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentExpenditureAdditionToLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS - Net Revenues According to Geographic Area (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 114,802<span></span>
</td>
<td class="nump">$ 81,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">114,766<span></span>
</td>
<td class="nump">81,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Reconciling Item [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">110,730<span></span>
</td>
<td class="nump">77,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">110,694<span></span>
</td>
<td class="nump">77,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member] | Reconciling Item [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,072<span></span>
</td>
<td class="nump">3,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,072<span></span>
</td>
<td class="nump">3,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International [Member] | Reconciling Item [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember', window );">ADMA BioManufacturing [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">113,716<span></span>
</td>
<td class="nump">80,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember', window );">ADMA BioManufacturing [Member] | United States [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">110,609<span></span>
</td>
<td class="nump">76,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember', window );">ADMA BioManufacturing [Member] | International [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,107<span></span>
</td>
<td class="nump">3,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember', window );">Plasma Collection Centers [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember', window );">Plasma Collection Centers [Member] | United States [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember', window );">Plasma Collection Centers [Member] | International [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 965<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Aggregate lease expense</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments for lease</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_OperatingAndFinancingLeaseLiability', window );">Operating and financing lease liabilities</a></td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_OperatingAndFinancingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_OperatingAndFinancingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASE OBLIGATIONS - Payments Under Lease Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Payments Under Lease Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2025</a></td>
<td class="nump">$ 1,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ended December 31, 2026</a></td>
<td class="nump">2,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">2,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">2,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">2,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">1,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total payments</a></td>
<td class="nump">14,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(4,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion</a></td>
<td class="num">(1,188)<span></span>
</td>
<td class="num">$ (1,218)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Balance at March 31, 2025</a></td>
<td class="nump">$ 8,298<span></span>
</td>
<td class="nump">$ 8,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective tax rate</a></td>
<td class="nump">19.60%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Estimated Annual Effective Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 6,546<span></span>
</td>
<td class="nump">$ 595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective tax rate</a></td>
<td class="nump">19.60%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 2,750<span></span>
</td>
<td class="nump">$ 584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash Financing and Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities', window );">Equipment acquired reflected in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 985<span></span>
</td>
<td class="nump">$ 1,351<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>May 06, 2025</div></th>
<th class="th"><div>May 05, 2025</div></th>
<th class="th"><div>May 01, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Amount drew from the credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit outstanding balance amount</a></td>
<td class="nump">$ 72.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Amount of loan repaid</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit outstanding balance amount</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=adma_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=adma_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( />)IUI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( />)IUJV>6KN\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( />)IUITTY5<(P8  ,,B   8
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&ULM9IM;ZLV&(;_BI5)TR8U#9B\]:R-
ME-+V+%M?<IINTS;M@PM.@@[@S#9-\^_W& BD1\9A*'QI0\)SAPN_71 NMXQ_
M%6M*)7J/PEA<==92;C[U>L);TXB(<[:A,7RR9#PB$C;YJB<VG!(_+8K"'K:L
M82\B0=R97*;OS?GDDB4R#&(ZYT@D443X[IJ&;'O5L3O[-YZ#U5JJ-WJ3RPU9
MT065OVWF'+9Z18H?1#06 8L1I\NKSM3^Y#I#59#N\7M M^+@-5(HKXQ]51LS
M_ZICJ2.B(?6DBB#P[XVZ- Q5$AS'OWEHI_A.57CX>I]^E\(#S"L1U&7A'X$O
MUU>=<0?Y=$F24#ZS[<\T!QJH/(^%(OV+MMF^_7X'>8F0+,J+X0BB(,[^D_?\
M1!P4X*H"G!?@;PILIZ+ R0N<%#0[LA3KAD@RN>1LB[C:&]+4B_3<I-5 $\2J
M&1>2PZ<!U,F)R]XH1UTDUH13<=F3D*D^Z7EY_756CROJ'?3 8KD6Z#;VJ?^Q
MO@?'4AP0WA_0-38&/A!^CAS[#&$+#S3'XQXKWR$+ZZH_'(U3G!XGC7,JXFZ8
MET"GE6@69T-&=;V_[V$O-),T$O_HSE@6V=='JG'Y26R(1Z\Z,/ $Y6^T,_G^
M.WMH_:3#/5'8!_I^0=\WI9?T+[L-U9&:RVVK^T6'9*QJB#0HD ;UD+XDA$O*
MPQUZIAO&I0[/'"5YHCLIKK&J(=ZPP!O6;#%.8*I-NVLUGSEK24*A!326-00<
M%8 CXT'=QC*0.QB.T';9$H#4O(?<A'/@UE&: __4SGJNL:@AX[A@'!L/:0HM
MZ*>M>!>2E0[)7%_9<,:RAE 7!=1%O9XYISQ@OEHO5,MIIQ5S4K%"5"X1QOJ&
MG+95KJA6/=*[0'@D1']2PM$=O*E?7LUA58CFLJ:,!]9@_R_&O%&K*<UQ7VPM
MH[&H*2,N&;%Q[2^FFOHK?YYXHJ7_5&D?^4OUL8UNL>=_IJM 2%A.)'HDD7:\
M'@F:WCQ,T?7LZ?[I\\Q=G*'9HWNNY6W#=>Q2=FRSKN2\+G1K#EUZ!D+[CGZE
M.RVQ.<JR+-L9C@=V7\O9A@#9I0'99F_).>^"D*+')'JE7$MH#@' KC,<X;$6
ML T%LDL'LLWBD@.^D'<T\Z$U@V7@9>/7@&N.' R[>'!A]?M8R]N&$=FE$MDU
MG<AC'%0O13U#"PFK*V(<N2R!'@T=F_GZT6M.O[G5(K<A2'9I2+99<7+=^[#$
MFHSB2%RW:^.NHU^$VI FN[0FVRP[^TDIY\U</HA7:?-6K+7FQ KA-5<UY,2E
M-&&SY^2<BS4-0^BIT8;$VHGW2$RE^IKKFN*5OH3-@G,PY\* A$ZZ8ES/9\ZY
M)WQ%T=3S* 1!C)]%:HG;L"=<VA,VVDG1H!&!!KU.!'PLM-WU2$YUB[9A1[BT
M(US+CFXCRE=J/'Z&!+DV=EUS8#5H&UJ$2RW"_3H:[+)8P@6W,GW!XIB&1V48
MGTAS\K/0AC3A4IIP+6F:^CZDB[/]"Y2>@Z=8N^@<B>P/!_DB_<P2^&N/M-QM
MN!0N70K7<JF"VU5;(!4O;!MKF<UQSR026J-VS85-.4N'PK4<JN L[&G.V5L0
M>_H&-F<^_J(%;<.<<&E.V*PZWX+.F9!@4'\%FTI!/))HC?K]H9:T#77"I3KA
MBSH3UWS-8(C>P<5 9O_B^,1U(A7*ST(;8N648N68C2@=L%-.267S'@G EM:+
MS55-L4JA<HZ($$MO.Z5M6WU5=R2D/QIW!X.!]IK.7-J4K]0GI];-I_M *-L_
MWF>=D]YY.E7:1_B#']W,*O02R! FWR6R\0^O/Z(%]1(.9T/+;4X"'8O@NG\A
MF?=5"]J&6SFE6SGF^T0OG/CIQ=PN>F6AEL\<H&ZM:;G:L"6GM"7'K#;[%D.W
M[]Z:Q'#)4G7K\$C0XW1Q,]7^B&@N;$I8>I%3RXL.^Q=(0_HC.GI*)*RIL6I9
M+?*)3"<_#UG:($U3#VV\3; S'CE]K!;EMT/(WL%C NJR)7UZ0B!/W1_*GA@H
MWBV>T)BFSR7TRMVSQSL>B+KJ$2BD2RBUSD?P_3Q[8B+;D&R3/G3PRJ1D4?IR
M38E/N=H!/E\R)O<;Z@N*YU8F_P%02P,$%     @ ]XFG6FUM1.^8!@  >!L
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M,;5=D-,=LD:<L5N<)R)-=2-1>0K.P$XHS<_J,O:</B,<]0E&?2UZE;L(!_T
M>7WB$W<P %7@ALIX4^^25H@IBUGZH"N8??/SL&EGM@&HO2GBQIR&K>D3L+M/
M&*]6O*SZNK$IMYW.> 9BNN6ZT;'2-%4_(,0+#:HV7$C"#I7%37N W>V!;M6+
MM$BHTN'7+2Z/N;6)P:;&GZ$(!F%[K6<#8B\B48?>XJ,M6W<_L->"M]8=;(H^
M#K$/#;X6G#_TNGI;W+0'^"V+YR/IJJ3AS?1]8SO9NK2VX*Q+Z\'1:Y'RG91.
MJT>>Y7J-L-8#O?-0!T#N7_/L3Y385F]*'H12(JT.-XRNF"P!^O>UT(WPX:1\
M^5*_;!O]!U!+ P04    " #WB:=:NV!W#@L#  !J"@  &    'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;*U676_:,!3]*U8V3:W4$2<A@780B0)5*W4M*MWV
M,.W!A NQZL29;:#;KY^=T(RT*1_=>""V<\_Q.3?7R>VLN'B0,8!"CPE+9=>*
ME<K.;%M&,21$-G@&J;XSXR(A2D_%W):9 #+-00FS78P#.R$TM<).OC8288<O
M%*,IC 22BR0AXM<Y,+[J6H[UM'!'Y[$R"W;8R<@<QJ"^9".A9W;),J4)I)+R
M% F8=:V><]9WL 'D$5\IK.3&&!DK$\X?S.1JVK6P400,(F4HB+XLH0^,&2:M
MX^>:U"KW-,#-\1/[16Y>FYD0"7W.OM&IBKM6VT)3F)$%4W=\=0EK0[[ABSB3
M^3]:%;&!#HX64O%D#=8*$IH65_*X3L0&P&F^ G#7 '=?@+<&>+G10EEN:T 4
M"3N"KY PT9K-#/+<Y&CMAJ;F,8Z5T'>IQJFP?WLS&-Z,AP.D1^/;ZZM![UY/
MSGO7O9O^$(TOA\/[,3H:$0&IBD'1B#!YC#ZB]\A&,M;+LF,K+<30V=%ZT_-B
M4_>533\3T4"><X)<[/HU\/YV^ "B$MZLPFUMO\R!6^; S?F\5_C&BBC0I:D0
MGZ$+FI(THH2A$9<T+[7OO8E40A?<CSJK!7>SGMN<PC.9D0BZECYF$L02K/##
M.R? G^J,_R>R2AJ\,@W>-O9PI \0" %3I*LN>CA!&1%H2=@"T!%-T8 S1H1$
M&8CBP1_79:/8HI5O85XARQ W,,9.QUYN^MP95G'0+!TT#W-0%"@B"Q5S07_K
M&\9)L5HKO^#W-W0YN/@],[!'8,6"7UKPWV1!OX&E(NF4IO-='OP7TIZ+WQ91
M41V4JH,WJ:92+G8G/=@I>%M$17"K%-S:*KC/DT2?['\H]-9^A;XSK"*_7<IO
M'R#_X"IOOTBGA^O+?)_(BH/3TL'IX0X.*/+3%\)<K^U[KNN[SRS410:!B_VF
M7V_!P7^_G?AP$_O5_)IY'P.UH?4.[(U&P'1A^D,[IZE$#&8:BQLM32**QJ:8
M*)[EO<&$*]UIY,-8-X,@3("^/^-</4U,NU&VE^$?4$L#!!0    ( />)IUK]
M7.HND 4  &<5   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULK9AK;^(X
M%(;_BL6.5C/2M(F=D(0N1>*2MDC#183.C+3:#RX8B":)&=O0[O[Z=4*:0.)X
M9R6^D OG'+_'E_,X[KY2]H/O"!'@+8X2?M_:";&_,PR^VI$8\UNZ)XG\9T-9
MC(5\9%N#[QG!Z\PIC@QDFHX1XS!I];K9NSGK=>E!1&%"Y@SP0QQC]O> 1/3U
MO@5;[R\6X78GTA=&K[O'6Q(0\;R?,_ED%%'684P2'M($,+*Y;_7AW1 YJ4-F
M\34DK_SL'J2IO%#Z(WT8K^];9JJ(1&0ETA!87HYD2*(HC21U_,R#MHHV4\?S
M^_?H#UGR,ID7S,F01M_"M=C=M[P66),-/D1B05^?2)Y0.XVWHA'/?L'KR=:U
M6F!UX(+&N;-4$(?)Z8K?\HXX<Y!QU XH=T!5![O!P<H=K"S1D[(LK1$6N-=E
M]!6PU%I&2V^ROLF\939AD@YC()C\-Y1^HC><34?^-/!'0-X%LR_C47\I'X*E
MO$S\Z3( LP<PF_N+_G(L#< -> Y&X..'3^ #"!.PW-$#Q\F:=PTAU:0QC57>
M\N#4,FIHV0(3FH@=!WZR)NM+?T-F4:2"WE,9(&W "6:WP(*? 3)16Z%G^.ON
MMD:.5?2LE<6SKM2S?_9?N&!R6O^EZLM36[:ZK72MW_$]7I'[EES,G+ C:?5^
M_PTZYA^JCKA2L(MNL8MNL771>PO_JS]]]@-5DB=/)_-,Z\^Q!Z'MF:AK',_E
MU\T\Z+GMPNI"5[O0U=;J&E(N -V /:/KPTK($G4DR8&H9)X"M<_:;UNNV:ZH
MK%O9R'5<M4JG4.EH53XRRGFJ<1,*E32GUJ@#S8Y;D5:WLCK0]-32W$*:JYWO
M^52>/@+_^SR=^,&=2J%[S8E\I6 7^7I%OIY^(LN(F*UV0)8_"8ZC).)>\DTY
M+%ZMPSWD5 :E;F.W3?60= J)':W$>81YC,%*JB(,2/0S+,)D"\B;W 5PHBS:
MG9H,B+RJ5H61:38L0&B6*#*U<OLQ92+\!V=\ETLQ3 1.MN%+1 #FG @U9,R:
M%E1=B@H;V+$:Y)Z1$VKE!G+O(7OS,]B21/9LE$T$O):0#M-"GFY/E()A7;!M
MNIVJYKH9;#M6IT$U*E4CK>HE%5+JK\V%/-2%5 ?!ZFQ0F$$7>0VE#I8 A5H0
M]<;3X6SB@X?%;'(&2J50JU[1;,^#5:%U,P0]!!N$EDB#MK[T+9_\!<CE?LS+
MWR=E^8-:.O[?^G>M:)=YE\B$>F:.T[I")#?#9$5C]6RO8] Y(TV>1MW(\NR&
M42E1"?6L+-3E4UPIKX["&]AQ:P5$86:Y3M-B+)$)M83JS<1.%F:=/K?>L&-7
MU2F,K*9J7.(-ZOEVH>TS2(B2;+".K1MH6[65IS"S;-3 -U@"#NH)EZ^Y@?\P
M6_CO*W#9_Z[>7\(ZMRSKG+*Y6 7>/-ML*!.HY!O2\VW.Z#',OG_EYW>^9H#
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MQMGMCN U8:F!_']#J7A_2!LHSE9[_P)02P,$%     @ ]XFG6C79* /I!0
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M@I;+K(NSJ50 )<JF.@.1B23":I $X_? M(A:-5%+2W1.BU7,B@*P)Y8'4<%
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M_#++^->#\NUU_?\0LW\!4$L#!!0    ( />)IUI=FE>O5 8  .(9   8
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M+5;%Z9+1E$DC /\OA-"O%^8!^\\ZP_\!4$L#!!0    ( />)IUK#?OIJG@8
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M;VE9 .MS8WS]PALT]_F3_P!02P,$%     @ ]XFG6IM9P=1U$0  )3$  !@
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6S-6UUSVSBR?=>O0'EG=ITJ6I;E
MKTR^JF3'SKKNQN.RXJ2V;MT'B(0DC$F02Y!6/+_^GFX _) EC[.S#_LP$TDD
M&HU&]^G3#?C=*B_O[5*I2GS/4F/?[RRKJGBSOV_CI<JD'>:%,G@RS\M,5OA:
M+O9M42J9\* LW1^/1B?[F=1FY\,[_NVF_/ NKZM4&W53"EMGF2P?SU2:K][O
M'.R$'V[U8EG1#_L?WA5RH::JNBMN2GS;;Z0D.E/&ZMR(4LW?[TP.WIP=T?O\
MPE>M5K;S6=!*9GE^3U^NDO<[(U)(I2JN2(+$/P_J7*4I"8(:__(R=YHI:6#W
M<Y!^R6O'6F;2JO,\_::3:OE^Y_6.2-1<UFEUFZ_^KOQZCDE>G*>6_R]6[MWC
MHQT1U[;*,S\8&F3:N'_E=V^'SH#7HRT#QG[ F/5V$[&6'V4E/[PK\Y4HZ6U(
MHP^\5!X-Y;2A39E6)9YJC*L^3.\^?Y[<_E/\>BFF5Y^NKRZOSB?77\3D_/S7
MN^LO5]>?Q,VO_[@ZO[J8OMNO,!^-VH^][#,G>[Q%]J'XG)MJ:<6%2532'[\/
M/1MEQT'9L_&S C_+<B@.#R(Q'HV/GY%WV"S^D.4=_NG%B_^=S&Q5PH?^;Y,=
MW#1'FZ>AN'IC"QFK]SL('*O*![7SX:]_.3@9O7UF$4?-(HZ>D_XG=_!YV>/A
MX.7B!S>E-K$N4F5%/A=Q;FR>ZD2ZZ#,)18_F1VP%4_&3P9>E0FS&>59(\ZC-
M0M1&UHFN5$(B$L2_^^2%X<M<&XF)9"HL9"A 1&7%4CXH,5/*D/1"EGA/&QI'
MP*6K1\15M>2):E/1-$6K[4(95<HT?:3GJJC<V J*W1E69$KSL.J33)4ZEF+W
MKW]Y/1Z/WMX-IT/Q:3*YX>\';U\)S(?1%5[+.IIJXP 4*QZ*B7DD0%.E,K'R
M4UDE3$Z35+F019%BDEFJQ*+&HODM*S(E347/>2Q]:&87TF+BVC2*3]J%0GF3
MR#*QXCQ/]!R">4?""B;3\T9WVJ6-(^^*A"W0#KIK!L$J-.-EL]:-$LYR_"-V
MZ4TOXW(R/0M"AO\I-[#+O$[A:DI0BO(N\%MM7 Y@'R 5I#$U!G9F^ .Y9!F_
M/TOL&VT2^P/]3CM.0A^5+(4BK!,?5:RR&3;)H]41-(G3.FD]Z]RME QP</K6
MPB=8HUM5Y&4EH"LE'7$PVOL?*)1B7*,[;_I4Q76I*ZV<:A??XZ4T"Q:;:<LI
MLVOKZ46[R7@$((V7XN"U0U(X9)HZG_7V1ZBFY'5..'#/6,D6[,:92C42DJR:
M2&O#?2AH.UT@.F^#J?*Z#8P_-OB&X&V]O53_JC5 !)G0@#K0" J'3-XKH6RE
M,W96TEU:T(W"J5XM927D? Y"X)P@(S>UD$8VAR(T(-$V3G,XVU!\4VZUF4S8
MG6QN.";[,_Q6)PNG,M9H:]@5+I595AF+H%5O]2CV)<A_)(=U.\@ 4"VA06<>
MR)G758UW"Y@O3^QP\!';CRBA=53+4D&*R[7._]P&AU3)<Y$71H(VN%1+8E4/
M!#WXKL0*O@R+0C^>&T@$-NB?!2-YS%:MN^.'0C&I"EH%W^[%\9;H[5B"? ,2
MV%'L$"%@0:EL#TC#!,!U"D,H".>TLM3 ;&T2QC3HX:&H]!)XP[UUU7=2MJ/^
MO(;3S[';6#9%[E#<699P$<P^V.#$&[?R/^..K1MZDQ.\6*N\KZ1:SG3:AKQW
M5'(*EVT)<&GF;6/<+&3]8*?G_'*C.J5Z4*;V"I!%L:]6)*TKND&<7GG' "UQ
M18X5MB1F>$8:H@PV+_-LW=<!;7IA.$UA+=T08/R$H!E_AY?7;C])R*+,K5U3
MKQE:JI1=#ENRCKJ*S4^N4\GO MNLAH-+J4OQ5:8UVZE-:U<&#+!F([%GQ+(L
MV<,[!HI564EM@H'7I^OR@498Y-?&P2+MDK7G#^16#S)U+WGJ0LN)%7XF)&*7
M"K\7\I%^C#A(D =7AO8\SFTE5DL-. "M*//OWBAS6N4#KS+!?S[P,:RL]A!S
MF0"R>]]R[*2CL8/W1,V0J.K*4HYW&3M1Y<9U SDTPBX&*],5IH[)*1_%K@5N
M72.KBI-7V[2+N.A**&M)\0]L<"H.19S"R5LJTT[<6=52 U* @H]1=X$/P PV
M'2,+?(0WG:0#K2VO:3B8!)/>-J9N?^N87W=S1T4I(M6_\Q.O.N$H17&*VM?E
M4T(?5]:I8 _GKMXVB&BK6B!ESR(1/QT.1ZC_TC20Z9]&PW'[0[4)\9^0D*B#
MV>FCVT6_58CF"JG#!CU@+M(LJ&K]+M0%3R\4+; !124Q=7AU@[-3"M!-&>!G
M@+FKO(06%XTL^Q28FJ$1^3<CJQ\8\#3'>\SAG-A2VWN.Q$9SZ=(F40GO1U#:
M+')R62Y)AN(LN)AS]79UB+N./X,.$((%)L< SE;J3$T\71NX<0KL>^FVN S>
M4=DYF\]6T%<N%J5:>.CN1 K2W^OCGUGL+P<_]_<WVH9"55X1]WWJT,/!E0&"
MPKI(&(-;N1(T!P(F)8]T3QXYC6,+>+,HG/+:=MXK:BR8S<G ;&NJ9;"F+LH9
M*H60=,"-4-D4".9,\AJ0^@N-@*1IIH\F?JS(![[JLFY+C]OIUX;*+O4"G!A\
MJ_12(E';EF/#3)0DO)=N,H5_ R[P+2_O][39PR]$+1RQQT;:)>0M<L=N&N-T
MH.OP%=5C:<CBC+>4*GO6@]^L%/@&^X_UY"8!9\ HR56;_Y+*65Y&5)QFCMU8
M,'&:,0)+6_C4-D.].M=>2J=85%F1YH^*7NY,2.X# (I;(OZ@RB551TZ53GJD
M!9SA37$9(+K=M+KR3(*T([Z&ITB:]-W7SP2&P%^G(S4$@2B$>A&[3)VQCMXA
M/(=1H%<4OTW-T)^]T;2S $*FQA=UMWCO0!0M)!  <$UP6X# /(?C+QKVTY_*
M!;/]0?^Y_#C9XW!\P*C@3,ZB3"J<25W ;=8B),->['6#Q8<'6S/QB( PES[]
M;WK,N<U@RMJJ;?4FJ&J-N2OF;EP7 'D(<I'!W(IY&L7XY?8*H)(7#,'<2_7.
M0&LB*J1=$J2YD.T0D<Q**1A*SH/KV1$"B6=H@W&S1P_[I:T0A)'_!'(A,@6"
M"!YYO4E$;_N[\OJ>P(B5^ JC!^BN*K"NJ4(PB&((Q1&_T_,R%"Y))%)"!A<U
M&)&@ G[PQ*-]V>\Y^76A\9OSZY:-SK?9 _9JI9!5&^)#Y)YZCURA88V6;,JK
M<[E04PU#2\$F4*^(LVQ@HE1C=NN.J&'XP0@SK .;ZRL2+F&[=0JITE:_0W'5
MM8NC^:1 2CVM!ZU6#DI0&A!];'-D8,M^\W/,1Y6<^AXKBCB\LLDJ3EN9_(;<
MZ.L35B?.R\1-M"J!_Y 'NNNJ[Z!>Y%M^,%])>3%W+!79J5QP: :H]G$;RH>H
M=8$UI6'UCL%YN%/?LOXMX&Q:R7#P"5ED!<;6?"# =&6U=8CUG5,/J>2S*"4"
M;&C^\)3?XBV:)E1[,9>@32CYO1V*9JX7<D1N!H!M'@=RZ;I#6_!O$:1K*C"K
M4L_JBI?L^>/DX^>).-/YYR[:B%EM$::6Z@)NG;CN7W#'1'.KS6^RH)]T1HF%
MH<=M7R]K-4J$TO[E#1'J-O"F$]7/47=R2_JVJ2,)VZACHCD2YV)7OVJK3%^^
M*L%@O,5".LMJDR_2?%:GVC0Y(A*3Z?G%]=772)Q=?;WZ-/G,.EVC7M_[^UF$
MB3#3FF-NF'&)K&I"#HCS-'4]#A@@KQ?+C0K=N)?/W<L$B.?4UR&*O[8MK 74
M"/#3SQFNP4!TQ?$U.M?0L;)M&.WJA^>LQ5D*E)SHNWW+XG8Q &2&V@K\W8%7
M(Z)E1>N^1G*1+?;<8-*.>O7.PO0<+EA1L3?YU/!(_U/#);$YX]'!V#5NRGOE
MB)DE$L6E8=@,O'=1$P$*SYW)F4PS-<0+UZ@)EV(RYZ." +>?=9) VPMID1."
M0E11$'W0KJ!HHX"Q*X!X8UO/2GUQY"LBGI+H?.F."II.<8B1,%EC6A03KDO%
MW!.(,TOU(H03I/8T"4J$-H<G%+XAJ=NF!P #L^3&!PZ*0DHKR-T?Z;R"P,GO
M)*-%1HVBWYEL,:7C;F,#=-R""$2MKW[4PB:[H<]!3RNC\9@;>W8XN.D'DBO<
M.=Y)@1;N0V'.G0"5.7MP#YAC($];!;T[#&$F]X3'K#$0.G((PAO_H4,*713T
MN P<0H%<@ PKEZ(\2:% L2[A^Z2M*SA0(;E%X+T^Z-PBF5]<Z0\;9-@YEXM]
MK6)_G!A!EO+'#.UD?P8#MVU#"WMP(65[RVQD)I1MC72M >_&S;)]WZ5-R+YK
M2*D]3YD\4_EE'8B$QD0(ESE74*TS(*8,T?D^+<?"BXJ#A3JQ'!H]\2Y1S61\
M3Q42\+@(69VWN%Q($Z@V3>@UT-FL+JUOQ5(^*_"*[^IJZK3%B@EE[WB@1Q;_
M;4JX6FH"T^>)87_2EA9RG\315EO/?N-J./='&JUN'C/6]'+Z4&+)*5@O\P[D
M=QH\#A&WYZ*MN25JHI=/LN:4Z]:BIQ'@&T6,HQX5:8<H:/')SO5&O*CD/:4G
M[MW93KD8/+F)DK7RUK? )668,MDK)!75*QAQF5/IUM2D5'K__I3<K>/:RPF"
M+]2>M$-Z[]%"8L\- NOVL>K'PQ<ZT-A?,V4V/B<,1B_;'D,P7.0[TVT1E\=Q
M7=J>?#I6 V R411/5OR,8ACHX?61TE37LTM%D6"WZ>Y/-)IIV2=?Q"R?]O*:
M9,4'C,]U\DZ/?MZ&H+VCL[#VH7BI6M1B7.7_GE*C'U)J.#CW5578*9\IFM^+
M]5SLVJFAKEX/>)JXC?6M*69C(R;JXT 3Y!W_;D*DUXSL]<^:<ZY.R>&/IADF
MD%E@Z;97Q/TQ+N1Z+1,BBS%!.9U;.%54O#0,U.WQ9P,N=!;9_LI\:HWS.I;:
M6>Y0? O(U#9HV@.</Q!GU*K-S)1XW"(<H>VL)/*EJC<*ETC^.(:<R6[O&H4Q
MP\&%+ T"S.[3<8>X 8+2O05LQQ1)4_U(M%$#/_;GH6E-UE!>-D$Y(IB7RBVJ
M-*[=_O%=&3J2L6]0>-(4W7MJ@^O.X?>#U&DP4.Q41 C%]TCS"<71[D^CT>AO
M]I78-76FN!)Z-?A)C$^B7T9'@V]\)U E>V"0)?7\\-(L=,:<,-(/8A)E<KY,
M0>/'AZ?1Z>EQ='1Z,CCC]?76U!N*R4;#@X,73]43?@->;;C%[O7HO$VKA.$T
MLQ5.*]VC/O<X=_1A<!C]\OHT>GUP]"<D(NLA3U1V<'0:'1_^J&ZU 4VAO;V=
MWF&-T>N3X^AX?#3XXCJO3L)>XR-K]CXZBDY.3Z+#X]'@XR8OZEK0&_S%T-N]
M?.&N>ZP47V((6KDF%3'02N^Q@D2V5;@7(.FR@_*]+K['X$^?FE2_P>&I9U&[
M^W7# 1UB(OHZM[( S0:?8T<S!U>F;0-!T4,7X70]"^3#UIAK,KWC)WNC7R)Q
MY6+C"_7^Q>Z7O("#GAZ-7KT15QD#L".O4+=]4WQL;BM80016ASME[>4)T.@F
M#R7="W-"SJ@3+#NW"\@UJN>.\9D3&.)97D2+YUW)1.V<DGR4 ;:M$W_$$LM,
M=00S%Z_!"..V3\)::-_3[5PE(>*ST,8P,YW3Z51CWX/CR#>>NBTO32>M($BF
M0L8-IX_^2@7UOH(G5!V[T;T6+DWSS0W^/[QB12<.XIKVRV_\T>:-O\Z'_'1O
M=-AL_C1(05#=-KMRWKM<Y%]EA0[>B@N'_N0)89MI![J.L3NM9Q7[TW@\VH-+
M.2MA(TS2-#JJI[[3N0L3A?9$<YERVT47/AZETU*7N)[Z6RB7/"_IW'CIUH'(
MH-RMI,MPCAQ$3??6]GKZ47,^Q_$)2>W56&HSL5^[&?H1 E^$(>V:,_Z0OYW\
M-_C;ILO.^YVKZTB@"[Z@;UTWS=UB;WYM_@9@XJZ^MZ^[/R  ["Z(TZ=JCJ&C
MX>GQCBC=I7SW!:[%%^%G>04:S!_I<%&5] *>T\E<^$(3-'\9\>'_ 5!+ P04
M    " #WB:=:&Y]<2\L#  !!"   &    'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;(562V_;.!"^ZU<0:E'L HKU\#.I;<!.TZT/R09)-CTL]D!)8XL(1:HD
M9<?_?H>4["JIDU[,(37SS3</#CW=2?6D"P!#GDLN],POC*DNPE!G!914]V0%
M K^LI2JIP:W:A+I20'-G5/(PB:)16%(F_/G4G=VJ^536AC,!MXKHNBRIVB^!
MR]W,C_W#P1W;%,8>A/-I13=P#^:?ZE;A+CRBY*P$H9D41,%ZYB_BB^7 ZCN%
M1P8[W9&)C225\LEN5OG,CRPAX) 9BT!QV<(E<&Z!D,:/%M,_NK2&7?F _M7%
MCK&D5,.EY-]9;HJ9/_%)#FM:<W,G=]^@C6=H\3+)M?LENT8WZ?LDJ[6196N,
M#$HFFI4^MWGH&$RB-PR2UB!QO!M'CN47:NA\JN2.**N-:%9PH3IK),>$+<J]
M4?B5H9V9KVX>KVX>_KY;7=U/0X. ]CC,6N-E8YR\8=PGUU*80I,KD4/^TCY$
M(D<VR8'-,GD7\)JJ'NG' 4FB9/@.7O\87=_A]7\?'?EWD6JCL O^.Q5H@S,X
MC6-OQH6N: 8S'UM?@]J"/__T(1Y%G]]A.3BR'+R'_KL:O&M\FEJ_YW5 O8<"
MR%IRO(!,;(BA*0=2*;EE.6AB\&,FRTH*$$83N29,;%&4BH&^\+ D66%KXGV!
M#,H4E-O\L1)H*6M-1:[_].[H#KO2@&*4:^\C&0^#27Q./I)1% S&?>\[7LTS
M)L[0:P9:>X/S8#R)R"@.1H/8^\H$PQ;.R4;*'#^.@N'DG PF09S$WH,TE'<Y
M(7P\3H)X,B%6BH*D/WQ) +4S7MO@*DYU20F2)!(#51T=>*YP,J!3(TD*I-8H
M,N'2@2SSNID:F([%_>75S>HQ(,O5X^JOQ;5#NZ$I._NV[!',K88.[(YQ;O$R
M*7#0O87I GU-@6XIXZXX.&R)IBC@ZGCO&#HIZ!:5.'H2U,XRR]G6CYI#-0FU
M4MI@U*96@+@"ULST7I?@F-$]FC <R(SO'6FFFRY(:_Y$<E5O<&#CS:$B Q=Y
M+9 C3M6<K#%47+8N;K2P85YB)U&Q__1ADL3CS^BE+&LA-UPB'&:BS8+NO:IY
MAPW3KAT5LP6QW7@2H6-@22G@U+AD8W8PZPQW;6JH>IU9A"]!94C;)3D@%,N&
M[X)=VX;!L<J;TB#"J;A>ZMFJ9F!]MT[9+\75DCO1%$SE9Q559M_.=S3JD5-C
M).R,==3:N,?+9J<6IIGPQ]/C^[AHGH6?ZLWCBK=XPX0F'-9H&O7&0Y^HYL%J
M-D96[I%(I4%*3BSPC0=E%?#[6DISV%@'QW\-\_\!4$L#!!0    ( />)IUI6
MPB.L<0,  %0'   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;)55;6_;
M-A#^SE]!:,60 (+U[K?9!NPDQ0(TK9>F&X9A'VCI9!&52)6DXF2_?D?*=M/
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MLUUMEG+_%@_YI):OD+5NG[#O?%-R+G;:R.8 )@4-%]V;W1_J< 08!'\!1 =
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M%N2YH1S6AG*_:52[<##G!5>I:"RS%:>ER6/#U6KH&YJS_2;[&<)[K<1SU+M
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MZ58-RP5%YDKJ(AR/8>4.;*!0UH:GFV#CIT%QSM4W4U<NW428MRAO0N%6Q+:
MYCE#T/1GG2W*\"PUVMI7\4N!#0Z*J\A*=$ =6 4B_CC,25>[T!J$A ER8[4N
M$O8AC_,QS0XJCD-8$'D<&4E"ZOO3-,IV*QJWF-CU[C?X'?/C[>0%JRA,E<(X
M=NS\>]CY N&SG[ZSD"KHV,+'B/9I^RGG(7S!V"X/WX'"V8\%<N?8.DJN9GUF
MPK>5<.-TY;]GS+5#@?&72X$>R- "O,\UVK=X0PS:#USW?P%02P,$%     @
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M5=FO*X&IJJ$-6%\HG.NZ!Q+0_UAR]C]02P,$%     @ ]XFG6O^'XMM(!
MDPD  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULG5;;;MLX$'WO5PS4
MH&@!PY8O28/$-F [V5Z0MH:=[6*QV =:&EE$*5$EJ2C>K]\9ZA*W2(+M/B2F
MAC-G;F=(3BMMOMD4T<%]IG(["U+GBHO!P$8I9L+V=8$Y[23:9,+1I]D/;&%0
MQ-XH4X-1&)X-,B'S8#[ULK693W7IE,QQ;<"662;,88E*5[-@&+2"C=RGC@6#
M^;00>]RB^[U8&_H:="BQS#"W4N=@,)D%B^'%<L+Z7N&KQ,H>K8$SV6G]C3\^
MQ+,@Y(!08>080=#/':Y0*0:B,+XWF$'GD@V/URWZ;SYWRF4G+*ZT^D/&+IT%
MYP'$F(A2N8VNWF.3SRGC15I9_Q^J6G=,RE%IG<X:8XH@DWG]*^Z;.AP9G(=/
M&(P:@Y&/NW;DH[P23LRG1E=@6)O0>.%3]=84G,RY*5MG:%>2G9MOKF\6M]=7
ML%YL;O^$V\WB\W:QNOWPY?-V.G"$SUJ#J,%:UEBC)[#&\$GG+K5PG<<8_V@_
MH+BZX$9M<,O1LX"?A.G#>-B#43@Z?09OW"4[]GCC7TX6_EKLK#/$D;\?R[N&
MG3P.RW-S80L1X2R@P;!H[C"8OWHY/ LOGPEZT@4]>0[]%SOT+-;CD9[W7SSM
MX\5MBK#262'R R@D_EL0.>@DD1'"KI0JEOF>1#'@]U(6-*\.$J,S6!AT:0]N
M;E;P^M7+\]$HO/0BOQY>OH&B-+84I.XT0XJ]0:S--9T:%!MYL(!)@GYR05AR
M"Q]%7M+I 9X5P[,>BP69$>-JOX[.#(;DWYX/K! '"QE34QWH("$/=!RX5%I(
M1"25= >0+" 7F2YY.X&38=@+P[ /UY(V#&$84LO$ 1P:FD/AL+;HHMX=H##Z
M3OIZ\)8^,JP(A;PB'% 8KL#P[:4E?4FI5D8ZASGDVE'&?=@P&M[3L6O1UX+!
M7$I^ZB2H)CY;FHXH[<;#9TJ+29,$*5 13L9-&K[T0"D+B)IN1@1FM%*D2;%?
MT:A]1$."&)9]>&>TM9G(>][[5V[V*A62SD%NOA<NM3!Q7>%%+#+8_FS5T*9+
M=TV4DS%GQS:K5&("U_<8E;Z]7SRE*(ICQ@EE-;5,9CLB"[&A3H.+4C.P!Y4P
MF.K2MBSL*&E0":[":\HWX_.?[JPW;5UM[XBN;$:>'5UA3=/HSC.";PVACBRJ
M5%+!*S3(O2(R$!4D:3#9*&:JI]5*QMYK0A3)(]ZUC@3LQ_Z/9O;AJC0MH?Z[
MV0_UYT&+4IK<ARQM@1R;_ ?CG^I@L* N/XQ?R69MW!&SI;E->:Z,)A5?>:*$
MU>0&H5""&%"/XCO,J>-VN=X^,F#C"4FH<8S$?R=A?T@WG%($WZ,X.$8FACKT
M6R#FKZ[R!\*V?'L@82OIPV-'[^#HHLS0[/USP%)>%%1]9W;2[L6QJ"_:!_7Z
MN4*5W\O<TIF8D&G8?WL:@*F? /6'TX6_=G?:T27NERF]FM"P NTG6KOV@QUT
M[[#YOU!+ P04    " #WB:=:,+B^YV\(   ;%@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6S%6-MN&SD2??=7$)I%D %DW>PX-]N ?$L\&U]@>S,/
MBWV@NBDU-VRRAV1;UG[]GB+9+<F1;&1?%C"L%D56G;J=*O;AW-@?KA#"LZ=2
M:7?4*;RO/O7[+BM$R5W/5$+CEZFQ)??X:F=]5UG!\W"H5/W18'#0+[G4G>/#
ML'9KCP]-[974XM8R5Y<EMXL3H<S\J#/L- MW<E9X6N@?'U9\)NZ%_T=U:_&M
MWTK)92FTDT8S*Z9'G?'PT\D^[0\;ODLQ=RO/C"R9&/.#OESF1YT! 1)*9)XD
M<'P\BE.A% D"C+^2S$ZKD@ZN/C?2+X+ML&7"G3@UZD^9^^*H\Z'#<C'EM?)W
M9OY5)'O>D;S,*!?^LWG<NP^-6>V\*=-A?"^ECI_\*?EAY<"'P98#HW1@%'!'
M10'E&??\^-":.;.T&]+H(9@:3@.<U!24>V_QJ\0Y?WQZ<W5U^7!U?OUPS\;7
M9^STYOKA\OK+^?7IY?G]8=]#!6WL9TG<210WVB)NCUT9[0O'SG4N\O7S?4!K
M\8T:?">C%P5><=MC>\,N&PU&[UZ0M]?:NQ?D[?TO]K)_CB?.6V3*OS:9'B7O
M;Y9,U?/)53P31QV4AQ/V472.W_PV/!A\?@'W?HM[_R7IOQZGE\5][.V\*''G
MB]#"<L6^B1G^7W'OA74[%]:4S*,HF3?AL\M\(=BI*2NN%TPZ9BRR<\$F(C/8
MY>K)OU%^M#L3UH,CF H"*VLR(7*I9XYQG;-,<5GBT4J'-89]F=$Z5>Y<^B+H
MT52'"C_5U@EFIDQZQR8UC@CG>D"IP2-@#,]R(QRV>R:>J@"@X#Z( "\%9#A,
MB%V=%8UR0.=!H8-&I5C!'P7C, >F2Z@5TRF) J 5F]_\]F$T?/_9,27_JF4N
M_:(+KG+@!$<Z0)Z61YD0/Y6:ZTP&$S3V8KVW\UWH'+]!7BD]@7<[M["OYCKX
MC70!0!G$<58I[DI\U#8K0$:,SZQ()@-GSGC8=VT>13D1E@W?4^4,A^PMR2&P
MH\'GL' ;!=TV@L:-H+!I^/GW]= &/3D!:E5/*1DH M0:H LVA=J!QW0]Q4-M
ML<K!O%K7L!GL)<NZ9(]&U3$"#H',1&,3G4>&4/QANYR87"*(T'AW_YT^)H+5
M#AAD#,"*%I(UOC\]O[[\WF,/*ZA+$.B*KR!E=R)V<T$.1=+D(?>2:75EMD$-
MEI).9)[&V8I;BC,=KL%S-F:6E3/$5[&7W;OFU3G"51$6[Z-SN7(H%:.H:;$"
M'6772R@,+DAN"F#JBG9/T=#8O,#V!3-SLF=\=C5>^E,UO0]^D@KY)E E9[4E
M%P/ENV<A!KR<8&#M-1L,>RM_!UKT]#49?HF>,L/R^;)^R(85DU;-H:.Z#AF+
M4/Z:12$,;^4V.&WT?P6/@1"*JK3Y;@CVJFI,0%S+_\2R[E(Z"DXL B5=(K9'
M&;V8&&=C2KEE3CTGDA>K:2Z0[:7P%+G:18LIFL^,!NN15X+) 1R$KAOOZJJ"
MCY%_DDA29+47+AP /4(_L52RD3RC ZYED=UH=B:RQ#&#P#$?NK]N#G=.SBC*
M 2D-4#&<9J+D+/'FLL)>3\HO5DXQ$+$_C54Y!BG!;I8$_$VBSJ#K;:+!M+GA
MN^@+1RTA0SLQ=E=J_,%?PL'?D?VIX/Z !9A?61A*AA][[+S]Z2;S)K@DS"O[
MZ_4E@BSB+RITS<:IWLC@.^@(_+W=O- %&P-7Z7S\AI?5Y[OVMY^8/![EH8U0
M:DB;>NR]J'R,X6BP]W%G:<>XGA%S'KQNQFN _WY^EG9\^W;:NKY=?17B'S6R
M%.B&@>QV;FA%BXB,FMOKR.YCIC_#]5K?ZA)QM$UX7LBL^*D#Q"("!759:!T
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M??,YCB_\EMOC:U,8A&NG8TI,<730>_^N$RFQ^>)-%5[_38SWI@R/A>#P%VW
M[U-C?/.%%+3O@X__"U!+ P04    " #WB:=:+F.T9\8(   ?&@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-BYX;6SM65MOVS@6?M>O./ 4LP[ Q+K+3I,
MN;2S TS:H&EW'A;[0$NT3502O:04-_WU>PXE^9+(3C)8[-.^6!+%<^%W+A\I
MGZV4_FX60E3PH\A+<SY85-7R=#0RZ4(4W)RHI2CQS4SI@E?XJ.<CL]2"9U:H
MR$>^Z\:C@LMR<'%FQ^[TQ9FJJUR6XDZ#J8N"Z\<KD:O5^< ;= -?Y'Q1T<#H
MXFS)Y^)>5-^6=QJ?1FLMF2Q$::0J08O9^>#2.[T*:;Z=\ \I5F;K'F@E4Z6^
MT\/OV?G )8=$+M**-'"\/(AKD>>D"-WX=ZMSL#9)@MOWG?:/=NVXEBDWXEKE
M?\JL6IP/Q@/(Q(S7>?5%K?XNVO5$I"]5N;&_L&KF^NX TMI4JFB%T8-"ELV5
M_VAQV!(8[Q/P6P'?^MT8LE[>\(I?G&FU DVS41O=V*5::71.EA24^TKC6XER
MU<7]A]]N/WSZ>G\VJE ;C8W25O*JD?3W2 9PJ\IJ8>!#F8EL5WZ$7JQ=\3M7
MKOR#"F^Y/H' 8^"[?G1 7[!>6F#U!2\L#?YY.365QOC_JV^5C9*P7PG5Q*E9
M\E2<#S#IC= /8G#QZR]>[+X_X&*X=C$\I/T@^@<E^_WRW!.G4^E\70BX5L62
MEX\@#8ARCD66@2RAPC<%+^L90E)KP?!!?Q>5+.? RPQS^@%K=8F55X&:@5F*
M5/*\>H1ESDW!CS.AL9 RF$J5J[E,S0ELV?KUE['O)>\-7-[<7L*55+=K2V0
MNXGFUI01<VL"JY!*U%BWGBJ115&7:IZK:8T(;'F-&ABDJBB$)N^>.][84:6A
M%5^IE,,77JF2P<<_&G_O[&K08MYUB&L4%-KT^)BB'FG01\2C$F6+! ZO9=$K
MF<M*"@,Y&JL0GVJA53U?8">T2_M62AJ]K_"E8<#SG+2M%C)= -=BXS'/V5HS
M^M#:H@6FM=;H3OX("Y5G\/'F$G*98H=$JSM!H+Z$"8-KKWJ68X 3VLH(F-:&
MYAFH2YJZLH,; <PL[&[&^J?%O,ZY1N-:/&!SI QXM"M+%U+,MJ0R3!C;M O^
M76@84C1]]_WUYYM;>^N]/X)*X8IX_OA3 ,I9<BE385>)R%@$R;JJ=2HPP?Y<
MR%Q J=I08 JB>5X^7QMKTT@OE28=LFR(B]R199K7V:8&*C[-$:,I,=-.B%.A
M*^0S!*7S)8.Y*-%4DV@\PTXLJ:<0I8!Z$'J!A CBQ[()!DV2E$S"5-THJ+(W
MQ8THI=((VK2"H1$"/BGT.SGJKRH"D<J9HG6'ZA$*S$^R=VVC\.&'2&OKU>?9
M#',#6RJR5Z_A:J5Z<J,%D,S4M!0$315BE"M#2"&8A-L/T>80-A+!34WI.UM7
MRU*KF:PHQ)E #! K8:>V8%(H</8ZNH!*07 L@U;!"=S;+8+\B;AC'F-F4(EO
MAQ*CA6LKFQS%4-M0;O(; 3(+M2J[2,^PG-2*9C<Q/\7NJ!'J;08#Y)]TX70$
MY RMK*H-@FN.G-YVYNQM(LY75?'<^8(MJ:QQC>_ \P*6>#'=,3=R[4C(DCAV
MKI6QG19QR^J4.J(5@BC B0G$X9AN$S="=4:0E\_:W=B/X9A^.X]2Z\96?->Y
M>8SV_7'<_#KWN!^RO?0)!U!VRVEMEQ0S-PQ1SEZ=&X&$@P%I-E54#07B+W\V
M UVR^Q$*((J_[2^;;NJ8A1.:;:_.9XR7[MXQ*'%?.HQ#.,()]NK\;A,2AI21
M1[LI&4;,=R,8CL<D$(8L\#WG ZG*)#%=DVH\PR?+#)BAN2KGQ[GE,VZ,P-P)
M63R9@._A3>*[31R[=T'@,G?B@9^P&"$)HH0E 86%\A'[_U9R-W$_18!M3CI=
M4#=A_Z-IW>MP!Y0)I5&YS*CC=!*F%1F[_A-#CJVY-GX'^E,+YL87\XJ@=]%Y
MUX:]DWW93AO(=0]^C<B0'\&$1:&["\$;5H>.^B%SDTD/2')ORFPP:>?LY-.[
M+H?:4#E;H?JVX0;G::MG6,J2&I@ER[S9#:@-(R"\_5T_/H*AQR9)A'G>:Z#U
M,G;';\=W: %&S3L0]Z\["%@8N3U05EOE<-HVN:[OMT7R;ET7&Q>'TR/P(I^-
M@W#7_+8^E(P\ET7QQ"%_CY'@.A1;ZC:TY:,5[30;UKZV-%:I]/LQG=.R/7.I
M!70$+]9LJ1JV;*B;]@*X[^&6#B7>:]J<,,C%O(59E@\8#M1DPVN;R0[Y\S15
M=;FN+(059D(08_+*[J9H*[/97&!R;#'TW_KV;"<6PVU,=G8LW'2D,!.:-D=D
MLH'UY$6R"__K9#=V&?*=Y;K$)\X;>QC[R5ZJ"UTVP;Z*LY,80A_[8[*?[,+(
M0R#P]W5DYR(EV-]7D5W(PL"JI^LKR<Z;!&1I$KR&[B(66/_MM9?N BQ2[ /T
M@ZX<9#Q_S.(XIJ;A1C$*$#%Y[ILYSV?(;. E=!,FNYSG)V-\ZU%+F$Q</*#[
MMB6^@O-@PWEM^%^@/-BB/))(^JBUXX17M+V-)V]CO";VG>PKVFL3R\VIXY4=
M.6+C*-E%X&V,YT4L#IXR'JP9SSG$>-#?^=L,ZHG4%B$].]R\P'C.0<;#O6T\
MV64\>,IXP?@OX#NT #]AO#WK]G#7XO:EM64H9X?QX#GCM56Q<9&Z=3!F4;1+
M>/"$\(+(M7EN"<_Y/^$](SSG+Q >?!+5II>0:]IBA5;G0LTU7RYD2EYQ!@UR
M[=E\^WRZPL;<G%L[LK*G2KE<BHS!BEYRTYXL#QPHUU\T+:DZ>TC5V6%2Z#:E
MW;ZS9=;=K5,WN/-AR:'#@LMB=T(]-(+V<1)2KL7M8Q*X2"IHKVP_.#D!\]P$
M)G$$M(?V+?_AM76G@](Y<(K=Z&^.*B_A$?[/\$AB%L;64WO0Q(&$3:*H<YB>
M)MXS/.(H )]HC]%I\KBY/L=CST:G4]ZP&/1]*AYM?;0OA)[;OR:HWK&,FN_W
MZ]'UOQ^7S4?_S?3FKQ,$=HY5B^4Z0U'W)(D&H)N_(YJ'2BWM7P!3556JL+?T
MP4IHFH#O9PI[<?M !M;_"5W\!U!+ P04    " #WB:=:G7<\W>8%  !:#@
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M#IFQTW)$69<H'Q-"[=@V>O"$-^RID#:L:R.Y6E+0N*[92F=R.=?KMNR!,">
MD(T5"%:%\(S>!K"EB$QL,S5!"!O//RTB4+;!#4C!N;%HCWP2Z4O[B@Y%BXL
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M8QV)VN?&JG\1M" 7,.T.LVHP>4M=D3?T=M3O1WU4I];,&//[I$)'=!YL.8*
MZ7AE8HH">U#GR6/48NZH1C79@+0YL$ $L<1?*FEN34$>[9$)-/^Y-766$_=K
MK+&/Z.@[-&.W"^ QA)=Z1:7,C%<8PUPK2B>"Y X=.OX'4C#T&B@Q(!Y>=CDA
MM$I$K"5IF<%U*[_5T(Z=X]<P! :!NT7O70C8.1=!UX@^M[C95JQ+2,>AH2AA
M>VV9D"&3)#62A5MW8FS*V8&5\)Y%:1_*0M[7X#/HQ^\')Q%]V>D?5!/:F>YS
MS;I(.B_Y"$QL $;O!U1IJ,&KP%QIY2'1$[XX;VWAQB6URQK!.C4<< C;S9*4
M=1%CY6[G#B_=XW50))70"VI" 5H(JZ1?,<!:SBYX)[IN$HKSAYU-$!2\#),+
MHVL.DH_/4#X67L6U0[M /?'D,W,;UAL.J0'-TG@RL589:]#*:U9'),$#XL=*
M6*^26@M+HC U7 =3+O1VAG?7QS9Y;%(U5S+M(M\<!\I#SE-IH5K(2N$#=O ,
MXWUEE2J76+F3?$,>PH([R>^5LL$12@$9'5S*V*/.<(T1Y=JK@\]-=QAUGS<(
M-!N+%@XN;P_;1=XXQO%9"9T7K#=X0,=-SJR:7)W ZRXM<Y7D3W!KUR0YTH 3
M%!:GC0DPZ>E1(L/=RNV/GK4B;;#]^:F<-QS6AR:LB*Z-QATLI$O-;%HE_S3F
M7"#<XV$TVO6T5O/ZD=#9YK?_#_"<?D0WGKB82F23JIK>E+_@?6)<2#.T"<N?
MC?8A*?N\Z2M@5R= :CI CH_BD^@CVO?E[K5N586T6;@[\J%([N:"M9W=7D\G
MS:ULM[RYV^)&D\%#],LYMO:CXU&';'-?;!Z\J<(=#9\VW/C",,<56UI>@/=S
M8_SF@0_87MK'_P%02P,$%     @ ]XFG6D7FS^Q, @  H04  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&ULK51A;]HP$/TKEE=-K;3AD 3:L212@56K
MM$ZHK-MGDQS$:F)GMD/:?S_;"1GM $W3OA#?^=Z[>X?OHD;(1Y4#:/14%ES%
M.->ZFA"BTAQ*J@:B FYNUD*65!M3;HBJ)-#,@<J"^)XW)B5E'">1\RUD$HE:
M%XS#0B)5ER65SU,H1!/C(=XY[MDFU]9!DJBB&UB"?J@6TEBD9\E8"5PQP9&$
M=8ROAY-9:.-=P'<&C=H[(ZMD)<2C-6ZS&'NV("@@U9:!FL\69E 4ELB4\;/C
MQ'U*"]P_[]AOG':C9445S$3Q@V4ZC_$51AFL:5WH>]%\AD[/R/*EHE#N%S5M
M[&B$45HK+<H.;"HH&6^_]*GKPQY@> S@=P#_-2 \ @@Z0."$MI4Y67.J:1))
MT2!IHPV;/;C>.+11P[C]%Y=:FEMF<#I9T&>T56@!TKT(G@*:,Y460M42T'OT
ML)RC\[,+=(881]]R42O*,Q41;7);!I)V>:9M'O](G@#=":YSA3[Q#+*7>&)J
M[@OW=X5/_9.$=U0.4#!\AWS/'QVH9_;W\/!$.4'?Q\#Q!?_2QT/M:NG"PW1V
M=B>JHBG$V RG KD%G+Q],QQ['P]I_4]D+Y2'O?+P%'ORU:R:6YZ*$M#Y%Z'4
MQ2&U+<784=C%LDW\\0?/-'Z[+^//J.'EE3?NH]KZR-YK+T%NW!)0*!4UU^W[
MZ;WMGIF:/>/F\97?[)]K-W;D-TV[O,SKV#"N4 %K0^D-+LWTRG8AM(86E9NI
ME=!F0MTQ-SL4I TP]VLA],ZP"?JMG/P"4$L#!!0    ( />)IUH3K8?K1 (
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MH KBCW0<KW)Z <_I+-M_H0FJ/US[\!]02P,$%     @ ]XFG6M(TLGQ5 P
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M@=#@HM]UB6KFOG&,K.I9FTN#DUN;!3Z5H&P"QA=2FIUC"[2/;_H74$L#!!0
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M-JWMPMK,4I0VP9Q7PA2P7UB!;CKG?P%02P,$%     @ ]XFG6D$L*MLE!0
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M8,(*6*"K-TSQ[%1MZ]T.C*QMNSN7!IMG>[O"KQ509(#O%U*:AP$%Z+]_IO\
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MG+=#KAV[79.\ZOMB;>)P?$*\R*=I$&ZKWY0'SLAS:11GCK'WE-SW4825U;*
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M@6ORYG\J CO%H,&$F8#5/4O0,ZKY1]F\U')A_PN.95W+N7V<<59P90BP/I&
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M4EF:.MY,:<RC=@&TOU+*[AQ'4/UQ]/\!4$L#!!0    ( />)IUI@[T]A7P(
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MQ>QP31T]2F- ^TLA]&%B#BC^1^C_ %!+ P04    " #WB:=:DN<0?+D"  #
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MCF$GNRB*/C#2V"(BD2Y)V<UB/[XD)<MRJ@A-H+[8(L4Y,^=PAN(,=HP_B 1
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MVGN!#3RJX:8=;-)!&+OGB;W9MK ?%3G!P.^BWFD+.FW!06U/NOA/"3LM!<]
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M=3[FC!$A406BINB$J/7W5ZQY/6VK_XC@Q; U^V%K/]S^ '2%E8J4&2UG+YU
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MP?U%26%24(A>H="!&YF9M8:K+,&DGN^3G$I3]*1I$K4"WC!U"IWP=XB"J-?
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MN::O%U0V@.XOI31/ [M ]3T4_P]02P,$%     @ ]XFG6O-X 5>G P  ;0P
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MW<C? \#4 OE]1:DX#!1 _0MC]B]02P,$%     @ ]XFG6N--T3,S P  CPD
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MC493YH!EMW]6$721WKAC*N3]G1;G\L4$3 V0_5-*Q;:B"(HW6/ 74$L#!!0
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M2+)\)46[&7W5RZ,]Y3[Y_@TAR9V$6/Q=Q6^Z?[MZ?W4ZW(@-]6!@X.LO@._
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M%WGFZ94^G4BVT;?B)9-XQ];# *@/7!G@\Q5C\C!1&^0?5H;_ E!+ P04
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MX<(9JJ8OS#M0.4&\7Q#"=QVY0/9WP/D+4$L#!!0    ( />)IUH-@GPTK 4
M /\D   9    >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;+6:76_;-A2&_PKA
M%44+!)5$?\1)'0..E78>8C>+T^RBV 5CT[902=1(*DZ _?B1DBR9B<Q$W<E-
M(LGBP\/7/N1Y)0ZVC/\4&THE>HC"6)RU-E(FIXXC%AL:$?&))316GZP8CXA4
MIWSMB(13LLP:1:&#7;?G1"2(6\-!=NV*#P<LE6$0TRN.1!I%A#^>TY!MSUI>
M:W?A.EAOI+[@# <)6=,YE=^3*Z[.G)*R#"(:BX#%B-/566ODG?JXKQMD=]P&
M="OVCI$>RAUC/_7)9'G6<G5$-*0+J1%$_;NG8QJ&FJ3B^*> MLH^=</]XQW]
M2S9X-9@[(NB8A7\%2[DY:_5;:$E7) WE-=O^3HL!=35OP4*1_47;_-Y>IX46
MJ9 L*AJK"*(@SO^3AT*(O088'VB BP;X28-V_T"#=M&@_=H>.D6#3J9,/I1,
M!Y](,AQPMD5<WZUH^B 3,VNMAA_$^GN?2ZX^#50[.1Q_FTXG-].+V<T<C68^
M&G^;W4QF7R]FX\G%''WPJ21!*#ZB=RB(T<V&I8+$2S%PI.I;$YQ%T<\X[P<?
MZ*>-IBR6&X$NXB5=FNT=%7,9.-X%?HZMP%'"/R'7.T+8]4[0][F//KS[6!>7
M'3,E"M/.,+B[PZ O9!&$@7Q$-Y1'Z+(&Z[\>VZF/SAAUN_RZVAFW?8![R81
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M<<"!=@YX7BME]X8+T(_,XB=02P,$%     @ ]XFG6JT.QDZ7"P  ?%L  !D
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MJ_[/)4MGK.X"^.?SJFH?7W07V!VX??Y?4$L#!!0    ( />)IUH/?[!Q\P4
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M%P!I G _$T+O)^: ]K\2_P502P,$%     @ ]XFG6DM#JFW] @  T0<  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C(N>&ULK55=;]HP%/TK5E9-G;0U$ CM
M&$3B4T7B2U#6AVD/)C'$JF.GM@/MO]^U QE0RO;0%V([]YZ<<X^YM[$5\DG%
MA&CTDC"NFDZL=5IW717&),'J1J2$PYN5D G6L)5K5Z62X,@F)<SU2J6:FV#*
MG:!ASZ8R:(A,,\K)5"*5)0F6KVW"Q+;IE)W]P8RN8VT.W*"1XC69$[U(IQ)V
M;H$2T81P105'DJR:3JM<[]1,O WX2<E6':R14;(4XLEL!E'3*1E"A)%0&P0,
MCPWI$,8,$-!XWF$ZQ2=-XN%ZC]ZWVD'+$BO2$>R11CIN.G<.BL@*9TS/Q/:>
M[/3X!B\43-E?M-W%EAP49DJ+9)<,#!+*\R=^V=7A( %PSB=XNP3O-*'Z3D)E
MEU"Q0G-F5E87:QPTI-@B::(!S2QL;6PVJ*'<N#C7$MY2R-/!?#&=#GNCWOBA
M-43=P;PSG,P7LQZ:]%&G-;]'_>'D$0W&_<ELU'H83,;H&YIG:<H(.*DQ0QVL
M8M2'NX &/+]3QISK+M&8,O4%PA?S+KJ^^H*N$.7H(1:9PCQ2#5<#>\/!#7=,
MVSE3[QVF%3027,<*]7A$HN-\%U07TKV]]+9W$7"$Y0VJE+\BK^3Y9_AT_C^]
M>H%.I7"B8O$J[SGQ[[+^:BV5EG#S?Y\K7PY?/0]OND%=I3@D30?^[HK(#7&"
MSY_*M=*/<]H_".RH$M6B$M5+Z($5GV(:(9 .MT83^(8^)SG'J5D<TZ\V@7?K
MEQKNYE#*VR#_KEK$'#'T"X;^1:_&@H?6(<HQ#RE?([C38-4&>)I=RS0GJBE1
M]7.T_8]TZH/ CNI0*^I0N^A4[SFCJ;FRT(YA*4ED.KMIT;"BIDF'(N-:@9NO
M>,F(+1,<R@S>,XJ7E-DJG2M2[8UMW^_\$VO?QI0K?OG$6_>@.R9$KNW04,@R
MR[M%<9K/I3;,)=N_3\YA7K5LFW;_PN3##GK!FG*%&%D!9.GF%DR1^0#)-UJD
MM@<OA8:.;I<QS%PB30"\7PFA]QOS@6**!W\ 4$L#!!0    ( />)IUI(L1.G
M= ,  %$1   9    >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;+686V_3,!2
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M=IJ] 5!+ 0(4 Q0    ( />)IUI&QTU(E0   ,T    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ]XFG6K9Y:N[R
M*P(  !$              ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ ]XFG6IE<G",0!@  G"<  !,              ( !Y $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " #WB:=:=-.57",&  ##(@  &
M            @($E"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ ]XFG6FUM1.^8!@  >!L  !@              ("!?@X  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( />)IUJ[8'<."P,  &H*
M   8              " @4P5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " #WB:=:_5SJ+I %  !G%0  &               @(&-&
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ]XFG6C79* /I
M!0  &R$  !@              ("!4QX  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( />)IUI=FE>O5 8  .(9   8              "
M@7(D  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #WB:=:
MPW[Z:IX&  #;#P  &               @('\*@  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ ]XFG6IM9P=1U$0  )3$  !@
M     ("!T#$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M />)IUH;GUQ+RP,  $$(   8              " @7M#  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " #WB:=:5L(CK'$#  !4!P  &0
M            @(%\1P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( />)IUK(T9<.#P,   H'   9              " @21+  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ ]XFG6H#$(7>3"0
M[!H  !D              ("!:DX  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " #WB:=:1RLM4+0(   X&0  &0              @($T
M6   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( />)IUK_
MA^+;2 0  ),)   9              " @1]A  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ ]XFG6C"XON=O"   &Q8  !D
M     ("!GF4  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( />)IUI8QHRQ(P4  , +   9              "
M@?J#  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ ]XFG
M6D7FS^Q, @  H04  !D              ("!5(D  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " #WB:=:$ZV'ZT0"  "*!@  &0
M        @('7BP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( />)IUI5WBD7.!(  ,0V   9              " @5*.  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ ]XFG6M(TLGQ5 P  HP<
M !D              ("!P:   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " #WB:=:^,Q)S*$"  "(!0  &0              @(%-I
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( />)IUK?Z+!*
M/P,  -(&   9              " @26G  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ ]XFG6@)I7+TB P  X@8  !D
M ("!FZH  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #W
MB:=:SS)@"94"  "I!0  &0              @('TK0  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( />)IUI!+"K;)04   L-   9
M          " @<"P  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#
M%     @ ]XFG6BNOA=DU!P  -!8  !D              ("!'+8  'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #WB:=:7KM)<AD#  !R
M!@  &0              @(&(O0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM
M;%!+ 0(4 Q0    ( />)IUI(&_4PP (  .T%   9              " @=C
M  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ ]XFG6MY2
M-J7A @  1 8  !D              ("!S\,  'AL+W=O<FMS:&5E=',O<VAE
M970S,RYX;6Q02P$"% ,4    " #WB:=:8.]/85\"  !B!0  &0
M    @('GQ@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M />)IUJ#;4E7A0,  "\,   9              " @7W)  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ ]XFG6I+G$'RY @  P <  !D
M             ("!.<T  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " #WB:=:*BTR,J,#  #(#@  &0              @($IT   >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( />)IUII0;B!M 0
M "44   9              " @0/4  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ ]XFG6KJE(MN: @  X08  !D              ("!
M[M@  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #WB:=:
M>J@%+5<"  "F!0  &0              @(&_VP  >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( />)IUK*'Z_-FP0  +09   9
M      " @4W>  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ ]XFG6NKX <%J P  D0H  !D              ("!'^,  'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #WB:=:0TN]<8(*  !N?0
M&0              @(' Y@  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( />)IUJ#_TYBHP,  -H5   9              " @7GQ  !X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ ]XFG6E#JPDM\
M @  E@8  !D              ("!4_4  'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " #WB:=:!E*09J<"  !\!P  &0
M@($&^   >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( />)
MIUHG5/U-5@0  *P<   9              " @>3Z  !X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ ]XFG6D/,0Q]S P  30T  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( />)IUK?^JC($P,  !H,   9
M  " @0,2 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
M]XFG6@V"?#2L!0  _R0  !D              ("!314! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " #WB:=:\A"+HD\"   ^!0  &0
M            @($P&P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( />)IUJM#L9.EPL  'Q;   9              " @;8= 0!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ ]XFG6@]_L''S!0
M<BT  !D              ("!A"D! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    " #WB:=:YU843P@#  #M"0  &0              @(&N
M+P$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( />)IUI]
MZY6Z90,  *L,   9              " @>TR 0!X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ ]XFG6@FH.BP] @  ?@4  !D
M     ("!B38! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
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M   H%   #0              @ &D0@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( />)IUJ7BKL<P    !,"   +              "  1%& 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( />)IUK^"\*/3@4  'XI   /              "
M ?I& 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #WB:=:)V75I0P"  "$
M)0  &@              @ %U3 $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #WB:=:[M7M&.8!  #U)   $P              @ &Y
L3@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     1P!' &@3  #04 $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>154</ContextCount>
  <ElementCount>267</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995301 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995302 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995303 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995304 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ConsolidatedCashFlow</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995306 - Disclosure - ORGANIZATION AND BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ORGANIZATIONANDBUSINESS</Role>
      <ShortName>ORGANIZATION AND BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995307 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995308 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995309 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995310 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995311 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995312 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995313 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995314 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995315 - Disclosure - SEGMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SEGMENTS</Role>
      <ShortName>SEGMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995316 - Disclosure - LEASE OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LEASEOBLIGATIONS</Role>
      <ShortName>LEASE OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995317 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995318 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATION</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995319 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996001 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996002 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/INVENTORIES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996003 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996004 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996005 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/DEBT</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996006 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996007 - Disclosure - SEGMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SEGMENTSTables</Role>
      <ShortName>SEGMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SEGMENTS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996008 - Disclosure - LEASE OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LEASEOBLIGATIONSTables</Role>
      <ShortName>LEASE OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/LEASEOBLIGATIONS</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996009 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/INCOMETAXES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996010 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATIONTables</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATION</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996011 - Disclosure - ORGANIZATION AND BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ORGANIZATIONANDBUSINESSDetails</Role>
      <ShortName>ORGANIZATION AND BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/ORGANIZATIONANDBUSINESS</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996016 - Disclosure - INVENTORIES - Components of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ComponentsofInventoryTable</Role>
      <ShortName>INVENTORIES - Components of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996017 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PROPERTYANDEQUIPMENTDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/PROPERTYANDEQUIPMENTTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996018 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyandEquipmentTable</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996019 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996020 - Disclosure - DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DEBTDetails</Role>
      <ShortName>DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/DEBTTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996021 - Disclosure - DEBT - Summary of Outstanding Senior Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable</Role>
      <ShortName>DEBT - Summary of Outstanding Senior Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996022 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsPreferredStock</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996023 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsCommonStock</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996024 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996025 - Disclosure - STOCKHOLDERS' EQUITY - Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996026 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ScheduleofAssumptionsTable</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Schedule of Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996027 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ScheduleofOptionActivityTable</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Schedule of Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996028 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Unvested RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Schedule of Unvested RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996029 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996030 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996032 - Disclosure - SEGMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SEGMENTSDetails</Role>
      <ShortName>SEGMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SEGMENTSTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996033 - Disclosure - SEGMENTS - Summarized Financial Information by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable</Role>
      <ShortName>SEGMENTS - Summarized Financial Information by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996034 - Disclosure - SEGMENTS - Net Revenues According to Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable</Role>
      <ShortName>SEGMENTS - Net Revenues According to Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996035 - Disclosure - LEASE OBLIGATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LEASEOBLIGATIONSDetails</Role>
      <ShortName>LEASE OBLIGATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/LEASEOBLIGATIONSTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996036 - Disclosure - LEASE OBLIGATIONS - Payments Under Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable</Role>
      <ShortName>LEASE OBLIGATIONS - Payments Under Lease Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996037 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/INCOMETAXESTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996038 - Disclosure - INCOME TAXES - Estimated Annual Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/EstimatedAnnualEffectiveTaxRateTable</Role>
      <ShortName>INCOME TAXES - Estimated Annual Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996039 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalCashFlowInformationTable</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ef20047548_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996040 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>adma-20250331.xsd</File>
    <File>adma-20250331_cal.xml</File>
    <File>adma-20250331_def.xml</File>
    <File>adma-20250331_lab.xml</File>
    <File>adma-20250331_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ef20047548_10q.htm">ef20047548_10q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="560">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20047548_10q.htm": {
   "nsprefix": "adma",
   "nsuri": "http://admabiologics.com/20250331",
   "dts": {
    "schema": {
     "local": [
      "adma-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "adma-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "adma-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "adma-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adma-20250331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ef20047548_10q.htm"
     ]
    }
   },
   "keyStandard": 226,
   "keyCustom": 41,
   "axisStandard": 22,
   "axisCustom": 0,
   "memberStandard": 32,
   "memberCustom": 18,
   "hidden": {
    "total": 12,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://admabiologics.com/20250331": 5,
    "http://fasb.org/us-gaap/2024": 3
   },
   "contextCount": 154,
   "entityCount": 1,
   "segmentCount": 51,
   "elementCount": 658,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 560,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://admabiologics.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://admabiologics.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://admabiologics.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GrossProfit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://admabiologics.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c14",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c14",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://admabiologics.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GainLossOnDispositionOfAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://admabiologics.com/role/ORGANIZATIONANDBUSINESS",
     "longName": "995306 - Disclosure - ORGANIZATION AND BUSINESS",
     "shortName": "ORGANIZATION AND BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "995307 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://admabiologics.com/role/INVENTORIES",
     "longName": "995308 - Disclosure - INVENTORIES",
     "shortName": "INVENTORIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://admabiologics.com/role/PROPERTYANDEQUIPMENT",
     "longName": "995309 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES",
     "longName": "995310 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://admabiologics.com/role/DEBT",
     "longName": "995311 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://admabiologics.com/role/STOCKHOLDERSEQUITY",
     "longName": "995312 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://admabiologics.com/role/RELATEDPARTYTRANSACTIONS",
     "longName": "995313 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "995314 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://admabiologics.com/role/SEGMENTS",
     "longName": "995315 - Disclosure - SEGMENTS",
     "shortName": "SEGMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://admabiologics.com/role/LEASEOBLIGATIONS",
     "longName": "995316 - Disclosure - LEASE OBLIGATIONS",
     "shortName": "LEASE OBLIGATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://admabiologics.com/role/INCOMETAXES",
     "longName": "995317 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATION",
     "longName": "995318 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://admabiologics.com/role/SUBSEQUENTEVENTS",
     "longName": "995319 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://admabiologics.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "996001 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://admabiologics.com/role/INVENTORIESTables",
     "longName": "996002 - Disclosure - INVENTORIES (Tables)",
     "shortName": "INVENTORIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://admabiologics.com/role/PROPERTYANDEQUIPMENTTables",
     "longName": "996003 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables",
     "longName": "996004 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://admabiologics.com/role/DEBTTables",
     "longName": "996005 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://admabiologics.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "996006 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://admabiologics.com/role/SEGMENTSTables",
     "longName": "996007 - Disclosure - SEGMENTS (Tables)",
     "shortName": "SEGMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://admabiologics.com/role/LEASEOBLIGATIONSTables",
     "longName": "996008 - Disclosure - LEASE OBLIGATIONS (Tables)",
     "shortName": "LEASE OBLIGATIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://admabiologics.com/role/INCOMETAXESTables",
     "longName": "996009 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATIONTables",
     "longName": "996010 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://admabiologics.com/role/ORGANIZATIONANDBUSINESSDetails",
     "longName": "996011 - Disclosure - ORGANIZATION AND BUSINESS (Details)",
     "shortName": "ORGANIZATION AND BUSINESS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment",
      "unitRef": "Facility",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment",
      "unitRef": "Facility",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable",
     "longName": "996012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill",
     "longName": "996013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition",
     "longName": "996014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "adma:DeferredRevenueRemainingAmortizationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "adma:DeferredRevenueRemainingAmortizationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable",
     "longName": "996015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of Basic and Diluted Earnings Per Share (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of Basic and Diluted Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c29",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://admabiologics.com/role/ComponentsofInventoryTable",
     "longName": "996016 - Disclosure - INVENTORIES - Components of Inventory (Details)",
     "shortName": "INVENTORIES - Components of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://admabiologics.com/role/PROPERTYANDEQUIPMENTDetails",
     "longName": "996017 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://admabiologics.com/role/PropertyandEquipmentTable",
     "longName": "996018 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)",
     "shortName": "PROPERTY AND EQUIPMENT - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable",
     "longName": "996019 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "adma:AccruedRebatesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "adma:AccruedRebatesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://admabiologics.com/role/DEBTDetails",
     "longName": "996020 - Disclosure - DEBT (Details)",
     "shortName": "DEBT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c46",
      "name": "adma:SeniorNotesPayableBeforeDebtDiscount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c70",
      "name": "adma:MinimumLiquidityCovenantsCreditFacilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable",
     "longName": "996021 - Disclosure - DEBT - Summary of Outstanding Senior Notes Payable (Details)",
     "shortName": "DEBT - Summary of Outstanding Senior Notes Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c46",
      "name": "adma:SeniorNotesPayableBeforeDebtDiscount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsPreferredStock",
     "longName": "996022 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsCommonStock",
     "longName": "996023 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants",
     "longName": "996024 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans",
     "longName": "996025 - Disclosure - STOCKHOLDERS' EQUITY - Equity Incentive Plans (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Equity Incentive Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c79",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c79",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://admabiologics.com/role/ScheduleofAssumptionsTable",
     "longName": "996026 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Assumptions (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Schedule of Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c87",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c87",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://admabiologics.com/role/ScheduleofOptionActivityTable",
     "longName": "996027 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Option Activity (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Schedule of Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c89",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c89",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable",
     "longName": "996028 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Unvested RSU Activity (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Schedule of Unvested RSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c91",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c91",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable",
     "longName": "996029 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c94",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "longName": "996030 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c103",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c103",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "996031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "adma:PlasmaSupplyAgreementTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "adma:PlasmaSupplyAgreementTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://admabiologics.com/role/SEGMENTSDetails",
     "longName": "996032 - Disclosure - SEGMENTS (Details)",
     "shortName": "SEGMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "adma:NumberOfFDALicensedPlasmaCollectionFacilities",
      "unitRef": "Facility",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "adma:NumberOfFDALicensedPlasmaCollectionFacilities",
      "unitRef": "Facility",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable",
     "longName": "996033 - Disclosure - SEGMENTS - Summarized Financial Information by Segment (Details)",
     "shortName": "SEGMENTS - Summarized Financial Information by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c24",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable",
     "longName": "996034 - Disclosure - SEGMENTS - Net Revenues According to Geographic Area (Details)",
     "shortName": "SEGMENTS - Net Revenues According to Geographic Area (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c137",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://admabiologics.com/role/LEASEOBLIGATIONSDetails",
     "longName": "996035 - Disclosure - LEASE OBLIGATIONS (Details)",
     "shortName": "LEASE OBLIGATIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable",
     "longName": "996036 - Disclosure - LEASE OBLIGATIONS - Payments Under Lease Obligations (Details)",
     "shortName": "LEASE OBLIGATIONS - Payments Under Lease Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://admabiologics.com/role/INCOMETAXESDetails",
     "longName": "996037 - Disclosure - INCOME TAXES (Details)",
     "shortName": "INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R61": {
     "role": "http://admabiologics.com/role/EstimatedAnnualEffectiveTaxRateTable",
     "longName": "996038 - Disclosure - INCOME TAXES - Estimated Annual Effective Tax Rate (Details)",
     "shortName": "INCOME TAXES - Estimated Annual Effective Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://admabiologics.com/role/SupplementalCashFlowInformationTable",
     "longName": "996039 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION - Supplemental Cash Flow Information (Details)",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION - Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails",
     "longName": "996040 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c67",
      "name": "us-gaap:ProceedsFromLinesOfCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c153",
      "name": "srt:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20047548_10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "adma_ADMABioManufacturingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ADMABioManufacturingSegmentMember",
     "presentation": [
      "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADMA BioManufacturing [Member]",
        "documentation": "Component of ADMA BioManufacturing that usually provides financial, operational and administrative support and is considered an operating segment.",
        "label": "ADMABio Manufacturing Segment Member"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ASCENIVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ASCENIVMember",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASCENIV [Member]",
        "documentation": "ASCENIV an Intravenous Immune Globulin (\"IVIG\") product indicated for the treatment of Primary Humoral Immunodeficiency (\"PI\"), also known as Primary Immunodeficiency Disease (\"PIDD\").",
        "label": "ASCENIVMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r48",
      "r53",
      "r960"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r722"
     ]
    },
    "adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, allowances for contractual credits and credit losses",
        "documentation": "Amount of allowance for contractual credits and doubtful accounts.",
        "label": "Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable [Member]",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued incentives",
        "label": "Accrued Bonuses, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable",
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses and other current liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued distribution fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "adma_AccruedRebatesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "AccruedRebatesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued rebates",
        "documentation": "Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product.",
        "label": "Accrued Rebates Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and other compensation",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r680"
     ]
    },
    "adma_AccruedTestingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "AccruedTestingCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued testing",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for testing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Testing Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/PropertyandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/PropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r169",
      "r534"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r722",
      "r1016"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r892",
      "r893",
      "r894",
      "r895",
      "r962",
      "r1017"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to net cash provided used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r782",
      "r798",
      "r833"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r785",
      "r801",
      "r836"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "adma_AgreementWithTermExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "AgreementWithTermExpirationDate",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement term expiring date",
        "documentation": "Date the agreement with term expired, in YYYY-MM-DD format.",
        "label": "Agreement With Term Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r786",
      "r802",
      "r828",
      "r837",
      "r841",
      "r849"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r73",
      "r345",
      "r968"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r287",
      "r288",
      "r700"
     ]
    },
    "adma_AmortizationOfLicenseRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "AmortizationOfLicenseRevenue",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of license revenue",
        "documentation": "Amount of noncash revenue related to amortization of license revenue.",
        "label": "Amortization Of License Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities (in Shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "adma_AresCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "AresCreditAgreementMember",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ares Credit Agreement [Member]",
        "documentation": "Ares credit agreement is a legally-binding contract documenting the terms of a loan agreement; it is made between a person or party borrowing money and a lender.",
        "label": "Ares Credit Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "adma_AresCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "AresCreditFacilityMember",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ares Credit Facility [Member]",
        "documentation": "Arrangement in which facility proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Ares Credit Facility Member"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ArethLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ArethLLCMember",
     "presentation": [
      "http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Areth, LLC [Member]",
        "documentation": "Name of the entity associated with related party.",
        "label": "Areth LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_AssetUnderConstructionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetUnderConstructionMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in Process [Member]",
        "label": "Asset under Construction [Member]",
        "documentation": "Asset in process of being built."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "terseLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r108",
      "r171",
      "r193",
      "r225",
      "r232",
      "r250",
      "r254",
      "r267",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r434",
      "r436",
      "r452",
      "r526",
      "r611",
      "r693",
      "r694",
      "r722",
      "r750",
      "r926",
      "r927",
      "r974"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r178",
      "r193",
      "r267",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r434",
      "r436",
      "r452",
      "r722",
      "r926",
      "r927",
      "r974"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r766",
      "r778"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r766",
      "r778"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r766",
      "r778"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans",
      "http://admabiologics.com/role/ScheduleofAssumptionsTable",
      "http://admabiologics.com/role/ScheduleofOptionActivityTable",
      "http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of consolidation and basis of presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingAndBuildingImprovementsMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings and Building Improvements [Member]",
        "label": "Building and Building Improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r778"
     ]
    },
    "adma_COMMITMENTSANDCONTINGENCIESDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "COMMITMENTSANDCONTINGENCIESDetailsTable",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_CalculationOfBasicAndDilutedEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "CalculationOfBasicAndDilutedEarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Calculation Of Basic And Diluted Earnings Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r167",
      "r678"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents - beginning of period",
        "periodEndLabel": "Cash and cash equivalents - end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r78",
      "r189"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r78"
     ]
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingEstimateLineItems",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable",
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill",
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Estimate [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsCommonStock",
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans",
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsPreferredStock",
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r227",
      "r351",
      "r352",
      "r353",
      "r355",
      "r358",
      "r363",
      "r365",
      "r574",
      "r575",
      "r576",
      "r577",
      "r707",
      "r872",
      "r888"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price per share (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant to purchase shares of common stock (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsCommonStock",
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r100",
      "r528",
      "r598"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r302",
      "r303",
      "r662",
      "r914",
      "r919"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants",
      "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails",
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r741",
      "r742",
      "r744",
      "r745",
      "r746",
      "r747",
      "r892",
      "r893",
      "r895",
      "r962",
      "r1014",
      "r1017"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r599"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r57",
      "r599",
      "r617",
      "r1017",
      "r1018"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 238,532,252 and 236,620,545 shares issued and outstanding at March 31, 2025 and December 31, 2024",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r530",
      "r722"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable",
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r39",
      "r40",
      "r261",
      "r661"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable",
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r39",
      "r40",
      "r261",
      "r570",
      "r661"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable",
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r39",
      "r40",
      "r261",
      "r661",
      "r874"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable",
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of consolidated revenues",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r39",
      "r40",
      "r261"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable",
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r39",
      "r40",
      "r261",
      "r661"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r120",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r199",
      "r225",
      "r234",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r693",
      "r694",
      "r876",
      "r877",
      "r926",
      "r927"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r120",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r199",
      "r225",
      "r234",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r693",
      "r694",
      "r876",
      "r877",
      "r926",
      "r927"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r372"
     ]
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate [Member]",
        "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r249",
      "r250",
      "r251",
      "r252",
      "r255",
      "r900"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of product revenue",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r193",
      "r267",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r452",
      "r693",
      "r926"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Product Revenue [Member]",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Product Revenue",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails",
      "http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r197",
      "r198",
      "r327",
      "r353",
      "r479",
      "r486",
      "r525",
      "r681",
      "r683"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails",
      "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails",
      "http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r924"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails",
      "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails",
      "http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r924",
      "r925"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable",
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk [Member]",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r261"
     ]
    },
    "adma_DEBTDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "DEBTDetailsTable",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "DEBTSummaryofOutstandingSeniorNotesPayableDetailsTable",
     "presentation": [
      "http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT - Summary of Outstanding Senior Notes Payable (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/DEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r191",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r310",
      "r311",
      "r323",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r339",
      "r346",
      "r347",
      "r349",
      "r460"
     ]
    },
    "adma_DebtInstrumentApplicableMargin": {
     "xbrltype": "percentItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "DebtInstrumentApplicableMargin",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Applicable margin",
        "documentation": "Percentage points added to the reference rate to compute the margin rate on the debt instrument.",
        "label": "Debt Instrument Applicable Margin"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r47",
      "r48",
      "r98",
      "r99",
      "r199",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r720",
      "r889",
      "r915",
      "r916",
      "r917",
      "r967",
      "r969"
     ]
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Frequency of periodic payment",
        "label": "Debt Instrument, Frequency of Periodic Payment",
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r43"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase applicable margin",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r325"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails",
      "http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r348",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r720",
      "r889",
      "r967",
      "r969"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r702",
      "r963",
      "r964"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r199",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r720",
      "r889",
      "r915",
      "r916",
      "r917",
      "r967",
      "r969"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payments",
        "label": "Debt Instrument, Periodic Payment, Interest",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scheduled principal payments",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information by period of debt redemption feature under terms of debt agreement."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of prepaid principal amount",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "documentation": "Percentage of principal amount of debt redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "adma_DebtInstrumentTermOfVariableRate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "DebtInstrumentTermOfVariableRate",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of variable rate",
        "documentation": "Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument Term Of Variable Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r966",
      "r967",
      "r969"
     ]
    },
    "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",
        "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",
        "documentation": "Indicates type of variable interest rate on debt instrument."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, net",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax provision",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r118",
      "r891"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, net of current portion",
        "label": "Deferred Revenue, Noncurrent",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "adma_DeferredRevenueRemainingAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "DeferredRevenueRemainingAmortizationPeriod",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization period",
        "documentation": "Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Deferred Revenue Remaining Amortization Period"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r805"
     ]
    },
    "adma_DepositsAndOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "DepositsAndOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits and other assets",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other.",
        "label": "Deposits And Other Noncurrent Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r27"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r225",
      "r237",
      "r254",
      "r693",
      "r694"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors [Member]",
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r904",
      "r1015"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r805"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r766",
      "r778"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r766",
      "r778",
      "r829"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r766",
      "r778",
      "r829"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable",
      "http://admabiologics.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BASIC EARNINGS PER COMMON SHARE (in Dollars per share)",
        "verboseLabel": "Basic earnings per common shares (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r214",
      "r216",
      "r219",
      "r220",
      "r221",
      "r224",
      "r429",
      "r432",
      "r446",
      "r447",
      "r521",
      "r539",
      "r686"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable",
      "http://admabiologics.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DILUTED EARNINGS PER COMMON SHARE (in Dollars per share)",
        "verboseLabel": "Diluted earnings per common share (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r216",
      "r219",
      "r220",
      "r221",
      "r224",
      "r429",
      "r432",
      "r446",
      "r447",
      "r521",
      "r539",
      "r686"
     ]
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedLineItems",
     "presentation": [
      "http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r219"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings/loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r223"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://admabiologics.com/role/EstimatedAnnualEffectiveTaxRateTable",
      "http://admabiologics.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r411",
      "r420",
      "r713"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense recognition period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense, non option (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense, stock options (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable",
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans",
      "http://admabiologics.com/role/ScheduleofAssumptionsTable",
      "http://admabiologics.com/role/ScheduleofOptionActivityTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock Options [Member]",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "adma_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "EmployeesMember",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees [Member]",
        "documentation": "A group of person working with the entity.",
        "label": "Employees Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SupplementalCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment acquired reflected in accounts payable and accrued liabilities",
        "documentation": "Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities.",
        "label": "Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants",
      "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails",
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r160",
      "r181",
      "r182",
      "r183",
      "r200",
      "r201",
      "r202",
      "r204",
      "r209",
      "r211",
      "r213",
      "r226",
      "r268",
      "r269",
      "r290",
      "r367",
      "r418",
      "r419",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r432",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r445",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r464",
      "r472",
      "r538",
      "r564",
      "r565",
      "r566",
      "r584",
      "r641"
     ]
    },
    "adma_EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "EquityIncentivePlanMember",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Incentive Plans [Member]",
        "documentation": "Equity compensation is often a significant portion of the total compensation paid to employees and other service providers.",
        "label": "Equity Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r782",
      "r798",
      "r833"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r768",
      "r779",
      "r795",
      "r830"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://admabiologics.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r786",
      "r802",
      "r837"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r786",
      "r802",
      "r837"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r786",
      "r802",
      "r837"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r786",
      "r802",
      "r837"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r786",
      "r802",
      "r837"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r789"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r912",
      "r913"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expense",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r621"
     ]
    },
    "adma_GenesisBPSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "GenesisBPSMember",
     "presentation": [
      "http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genesis [Member]",
        "documentation": "Name of the entity associated with related party.",
        "label": "Genesis BPSMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet",
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r274",
      "r520",
      "r694",
      "r699",
      "r714",
      "r722",
      "r908",
      "r909"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://admabiologics.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r285",
      "r699"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges related to goodwill",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r275",
      "r281",
      "r285",
      "r699",
      "r714"
     ]
    },
    "adma_GrifolsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "GrifolsAgreementMember",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "A&amp;R Grifols Agreement [Member]",
        "documentation": "Restated Plasma Purchase Agreement with Grifols used in the manufacture of ASCENIV.",
        "label": "Grifols Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r68",
      "r107",
      "r193",
      "r267",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r452",
      "r688",
      "r693",
      "r897",
      "r899",
      "r901",
      "r902",
      "r903",
      "r926"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r766",
      "r778"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "INCOME BEFORE INCOME TAXES",
        "terseLabel": "Income (loss) before taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r102",
      "r107",
      "r522",
      "r536",
      "r688",
      "r693",
      "r897",
      "r899",
      "r901",
      "r902",
      "r903"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r298",
      "r299",
      "r449",
      "r450",
      "r451",
      "r561",
      "r563",
      "r626",
      "r674",
      "r715",
      "r985"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299",
      "r449",
      "r450",
      "r451",
      "r561",
      "r563",
      "r626",
      "r674",
      "r715",
      "r985"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r407",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r421",
      "r423",
      "r424",
      "r425",
      "r579",
      "r713"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement",
      "http://admabiologics.com/role/EstimatedAnnualEffectiveTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r119",
      "r212",
      "r213",
      "r225",
      "r240",
      "r254",
      "r410",
      "r411",
      "r422",
      "r541",
      "r713"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "adma_IncreaseDecreaseInDepositsAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "IncreaseDecreaseInDepositsAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deposits and other assets",
        "documentation": "Amount of increase (decrease) in deposits and operating assets classified as other.",
        "label": "Increase Decrease In Deposits And Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current and non-current liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "adma_IncreaseInMinimumAnnualPriceTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "IncreaseInMinimumAnnualPriceTerm",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in minimum annual price, term",
        "documentation": "Increase in annual price term period on usage of RSV Plasma, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Increase In Minimum Annual Price Term"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r786",
      "r802",
      "r828",
      "r837",
      "r841",
      "r849"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r767",
      "r853"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r767",
      "r853"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r767",
      "r853"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r910",
      "r911"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "terseLabel": "Unallocated interest expense, primarily related to interest on senior debt (see Note 6)",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r886"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/SupplementalCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r187",
      "r188"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/INVENTORIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORIES",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ComponentsofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ComponentsofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://admabiologics.com/role/ComponentsofInventoryTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ComponentsofInventoryTable",
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total inventories",
        "terseLabel": "Inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r679",
      "r722"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r166",
      "r176",
      "r270",
      "r271",
      "r272",
      "r488",
      "r684"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ComponentsofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ComponentsofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ComponentsofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ComponentsofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r791",
      "r792",
      "r793",
      "r794"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "verboseLabel": "Unallocated interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r235",
      "r254",
      "r693",
      "r885"
     ]
    },
    "adma_KEDPlasmaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "KEDPlasmaAgreementMember",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "A&amp;R Grifols Agreement [Member]",
        "documentation": "Plasma Purchase Agreement with KEDPlasma LLC for usage of RSV Plasma.",
        "label": "KEDPlasma Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LandMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land [Member]",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r471"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASE OBLIGATIONS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/LEASEOBLIGATIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments Under Lease Obligations",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ended December 31, 2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remainder of 2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://admabiologics.com/role/LEASEOBLIGATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASE OBLIGATIONS",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r47",
      "r48",
      "r49",
      "r52",
      "r53",
      "r54",
      "r55",
      "r193",
      "r267",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r435",
      "r436",
      "r437",
      "r452",
      "r597",
      "r687",
      "r750",
      "r926",
      "r974",
      "r975"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r101",
      "r532",
      "r722",
      "r890",
      "r907",
      "r965"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r165",
      "r193",
      "r267",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r435",
      "r436",
      "r437",
      "r452",
      "r722",
      "r926",
      "r974",
      "r975"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails",
      "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit outstanding balance amount",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r99",
      "r983"
     ]
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving facility percentage",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount revolving credit facility",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r51"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "adma_LongTermLiabilityEndOfTermFeePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "LongTermLiabilityEndOfTermFeePayable",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "End of term fee",
        "documentation": "Principal balance of the loans and any other obligations advanced or otherwise owed.",
        "label": "Long Term Liability End Of Term Fee Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r309",
      "r405",
      "r701",
      "r920",
      "r921"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable",
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r710",
      "r732",
      "r737",
      "r931",
      "r984",
      "r986",
      "r987",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_ManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ManufacturingFacilityMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing and Laboratory Equipment [Member]",
        "label": "Manufacturing Facility [Member]",
        "documentation": "Structure used in the manufacturing of goods."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MaterialReconcilingItemsMember",
     "presentation": [
      "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciling Item [Member]",
        "label": "Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]",
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r252",
      "r255",
      "r693",
      "r694"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://admabiologics.com/role/ScheduleofAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r123",
      "r125",
      "r126",
      "r128",
      "r158",
      "r159",
      "r305",
      "r306",
      "r307",
      "r308",
      "r375",
      "r405",
      "r448",
      "r487",
      "r560",
      "r562",
      "r569",
      "r589",
      "r590",
      "r649",
      "r651",
      "r653",
      "r654",
      "r656",
      "r672",
      "r673",
      "r698",
      "r707",
      "r711",
      "r716",
      "r717",
      "r718",
      "r719",
      "r733",
      "r928",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "adma_MinimumLiquidityCovenantsCreditFacilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "MinimumLiquidityCovenantsCreditFacilities",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum liquidity covenant",
        "documentation": "The carrying amount of minimum liquidity requirements required to be maintained by the borrower per the Company's credit facilities covenants under the loan agreement that are not restricted as to withdrawal or usage.",
        "label": "Minimum Liquidity Covenants Credit Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://admabiologics.com/role/DEBTDetails",
      "http://admabiologics.com/role/ScheduleofAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r123",
      "r125",
      "r126",
      "r128",
      "r158",
      "r159",
      "r305",
      "r306",
      "r307",
      "r308",
      "r375",
      "r405",
      "r448",
      "r487",
      "r560",
      "r562",
      "r569",
      "r589",
      "r590",
      "r649",
      "r651",
      "r653",
      "r654",
      "r656",
      "r672",
      "r673",
      "r698",
      "r707",
      "r711",
      "r716",
      "r717",
      "r718",
      "r733",
      "r928",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable",
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r710",
      "r732",
      "r737",
      "r931",
      "r984",
      "r986",
      "r987",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable",
      "http://admabiologics.com/role/ConsolidatedCashFlow",
      "http://admabiologics.com/role/ConsolidatedIncomeStatement",
      "http://admabiologics.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCOME",
        "verboseLabel": "Net income",
        "netLabel": "Net income available to common stockholders (numerator) (in Dollars)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r80",
      "r103",
      "r163",
      "r179",
      "r180",
      "r183",
      "r193",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r212",
      "r213",
      "r218",
      "r267",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r429",
      "r432",
      "r447",
      "r452",
      "r537",
      "r619",
      "r639",
      "r640",
      "r748",
      "r926"
     ]
    },
    "adma_NetRevenuesAccordingToGeographicAreaAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "NetRevenuesAccordingToGeographicAreaAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Revenues According To Geographic Area Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r791",
      "r792",
      "r793",
      "r794"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r786",
      "r802",
      "r828",
      "r837"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International [Member]",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://admabiologics.com/role/SupplementalCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash Financing and Investing Activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other expense, net",
        "terseLabel": "Other expense, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER INCOME (EXPENSE):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfBusinessDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "NumberOfBusinessDays",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of business days",
        "documentation": "Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Number Of Business Days"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of business days for prior written notice",
        "documentation": "Number of business days for prior written notice to pay outstanding principal loans, Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Number Of Business Days For Prior Written Notice To Prepay Outstanding Principal"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "NumberOfCustomers",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable",
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of customers (in Customer)",
        "documentation": "Number of major customers of the organization.",
        "label": "Number Of Customers"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfFDAApprovedProduct": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "NumberOfFDAApprovedProduct",
     "presentation": [
      "http://admabiologics.com/role/ORGANIZATIONANDBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of FDA approved product",
        "documentation": "Number of products approved by FDA.",
        "label": "Number Of FDAApproved Product"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfFDALicensedPlasmaCollectionFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "NumberOfFDALicensedPlasmaCollectionFacilities",
     "presentation": [
      "http://admabiologics.com/role/SEGMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of FDA-licensed plasma collection facilities",
        "documentation": "Number of plasma collection facilities having FDA license.",
        "label": "Number Of FDALicensed Plasma Collection Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://admabiologics.com/role/SEGMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r898"
     ]
    },
    "adma_NumberOfPlasmaCollectionFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "NumberOfPlasmaCollectionFacilities",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of plasma collection facilities (in Facility)",
        "documentation": "Number of wholly-owned plasma collection facilities of the entity.",
        "label": "Number Of Plasma Collection Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "NumberOfPlasmaCollectionFacilitiesUnderDevelopment",
     "presentation": [
      "http://admabiologics.com/role/ORGANIZATIONANDBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of FDA-licensed plasma collection facilities",
        "documentation": "Number of plasma collection facilities under various stages of development.",
        "label": "Number Of Plasma Collection Facilities Under Development"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfRenewalTerms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "NumberOfRenewalTerms",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of renewal terms (in Term)",
        "documentation": "Number of renewal terms to extend purchase agreement, if agreed to by the parties.",
        "label": "Number Of Renewal Terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Equipment and Computer Software [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "adma_OperatingAndFinancingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "OperatingAndFinancingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LEASEOBLIGATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating and financing lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance leases.",
        "label": "Operating And Financing Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Operating Costs and Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plasma Center Operating Expenses [Member]",
        "label": "Operating Expense [Member]",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING EXPENSES:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "INCOME FROM OPERATIONS",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r688",
      "r897",
      "r899",
      "r901",
      "r902",
      "r903"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/LEASEOBLIGATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments Under Lease Obligations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet",
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of lease obligations",
        "negatedLabel": "Current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet",
      "http://admabiologics.com/role/PaymentsUnderLeaseObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease obligations, net of current portion",
        "verboseLabel": "Balance at March 31, 2025",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LEASEOBLIGATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payments for lease",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-to-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://admabiologics.com/role/LEASEOBLIGATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r721"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments [Member]",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r255",
      "r693",
      "r694"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND BUSINESS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/ORGANIZATIONANDBUSINESS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND BUSINESS",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r96",
      "r571",
      "r572"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCostAndExpenseOperating",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plasma center operating expenses",
        "label": "Other Cost and Expense, Operating",
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r540",
      "r693"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r784",
      "r800",
      "r835"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r787",
      "r803",
      "r838"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r787",
      "r803",
      "r838"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958"
     ]
    },
    "adma_PlasmaCollectionCentersSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "PlasmaCollectionCentersSegmentMember",
     "presentation": [
      "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plasma Collection Centers [Member]",
        "documentation": "Component of Plasma Collection Centers segment that usually provides financial, operational and administrative support and is considered an operating segment.",
        "label": "Plasma Collection Centers Segment Member"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PlasmaPurchaseAgreementOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "PlasmaPurchaseAgreementOneMember",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2011 Plasma Purchase Agreement [Member]",
        "documentation": "Plasma purchase agreement to purchase plasma containing antibodies to RSV to be used in the manufacture of ASCENIV.",
        "label": "Plasma Purchase Agreement One Member"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PlasmaPurchaseAgreementRenewalPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "PlasmaPurchaseAgreementRenewalPeriod",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plasma purchase agreement renewal period",
        "documentation": "Plasma purchase agreement renewal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Plasma Purchase Agreement Renewal Period"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PlasmaSupplyAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "PlasmaSupplyAgreementTerm",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plasma supply agreement term",
        "documentation": "Plasma supply agreement term period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Plasma Supply Agreement Term"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsPreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of nonredeemable preferred shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsPreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r351"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r599"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r351"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsPreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "verboseLabel": "Preferred stock, outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r599",
      "r617",
      "r1017",
      "r1018"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r529",
      "r722"
     ]
    },
    "adma_PrepaidAfterTheFirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "PrepaidAfterTheFirstAnniversaryMember",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid after the First Anniversary [Member]",
        "documentation": "The first anniversary representing most prepaid of after period of debt redemption features under terms of the debt agreement.",
        "label": "Prepaid After The First Anniversary Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "adma_PrepaidOnOrPriorToFirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "PrepaidOnOrPriorToFirstAnniversaryMember",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid on or Prior to First Anniversary [Member]",
        "documentation": "The first anniversary representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Prepaid On Or Prior To First Anniversary Member"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PrepaidOnOrPriorToThirdAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "PrepaidOnOrPriorToThirdAnniversaryMember",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid on or Prior to Third Anniversary [Member]",
        "documentation": "The third anniversary representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Prepaid On Or Prior To Third Anniversary Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails",
      "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount drew from the credit facility",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r889"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from the exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r157",
      "r257",
      "r489",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r676",
      "r708",
      "r731",
      "r733",
      "r734",
      "r738",
      "r739",
      "r879",
      "r922",
      "r923",
      "r931",
      "r984",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r157",
      "r257",
      "r489",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r676",
      "r708",
      "r731",
      "r733",
      "r734",
      "r738",
      "r739",
      "r879",
      "r922",
      "r923",
      "r931",
      "r984",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "adma_PropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "PropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://admabiologics.com/role/PropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r471"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/PROPERTYANDEQUIPMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r113",
      "r116",
      "r117"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/PropertyandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/PropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r168",
      "r535"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://admabiologics.com/role/PropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY, PLANT AND EQUIPMENT [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://admabiologics.com/role/PropertyandEquipmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet",
      "http://admabiologics.com/role/PropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r471",
      "r523",
      "r535",
      "r722"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://admabiologics.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://admabiologics.com/role/PropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r471"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "QuantityOfRespiratorySyncytialVirusPlasmaUsed",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quantity of RSV plasma used (in L)",
        "documentation": "Respiratory Syncytial Virus (RSV) Converted human plasma used by company.",
        "label": "Quantity Of Respiratory Syncytial Virus Plasma Used"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://admabiologics.com/role/DEBTDetails",
      "http://admabiologics.com/role/ScheduleofAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r123",
      "r125",
      "r126",
      "r128",
      "r158",
      "r159",
      "r305",
      "r306",
      "r307",
      "r308",
      "r373",
      "r375",
      "r400",
      "r401",
      "r402",
      "r405",
      "r448",
      "r484",
      "r485",
      "r487",
      "r560",
      "r562",
      "r569",
      "r589",
      "r590",
      "r649",
      "r651",
      "r653",
      "r654",
      "r656",
      "r672",
      "r673",
      "r698",
      "r707",
      "r711",
      "r716",
      "r717",
      "r718",
      "r719",
      "r733",
      "r742",
      "r918",
      "r928",
      "r963",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://admabiologics.com/role/DEBTDetails",
      "http://admabiologics.com/role/ScheduleofAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r123",
      "r125",
      "r126",
      "r128",
      "r158",
      "r159",
      "r305",
      "r306",
      "r307",
      "r308",
      "r373",
      "r375",
      "r400",
      "r401",
      "r402",
      "r405",
      "r448",
      "r484",
      "r485",
      "r487",
      "r560",
      "r562",
      "r569",
      "r589",
      "r590",
      "r649",
      "r651",
      "r653",
      "r654",
      "r656",
      "r672",
      "r673",
      "r698",
      "r707",
      "r711",
      "r716",
      "r717",
      "r718",
      "r719",
      "r733",
      "r742",
      "r918",
      "r928",
      "r963",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r906"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r768",
      "r779",
      "r795",
      "r830"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r374",
      "r476",
      "r477",
      "r527",
      "r533",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r616",
      "r618",
      "r648"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r476",
      "r477",
      "r478",
      "r479",
      "r527",
      "r533",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r616",
      "r618",
      "r648"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r622",
      "r623",
      "r626"
     ]
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased materials amount",
        "label": "Related Party Transaction, Purchases from Related Party",
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r374",
      "r476",
      "r477",
      "r527",
      "r533",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r616",
      "r618",
      "r648",
      "r973"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r474",
      "r475",
      "r477",
      "r480",
      "r580",
      "r581",
      "r582",
      "r624",
      "r625",
      "r626",
      "r645",
      "r647"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails",
      "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of loan repaid",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r889"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r197",
      "r198",
      "r327",
      "r353",
      "r479",
      "r486",
      "r525",
      "r682",
      "r683"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://admabiologics.com/role/ConsolidatedIncomeStatement",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development (in Dollars)",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r674",
      "r693",
      "r982"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volume supplied period",
        "documentation": "Supplied period on usage of RSV plasma in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Respiratory Syncytial Virus Plasma Volume Supplied Period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r780",
      "r796",
      "r831"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r781",
      "r797",
      "r832"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r788",
      "r804",
      "r839"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units [Member]",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans",
      "http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r93",
      "r531",
      "r567",
      "r568",
      "r578",
      "r600",
      "r722"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r200",
      "r201",
      "r202",
      "r204",
      "r209",
      "r211",
      "r213",
      "r268",
      "r269",
      "r290",
      "r418",
      "r419",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r432",
      "r438",
      "r440",
      "r441",
      "r443",
      "r445",
      "r461",
      "r464",
      "r564",
      "r566",
      "r584",
      "r1017"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement",
      "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUES",
        "verboseLabel": "Revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r225",
      "r233",
      "r234",
      "r248",
      "r254",
      "r257",
      "r259",
      "r261",
      "r370",
      "r371",
      "r489"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SEGMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Revenues According to Geographic Area",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r675",
      "r685"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails",
      "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails",
      "http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility [Member]",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "adma_SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "SEGMENTSNetRevenuesAccordingtoGeographicAreaDetailsTable",
     "presentation": [
      "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENTS - Net Revenues According to Geographic Area (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_SUBSEQUENTEVENTSDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "SUBSEQUENTEVENTSDetailsTable",
     "presentation": [
      "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCalculationofBasicandDilutedEarningsPerShareDetailsTable",
     "presentation": [
      "http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of Basic and Diluted Earnings Per Share (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Revenues [Member]",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r873"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "adma_ScheduleOfAssumptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ScheduleOfAssumptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Assumptions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SUPPLEMENTALDISCLOSUREOFCASHFLOWINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Information",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfChangeInAccountingEstimateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfChangeInAccountingEstimateTable",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable",
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill",
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Estimate [Table]",
        "documentation": "Disclosure of information about change in accounting estimate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r208"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Outstanding Senior Notes Payable",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Calculation of Basic and Diluted Earnings Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Annual Effective Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r713",
      "r961"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/INVENTORIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r63",
      "r64",
      "r65"
     ]
    },
    "adma_ScheduleOfOptionActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ScheduleOfOptionActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Option Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://admabiologics.com/role/PropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r471"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://admabiologics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r622",
      "r623",
      "r626"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SEGMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summarized Financial Information Concerning Reportable Segments",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofAssumptionsTable",
      "http://admabiologics.com/role/ScheduleofOptionActivityTable",
      "http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable",
      "http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r94"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "adma_ScheduleOfStockBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ScheduleOfStockBasedCompensationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Based Compensation Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsCommonStock",
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans",
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsPreferredStock",
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r89",
      "r91",
      "r92",
      "r93",
      "r173",
      "r174",
      "r175",
      "r227",
      "r351",
      "r352",
      "r353",
      "r355",
      "r358",
      "r363",
      "r365",
      "r574",
      "r575",
      "r576",
      "r577",
      "r707",
      "r872",
      "r888"
     ]
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unvested RSU Activity",
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "adma_ScheduleOfUnvestedRsuActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ScheduleOfUnvestedRsuActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Unvested Rsu Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r108",
      "r225",
      "r229",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r261",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r289",
      "r300",
      "r301",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r690",
      "r693",
      "r694",
      "r699",
      "r736",
      "r984",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentExpenditureAdditionToLongLivedAssets",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenditures for additions to long-lived assets",
        "label": "Segment, Expenditure, Addition to Long-Lived Assets",
        "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r243",
      "r254",
      "r693",
      "r694"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r124",
      "r127",
      "r129",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r259",
      "r260",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r586",
      "r587",
      "r588",
      "r650",
      "r652",
      "r655",
      "r657",
      "r660",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r677",
      "r709",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r735",
      "r742",
      "r931",
      "r984",
      "r986",
      "r987",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENTS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SEGMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENTS",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r244",
      "r246",
      "r247",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r261",
      "r689",
      "r691",
      "r692",
      "r693",
      "r695",
      "r696",
      "r697"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, marketing and distribution",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Consolidated selling, general and administrative expense",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, General and Administrative [Member]",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorLongTermNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorLongTermNotes",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet",
      "http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior notes payable, net of discount",
        "verboseLabel": "Senior notes payable",
        "label": "Senior Notes, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r722"
     ]
    },
    "adma_SeniorNotesPayableBeforeDebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "SeniorNotesPayableBeforeDebtDiscount",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails",
      "http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior notes payable before debt discount",
        "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.",
        "label": "Senior Notes Payable Before Debt Discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow",
      "http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity incentive plans, vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofAssumptionsTable",
      "http://admabiologics.com/role/ScheduleofOptionActivityTable",
      "http://admabiologics.com/role/ScheduleofStockBasedCompensationExpenseTable",
      "http://admabiologics.com/role/ScheduleofUnvestedRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised",
        "documentation": "Number of shares under fully vested and expected to vest options that were exercised during the current period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercised Number"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercised Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired",
        "documentation": "Number of shares under fully vested and expected to vest options for which rights to exercise lapsed.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Expired Number"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired",
        "documentation": "Weighted-average exercise price, for fully vested and expected to vest that were expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Expired Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited",
        "documentation": "Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Forfeited Number"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited",
        "documentation": "Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Forfeited Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "documentation": "Number of shares under fully vested and expected to vest options that were granted during the current period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Granted Number"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Granted Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, vested and expected to vest, beginning balance",
        "periodEndLabel": "Options outstanding, vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, vested and expected to vest, beginning balance",
        "periodEndLabel": "Options outstanding, vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://admabiologics.com/role/ScheduleofAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r190"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable",
      "http://admabiologics.com/role/SummarizedFinancialInformationbySegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r108",
      "r162",
      "r225",
      "r229",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r261",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r289",
      "r292",
      "r300",
      "r301",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r690",
      "r693",
      "r694",
      "r699",
      "r736",
      "r984",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsWarrants",
      "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails",
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r57",
      "r60",
      "r61",
      "r160",
      "r181",
      "r182",
      "r183",
      "r200",
      "r201",
      "r202",
      "r204",
      "r209",
      "r211",
      "r213",
      "r226",
      "r268",
      "r269",
      "r290",
      "r367",
      "r418",
      "r419",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r432",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r445",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r464",
      "r472",
      "r538",
      "r564",
      "r565",
      "r566",
      "r584",
      "r641"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r124",
      "r127",
      "r129",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r259",
      "r260",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r586",
      "r587",
      "r588",
      "r650",
      "r652",
      "r655",
      "r657",
      "r660",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r677",
      "r709",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r735",
      "r742",
      "r931",
      "r984",
      "r986",
      "r987",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r226",
      "r464",
      "r489",
      "r573",
      "r585",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r599",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r618",
      "r620",
      "r621",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r641",
      "r743"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r226",
      "r262",
      "r464",
      "r489",
      "r573",
      "r585",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r599",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r618",
      "r620",
      "r621",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r641",
      "r743"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r783",
      "r799",
      "r834"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants",
     "presentation": [
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cashless exercise of warrants (in Shares)",
        "documentation": "Number of shares issued during the period as a result of the cashless exercise of warrants.",
        "label": "Stock Issued During Period Shares Cashless Exercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r56",
      "r57",
      "r93",
      "r386"
     ]
    },
    "adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "StockIssuedDuringPeriodValueCashlessExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cashless exercise of warrants",
        "documentation": "Aggregate change in value for stock issued during the period as a result of the cashless exercise of warrants.",
        "label": "Stock Issued During Period Value Cashless Exercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r57",
      "r60",
      "r61",
      "r93"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase program authorized amount",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet",
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL STOCKHOLDERS' EQUITY",
        "periodStartLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r60",
      "r61",
      "r84",
      "r601",
      "r617",
      "r642",
      "r643",
      "r722",
      "r750",
      "r890",
      "r907",
      "r965",
      "r1017"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r160",
      "r161",
      "r182",
      "r200",
      "r201",
      "r202",
      "r204",
      "r209",
      "r211",
      "r268",
      "r269",
      "r290",
      "r367",
      "r418",
      "r419",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r432",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r445",
      "r453",
      "r454",
      "r458",
      "r462",
      "r472",
      "r565",
      "r566",
      "r583",
      "r601",
      "r617",
      "r642",
      "r643",
      "r658",
      "r749",
      "r890",
      "r907",
      "r965",
      "r1017"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r192",
      "r350",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r367",
      "r444",
      "r644",
      "r646",
      "r659"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r482"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails",
      "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r482"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails",
      "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r482"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r482"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r483"
     ]
    },
    "adma_SummarizedFinancialInformationBySegmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "SummarizedFinancialInformationBySegmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summarized Financial Information By Segment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "adma_SummaryOfOutstandingSeniorNotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "SummaryOfOutstandingSeniorNotesPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Outstanding Senior Notes Payable Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "adma_TaxesPaidOnVestedRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "TaxesPaidOnVestedRestrictedStockUnits",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Taxes paid on vested restricted stock units",
        "documentation": "Amount of cash outflow related to taxes on vested Restricted Stock Units.",
        "label": "Taxes Paid On Vested Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48"
     ]
    },
    "adma_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "TermLoanMember",
     "presentation": [
      "http://admabiologics.com/role/DEBTDetails",
      "http://admabiologics.com/role/SUBSEQUENTEVENTSDetails",
      "http://admabiologics.com/role/SummaryofOutstandingSeniorNotesPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Term Loan Member"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ThreeCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "ThreeCustomersMember",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsAccountsReceivable",
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Three Customers [Member]",
        "documentation": "Information about number of customers accounting for a percentage of consolidated revenues.",
        "label": "Three Customers Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r972"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://admabiologics.com/role/STOCKHOLDERSEQUITYDetailsEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "adma_TwoCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "TwoCustomersMember",
     "presentation": [
      "http://admabiologics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Customers [Member]",
        "documentation": "Information about number of customers accounting for a percentage of consolidated revenues.",
        "label": "Two Customers Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://admabiologics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://admabiologics.com/role/NetRevenuesAccordingtoGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States [Member]",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://admabiologics.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r111",
      "r112",
      "r114",
      "r115"
     ]
    },
    "adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units, net of shares withheld for taxes",
        "documentation": "Value of stock related to restricted stock awards issued during the period, net of shares withheld to cover grantees' income tax liability.",
        "label": "Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes Amount"
       }
      }
     },
     "auth_ref": []
    },
    "adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20250331",
     "localname": "VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares",
     "presentation": [
      "http://admabiologics.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units, net of shares withheld for taxes (in Shares)",
        "documentation": "Number of shares issued during the period related to restricted stock awards, net of shares withheld to cover grantees' income tax liability.",
        "label": "Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r741",
      "r744",
      "r745",
      "r746",
      "r747"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable",
      "http://admabiologics.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in Shares)",
        "verboseLabel": "Total shares - diluted (denominator)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r221"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://admabiologics.com/role/CalculationofBasicandDilutedEarningsPerShareTable",
      "http://admabiologics.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Shares)",
        "verboseLabel": "Weighted-average number of common shares (denominator)",
        "netLabel": "Weighted-average number of common shares",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r221"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-14"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/230/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(C)",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(ii)",
   "Publisher": "SEC"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)",
   "Publisher": "SEC"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "6",
   "Subsection": "04",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "SEC"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0001140361-25-017747-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-25-017747-xbrl.zip
M4$L#!!0    ( />)IUHC+?ABS1,  '7-   1    861M82TR,#(U,#,S,2YX
M<V3M76UWVKBV_CZ_0C=?;L^:FY) TC9=;<\R8%): I27I.U99\TRM@!-C4TE
M.PG]]5>2;3"V)<LDS7BF_A1B2_M%C_;6UM:+W_S[?F6#6X@)<IVW1Z?/3XX
M=$S70L[B[=%T?*R-6]WNT;_? ?#;F_\Y/@:7T('8\* %9AO0<E?KL8G !!L.
MF;MX!9YYJW^!8[#TO/7K6NWN[NZY2<L0$V%(7!^;D+ 'X/B8$HQ(MC!D!%^#
M&TKURMB DY?@].+U^:O7)Z_ =-("]9/Z>5#EMS?WY#4QEW!E &C#%72\#F7;
MAG/#M[VW1]]]PT9S!*TC0/5R:%GL'7N;-21OCT*9Y@:9/7?QHK9]5:/TSXZ
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MQ"W$Q@)&DX\A'3JWYFMYF+4KY_,/ T"JOF3M^^>(1?]#^)_?_??5E&8 ?JH
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MBT?+-R_GXH'K_=FI]?9QL5C,6_]W]2I%?B_R8H_SWV^N[_0A'($<,BD#IBX
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M<\2VR)9/,Z0I=JG/(,E8<;<-_PC9/;3+9C2D(^3W>0'=Y:6+WN]O4$L#!!0
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M&;V69\=>XB8,%G=6Z-J6[W1=+XZ08UK8)SMC.$8X\9,DI,5-8>F1U3FP5NO
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ME /_M8,65NQ%KVXR,H>L[\9P_>B6/'*;?>?V]/%L50/S&JPLUZ_-:OKT?D9
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MC@3DF-_95CDC:D%X=#J PXY-J#UK3D1J.5)J_1APQ^&C0V_+D"@[V+Y5&]E
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M)<IO2QI;2RESX7MR>$$.K0R5.RH#^M%! E7:.NU2C'99MJ\NP-J Z]K2&K_
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M' "D2!$ 08@$V#VSM7?2MO$X..='X.#@//[T_SYN _2,X\2/PO_^XO77K[Y
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M.KD>31:C:T3^M9C>CJ\'RQ$@B_SG;C19+M#T!DUGH_E@.28-T,_9>'_/,>8
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M,L=?V5>%+M$#?O3#$ ZW:(,8C8[/ME80U-K7T]$;MY:E[&S"149=%1@P^;4
M!O\&P;EOT]/XT0O]W^@3^3 *DRCPU_0',NN,X(=,0G^<;K@2Y@6YX27I*(:A
M'9ILFN%:H5CFISA_-YB,_T;]66G S=7]8CP9+81A$(YVQE915'*.;8VQ9WPC
M@]4JVH-#R>.,S+^"X*!N@*^8J.4S7P5F.142A"[N[^X&\Y\@2&<Q?C<9WXR'
M@\D2#8;#Z?UD.9Z\0[/I[7@( 6-BR+J(_J^5:2DC@)HEYD_H S+HV@_VY%J+
M%WBUC^GEEFB^1 7&:^;*M-WM,Y"/O!@T(M"<Z7/BU4$\0 =O'EU2:A/<W2U#
M\G44.Z!CC]-'%Q??0/?@*WU$';/>_"L$\V=(_GRX]I-5$"7[&'<6GBF?J76+
MI.H[4! B=5I^/YHLI_->;>,:DBM[B:I7;1S:RX>=X,X  T/;MUD7IU?&X_F\
MH7L+M$@80@QD2VH[WJ#>2;Q,@-BK^U-EI[E'TRR&U^#T,".<2(E^#]?<78>A
M\O7S60Z:KR5(\@7.YA#PN/R)W@XA]\(,@N9[$B6O+=4BJ/0X81QG)1W^ZK D
MW3O0GG5F;-^69P2V(T42N-U&X>/E+='!UFA)?N^#GS1-F5;Q(^H3W*JBU0+<
M"3=:W]O:UQB44[D($%$1I-0I=KPC-0KCK%<Y6K1/$).<D+7K;U^MJU-!ZD@2
MJ22S?PUIG)-9:N8=P+\5<@<-5JMX[P5=60I5,UF]1RH(D=E#AL/Y_8@H*G^=
M0<X?ED1JNOQA-$?#^_D<-)=BBJG>7#4UA%O"60UC#*^:="R\+B>JHM'TQ5]U
M9IYN,+===:81;3)DLC%0EI^%[G0L4P%/^8D*@PF1Z<:2W1P1)\;MAJPSU8*T
M9G(!6@>6%2VZE.J1Q^&*BW"-*%S5.79[BU)C=#JQXVA3)M*F!O\67IE%IGO*
M-7Y(.S?;2R:QJFF):9#L$->C*Z$!R 5ZU!(JPD6Q1%-7WQBO_?3&6P'6#AT8
M=@036+8:5BF0.=O1ABAK68WZ<N-/)950R4E*O$AC"R"+&>MHMS@9W*8C4GEJ
MF;^&+&-OCSR*Q (J0D*P5 ,?GR1._S$'+V/=O8%T*&" _'24?WDL"TX-I0EE
MPH;W]"3U5T1CO,,>;*Q@[7#\]0O9#M*M+LDX()@Z#7@)7H-; 5&RF-]8',/H
MS+1[;$)NZ_1YX<6+U],=S1?T'B<I7H.%B*AHX'JYC.!7A0#^R7[[@..6-P]K
M9+>]+35)I6%A?3)O2C8*BH[M+] S'9,9-OFHD/D%?GU1\$-_Z$/2?,NHKF2P
ML"6Z#K0H_1PDEA8IS(S9&*"8-JJB\]_P[%)RAA>2[HG\@/W')VCSC&/O$8\^
MXGCE)W@6^\>OY9,YJY2+<1,'Y7;1-HZUSW3GT/DP[.XGM8)VE0C)^<H[/AG_
MC? >4'1V[)HQ^5F*JB2-]S12B)JDET]>R!<VB4(&K'Y=\1K3W=7^T=TAV72)
MLFQKBM/M4_KT39':RE=N)(MNS I='5@F2Q2=32/I2?-OM'4J"N,7  MTGAQ^
M[\C0Z;67XAO/C]][P;XWU[$VE^0T1:_CQ1L<1I_K!J&-?<M[AYX,G24_[L'B
M&QQO_X9NK^@ZSY'FI$;E+32&);3O,Z&:R7(0K)00Q6LJ>S^--HB77LFZ7: L
M+;G[T&X-82KJDU8886CLGN. C$C@'J>')8%K FD*":0[\KNHG<XJN.JHD2!L
M/KJEQ6]G XCH6\X'D\5@*"U[ZT9_T)5K$6):[##U\HJV6S]E.5_"-2O^\XA#
MR-/1N6M@L[GM.L4WHDU:F_GN;KQD59@A4F,XI2E=1A-%/A<G?F0F&"BYF#5F
MEK%G"GZ$:>9X![GQP\>.D"F=QFJ">@D1LO-U](Y!30@L%_IFC:Q*.J!JK8:^
M::6D5[1(64N.:I*!;6!#/KUL#RHV1K2UP'_-LON:6C*9+YMBG>:FJTQ/N]HG
M?HB3A .OTU(7PKF<E+H042+;3G@3MVAI)#=AB0OID@UWE7S@=SAZC+W=$[B'
MMK2QR,>VHGXK29# I-BL!XZQM=+)-A?U.LWCF&\A#W-7M[23P6UN(>6I9>DM
M1H/%"$VO;L?O!O)[EX/M0RR5XGXA6-\YJ6&SFB5TV$+ %C=?)=?[KBY5C::V
MFNBU 6&R;#V\);H/USA&=" T?0C\1U:GMB]P,Q%_*75K4U:= =5;<C9B+)[Q
M4)BO]:U,<UH'511T:5-G8.'M'"M.3<5;WA,;\.$\V_G2^V@A@:1\)@>V<R$A
MZJKWM,Y]CPQ'&K*KFLKEZS;U"]_O=@'5Y;P <KS?!-'+*.@TS;K6E!93\^K0
M(\U /9O=CL!R-+A%U^/%\':ZN)^/("/U<+#X =W<3C^@\>1F.K]C>=3[ [\F
M@B_=#76Y=49]Y_U#@G_=DQ%'SYWB4#*-5>N"A @IX*X6HQ_O(5G1Z+W48.D$
M3FJ9E2&D6/,Y^?(A&6!G28C*@[>-D?JL'Z7Y99F$%HO1<N%Z:Q'+H92?H[J8
ML^7.4R5U*O[3.:RG?A%1(3->\W0N'NWSO=.$[RH!57$A6I_Y:<)+V9P4L!FD
M0R^.#T0S[\(C4F].^_D7M>AJ6C/+>5DD;>F>EC_28X5YQCRHW9',\0J3X1\"
M#%4F&;3;WIQ44W61>E4C1964('D2/-H%Q7F?<HY/A]5:E#(4U&N1K_N,U-%X
MY_EKGB(PRV95VB];!I7.C!W8E^I3R-:2)3. LIZJU&?LK'2;5E9;SN7LLGI<
M,3<TI3SE-AN3P)H54"$[Y;LH6K_X0= R_K2FM%]#H9XHF1DJ[\IA=K*]N;%!
MZ8NU;(S29(.YVM81JHK(L;YWU2 D^[/+_4<E]:IDS1(G;C#9D-:Y03.'4,NB
M5DQD>]N0DR++H\@[H-3[*-DN'.54K!->.:^B<MGFFT/Y664.\0G3S7W"=J-.
MWX1/Y[)N!U*2(_/MAE:7:72Y3_"ICM.#-UZ)_.2/NJ)5&]B/O/76(QC=18F?
MY@EB)X1Z;G^@C"JC";H 1+Y]]?;M:PH3O4'L7?6UZ)'N.JQ;03.NH,4F7!H)
M"."BO_AS'OU+6847:;3ZY2D*UD0@G6;WU)[6P:5,ES:9ZU.A[@+X^DL3A;K4
MC)J*O>0,T(0_IG>TPB3=VL(5$]E6K.2DU%C%"TG.G9K&ZX4FP5&[1O+,<,6K
MAW1KICR9Q+X97$Q(G6%RQUJ[U9S4@A+9(@6+- YW"RG6/OCITW"?I$2GS_/I
M'[J!C-:4MC<=':)JMA\:J1.%$,V[SJYZ,7[&X=YIE'L3"9=CV#0YTM:5KV/8
MU4SF0,-24Z2/MH"Z_49'MU^7<-.3:;US;P5BK8CF.R::$#]" /%YPA$EMSB1
M3I]NY.V(XIPL23CTHQ@J?BYQO)U$:>OUF40S6#?F"(B01I1!2Q1"DTP3H19!
M>H3X"3WKG29(D4NL'*LJ7G$'YOAG'#]$1OP7?:TB ;CUN#N+X<:)I#.;[IQI
M*T?C2D?6^^H\#DY?*3%UYGNNT^5?ZDJZYSLUYTN%*;+FBYG0U&I!3749+//3
M8Q2NIQOXS0W&_.*B98#5&LC6/4&;(@EZ1F!]W2 R_A9ML*,+9V/YY/97[94;
M:P<2U:.SO:A^/A>OR;54R:RMIU< G=VI/RJI>I/28TKK)B<-74.+,I'FD67W
M\E)T1]CWA-Z^OD"P!?;PZM:"<,XIA'U:XK&['4$^D6UKE)P46<T&^K 71N%E
M3<5/)[BJE6 )4.JUG^$T+D_*U+J%4SZ3 P=Q.34F>;K<VC)K1:B9ANNL^$I;
MS\/J!V&[5HVF[[^]?.]M]L*K\:9K[/C-KEUTABZ"540S6+>$"8B0NW'SRS5M
M>H'^[ZNO7[UZ]1KMO!@]0\<+]/K5!?D5_!]*(/MM@KQ]^A3%_F]X3;3=*/NM
MGR1[7L6E4-W%J5E'(>\3AV\AO\[P:RD/.?/B:4P3_:SIZ#,<TT3"G8)/.JF+
M^Y4>:;4H31A*<W2B+_T074=!X,4)(@HQP^)7/0)=G>CE.%0RZ9S8E\(<=,!D
MD'_/G0*R,IF;B!<%1;KXJ^R#%(?LMU\YCGC1D*X<<T*&F/I0B88NE)6R@+7B
M;+85MQIZ&D*M<*(*L=:#G4XJX#JXG7*E_6U!PZ*D09C(GE215[V@/A])G57X
M333^F*J0%C8&/E$?]@1&2L/M@.O:O=X)RL*L@U:!#>=9FJ*PL\M=97C[SG)E
M J2IEJ$9N]*A2_0<I;3,IN!N]_:5\G+WYNT?+[Y]^^;BS;=OZ+WNS=O?7_S^
MS:N+;W_WK?K65[6OTQ;7>(6A[%?VV]^YMFF)P')JR*HPO!5\6KH2ZLSH0 W7
M($N-[:870;?X:G()U&6-J59>&+_CVY]J)C?6> DU6E#3N_,YTN\TA"K!F.S&
MUPJTNKOM*:=R8>!2$=0$7[7WASZ@J^;J4,L+8^M59>1.;@RR67J!*^5]00@I
MU66A#VB27Q14BS?&T&"]]L$CQPMFGK\>AT-OYZ=>V[DQ9+,XR2 EID46HY6W
M1I &YY+ 9L4Z.#9BU BN%*^E6+$Q<.8X]?P0KT=>#(5@D\%JM=_N:46T:[SQ
M5W[[M?!J)[3^MEA/DSST+VL(85K0TJW-0E^<Y1)X6NL_PS#&78)O"+&B4+ \
M-Q $X)/_OUYZ'UO'77,*;)M"#&B4%FM\/YK<%_QK7,'16.QE?)KQQ8G1W9!8
MD2&>#^4V@:9;&9YECA]&23K=\)E;UZ>+8[O1H@L42'7GA#IN[^)HO5^E_0@A
M%@BEK""?KNO\. ">]["KW-_R>5Q& I\2(W/WG8WF W#)1*._SD:3Q6CQ?5\<
M^V5B$_J,"Y=K:E&<XP2#K7\0$A7H&0?1#CP_^12MJR:JN1QHPPIR9/H&[T-?
M1-;'7JZU80TAE@^INJ6["4.MI4NL/8AE4GQ6</V&W[Z$C.-6::@ G#UD:#Y>
MOK6T?5RHIG(2*:8@2/:*'WC)UD,KPGT<HRAKG2=/=OUZH"/.2J2(B@7FMKDM
M1,O]1D/IIIO3S+AMF^C4DSE01]04R0PKA4Z@O_JGN9$=)UG2$FG)>%?/!?.J
M[4$ :95Q2. :$/@.UEL_]$$)2OUGW(W.HCFIB\U,CS1I&@W:^0(]LN[T\/1*
M [BN^]Y$VN5$#]I\<1'^JD^>,%=.7LX<_,KJA9B=4XXS='0ORW.B92=1F!_L
M+$5S5C^@FVMT_7PN]I-:JF3WZN4/HSGBQ26_Y'?KKYPFD]06:!%K>NLW5H_&
MX3-.:%PE&WP,"B7Y3<O8DDYC_7XMHT1>%H+^F>A T-KQA:U.6N4B$(J%NKE(
MJT@2'2OWH1=0^))3Q?\L!7'>?5FZ-W1Q8Y9/YL+*JJ1(F5FAHGHXNQ_7BJ]R
M0U:O^.PRU7RP*Z+7;%IW/9#-XD*ID- B#9F(GOT$[L*;*.;[#U3^*)M9G.Q"
M2L$)ZU,+5FRL/&0>"YD7\967^*N682.>P[9O@) *"5RN!HOQ$(T&\\EX\FZ!
M9D0-A2P<TPE:_#"8CVH#C-U@22G+(I+DK'#RX"\E1YRKB?P18=Z%<G_%_1N9
M8V.];#Y)T9SUCG\ZZK4?[-/6/61EL[@X'B2TR+))CF_OEZ/KL[[X'J#J1*PJ
M7!7YX<)8I:!']-7S/\N_^S[F?&A'/.?8GSY@J..$UP,B$>\13_809S?=5/SO
M.S)'-9[>Q4[1E$C)%O)A-'[W ]E#+@?O1_/!NU%I^UB@Z?URL1Q,KLGNXM2
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M^151L&-"2IU\V[2)./G,_=C?I/0I,RNM]N2"'Z;TE VC\#+[N7#B]FX+K,5
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MMZU9C*'4?.9UE-7,"-?48M?)86E(1"^ IT.I-#LZ[9J_/U#S;U0V")^<L[W
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MFLL^OWKKZ4SC<!/%6ZHCD-L(^Z.%U#>-J'"!0S-2E?4"_-^(]GOCAQ[91+P
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MQB3*@?G''JN]*F$;@S-G1\N6 -F$-T3\#A%*I^^M?EL@4@[1[WIG,]"1M2E
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MAB.0F;#2"#WRH5R_YJH%6 218O$FVODUWN"8%A&E7]0<;ST_A!1>Q0IW@GI
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M#H/652L#$NS#U(1,:7(4/A1*8*P+E-!AD+=/GZ+8_XW\ >(ZDM.X#C>ZF3E
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M;MIPJ>[6@_SA:M5-O713 )5=<>=XC;<[6A$<QWZT[@1+6E-:/$=UZ-'SQ;Y
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MI3*:"I5B"3;L3,L]:HI;-BXY^_G Y!.F1^26?\]<Z6 :+&C[*?D_\HN' S/
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M"D1<(" # 1TH(P0!)4Y5D\[Y+%0Q[0C7)EYAKQR'1'VC=HH;J)T([MC3#?O
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M&5OR1F5Z'>]8T#/[5]\W<SK/#MYY@F*F=[03]$SXX7WB]]K9MME?IJ1+]PT
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M] F*P5;7D_5,55C%(/;?'#O(].G.B\=@VK3.;]CLF7F:P>/YF$"0L7O>D;"
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MS9!CN=[(#8YFJRI.P]E)\D!S7$Z3*U&:<TC.W8\\UL@F*.Z6EH)#B[ICY+7
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M##FVKSM##<@%"CHH#]4T6;5?SL; .Z_KQB!5:\ *1YJU>HXEBJW;&\XYOZZ
MFL@+%*'0WC)KJ)Z'6"]>SA;!-:FK\R1-7115N5P\YMR<I%.1RX:K\HNC+EXJ
MHSC9&C!ZW$;M9SPV7'<&2?HB7H1#R;^6FPT8)2F<B8VDGSL^DI$76$I0,$.0
M;<QKKN U5[ -N8)<*^1E90T.'&RBT P+/.)R2'Z9, Z?0UA&27%406:"5:F
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M["-9CF9)A1\J+!$NEU_Q-%57=Q>8U0YRS/7&\#Y=QJ/+DGM9;EU.E!#]+F!
M3OBZC(.7)]<X+Z]0Y<NQS4L0QM\[CYM(<?2H9)3>:H@ 0Q<8O&5MG4%BB<:
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M1D!2;/<]^,>12P@U'$@64:GQ@K(<D?O.\?*]X5E$V<[?MZ:6\E0,TJ10:B%
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M=;"1$E[)#:XT+E:DA$5X4/J)\LBV8)/AZ"=*_UKQS2M-@B7357,L('V7YU9
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M^A5YF3LS5><(%SO87<T[E(VK>=<%'H.[[[PO=60I,9H2$JW%2__Z%Y&9VD"
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MU\ N3LC%^UFWP/0RV!F_N5.@19WTD.]-[,6F8#S]U1<FM[U05IQNF^0G@,3
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M?"3+18H3RQ(P/OA?*O-^K,BAM]^0BI61RG&X-0Z%UE7!0@(0*(PW,.@)>*"
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M#E>WXW.M1'1> 3HOEZ1Z(]M#TRS!M&\1G!-@1B=[B0@0HYDM,%N;V9H .R+
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M3;-AU.U8\;@RTI4]'NN[Q^,.;B>2L!?+UJ89*I[47I BCU/"F$MS.@7H,H#
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M,-%7L<!W*+?8VNK L+K.>=H+H3_(.G(EGQSL7,/FWGA8#H%M.@50.;XD"M0
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M.=-_GDWU,2SU@\+_"YQFY)Z!%*9FXP+8R!#+G8_$IN'C<)11PK+)!&2/E!O
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MW%JIW"ITL4+O*&"2 UWLBLUM;*?DCX/69E@3+::?"?]8H8TML^<PV(!']T)
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M8RS]7R-Z8&6:,K51I/V-9,#]!$.-R!K*I6X?0/KSTV]:5Q*D3RBQQ!-'.[&
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MV&H5U8CY67K.:3>/U8BM]NMAMD4UXJ^6T%W9:XC=P<Y,I]1ME]5*)5L+L"A
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MUDTN0^ZY%5>DEY%?C(C,H'.2="Z9>!X,^78.?WEMQ>4D7(X;' -^37&E%2O
MAV!G_3C3)G#3!R#_)_(*3_W$%.[A] O_P["5S9^JN 61H"*=IRN9*_R'TF]=
ML0A:P@AXNX-=I#0\;&@7V?J8Q7;7$0[^3YH"^BEPCK^1,_5^@LYE/+# S/H
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M@-P8C!R\DY0&]''"DCS: ((!$9W!>I4I;-X6,MF'J @3J<K@\UFY7.&J@2^
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MZ[P4ZB0;&\PW&:PNX1),X G]@5$J)-@Z;^LIO(&I!)3@7[#P*&08TK"Y!R$
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MQS7NE>.N(^8<3'79EQVQ-4$.$Z'P91['6:J4SQ*>+."#NY@HP4S/S+Y<X]R
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M,]<>7QY!%)Q#$_;2Z;P!HKX,3G://:X'K[N;N1F\P5 >=L3YMV2J3<0\FKA
M/(OD//=9'@2K#3]?S\;))9P'U%MNJH*>,IM*J%R"]U5V4S-<P*N;PF/'XS&C
M9@\T/&7-@&>ECBY.&8EN.H>3(9,!04=TR>_DEN_[>V@2WS8];YN>MTW/VZ;G
M;=/SMNEYV_2\\LINFYZW3<]/(:'XJW5/[Z/><Z_=K[?M=-U_$9_L'=XR8[W,
M&]VEU+&.LL9&KOJRA,7K6/4-*;@BR2SGZ1%/OL2(YIS!J!%8/R_+^^E17%_/
MQ4V%\<%>/#B^;>UGM<=\J!-SWTMV&!^>W'988@VQRZ/;FU<"UH$P&&VNA*=]
M')X?GL2'@X,U[.Z=^KN>UH%XOK\?[^_==LI@'0U9#R/M'@_+$Y?R07QRM!7R
M%35#_'+_[L[/$Y[8>&4;@Q4G3ITBCWY(D1T9+NJ)'Y/]^/!XW5O^A1^307QT
ML@[-LM&&P+H]\V21*$2?PGOJH7CRLK]_=+*5_=5D?W^PCB5[J@;B/5J >\Y!
M;6I#Y^/-/KTXNKOGO:E#=VM.I6V%IRD\!WMWSV1\72-R/>TO#ZOV[K49\GZD
M=IV/?#? DH=9U@W6>U^[]-P%)N7AA:>O1_9F8- ;.OK\[L*;FAC/+()*JXGQ
MN@>X1RCWY5!>EN]*I!B.6?&(/<\U)RKCVJ'K5@SHB:@GT$'3EEXK8F$FQ(<I
M[8A%SO"\(!X"'=_!N6UI'QW%X\"15]##2(>C\M;Z7,>8>,E''@LG7NI_,C-)
MHS>S"\1U5A)-Q [?C?Z\R":&*,,M)Q[A4,]RA+&?$NEU)FC:N)9=]R2D7OS%
MB/'-&3R]\^F4$EFYL;\];KS:MX,#[S>Z>TP<07W R+A=@KF75E+\/3PS\94Y
M"K]Z?EXD*0.*MQ<XI,ANL"7KEME?P^7*15F9Z3*,V"OW:-YS\_%;"ZJRRKE=
MRUNLXTAW8<+P^3S>'33DQIW/6QSZFXZT\C\[$:N2SP830,3B@J#6,\.T\G3J
MRHN$.9F(/:=@,/4+/(74]_OAXQ_R1U192*_MV(JXO;F[(1G>,F"X1<IZ8]+2
M=4B;STA1STW4996//H$@LW##Q_%-=Z,E()=O8UOZ:?(:$O1&J /'8%6$M_N1
M38E]#FD21^ZK:%83>1XJ'%#7KH?;D>MX#%/+6Q?8<V(?:%ZM-(RTOAN]SDJ$
M9]=-P^N?3_(AJE+B/!<-#8]J\$;RM[*>SY$[_@+;$TB<ZTG%IPBYZ^%-)B9)
MB2J(%5T*BFY1JA3QNUANC^3*PKL+:[=_P0;?.A&9\%DI?9*$QE4FR1"U-))>
M(&<"4GS318AEB>@RT%04F0$C100U(^-=%\YTR(21H4J."6>^GC(6.2Y!)EWG
ME_!U-EE4K"CXI=%<5 B;/S*6XM[R0<=17=D?RXML/B?-0VQ+/)(!JUL0J<6X
M-KCDA?R"VT'H_7 YRO!)-2.\BQ-#\&K"U(344J,BMT3V9G:9%?F,:3GFX$AF
M(V2$L1STL.HY$:J(RF-Z>._L_['[<3<ZQTD9N8@SR\2(514X7\H4N$3@+CKA
M:#<ZG6"#[#D1Y8Z2V2PGJJ<T&U6B52IAA6(ZW7&-YAS<W2EZ7"-ZG$!&X7>.
MT<4C6(F)_0HO3W0HY!K%@>PR<4"!^P1?K,"/ NU'%!IHT9'( #?=Y>+'< B*
M!+FESFL0RAPD<I[#TJ&E4!(CV=)S,Z./VD>DQS8Y?IY2",$SBPV1M:+3D8/<
M9R/FSGE3(]$.4VJ^R](4-NA-0O1.*0H&I6%)?%!^A<> )U!J)45!'R0OD"JA
M!L- ASJ)2M!2V1B>!M9;1U:8J4<6G0\BJR/KNNR"+K76"2X/&V-YA)"Y:0>M
MR<)6L&&-2'9+X[.0"+,Z4^SXA'W!0;3T/+"H)$V7L$=Y7<I)-(7]1HI'4!F8
MZ?5\)2+#-40-!]*)=77< G@E[/I$OI7FG9DG"->*K^-=I80WA<^"9UU.$Z\<
MZ:L@V1K6$7Q.]0#0GX9F =N/9Z',B04OT:L'^BXXIE?,#X<"/40BGPFY"2"]
MI=%1H)&QI@,6.*U'RIZ1$8E*@\A"#1%S \&AQ<LG8C'=)61X<!67M-L(KB6(
M_.;']^/QSD]" ?[QPH"W<HJ$(^<B6?=KWY<F^/H5HNM56+##J5D:FEV?2[S#
M%PR3'_TW>=9*8T[RI-)<A4Y*[>_2!)<W'V+'0VRO-KL\8#VC@UT_;>EG+>U/
MT?])HBS]KV_^NT;ZF(KHM?X%PODO^,5$_PT>RVB2EQCA_>MTF-?5O\#[^62J
M?WW(RD_?@**H\(']2Y!\>Y>(O$M$=(F(+Q'A)7:_^9%&-^E9[W"9SK>]S;F)
M1N!,%=2Y>G'/,=&?S'T*=CPOE?J4WJB -T(.*XZ/21\BNX[?KN31,8.%>(^4
M6F:&I'Y-3GF*68@U1WC62H];U3$S>DP[0_)DQ(_I(! G@D;BXFDR5Y.[Y[(-
M:4[:DSRO_S ]%ACT[)+WT]&U9>@5U$)&I)QB(>-T>97,R>B/X+\Q+178PW-B
MZ4)5BBMV#076!;C'WQ[[W&X^UR=3:^7]:ZB<IQXM6T*V49PW[TGI(1+9-78A
MC V*P.HLYFB]R"6)Z<43I/\S:&29D]=-M3I>I<'>'NX*YI_RC*GO.EBYKSQ?
M8^:S<$??[NV^]$+J&9ZJ_\">6E*]T!L!^9]9*CHWUTJO-JX+LKXIG,:ZE%C^
MUQQN,C@DIO/!X(?H8STL0=C0KWPCO%-PZ7=@[E[HIN#CO\KAMK.%$G]^>[#G
M;5!"S=A5@\*\+IES*D7KC_FSWN\XZMKF;D[1V93G.>+G^8'Z/@J4!F0];Y+!
M"M^L'3"VCY.(P-D7XPR&SWRK3(#77*__47NN[U/KWH^;T/G]+<)"#\+"R19A
M89-]H</E?2%\Z2*?E.0'_88IN!0=#NOHZ-_I6+N_!UY,WV<>W46Y-OG\XQOD
M=[84A,[;BGK>9X.Y@-&S2@V&V^C(U&RMY&U&_MO,[=O$J&O)]R#MG@4$HA\@
M6BZCP4&R,SAZ;KZCKPZ.4OF78^;\R"S &(.^^2SF^Y1-_^#DX)#N0;RA<-GG
M^ 4TF/M[/_@?IE\-?OB.G!P-VS%*AA!5.(+K@JP'>R5>YLBG3X>055Z:J8MK
M<AHTKW2%[A=<+"<F5B2O=2\1/#FL ]* %Z@8X:EC7C&T^[%0 I(CX7)64IL2
M!X78RY49$)/PV3ASU*(?W[P2[E=PX&B)*2$'[R.)26+E1O[+:<V5&TX33*?U
MC#D&E546S$MR[EAOA?&7@VHEPS:?87?(V\G'8PC="Y$ _;OS1^7OO%WH1L&'
MR-/,D3,UOZ+70O\6WJ>D7&X!CA1Y#VX/G,B5J\2E#WY6K@^K_[!B4=9S-->E
MZ =B'M4B)-4S<!55>]SCGES1$<9$"<E#9 *UM=QAMWZ5'RAH"I<"'Y![=^'X
MKD^-ST$,L2D?VCL\)9><.*3 )UA*27"L<!M%@5HBW2J'-2D'7R?PD6[__R>K
M*DY5CJ6FCOS'F*!%RNP+6)<K,YDXJTQY7,IQH[38N@1+<C(L\TE==<IQ3B$X
M[%3IR*O]VU)*96J$JAT>(500]JS!+6^\'S)DZ]4S^),((8?MDOP=%TD-;Y"A
M2H304>0[(80H#&XI'A]B0T1J*H-:2QU!G]<:'1;.EMBJSO)Z0CC5*1LP2]PC
MH]OO22Z?02E<V(3VO&!V9E+F4M[#R!->'8*&7(IK^$]ZTX=D67;YKC-]-?%%
MH_?X:F_MJWW05]O<!HC?B0_;20-(II?06VW_O/*TY/*Z*]..>UX+)1.M.."I
MPY)MX=F-133)/J'N\AC [1?BU9[QGGR>;5YBA;S$P=[7FI>X#G"F5^EP!N"W
MTP^__^OLS$;\^.\(_NT%^/*KVPGXC8]!%WW_^S_>?(C.?GW[_L.[T]_/WO^Z
MXLTV*/LR6#[[\@MX2A-.NQA\7I=WH;]$WE^"C$O[KX^>:[E=T@(KPD.#>#]^
MK4&;;B;TFG/WFNSR3I)L"C\6&>7&.SK6T$ZP/L$:>U':_@'M4*(6 W*NYME,
M'"7?:Z[(=J&M<,6=F;,1$76!PKW;#\A=<GX3A"O9IW#Z2U<>82.(G08X8$(.
MO+,K\[R4_H?.'@FN#-E"Q<:7@==]TJYS:O@0GBY_"K&>^J^WW,!B#R#^,M)?
MNJ-WW8W]K]SJ/(9';ZEFA65CJ.6N]I&"6.S2C+I?9IU-EIU=OS\9#"DS+"F6
M[F&D_41C4^DUHK,V33X91MS%]E-J",_T9$VG^4PZ1S'<QK"9(MZ"RJ?4&DM%
M3KY/FH.7A!$)B&^!;8P8 VC%"CYO6V"IB7(W.G4-M%(<%$WBON E!;*9*]S*
M&^B=8[_)IW4C"A8Q:S%&9P-^P 5R"0KT+% 526;5WS;)K'*OT 7II"&VQ(%W
M4:.?BZH'G)$"7>,J/S?T *1 I2O1RZ#HX_^W+:5S"()J["U\"ARFG?_F0B*U
MAL(__S]^+=@)OMPXFY"*M"KZXYM7,3P1W 0-P2=N4/0W4E,*7D:AN;%K#<]"
M939XV0LY'6HXKW'G1@TW>+FL+_&__M^3%\<G/RRAQ>@#?M=C,KK((,A-/;1G
MW*<D^OGT]#<IK&M?.:%.<S#UVHP,]0E+/'5H/S3."JPR0\#0UR9F6\# &([A
M- ^EGDLI*NG0A(]QVV)EQ+Y=&K)BC"(M>3!N#?3#J;MZ-('-8]=D'4[.$Q.0
M/R6?@GT/<@2S(N54MC=<-,8J.S:WPIT_)>?T8Z6S2-P9;"8"-XZ?3XOZ''TW
MSA"Q=.A(BF'-=B4MT?F0)"3L;Z2.7W7X@D<2]5S [;AYH/%WU&2(7V3UK<N9
MV9YI2L7ZK=O<L,QMG%>8"I@L?'$&!PMU'NOK1%.;\$8SS(#BP]>8#LU0._V;
MF[>D.=?V4V@65A*\HT1Z</F>W/-)_>K<;L0MT7Q:M(L;?-+R DLJN+;:)>DZ
M1L61G 3-E*@4<5P".UU898.?22EMU<*4]ZK76I?=GBS)=$5X0J:$FD^A!'6U
MY7.TD/5,%2$:.E!WE?\9KA70QD3G17X%YS+3THGX,6HW44PQ@6NDB@&QP@C"
M$[@I'S.\"J9EN1L?KTXZU<HZ)FA-9:T#GW9Y))R]H+O'X20'"]P89)2T-WP$
MAS[*; I"6W S'J>"*7>\E:PU2]9/>=4_76,/MC_U@?WY6'? 4AHJ(6X1+TIK
MB0OV#6.*;KV8F^M2V0B3_7,.IDLLCZ&4O'U]ZKNH;CHAJ<'IT)$$$K08=)M&
MQ])1F=?52'KXJ=_ NT'<ZH&W\S;>34;-R0NN[Y5E;6=?AJCQ5=."+N=N_5%6
M6>W++7ZP;UB?X1("#[2@DZLCK'RGK1BO6XQ5="F;;@?"KK%F+E&SW8O[BQ-D
MC@7A3K%"B<7=2XRO=0@+S[UKTC[]^.K-KV?_I#HPSE\E'*2AX_C;V>O7;#G4
ME7%?PSC7F$_>Y>$W>BV:=9Y0B87[<G'0)O'% PR=CE?5LPF%Y2[N'H%EI$F;
MBIV[I/";)4#;8'6>@UUM2R5=1H^"[F'T4Y9/\O-L5$:_@,Z8E;;)FURHYQ)5
M__3+J;8I.<UAFPJHHXBC?Y[1N\S,U5:)K#M^T;2!%210_")'FK&53,DL;Q:V
MKXP=UW=202-WVMX-'M$DMT.2YO-<6I>=7^VE7V.B$4(C)I]W8Z?8))V"9% 3
M/\\"PG/B\-4.! O49U%EPSQ=1!\^_E.#() :;I'6% <81$.E39YNI6>S)DIG
MQRE3T^GZNT]MQ7#]831[.#8>E7E$W3*#SI5LF3I>X)FGE+',]2]Q&":+I+@P
M%14)1N0X[!",VXFT44@X0AE-V0GW'+^Q55'SPNS0%_(2%E?/C4;'L4P1@IA)
M2"T-2!H&T_G)>/R$QC!Y=C:FWG[L(U$J,*Z-;V5M_;+&!3(P?9IH"XP:JREM
M^O* 0+0QC40./HM9'1"]J82AH4CEA<=7Y_Z BF24S-FB<YZE(,^!QZ38"*,(
MS,P5<?_.FRUG$!A>V3X?R?Z0U2RSRG3[&[97R"_DAQ2!][CA4;L"\WB[_][;
M(SZJV%[E>3]V W%';9B/$B-KS1X8625=ZR#)&CL?RX\$45FXK^*\59&-;-D1
MS0Y.(_D;YR4S*-'0OJAD""NIGH+/AQ+% J+I!4Q03&2 SXO_Q,^2N;U"ON3P
M%?!PS*0=EV:\<S@J4\\^>NND9(>Z'H^NLCJOO^WOZ>GO&6S[>Y:2O*_$/O[#
M0BW@$&,2C>$(C.!YP54!9XO[+QC>VK#9"R$I'"J90_K27*R@8#<906P8B7PY
M/!:@!>K2>/<>K= !HKF.OE8/LMFV,<3">CRZZOK2I.F,&Y[);*B'_6^:Q]<Z
M)I@G+D4MM;U4:0HW6 UB37Y9.\<I \@U8IE8$5.I(LP64"[DE.-D<-1PY+82
ML6Z)&$?SBT4)KD4R(UKEA09T./E#_H@XMZ JS)P=H%J\:&6/\-UL#_JF*X9K
M)-!LL5R5DOI;I7%7U;2&U[^,P^V8F-K*PSUXY$2-H!$ZH52]0VPIG.<OS) J
M@*Y4 NK"1D\-_$RDZE;3D^$,3XZ@4_6$6R@DUB_\PJ*%J? 0ACPOV-T5<U_3
MN6 I_4[BXJ[2*/O(=).]-D:09 ;9$KF+2M/5;G0*%H]R!O+5;EW89^+:'8[>
M9(R$&WCGK>S>@^PB>-X.C?M*%H&"19?.:N@?2DIQ98Q0,CYGW :BJ@NKVQ!2
M9;G-#& F0/_J9RVEMP1W0;+LU#'!F0"=9*R8G_[*"WK;2M+UH'#R0WONF@\G
M$7/6Q#GT'LKV1Q2&=+C+K'24,CJ[FR0YXRI8"KFX+5O=A_B>OGYWB@6;5Q0/
MEKZ/+.GXH&61K&6:SS#Q*FF//V942/I8D2A194!T82D^F05^0^F!J&Y"SB X
M_Z,%B-U5HX\'DV9@GX,:,LHG0_50$PYB':&]#U,=4X05@R?*BB"]L=5Z]R V
M@G%4(E:!2:_!BWHE*,^O\F(NZ0EVR*4G 3&C4%^,L2.')$CK@_AU6R!LX":!
M4IF(G%(#F9W['67%J)[*9*7*%:H4UPU!CU5Q:^R<&%I+BYN=E6A!N1$/HU \
M FA]-R"I]:5)T1F=7;03+@\/EJ"R0(9)Q:!/C.L)DE:8RNLQX:%I4V&7.8'C
M<].4]U6N7%^ ^V[ ITHES2G!'8,0H,M$'\;DY<16R24 .3>5EK736*N"<U-1
MDRV9/H*%5#L('Z0FG%)MF!<^I,DT.=]&#VN7HE>+(>J!*AE]\AWKDC%48!<*
M!%,VFCS"_0,+EKFBC)4AZ>6B9$#%@'+.[*G47>$WP;,S%2-RUNA<55=Y\2FT
M81<)^(.!DR3X!;5 &F_EX!ZB2.=;^NWQ[+QB<#CF@,[A7MB@D-WU4KOK\*.N
M=5CZ";B<[!JWJ8_/;YW6-"9$A6)".,=I0<#EBQ*-Q?8+?65&[29"'QDI(?C-
M,/-:,$3V-*LHWXV&BR!PMW)U'PW^7'F3@4H4@AV+0:T@%+4_O^Y7^GEL$3O<
MC5;9!*="ZHFVL<5O?1]CV79';8]V]Y/[[)I>1"XUMSHWS?YX9RQG!D6*3*7?
MN+\5E_M50YJVG%'CNF9C* >-<Q8+D)*KI$B=S_OK^U^<SRM>A'3J;?=JS7OU
M=E)C7L[R*%"]*OD,YW(B@6;9,!?X5[+[;,Q=:Y@8"MSFU,!!)U0D^#"3'#?B
MC\L<1R;]V916HDZH"(+DL[C%'44K/.8^>,8VUW=? RG2DL&X\[9/RYN(E2,K
M6VQD'Q?16&3-\ C45>+@@#'F!.6-@"<0CS &5"@4GCFYW:ZNN%MT]5L.9O=>
M<S49N1D^JG/0^;4I1T4V-#K1BP&@L@_P$###(RM"46;LP'-/ISQG^ON^JUE.
MFLA FJE\QFX;#S/_3U[KC##"FYW/$,":,9DX2O'JYGVWH"<K,.QH=!FY$21V
M)W#JJ#2&*<.0S".;&N4J:$];PXFPWY@2=8F\/F?LDNB<LG#4+YEFZ+SP[#"2
M03 E T-,85KVE8Z7=+]"@)<V<Z1'/L:W,5,LV&BA@U+;PB*A<U%4XLE+7EL"
MF1-">8+(RGP$I!3$!F?<O? +_B;L'C$O*<Y.=N[XF=]_(.^4-N6*"CJXWS@L
M%O>68P(5W=V(8/NZ?*RD67N" Q?:DZ?VP+F,GFDSEC<2[R*34@ ],,*M$)-/
MW(Z/Z#;"\Q($]P<[%_Z6W9.=7_*<LF64XJ6<JD[!RZ#Y AX,Y\I3TEX\;*[;
M45HXTRW(].,W>^U_K<U>MS5Q)9R'"=MA,<PZ>'6/ !Y+,'#>!S1!_%#8!%$7
M.,$J>"M+0[3< 4GIQA5&XLV38X\'=+4UQD^5/1\[4#ZX?5I_N&--007>?D(U
M"[K]_LO=_9#E\,71[DD?#>E;K-VQA<3&&JF=[._M'=I:<\?CNB24/ ,.XWB
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M?=T"J^I=-.GFU/42VH]S6HDK@H_0^!'92PQ")=G P_7&./P%.SSOKBB=.S3
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MGFN!2D02(N':!0D\?9>.Z?@&OFP8V=DJ5>YFK6H4[Z) S\,;IM5N'M^%;HY
M)>B=PM>Y78PR4[P\VJ$S6[1E0 N3N/5A@LY;?U:]W1? SCC?+GO\4O" X$Q@
M><Y5M)WBNM)F-(MZ*VY9@:RDR!/KH.X<?,VPRVPZ*0WFR//*0RN1*(%$DXJ!
MN*?"$F<G"4C]-/I_DP8L<O<3+&&W^QOS[JE]?EMR6:7D\N)K+;FL.-VU6A:4
MJPG>W$0PL.KW:82HW%;3=$"O<I?:]9\1'6QMJG(=ROGS ^P&>A6/$"=#N!:<
M:S\/U!C1"(=K^W*KMZZQ/JPC_EM["15)C-I*J81E&X@(AXZY$[,@<N/FE,L,
M](5V]5I ,J]!E*D1=J-7>L'*Y:;":\O\"MEBINV#!XFYML;-URY5Y$TK@>G#
MYBAR<[5<QXU"Z /6'.1#Z.]:HJHZ5;:+4>.ILK(SZ^R8O#VESMDG=RU],5@
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MEKR/R)6[B'$D5"O.A\_WX@C_]SO08L+V9@SF[FO;C#EQGKH+_]F7<.OB;%.
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M4'H.HA=.N&-_H'&JYDQM3Z!K2ASR4<^,&@KIUZ)].(Z/@[_CLC":.TB0)<+
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M6BFO,,+=3GR>.4H7I3691 50U\.-F(SJ583\)PT^$0^9U_MZ8]<LV,LD9&Y
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M/MY=]K3#KG%E6C*Z4RMXW2\.L]FTXP0PZ",-<%8<X+Z5"2/MW6+H]&!$R+
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MA*S+!M<)"G\(9[S0D7^&\3QPBTEQ^#MQG>#74?E%I18ML(V$K5"'C[LN+9N
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M5W$-6$86LW_!^K="[D@VQK+W0-G:0!D&XGEN4AX67&3T_ADT#E7_IZ2Q/#X
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MQW.+WV8<V"O(*NZ5^-[2,[>YYYK'S[G-;2-LFSLK?MGK\%]02P,$%     @
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MONU.(&%7OZEB@S OP7\#4$L! A0#%     @ ]XFG6B,M^&+-$P  =<T  !$
M             ( !     &%D;6$M,C R-3 S,S$N>'-D4$L! A0#%     @
M]XFG6L@IB<5>#0  /IP  !4              ( !_!,  &%D;6$M,C R-3 S
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( />)IUJ9K;9I6CX  "?5 P 5
M      "  8TA  !A9&UA+3(P,C4P,S,Q7V1E9BYX;6Q02P$"% ,4    " #W
MB:=:Z_SBI$^1  #TWP8 %0              @ $:8   861M82TR,#(U,#,S
M,5]L86(N>&UL4$L! A0#%     @ ]XFG6E&4HQ'S/@  @P\$ !4
M     ( !G/$  &%D;6$M,C R-3 S,S%?<')E+GAM;%!+ 0(4 Q0    ( /B)
MIUKK8.%8%M0! %EW#P 2              "  <(P 0!E9C(P,#0W-30X7S$P
M<2YH=&U02P$"% ,4    " #XB:=:*&!X+\D'   L)@  %0
M@ $(!0, 968R,# T-S4T.%]E>#,Q+3$N:'1M4$L! A0#%     @ ^(FG6@60
M5 K;!P  _24  !4              ( !! T# &5F,C P-#<U-#A?97@S,2TR
M+FAT;5!+ 0(4 Q0    ( /B)IUH7F!%*A00  &X/   5              "
M 1(5 P!E9C(P,#0W-30X7V5X,S(M,2YH=&U02P$"% ,4    " #XB:=:_GWQ
M2'@$  !D#P  %0              @ '*&0, 968R,# T-S4T.%]E>#,R+3(N
9:'1M4$L%!@     *  H EP(  '4> P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>ef20047548_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:adma="http://admabiologics.com/20250331"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="adma-20250331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2025-05-02</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidAfterTheFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToThirdAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-06</startDate>
            <endDate>2025-05-06</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-05</startDate>
            <endDate>2025-05-05</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-06</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-06</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2025-01-07</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2024-01-10</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2024-03-14</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2024-02-24</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:GenesisBPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:GenesisBPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:GrifolsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:KEDPlasmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:GrifolsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:KEDPlasmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-01</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Facility">
        <measure>adma:Facility</measure>
    </unit>
    <unit id="Product">
        <measure>adma:Product</measure>
    </unit>
    <unit id="Customer">
        <measure>adma:Customer</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Term">
        <measure>adma:Term</measure>
    </unit>
    <unit id="L">
        <measure>adma:L</measure>
    </unit>
    <unit id="Segment">
        <measure>adma:Segment</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-9495">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0" id="ixv-26">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-9496">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-9497">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-40">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-50">001-36728</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-54">ADMA BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-67">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-71">56-2590442</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-9498">465 State Route 17</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-9499">Ramsey</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-9500">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-90">07446</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-9501">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-9502">478-5552</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-132">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-136">ADMA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-9503">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-9504">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-9505">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-9506">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-9507">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-188">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c0" id="ixv-9508">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-9509"
      unitRef="shares">238734246</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-9510" unitRef="usd">71625000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-9511" unitRef="usd">103147000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="-3" id="ixv-9512" unitRef="usd">99412000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="-3" id="ixv-9513" unitRef="usd">49999000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c2" decimals="-3" id="ixv-9514" unitRef="usd">172188000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="-3" id="ixv-9515" unitRef="usd">170235000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="-3" id="ixv-9516" unitRef="usd">8589000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-9517" unitRef="usd">8029000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" id="ixv-9518" unitRef="usd">351814000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" id="ixv-9519" unitRef="usd">331410000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-9520" unitRef="usd">57710000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" id="ixv-9521" unitRef="usd">54707000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c2" decimals="-3" id="ixv-9522" unitRef="usd">452000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="-3" id="ixv-9523" unitRef="usd">460000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c2" decimals="-3" id="ixv-9524" unitRef="usd">3530000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c3" decimals="-3" id="ixv-9525" unitRef="usd">3530000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c2" decimals="-3" id="ixv-9526" unitRef="usd">80855000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c3" decimals="-3" id="ixv-9527" unitRef="usd">84280000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-9528" unitRef="usd">8020000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-9529" unitRef="usd">8634000</us-gaap:OperatingLeaseRightOfUseAsset>
    <adma:DepositsAndOtherNoncurrentAssets contextRef="c2" decimals="-3" id="ixv-9530" unitRef="usd">8188000</adma:DepositsAndOtherNoncurrentAssets>
    <adma:DepositsAndOtherNoncurrentAssets contextRef="c3" decimals="-3" id="ixv-9531" unitRef="usd">5657000</adma:DepositsAndOtherNoncurrentAssets>
    <us-gaap:Assets contextRef="c2" decimals="-3" id="ixv-9532" unitRef="usd">510569000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" id="ixv-9533" unitRef="usd">488678000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="-3" id="ixv-9534" unitRef="usd">20607000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="-3" id="ixv-9535" unitRef="usd">20219000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c2" decimals="-3" id="ixv-9536" unitRef="usd">31560000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c3" decimals="-3" id="ixv-9537" unitRef="usd">33962000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-9538" unitRef="usd">143000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-9539" unitRef="usd">143000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-9540" unitRef="usd">1188000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-9541" unitRef="usd">1218000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-9542" unitRef="usd">53498000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-9543" unitRef="usd">55542000</us-gaap:LiabilitiesCurrent>
    <us-gaap:SeniorLongTermNotes contextRef="c2" decimals="-3" id="ixv-9544" unitRef="usd">72527000</us-gaap:SeniorLongTermNotes>
    <us-gaap:SeniorLongTermNotes contextRef="c3" decimals="-3" id="ixv-9545" unitRef="usd">72337000</us-gaap:SeniorLongTermNotes>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c2" decimals="-3" id="ixv-9546" unitRef="usd">1512000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c3" decimals="-3" id="ixv-9547" unitRef="usd">1547000</us-gaap:DeferredRevenueNoncurrent>
    <adma:LongTermLiabilityEndOfTermFeePayable contextRef="c2" decimals="-3" id="ixv-9548" unitRef="usd">1313000</adma:LongTermLiabilityEndOfTermFeePayable>
    <adma:LongTermLiabilityEndOfTermFeePayable contextRef="c3" decimals="-3" id="ixv-9549" unitRef="usd">1313000</adma:LongTermLiabilityEndOfTermFeePayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-9550" unitRef="usd">8298000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-9551" unitRef="usd">8561000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c2" decimals="-3" id="ixv-9552" unitRef="usd">2000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c3" decimals="-3" id="ixv-9553" unitRef="usd">360000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" id="ixv-9554" unitRef="usd">137150000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" id="ixv-9555" unitRef="usd">139660000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="4"
      id="ixv-9556"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="4"
      id="ixv-9557"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c2" decimals="0" id="ixv-9558" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" id="ixv-9559" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c2" decimals="0" id="ixv-9560" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c3" decimals="0" id="ixv-9561" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c2" decimals="0" id="ixv-9562" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c3" decimals="0" id="ixv-9563" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c2" decimals="-3" id="ixv-9564" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c3" decimals="-3" id="ixv-9565" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="4"
      id="ixv-9566"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="4"
      id="ixv-9567"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" id="ixv-9568" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" id="ixv-9569" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" id="ixv-9570" unitRef="shares">238532252</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" id="ixv-9571" unitRef="shares">238532252</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" id="ixv-9572" unitRef="shares">236620545</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" id="ixv-9573" unitRef="shares">236620545</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" id="ixv-9574" unitRef="usd">24000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" id="ixv-9575" unitRef="usd">24000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" id="ixv-9576" unitRef="usd">655074000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" id="ixv-9577" unitRef="usd">657577000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-9578" unitRef="usd">-281679000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" id="ixv-9579" unitRef="usd">-308583000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-9580" unitRef="usd">373419000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-9581" unitRef="usd">349018000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" id="ixv-9582" unitRef="usd">510569000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" id="ixv-9583" unitRef="usd">488678000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c0" decimals="-3" id="ixv-9584" unitRef="usd">114802000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c4" decimals="-3" id="ixv-9585" unitRef="usd">81875000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="-3" id="ixv-9586" unitRef="usd">53705000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c4" decimals="-3" id="ixv-9587" unitRef="usd">42767000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="-3" id="ixv-9588" unitRef="usd">61097000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c4" decimals="-3" id="ixv-9589" unitRef="usd">39108000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-9590" unitRef="usd">826000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" id="ixv-9591" unitRef="usd">450000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCostAndExpenseOperating contextRef="c0" decimals="-3" id="ixv-9592" unitRef="usd">1286000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating contextRef="c4" decimals="-3" id="ixv-9593" unitRef="usd">1005000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="-3" id="ixv-9594" unitRef="usd">25000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c4" decimals="-3" id="ixv-9595" unitRef="usd">193000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-9596" unitRef="usd">24079000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c4" decimals="-3" id="ixv-9597" unitRef="usd">15639000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-9598" unitRef="usd">26216000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c4" decimals="-3" id="ixv-9599" unitRef="usd">17287000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-9600" unitRef="usd">34881000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="-3" id="ixv-9601" unitRef="usd">21821000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="-3" id="ixv-9602" unitRef="usd">608000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c4" decimals="-3" id="ixv-9603" unitRef="usd">384000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c0" decimals="-3" id="ixv-9604" unitRef="usd">1975000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c4" decimals="-3" id="ixv-9605" unitRef="usd">3769000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-9606" unitRef="usd">-64000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c4" decimals="-3" id="ixv-9607" unitRef="usd">-35000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-9608" unitRef="usd">-1431000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="-3" id="ixv-9609" unitRef="usd">-3420000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" id="ixv-9610" unitRef="usd">33450000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c4" decimals="-3" id="ixv-9611" unitRef="usd">18401000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-9612" unitRef="usd">6546000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c4" decimals="-3" id="ixv-9613" unitRef="usd">595000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-9614" unitRef="usd">26904000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" id="ixv-9615" unitRef="usd">17806000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-9616"
      unitRef="usdPershares">0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c4"
      decimals="2"
      id="ixv-9617"
      unitRef="usdPershares">0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-9618"
      unitRef="usdPershares">0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c4"
      decimals="2"
      id="ixv-9619"
      unitRef="usdPershares">0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="0" id="ixv-9620" unitRef="shares">237775476</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c4" decimals="0" id="ixv-9621" unitRef="shares">228874847</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c0" decimals="0" id="ixv-9622" unitRef="shares">244676350</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c4" decimals="0" id="ixv-9623" unitRef="shares">236414374</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="c5" decimals="0" id="ixv-9624" unitRef="shares">236620545</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-9625" unitRef="usd">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="-3" id="ixv-9626" unitRef="usd">657577000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="-3" id="ixv-9627" unitRef="usd">-308583000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-9628" unitRef="usd">349018000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c8" decimals="-3" id="ixv-9629" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c9" decimals="-3" id="ixv-9630" unitRef="usd">4624000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c10" decimals="-3" id="ixv-9631" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c0" decimals="-3" id="ixv-9632" unitRef="usd">4624000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants contextRef="c8" decimals="0" id="ixv-9633" unitRef="shares">866302</adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants contextRef="c8" decimals="-3" id="ixv-9634" unitRef="usd">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants contextRef="c9" decimals="-3" id="ixv-9635" unitRef="usd">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants contextRef="c10" decimals="-3" id="ixv-9636" unitRef="usd">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants contextRef="c0" decimals="-3" id="ixv-9637" unitRef="usd">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares contextRef="c8" decimals="0" id="ixv-9638" unitRef="shares">1016005</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount contextRef="c8" decimals="-3" id="ixv-9639" unitRef="usd">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount contextRef="c9" decimals="-3" id="ixv-9640" unitRef="usd">-7228000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount contextRef="c10" decimals="-3" id="ixv-9641" unitRef="usd">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount contextRef="c0" decimals="-3" id="ixv-9642" unitRef="usd">-7228000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c8" decimals="0" id="ixv-9643" unitRef="shares">29400</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c8" decimals="-3" id="ixv-9644" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c9" decimals="-3" id="ixv-9645" unitRef="usd">101000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c10" decimals="-3" id="ixv-9646" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="-3" id="ixv-9647" unitRef="usd">101000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="-3" id="ixv-9648" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c9" decimals="-3" id="ixv-9649" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="-3" id="ixv-9650" unitRef="usd">26904000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-9651" unitRef="usd">26904000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c11"
      decimals="0"
      id="ixv-9652"
      unitRef="shares">238532252</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c11" decimals="-3" id="ixv-9653" unitRef="usd">24000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c12" decimals="-3" id="ixv-9654" unitRef="usd">655074000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c13" decimals="-3" id="ixv-9655" unitRef="usd">-281679000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="-3" id="ixv-9656" unitRef="usd">373419000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c14"
      decimals="0"
      id="ixv-9657"
      unitRef="shares">226063032</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="-3" id="ixv-9658" unitRef="usd">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" id="ixv-9659" unitRef="usd">641439000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-9660" unitRef="usd">-506256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" id="ixv-9661" unitRef="usd">135206000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c18" decimals="-3" id="ixv-9662" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c19" decimals="-3" id="ixv-9663" unitRef="usd">2141000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c20" decimals="-3" id="ixv-9664" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c4" decimals="-3" id="ixv-9665" unitRef="usd">2141000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants
      contextRef="c18"
      decimals="0"
      id="ixv-9666"
      unitRef="shares">4545503</adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants contextRef="c18" decimals="-3" id="ixv-9667" unitRef="usd">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants contextRef="c19" decimals="-3" id="ixv-9668" unitRef="usd">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants contextRef="c20" decimals="-3" id="ixv-9669" unitRef="usd">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants contextRef="c4" decimals="-3" id="ixv-9670" unitRef="usd">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares
      contextRef="c18"
      decimals="0"
      id="ixv-9671"
      unitRef="shares">774889</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount contextRef="c18" decimals="-3" id="ixv-9672" unitRef="usd">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount contextRef="c19" decimals="-3" id="ixv-9673" unitRef="usd">-2476000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount contextRef="c20" decimals="-3" id="ixv-9674" unitRef="usd">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount contextRef="c4" decimals="-3" id="ixv-9675" unitRef="usd">-2476000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c18"
      decimals="0"
      id="ixv-9676"
      unitRef="shares">386341</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c18" decimals="-3" id="ixv-9677" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c19" decimals="-3" id="ixv-9678" unitRef="usd">1029000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20" decimals="-3" id="ixv-9679" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c4" decimals="-3" id="ixv-9680" unitRef="usd">1029000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c18" decimals="-3" id="ixv-9681" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c19" decimals="-3" id="ixv-9682" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c20" decimals="-3" id="ixv-9683" unitRef="usd">17806000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" id="ixv-9684" unitRef="usd">17806000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c21"
      decimals="0"
      id="ixv-9685"
      unitRef="shares">231769765</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c21" decimals="-3" id="ixv-9686" unitRef="usd">23000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c22" decimals="-3" id="ixv-9687" unitRef="usd">642133000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c23" decimals="-3" id="ixv-9688" unitRef="usd">-488450000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c24" decimals="-3" id="ixv-9689" unitRef="usd">153706000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-9690" unitRef="usd">26904000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" id="ixv-9691" unitRef="usd">17806000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" id="ixv-9692" unitRef="usd">1969000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c4" decimals="-3" id="ixv-9693" unitRef="usd">2114000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c0" decimals="-3" id="ixv-9694" unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c4" decimals="-3" id="ixv-9695" unitRef="usd">-23000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-9696" unitRef="usd">3425000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c4" decimals="-3" id="ixv-9697" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-9698" unitRef="usd">4624000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c4" decimals="-3" id="ixv-9699" unitRef="usd">2141000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c0" decimals="-3" id="ixv-9700" unitRef="usd">190000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c4" decimals="-3" id="ixv-9701" unitRef="usd">253000</us-gaap:AmortizationOfDebtDiscountPremium>
    <adma:AmortizationOfLicenseRevenue contextRef="c0" decimals="-3" id="ixv-9702" unitRef="usd">-36000</adma:AmortizationOfLicenseRevenue>
    <adma:AmortizationOfLicenseRevenue contextRef="c4" decimals="-3" id="ixv-9703" unitRef="usd">-36000</adma:AmortizationOfLicenseRevenue>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="-3" id="ixv-9704" unitRef="usd">49413000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c4" decimals="-3" id="ixv-9705" unitRef="usd">22200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="-3" id="ixv-9706" unitRef="usd">1953000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c4" decimals="-3" id="ixv-9707" unitRef="usd">4826000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" id="ixv-9708" unitRef="usd">2596000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c4" decimals="-3" id="ixv-9709" unitRef="usd">-1593000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <adma:IncreaseDecreaseInDepositsAndOtherAssets contextRef="c0" decimals="-3" id="ixv-9710" unitRef="usd">-120000</adma:IncreaseDecreaseInDepositsAndOtherAssets>
    <adma:IncreaseDecreaseInDepositsAndOtherAssets contextRef="c4" decimals="-3" id="ixv-9711" unitRef="usd">982000</adma:IncreaseDecreaseInDepositsAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="-3" id="ixv-9712" unitRef="usd">142000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c4" decimals="-3" id="ixv-9713" unitRef="usd">447000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c0" decimals="-3" id="ixv-9714" unitRef="usd">-2401000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c4" decimals="-3" id="ixv-9715" unitRef="usd">772000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c0" decimals="-3" id="ixv-9716" unitRef="usd">-650000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c4" decimals="-3" id="ixv-9717" unitRef="usd">677000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-9718" unitRef="usd">-19675000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="-3" id="ixv-9719" unitRef="usd">-2218000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-9720" unitRef="usd">4701000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c4" decimals="-3" id="ixv-9721" unitRef="usd">2347000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c0" decimals="-3" id="ixv-9722" unitRef="usd">19000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c4" decimals="-3" id="ixv-9723" unitRef="usd">15000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-9724" unitRef="usd">-4720000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c4" decimals="-3" id="ixv-9725" unitRef="usd">-2362000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <adma:TaxesPaidOnVestedRestrictedStockUnits contextRef="c0" decimals="-3" id="ixv-9726" unitRef="usd">7228000</adma:TaxesPaidOnVestedRestrictedStockUnits>
    <adma:TaxesPaidOnVestedRestrictedStockUnits contextRef="c4" decimals="-3" id="ixv-9727" unitRef="usd">2476000</adma:TaxesPaidOnVestedRestrictedStockUnits>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="-3" id="ixv-9728" unitRef="usd">101000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c4" decimals="-3" id="ixv-9729" unitRef="usd">1029000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-9730" unitRef="usd">-7127000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c4" decimals="-3" id="ixv-9731" unitRef="usd">-1447000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-9732" unitRef="usd">-31522000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c4" decimals="-3" id="ixv-9733" unitRef="usd">-6027000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-9734" unitRef="usd">103147000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c17" decimals="-3" id="ixv-9735" unitRef="usd">51352000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-9736" unitRef="usd">71625000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c24" decimals="-3" id="ixv-9737" unitRef="usd">45325000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0" id="ixv-2570">&lt;div style="text-indent: -27pt; padding-left: 27pt;"&gt;
    &lt;div style="float: left; width: 27.0pt; white-space: nowrap;"&gt;
     &lt;span style="font-weight: bold;"&gt;1.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span style="font-weight: bold; text-decoration: underline;"&gt;ORGANIZATION AND BUSINESS&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 33.75pt; text-align: justify;"&gt;
   &lt;span style="color: rgb(0, 0, 0);"&gt;ADMA Biologics, Inc. (&#x201c;ADMA&#x201d; or the &#x201c;Company&#x201d;) is a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company&#x2019;s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-indent: 33.75pt;"&gt;
   &lt;span style="color: rgb(0, 0, 0);"&gt;&#160;&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-indent: 33.75pt; text-align: justify;"&gt; &lt;span style="color: rgb(0, 0, 0);"&gt;ADMA operates through its wholly owned subsidiaries ADMA BioManufacturing, LLC (&#x201c;ADMA BioManufacturing&#x201d;) and ADMA BioCenters Georgia Inc. (&#x201c;ADMA BioCenters&#x201d;). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of certain assets held by the Company&#x2019;s former third-party contract manufacturer, which included the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;)-licensed BIVIGAM and Nabi-HB immunoglobulin products, and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the &#x201c;Boca Facility&#x201d;). ADMA BioCenters is the Company&#x2019;s source plasma collection business with ten plasma collection facilities located throughout the United States, all of which hold an approved license with the FDA.&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-indent: 33.75pt;"&gt;
   &lt;span style="color: rgb(0, 0, 0);"&gt;&#160;&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-indent: 33.75pt; text-align: justify;"&gt; &lt;span style="color: rgb(0, 0, 0);"&gt;The Company has three FDA-approved products, all of which are currently marketed and commercially available: (i) ASCENIV (Immune Globulin Intravenous, Human &#x2013; slra 10% Liquid), an intravenous immune globulin (&#x201c;IVIG&#x201d;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#x201c;PI&#x201d;), also known as Primary Immunodeficiency Disease (&#x201c;PIDD&#x201d;) or Inborn Errors of Immunity, for which the Company received FDA approval in April&#160;&#160;2019 and commenced first commercial sales in October 2019; (ii) BIVIGAM (Immune Globulin Intravenous, Human), an IVIG product indicated for the treatment of PI, and for which the Company received FDA approval in May 2019 and commenced commercial sales in August 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (&#x201c;HBsAg&#x201d;) and other listed exposures to Hepatitis B. In addition to its commercially available immunoglobulin products, the Company generates revenues from the sale of intermediates that result from the immunoglobulin production process and from time to time provides contract manufacturing and laboratory services for certain clients. The Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.&lt;/span&gt; &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment
      contextRef="c0"
      decimals="0"
      id="ixv-9738"
      unitRef="Facility">10</adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment>
    <adma:NumberOfFDAApprovedProduct
      contextRef="c0"
      decimals="0"
      id="ixv-9739"
      unitRef="Product">3</adma:NumberOfFDAApprovedProduct>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-2591">&lt;div style="text-indent: -27pt; padding-left: 27pt;"&gt;
    &lt;div style="float: left; width: 27.0pt; white-space: nowrap;"&gt;
     &lt;span style="font-weight: bold;"&gt;2.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span style="font-weight: bold; text-decoration: underline;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Principles of consolidation and basis of presentation&lt;/span&gt;&lt;/div&gt;

  &lt;div&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;). &lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2024 included in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 18, 2025. All intercompany balances and transactions have been eliminated in consolidation. The preparation of our interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed. We have made reasonable estimates and judgments of such items within our financial statements and there may be changes to those estimates in future periods. &lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;During the three months ended March 31, 2025 and 2024, comprehensive income was equal to the net income amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year.&lt;/span&gt;
  &lt;/div&gt;&lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include rebates deducted from gross revenues and estimates related to Company&#x2019;s effective tax rate.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Fair Value of Financial Instruments&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company&#x2019;s senior credit facility (see Note 6) approximates fair value, based on a Level 3 classification under the fair value hierarchy, due to the variable interest rate on this debt.&#160;&#160;&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Accounts Receivable&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;Accounts receivable is reported at realizable value, net of allowances for customer credits and credit losses in the amount of $3.0 million and $0.2 million at March 31, 2025 and December 31, 2024, respectively. &lt;/span&gt;&lt;span style="color: rgb(33, 37, 41);"&gt;The Company extends credit to its customers based upon an evaluation of each customer&#x2019;s financial condition and credit history. Evaluations of the financial condition, payment history and associated credit risk of customers are performed on an ongoing basis.&lt;/span&gt;&lt;span&gt; Based on these evaluations, the Company has concluded that its credit risk is minimal. At March 31, 2025 and December 31, 2024, three customers accounted for an aggregate of approximately 85% and 91%, respectively, of the Company&#x2019;s total accounts receivable.&lt;/span&gt; &lt;/div&gt;
  &lt;div style="margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Inventories&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 33.75pt; text-align: justify;"&gt;
   &lt;span style="color: rgb(0, 0, 0);"&gt;Raw materials inventory consists of various materials purchased from suppliers, including normal source plasma and Respiratory Syncytial Virus (&#x201c;RSV&#x201d;) high titer plasma, used in the production of the Company&#x2019;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable supplies and depreciation. The Boca Facility overhead allocation to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#x2019;s FDA-approved products relative to the total square footage of the facility.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-indent: 33.75pt; text-align: justify;"&gt;
   &lt;span style="color: rgb(0, 0, 0);"&gt;&#160;&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-indent: 33.75pt; text-align: justify;"&gt;
   &lt;span style="color: rgb(0, 0, 0);"&gt;Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#x2019;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. &lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Goodwill&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at March 31, 2025 and December 31, 2024 was $3.5 million. All of the Company&#x2019;s goodwill is attributable to its ADMA BioManufacturing business segment.&#160;&#160;&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify; margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;The Company did not record any impairment charges related to goodwill for the three months ended March 31, 2025 and 2024.&lt;/span&gt; &lt;/div&gt;&lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Revenue Recognition&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;Revenues are comprised of (i) revenues from the sale of the Company&#x2019;s immunoglobulin products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company&#x2019;s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediates; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest AG (&#x201c;Biotest&#x201d;) in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years. &lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based on when the product is shipped or delivered, depending on the sales terms, and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#x2019;s immunoglobulin products is recognized when the product reaches the customer&#x2019;s destination, and is recorded net of estimated rebates, wholesaler distribution and related fees, customer incentives, including prompt pay discounts, wholesaler chargebacks, group purchasing organization fees and reimbursements for patient assistance. These estimates are based on historical experience and certain other assumptions, and while the Company believes that such estimates are reasonable, they are subject to change based on future experience and other factors. &lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company. &#160;&#160;&#160;&#160;&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify; margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;Product revenues from the sale of human plasma collected at the Company&#x2019;s plasma collection centers are recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;For the three months ended March 31, 2025, three customers represented an aggregate of approximately 74% of the Company&#x2019;s consolidated revenues. For the three months ended March 31, 2024, two customers represented an aggregate of approximately 70% of the Company&#x2019;s consolidated revenue. &lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Cost of Product Revenue&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;Cost of product revenue includes costs associated with the manufacture of the Company&#x2019;s FDA-approved products, intermediates and the collection of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the activities of these operations are attributable to new products or processes in development, the expenses are classified as research and development expenses. &lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div&gt; &lt;span style="color: rgb(0, 0, 0); font-style: italic; text-decoration: underline;"&gt;Earnings/loss Per Common Share&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-style: italic;"&gt;&#160;&#160;&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;For the three months ended March 31, 2025, basic and diluted earnings per share are calculated as follows:&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 89%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; height: 23.0pt;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-top: none; border-left: none; border-right: none; border-bottom: 2px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none; white-space: nowrap;"&gt;



      &lt;span style="font-weight: bold;"&gt;Three Months Ended
&lt;br/&gt;
      March 31, 2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Net income available to common stockholders ($000's) (numerator)
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;26,904&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Weighted-average number of common shares (denominator)
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;237,775,476&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Basic earnings per common shares
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;0.11&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Weighted-average number of common shares
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;237,775,476&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Potential shares of common stock arising from outstanding stock options
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;3,987,814&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Potential shares of common stock arising from outstanding warrants
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;47,536&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Potential shares of common stock arising from unvested RSUs
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;2,865,524&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Total shares - diluted (denominator)
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;244,676,350&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-left: none; border-right: none; border-top: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Diluted earnings per common share
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;0.11&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;&lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;For the three months ended March 31, 2025 and 2024, there were no shares with an anti-dilutive effect that needed to be excluded from the earnings per share computation. &lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Recent Accounting Pronouncements&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): &lt;/span&gt;&lt;span style="font-style: italic;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span&gt;. This Update requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid and became effective for public business entities for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that this Update may have on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 27pt; text-align: justify;"&gt;
   &lt;span&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="font-style: italic;"&gt;Income Statement - Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures&lt;/span&gt;&lt;span&gt; (Subtopic 220-40). The amendments in this Update require disclosure, in the notes to the financial statements, of specified information about certain costs and expenses, including but not limited to, purchases of inventory, employee compensation and selling expense. This Update becomes effective for fiscal years beginning after December 15, 2026. The Company is currently evaluating the impact that this Update may have on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;
  &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-2598">&lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Principles of consolidation and basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;). &lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2024 included in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 18, 2025. All intercompany balances and transactions have been eliminated in consolidation. The preparation of our interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed. We have made reasonable estimates and judgments of such items within our financial statements and there may be changes to those estimates in future periods. &lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;During the three months ended March 31, 2025 and 2024, comprehensive income was equal to the net income amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year.&lt;/span&gt;
  &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-2631">&lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include rebates deducted from gross revenues and estimates related to Company&#x2019;s effective tax rate.&lt;/span&gt;
  &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c0" id="ixv-2639">&lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Fair Value of Financial Instruments&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company&#x2019;s senior credit facility (see Note 6) approximates fair value, based on a Level 3 classification under the fair value hierarchy, due to the variable interest rate on this debt.&#160;&#160;&lt;/span&gt;
  &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c0" id="ixv-2647">&lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Accounts Receivable&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;Accounts receivable is reported at realizable value, net of allowances for customer credits and credit losses in the amount of $3.0 million and $0.2 million at March 31, 2025 and December 31, 2024, respectively. &lt;/span&gt;&lt;span style="color: rgb(33, 37, 41);"&gt;The Company extends credit to its customers based upon an evaluation of each customer&#x2019;s financial condition and credit history. Evaluations of the financial condition, payment history and associated credit risk of customers are performed on an ongoing basis.&lt;/span&gt;&lt;span&gt; Based on these evaluations, the Company has concluded that its credit risk is minimal. At March 31, 2025 and December 31, 2024, three customers accounted for an aggregate of approximately 85% and 91%, respectively, of the Company&#x2019;s total accounts receivable.&lt;/span&gt; &lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts contextRef="c2" decimals="-5" id="ixv-9740" unitRef="usd">3000000</adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts>
    <adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts contextRef="c3" decimals="-5" id="ixv-9741" unitRef="usd">200000</adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts>
    <adma:NumberOfCustomers
      contextRef="c25"
      decimals="INF"
      id="ixv-9742"
      unitRef="Customer">3</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c25"
      decimals="INF"
      id="ixv-9743"
      unitRef="pure">0.85</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c26" decimals="2" id="ixv-9744" unitRef="pure">0.91</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0" id="ixv-2657">&lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Inventories&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 33.75pt; text-align: justify;"&gt;
   &lt;span style="color: rgb(0, 0, 0);"&gt;Raw materials inventory consists of various materials purchased from suppliers, including normal source plasma and Respiratory Syncytial Virus (&#x201c;RSV&#x201d;) high titer plasma, used in the production of the Company&#x2019;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable supplies and depreciation. The Boca Facility overhead allocation to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#x2019;s FDA-approved products relative to the total square footage of the facility.&lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 33.75pt; text-align: justify;"&gt;
   &lt;span style="color: rgb(0, 0, 0);"&gt;Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#x2019;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. &lt;/span&gt;
  &lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c0" id="ixv-2670">&lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Goodwill&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at March 31, 2025 and December 31, 2024 was $3.5 million. All of the Company&#x2019;s goodwill is attributable to its ADMA BioManufacturing business segment.&#160;&#160;&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;The Company did not record any impairment charges related to goodwill for the three months ended March 31, 2025 and 2024.&lt;/span&gt; &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:Goodwill contextRef="c2" decimals="-5" id="ixv-9745" unitRef="usd">3500000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c3" decimals="-5" id="ixv-9746" unitRef="usd">3500000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c0" decimals="0" id="ixv-9747" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c4" decimals="0" id="ixv-9748" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0" id="ixv-2699">&lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Revenue Recognition&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;Revenues are comprised of (i) revenues from the sale of the Company&#x2019;s immunoglobulin products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company&#x2019;s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediates; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest AG (&#x201c;Biotest&#x201d;) in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years. &lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based on when the product is shipped or delivered, depending on the sales terms, and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#x2019;s immunoglobulin products is recognized when the product reaches the customer&#x2019;s destination, and is recorded net of estimated rebates, wholesaler distribution and related fees, customer incentives, including prompt pay discounts, wholesaler chargebacks, group purchasing organization fees and reimbursements for patient assistance. These estimates are based on historical experience and certain other assumptions, and while the Company believes that such estimates are reasonable, they are subject to change based on future experience and other factors. &lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company. &#160;&#160;&#160;&#160;&lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;Product revenues from the sale of human plasma collected at the Company&#x2019;s plasma collection centers are recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.&lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;For the three months ended March 31, 2025, three customers represented an aggregate of approximately 74% of the Company&#x2019;s consolidated revenues. For the three months ended March 31, 2024, two customers represented an aggregate of approximately 70% of the Company&#x2019;s consolidated revenue. &lt;/span&gt; &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <adma:DeferredRevenueRemainingAmortizationPeriod contextRef="c0" id="ixv-9749">P22Y</adma:DeferredRevenueRemainingAmortizationPeriod>
    <adma:NumberOfCustomers
      contextRef="c27"
      decimals="0"
      id="ixv-9750"
      unitRef="Customer">3</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c27" decimals="2" id="ixv-9751" unitRef="pure">0.74</us-gaap:ConcentrationRiskPercentage1>
    <adma:NumberOfCustomers
      contextRef="c28"
      decimals="0"
      id="ixv-9752"
      unitRef="Customer">2</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c28" decimals="2" id="ixv-9753" unitRef="pure">0.70</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c0" id="ixv-2723">&lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Cost of Product Revenue&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;Cost of product revenue includes costs associated with the manufacture of the Company&#x2019;s FDA-approved products, intermediates and the collection of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the activities of these operations are attributable to new products or processes in development, the expenses are classified as research and development expenses. &lt;/span&gt;
  &lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-2731">&lt;div&gt; &lt;span style="color: rgb(0, 0, 0); font-style: italic; text-decoration: underline;"&gt;Earnings/loss Per Common Share&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-style: italic;"&gt;&#160;&#160;&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;For the three months ended March 31, 2025, basic and diluted earnings per share are calculated as follows:&lt;/span&gt; &lt;/div&gt;&lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 89%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; height: 23.0pt;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-top: none; border-left: none; border-right: none; border-bottom: 2px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none; white-space: nowrap;"&gt;



      &lt;span style="font-weight: bold;"&gt;Three Months Ended
&lt;br/&gt;
      March 31, 2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Net income available to common stockholders ($000's) (numerator)
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;26,904&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Weighted-average number of common shares (denominator)
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;237,775,476&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Basic earnings per common shares
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;0.11&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Weighted-average number of common shares
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;237,775,476&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Potential shares of common stock arising from outstanding stock options
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;3,987,814&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Potential shares of common stock arising from outstanding warrants
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;47,536&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Potential shares of common stock arising from unvested RSUs
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;2,865,524&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Total shares - diluted (denominator)
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;244,676,350&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-left: none; border-right: none; border-top: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Diluted earnings per common share
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;0.11&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;&lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;For the three months ended March 31, 2025 and 2024, there were no shares with an anti-dilutive effect that needed to be excluded from the earnings per share computation. &lt;/span&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-2736">&lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;For the three months ended March 31, 2025, basic and diluted earnings per share are calculated as follows:&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 89%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top; height: 23.0pt;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-top: none; border-left: none; border-right: none; border-bottom: 2px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none; white-space: nowrap;"&gt;



      &lt;span style="font-weight: bold;"&gt;Three Months Ended
&lt;br/&gt;
      March 31, 2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Net income available to common stockholders ($000's) (numerator)
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;26,904&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Weighted-average number of common shares (denominator)
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;237,775,476&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Basic earnings per common shares
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;0.11&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Weighted-average number of common shares
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;237,775,476&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Potential shares of common stock arising from outstanding stock options
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;3,987,814&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Potential shares of common stock arising from outstanding warrants
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;47,536&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Potential shares of common stock arising from unvested RSUs
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;2,865,524&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Total shares - diluted (denominator)
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-left: none; border-right: none; border-bottom: 2px solid black; border-top: none;"&gt;244,676,350&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-left: none; border-right: none; border-top: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Diluted earnings per common share
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;0.11&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-9754" unitRef="usd">26904000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-9755"
      unitRef="shares">237775476</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-9756"
      unitRef="usdPershares">0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-9757"
      unitRef="shares">237775476</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c29"
      decimals="INF"
      id="ixv-9758"
      unitRef="shares">3987814</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c30"
      decimals="INF"
      id="ixv-9759"
      unitRef="shares">47536</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c31"
      decimals="INF"
      id="ixv-9760"
      unitRef="shares">2865524</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-9761"
      unitRef="shares">244676350</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-9762"
      unitRef="usdPershares">0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c0" decimals="0" id="ixv-9763" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c4" decimals="0" id="ixv-9764" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-2835">&lt;div&gt; &lt;span style="font-style: italic; text-decoration: underline;"&gt;Recent Accounting Pronouncements&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): &lt;/span&gt;&lt;span style="font-style: italic;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span&gt;. This Update requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid and became effective for public business entities for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that this Update may have on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 27pt; text-align: justify;"&gt;
   &lt;span&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="font-style: italic;"&gt;Income Statement - Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures&lt;/span&gt;&lt;span&gt; (Subtopic 220-40). The amendments in this Update require disclosure, in the notes to the financial statements, of specified information about certain costs and expenses, including but not limited to, purchases of inventory, employee compensation and selling expense. This Update becomes effective for fiscal years beginning after December 15, 2026. The Company is currently evaluating the impact that this Update may have on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;
  &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0" id="ixv-2853">&lt;div style="text-indent: -27pt; padding-left: 27pt;"&gt;
    &lt;div style="float: left; width: 27.0pt; white-space: nowrap;"&gt;
     &lt;span style="font-weight: bold;"&gt;3.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span style="font-weight: bold; text-decoration: underline;"&gt;INVENTORIES&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: 27pt; clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;The following table provides the components of inventories:&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: center;"&gt;&#160;
  &lt;/div&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width : 9%; white-space : nowrap; "&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;



      &lt;span style="font-weight: bold;"&gt;March 31, &lt;br/&gt;

      2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align : center; width : 9%; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; "&gt;



      &lt;span style="font-weight: bold;"&gt;December 31,&lt;br/&gt;

      2024&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center;"&gt;


      &lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Raw materials
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;75,819&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;60,473&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Work-in-process
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;49,780&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;61,641&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Finished goods
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;46,589&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;48,121&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Total inventories
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;172,188&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;170,235&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;&lt;div style="text-align: center;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;Raw materials includes plasma and other materials expected to be used in the production of ASCENIV, BIVIGAM and Nabi-HB. These materials will be consumed in the production of goods expected to be available for sale or otherwise have alternative uses that provide a probable future benefit.&#160;&#160;&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the Company&#x2019;s immunoglobulin products. &lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available for commercial sale, as well as plasma collected at the Company&#x2019;s plasma collection centers that is expected to be sold to third-party customers. &lt;/span&gt;
  &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0" id="ixv-2860">&lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;The following table provides the components of inventories:&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: center;"&gt;&#160;
  &lt;/div&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width : 9%; white-space : nowrap; "&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;



      &lt;span style="font-weight: bold;"&gt;March 31, &lt;br/&gt;

      2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align : center; width : 9%; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; "&gt;



      &lt;span style="font-weight: bold;"&gt;December 31,&lt;br/&gt;

      2024&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center;"&gt;


      &lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Raw materials
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;75,819&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;60,473&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Work-in-process
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;49,780&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;61,641&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Finished goods
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;46,589&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;48,121&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Total inventories
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;172,188&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;170,235&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c2" decimals="-3" id="ixv-9765" unitRef="usd">75819000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c3" decimals="-3" id="ixv-9766" unitRef="usd">60473000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c2" decimals="-3" id="ixv-9767" unitRef="usd">49780000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c3" decimals="-3" id="ixv-9768" unitRef="usd">61641000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c2" decimals="-3" id="ixv-9769" unitRef="usd">46589000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c3" decimals="-3" id="ixv-9770" unitRef="usd">48121000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c2" decimals="-3" id="ixv-9771" unitRef="usd">172188000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="-3" id="ixv-9772" unitRef="usd">170235000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-2957">&lt;div style="text-indent: -27pt; padding-left: 27pt;"&gt;
    &lt;div style="float: left; width: 27.0pt; white-space: nowrap;"&gt;
     &lt;span style="font-weight: bold;"&gt;4.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span style="font-weight: bold; text-decoration: underline;"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;Property and equipment and related accumulated depreciation are summarized as follows:&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;


      &lt;span style="font-weight: bold;"&gt;March 31, 2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;


      &lt;span style="font-weight: bold;"&gt;December 31, 2024&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center;"&gt;


      &lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Manufacturing and laboratory equipment
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;21,916&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;21,305&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Office equipment and computer software
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;6,142&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;5,772&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Furniture and fixtures
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;5,939&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;5,840&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Construction in process
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;11,225&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;8,149&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Leasehold improvements
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;21,103&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;21,066&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Land
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;4,339&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;4,339&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Buildings and building improvements
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;22,542&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;21,788&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;93,206&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;88,259&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Less: Accumulated depreciation
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;(35,496&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;(33,552&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;)&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Total property and equipment, net
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;57,710&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;54,707&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;&lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt;"&gt; &lt;span style="color: rgb(0, 0, 0);"&gt;The Company recorded depreciation expense on property and equipment for the three months ended March 31, 2025 and 2024 of $1.9 million.&lt;/span&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-2964">&lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;Property and equipment and related accumulated depreciation are summarized as follows:&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;


      &lt;span style="font-weight: bold;"&gt;March 31, 2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;


      &lt;span style="font-weight: bold;"&gt;December 31, 2024&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center;"&gt;


      &lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Manufacturing and laboratory equipment
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;21,916&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;21,305&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Office equipment and computer software
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;6,142&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;5,772&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Furniture and fixtures
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;5,939&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;5,840&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Construction in process
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;11,225&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;8,149&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Leasehold improvements
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;21,103&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;21,066&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Land
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;4,339&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;4,339&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Buildings and building improvements
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;22,542&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;21,788&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;93,206&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;88,259&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Less: Accumulated depreciation
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;(35,496&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;(33,552&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;)&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Total property and equipment, net
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;57,710&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;54,707&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c32" decimals="-3" id="ixv-9773" unitRef="usd">21916000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c33" decimals="-3" id="ixv-9774" unitRef="usd">21305000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c34" decimals="-3" id="ixv-9775" unitRef="usd">6142000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c35" decimals="-3" id="ixv-9776" unitRef="usd">5772000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c36" decimals="-3" id="ixv-9777" unitRef="usd">5939000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c37" decimals="-3" id="ixv-9778" unitRef="usd">5840000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c38" decimals="-3" id="ixv-9779" unitRef="usd">11225000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c39" decimals="-3" id="ixv-9780" unitRef="usd">8149000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c40" decimals="-3" id="ixv-9781" unitRef="usd">21103000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c41" decimals="-3" id="ixv-9782" unitRef="usd">21066000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c42" decimals="-3" id="ixv-9783" unitRef="usd">4339000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c43" decimals="-3" id="ixv-9784" unitRef="usd">4339000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c44" decimals="-3" id="ixv-9785" unitRef="usd">22542000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c45" decimals="-3" id="ixv-9786" unitRef="usd">21788000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="-3" id="ixv-9787" unitRef="usd">93206000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="-3" id="ixv-9788" unitRef="usd">88259000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-9789" unitRef="usd">35496000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-9790" unitRef="usd">33552000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-9791" unitRef="usd">57710000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" id="ixv-9792" unitRef="usd">54707000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="-5" id="ixv-9793" unitRef="usd">1900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c4" decimals="-5" id="ixv-9794" unitRef="usd">1900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-3098">&lt;div style="text-indent: -27pt; padding-left: 27pt;"&gt;
    &lt;div style="float: left; width: 27.0pt; white-space: nowrap;"&gt;
     &lt;span style="font-weight: bold;"&gt;5.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span style="font-weight: bold; text-decoration: underline;"&gt;ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: 18pt; clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;Accrued expenses and other current liabilities at March 31, 2025 and December 31, 2024 are as follows:&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;


      &lt;span style="font-weight: bold;"&gt;March 31, 2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap; vertical-align: middle;"&gt;


      &lt;span style="font-weight: bold;"&gt;December 31, 2024&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center;"&gt;


      &lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Accrued rebates
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;"&gt;4,847&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;"&gt;4,155&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Accrued distribution fees
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;12,115&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;11,565&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Accrued incentives
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;1,671&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;5,892&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Accrued interest
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;1,893&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;2,857&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Accrued testing
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;463&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;827&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Accrued payroll and other compensation
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;1,924&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;3,332&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Income taxes payable
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;6,601&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;3,481&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Other
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;2,046&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;1,853&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Total accrued expenses and other current liabilities
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;31,560&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;33,962&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-3105">&lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;Accrued expenses and other current liabilities at March 31, 2025 and December 31, 2024 are as follows:&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;


      &lt;span style="font-weight: bold;"&gt;March 31, 2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap; vertical-align: middle;"&gt;


      &lt;span style="font-weight: bold;"&gt;December 31, 2024&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center;"&gt;


      &lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Accrued rebates
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;"&gt;4,847&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;"&gt;4,155&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Accrued distribution fees
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;12,115&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;11,565&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Accrued incentives
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;1,671&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;5,892&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Accrued interest
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;1,893&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;2,857&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Accrued testing
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;463&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;827&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Accrued payroll and other compensation
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;1,924&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;3,332&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Income taxes payable
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;6,601&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;3,481&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Other
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;2,046&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;1,853&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Total accrued expenses and other current liabilities
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;31,560&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;33,962&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <adma:AccruedRebatesCurrent contextRef="c2" decimals="-3" id="ixv-9795" unitRef="usd">4847000</adma:AccruedRebatesCurrent>
    <adma:AccruedRebatesCurrent contextRef="c3" decimals="-3" id="ixv-9796" unitRef="usd">4155000</adma:AccruedRebatesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c2" decimals="-3" id="ixv-9797" unitRef="usd">12115000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c3" decimals="-3" id="ixv-9798" unitRef="usd">11565000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="c2" decimals="-3" id="ixv-9799" unitRef="usd">1671000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="c3" decimals="-3" id="ixv-9800" unitRef="usd">5892000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c2" decimals="-3" id="ixv-9801" unitRef="usd">1893000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c3" decimals="-3" id="ixv-9802" unitRef="usd">2857000</us-gaap:InterestPayableCurrent>
    <adma:AccruedTestingCurrent contextRef="c2" decimals="-3" id="ixv-9803" unitRef="usd">463000</adma:AccruedTestingCurrent>
    <adma:AccruedTestingCurrent contextRef="c3" decimals="-3" id="ixv-9804" unitRef="usd">827000</adma:AccruedTestingCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c2" decimals="-3" id="ixv-9805" unitRef="usd">1924000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c3" decimals="-3" id="ixv-9806" unitRef="usd">3332000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c2" decimals="-3" id="ixv-9807" unitRef="usd">6601000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c3" decimals="-3" id="ixv-9808" unitRef="usd">3481000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-9809" unitRef="usd">2046000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-9810" unitRef="usd">1853000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c2" decimals="-3" id="ixv-9811" unitRef="usd">31560000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c3" decimals="-3" id="ixv-9812" unitRef="usd">33962000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-3226">&lt;div style="text-indent: -27pt; padding-left: 27pt;"&gt;
    &lt;div style="float: left; width: 27.0pt; white-space: nowrap;"&gt;
     &lt;span style="font-weight: bold;"&gt;6.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span style="font-weight: bold; text-decoration: underline;"&gt;DEBT &lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;A summary of outstanding senior notes payable is as follows:&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;


      &lt;span style="font-weight: bold;"&gt;March 31, 2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;


      &lt;span style="font-weight: bold;"&gt;December 31, 2024&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center;"&gt;


      &lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Term loan
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;32,500&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;32,500&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Revolving credit facility
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;42,500&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;42,500&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Less:
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;
     &lt;div&gt;
      Debt discount
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;(2,473&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;(2,663&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;)&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Senior notes payable
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;72,527&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;72,337&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;&lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: rgb(0, 0, 0);"&gt;On December 18, 2023 (the &#x201c;Ares Closing Date&#x201d;), the Company and all of its subsidiaries entered into a new senior secured credit facility (the &#x201c;Ares Credit Agreement&#x201d;) with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation (collectively, &#x201c;Ares&#x201d;). The Ares Credit Agreement provided for a total of $135.0 million in senior secured credit facilities (the &#x201c;Ares Credit Facility&#x201d;) consisting of (i) a term loan in the aggregate principal amount of $62.5 million and (ii) a revolving credit facility in the aggregate principal amount of $72.5 million (collectively, the &#x201c;Ares Loans&#x201d;), both of which were fully drawn on the Ares Closing Date. The Ares Credit Facility has a maturity date of December 20, 2027 (the &#x201c;Ares Maturity Date&#x201d;).&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: rgb(0, 0, 0);"&gt;Borrowings under the term loan bear interest at the adjusted Term SOFR for a &lt;span style="-sec-ix-hidden: hidden-fact-2"&gt;three&lt;/span&gt;&#x2011;month tenor in effect on the day that is two business days prior to the first day of the applicable calendar quarter plus 6.50% (the &#x201c;Initial &lt;span style="-sec-ix-hidden: hidden-fact-3"&gt;SOFR&lt;/span&gt; Term Loan Applicable Margin&#x201d;). Borrowings under the revolving facility bear interest at the adjusted Term SOFR for a &lt;span style="-sec-ix-hidden: hidden-fact-4"&gt;three&lt;/span&gt;&#x2011;month tenor in effect on the day that is two business days prior to the first day of the applicable calendar quarter&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-style: italic;"&gt;&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;plus&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-style: italic;"&gt;&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;3.75% (the &#x201c;SOFR Revolving Facility Applicable Margin&#x201d;). As of March 31, 2025 and December 31, 2024, the interest rate on the term loan was approximately 10.80% and 10.85%, respectively, and the interest rate on the revolving facility was approximately 8.05% and 8.34%, respectively. &lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: rgb(0, 0, 0);"&gt;On the Ares Maturity Date, the Company is required to pay Ares the entire outstanding principal amount underlying the Ares term loan and revolving loan (together, the &#x201c;Ares Loans&#x201d;) and any accrued and unpaid interest thereon. Prior to the Ares Maturity Date, there are no scheduled principal payments on the Ares Loans. After giving effect to the principal payments made during the year ended December 31, 2024, the Company is required to make quarterly interest payments to Ares of approximately $1.8 million. The Company may prepay the outstanding principal under the revolving facility, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon three business days&#x2019; prior written notice with no prepayment premium. However, in the event the Company pays down an aggregate amount under the revolving facility that is greater than 50% of the $72.5 million commitment amount, the Company will still be required to pay interest on 50% of this amount, or $36.3 million, through the Ares Maturity Date. The Company may prepay the outstanding principal on the term loan, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon three business days&#x2019; prior written notice, subject to the payment to Ares of a prepayment premium equal to (i) the present value as of such date of all remaining required interest payments on the principal amount being repaid plus 1.5% of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Ares Closing Date, (ii) 1.5% of the prepaid principal amount, if prepaid after the first anniversary of the Ares Closing Date and on or prior to the second anniversary of the Ares Closing Date, or (iii) 1.0% of the prepaid principal amount, if prepaid on or prior to the third anniversary of the Ares Closing Date. As further discussed in Note 14 &#x2013; Subsequent Events, on May 6, 2025, the Company repaid $30.0 million against the term loan using a draw of $30.0 million against the revolving credit facility made on May 5, 2025; accordingly, the outstanding balance of the term loan facility as of May 6, 2025 was $2.5 million and the outstanding balance of the revolving loan facility as of May 6, 2025 was $72.5 million.&#160;&#160;&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: rgb(0, 0, 0);"&gt;All of the Company&#x2019;s obligations under the Ares Credit Agreement are secured by a first-priority lien and security interest in substantially all of the Company&#x2019;s tangible and intangible assets, including intellectual property and all of the equity interests in the Company&#x2019;s subsidiaries. The Ares Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar debt financings. The negative covenants include certain financial covenants, including maximum total leverage ratios and a $15.0 million minimum liquidity covenant, and also restrict or limit the Company&#x2019;s ability and the ability of the Company&#x2019;s subsidiaries to, among other things and subject to certain exceptions contained in the Ares Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#x2019;s or the Company&#x2019;s subsidiaries&#x2019; business activities; make certain Investments or Restricted Payments (each as defined in the Ares Credit Agreement); engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company&#x2019;s ability to make loan repayments under the Ares Credit Agreement. As of March 31, 2025, the Company was in compliance with all of the covenants contained in the Ares Credit Agreement.&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify; color: rgb(0, 0, 0);"&gt;
   &lt;span&gt;&#160;&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify; color: rgb(0, 0, 0);"&gt; &lt;span&gt;Events of Default on the Ares Loans include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. If there is an event of default, the Company will incur an increase in the rate of interest on the Ares Loans of 2% per annum.&lt;/span&gt; &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c0" id="ixv-3233">&lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;A summary of outstanding senior notes payable is as follows:&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;


      &lt;span style="font-weight: bold;"&gt;March 31, 2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;


      &lt;span style="font-weight: bold;"&gt;December 31, 2024&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center;"&gt;


      &lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Term loan
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;32,500&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;32,500&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Revolving credit facility
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;42,500&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;42,500&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Less:
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;
     &lt;div&gt;
      Debt discount
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;(2,473&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;(2,663&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;)&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Senior notes payable
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;72,527&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;72,337&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <adma:SeniorNotesPayableBeforeDebtDiscount contextRef="c55" decimals="-5" id="ixv-9813" unitRef="usd">32500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount contextRef="c56" decimals="-5" id="ixv-9814" unitRef="usd">32500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount contextRef="c57" decimals="-5" id="ixv-9815" unitRef="usd">42500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount contextRef="c58" decimals="-5" id="ixv-9816" unitRef="usd">42500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c2" decimals="-3" id="ixv-9817" unitRef="usd">2473000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c3" decimals="-3" id="ixv-9818" unitRef="usd">2663000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:SeniorLongTermNotes contextRef="c2" decimals="-3" id="ixv-9819" unitRef="usd">72527000</us-gaap:SeniorLongTermNotes>
    <us-gaap:SeniorLongTermNotes contextRef="c3" decimals="-3" id="ixv-9820" unitRef="usd">72337000</us-gaap:SeniorLongTermNotes>
    <adma:SeniorNotesPayableBeforeDebtDiscount contextRef="c46" decimals="-6" id="ixv-9821" unitRef="usd">135000000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount contextRef="c47" decimals="-5" id="ixv-9822" unitRef="usd">62500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount contextRef="c48" decimals="-5" id="ixv-9823" unitRef="usd">72500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c49" id="ixv-9824">2027-12-20</us-gaap:DebtInstrumentMaturityDate>
    <adma:NumberOfBusinessDays contextRef="c51" id="ixv-9825">P2D</adma:NumberOfBusinessDays>
    <adma:DebtInstrumentApplicableMargin contextRef="c51" decimals="4" id="ixv-9827" unitRef="pure">0.065</adma:DebtInstrumentApplicableMargin>
    <adma:NumberOfBusinessDays contextRef="c54" id="ixv-9828">P2D</adma:NumberOfBusinessDays>
    <adma:DebtInstrumentApplicableMargin contextRef="c54" decimals="4" id="ixv-9830" unitRef="pure">0.0375</adma:DebtInstrumentApplicableMargin>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c55" decimals="4" id="ixv-9831" unitRef="pure">0.108</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c56" decimals="4" id="ixv-9832" unitRef="pure">0.1085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c57" decimals="4" id="ixv-9833" unitRef="pure">0.0805</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c58" decimals="4" id="ixv-9834" unitRef="pure">0.0834</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c59" decimals="-6" id="ixv-9835" unitRef="usd">0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment contextRef="c49" id="ixv-9836">quarterly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c49" decimals="-5" id="ixv-9837" unitRef="usd">1800000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal contextRef="c49" id="ixv-9838">P3D</adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage contextRef="c60" decimals="2" id="ixv-9840" unitRef="pure">0.50</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <adma:SeniorNotesPayableBeforeDebtDiscount contextRef="c61" decimals="-5" id="ixv-9841" unitRef="usd">72500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage contextRef="c60" decimals="2" id="ixv-9842" unitRef="pure">0.50</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c62" decimals="-5" id="ixv-9843" unitRef="usd">36300000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal contextRef="c49" id="ixv-9844">P3D</adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed contextRef="c63" decimals="3" id="ixv-9846" unitRef="pure">0.015</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed contextRef="c64" decimals="3" id="ixv-9847" unitRef="pure">0.015</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed contextRef="c65" decimals="3" id="ixv-9848" unitRef="pure">0.01</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c66" decimals="-5" id="ixv-9849" unitRef="usd">30000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c67" decimals="-5" id="ixv-9850" unitRef="usd">30000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCredit contextRef="c68" decimals="-5" id="ixv-9851" unitRef="usd">2500000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="c69" decimals="-5" id="ixv-9852" unitRef="usd">72500000</us-gaap:LineOfCredit>
    <adma:MinimumLiquidityCovenantsCreditFacilities contextRef="c70" decimals="-5" id="ixv-9853" unitRef="usd">15000000</adma:MinimumLiquidityCovenantsCreditFacilities>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="c71" decimals="2" id="ixv-9854" unitRef="pure">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-3355">&lt;div style="text-indent: -27pt; padding-left: 27pt;"&gt;
    &lt;div style="float: left; width: 27.0pt; white-space: nowrap;"&gt;
     &lt;span style="font-weight: bold;"&gt;7.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span style="font-weight: bold; text-decoration: underline;"&gt;STOCKHOLDERS&#x2019; EQUITY &lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div&gt;
   &lt;span style="font-style: italic; text-decoration: underline;"&gt;Preferred Stock&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001, par value per share. There were no shares of preferred stock outstanding at March 31, 2025 and December 31, 2024.&lt;/span&gt; &lt;/div&gt;&lt;div&gt;
   &lt;span style="font-style: italic; text-decoration: underline;"&gt;Common Stock&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;As of March 31, 2025 and December 31, 2024, the Company was authorized to issue 300,000,000 shares of its common stock, $0.0001 par value per share, and 238,532,252 and 236,620,545 shares of common stock were outstanding as of March 31, 2025 and December 31, 2024, respectively. After giving effect to shares reserved for the issuance of warrants and for awards issued under the Company&#x2019;s equity incentive plans, 36,622,488 shares of common stock were available for issuance as of March 31, 2025. &lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div&gt;
   &lt;span style="font-style: italic; text-decoration: underline;"&gt;Warrants&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;On January 7, 2025, affiliates of a former noteholder of the Company exercised warrants to purchase an aggregate of 966,554 shares of common stock on a cashless basis, and the Company issued 866,302 shares of common stock to these entities. On January 10, 2024, a former noteholder of the Company exercised a warrant to purchase 4 million shares of the Company&#x2019;s common stock on a cashless basis and the Company issued 1,977,514 shares of common stock to this noteholder. On March 8, 2024, affiliates of a former noteholder exercised warrants to purchase an aggregate of 3,388,681 shares of the Company&#x2019;s common stock on a cashless basis and the Company issued 2,482,205 shares of common stock to such noteholders. On March 14, 2024, an entity associated with another former noteholder of the Company exercised a warrant to purchase 169,651 shares of the Company&#x2019;s common stock on a cashless basis and the Company issued 85,784 shares of common stock to this entity. &lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;On February 24, 2024, a warrant to purchase 34,800 shares of the Company&#x2019;s common stock held by a former noteholder of the Company expired in accordance with its terms. At March 31, 2024 and December 31, 2023, the Company had outstanding warrants to purchase an aggregate of 4,909,774 and 12,502,906 shares, respectively, of common stock, with weighted-average exercise prices of $2.51 and $2.32 per share, respectively, with expiration dates ranging between October 2024 and May 2030.&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;There were no outstanding warrants as of March 31, 2025 and outstanding warrants to purchase 966,554 shares of common stock as of December 31, 2024. &lt;/span&gt; &lt;/div&gt;
  &lt;div style="margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div&gt;
   &lt;span style="font-style: italic; text-decoration: underline;"&gt;Equity Incentive Plans&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;The fair value of stock options granted under the Company&#x2019;s equity incentive plans was determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimate. The following assumptions were used to determine the fair value of options granted during the three months ended March 31, 2025 and 2024:&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;&lt;/div&gt;

  &lt;table cellpadding="0" style="font-size: 9.5pt; border-collapse: collapse; border-spacing: 0px; width: 100%; margin-left: auto; margin-right: auto;"&gt;
 &lt;tr&gt;&lt;td style="width: 79%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td colspan="3" style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:1"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; text-align: center;" valign="top"&gt;
  &lt;div&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="padding: 0in 5.4pt 0in 5px; text-align: center;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; text-align: center;" valign="top"&gt;
  &lt;div&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="vertical-align: bottom;" valign="top"&gt;
  &lt;div&gt;Expected term&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="padding-top : 0in; padding-right : 5.4pt; padding-bottom : 0in; text-align : center; vertical-align : bottom; white-space : nowrap; " valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;5.5 - 6.3 years&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
  &lt;td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-top : 0in; padding-right : 5.4pt; padding-bottom : 0in; text-align : center; vertical-align : bottom; white-space : nowrap; " valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;5.5 - 6.3 years&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:3"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Volatility&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;66%&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
  &lt;td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;66%&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Dividend yield&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;0.0&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
  &lt;td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;0.0&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:5;mso-yfti-lastrow:yes"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Risk-free interest rate&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;4.40%&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
  &lt;td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;4.29%&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
 &lt;/tr&gt;
&lt;/table&gt;&lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;A summary of the Company&#x2019;s option activity under the Company&#x2019;s equity incentive plans and related information is as follows:&lt;/span&gt; &lt;/div&gt;


  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;


      &lt;span style="font-weight: bold;"&gt;Shares&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom; white-space: nowrap;"&gt;




      &lt;span style="font-weight: bold;"&gt;Weighted &lt;br/&gt;

      Average &lt;br/&gt;

      Exercise Price&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Options outstanding, vested and expected to vest at December 31, 2024
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;5,141,516&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;3.90&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Forfeited
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;(1,101&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;1.29&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Expired
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;(10,480&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;4.89&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Granted
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;683,720&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;16.07&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Exercised
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;(39,173&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;6.61&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Options outstanding, vested and expected to vest at March 31, 2025
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;5,774,482&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;5.32&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Options exercisable
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;3,086,687&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;3.21&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;&lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;As of March 31, 2025, the Company had $12.7 million of unrecognized compensation expense related to options granted under the Company&#x2019;s equity incentive plans, which is expected to be recognized over a weighted-average period of 3.1 years.&#160;&#160;&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;The Company&#x2019;s RSUs generally vest annually over a period of four years for employees and semi-annually over a period of one year for directors. A summary of the Company&#x2019;s unvested RSU activity and related information is as follows: &lt;/span&gt; &lt;/div&gt;


  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;Shares&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;




      &lt;span style="font-weight: bold;"&gt;Weighted &lt;br/&gt;

      Average Grant &lt;br/&gt;

      Date Fair Value&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Balance at December 31, 2024
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;5,745,990&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Granted
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;1,658,458&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;16.11&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Vested
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;(1,455,350&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;4.17&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Forfeited
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;(93,611&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;6.64&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Balance at March 31, 2025
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;5,855,487&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;8.82&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;&lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;As of March 31, 2025, the Company had $48.3 million of unrecognized compensation expense related to unvested RSUs granted under the Company&#x2019;s equity incentive plans, which is expected to be recognized over a weighted-average period of 3.4 years.&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify; margin-left: 9pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;Total stock-based compensation expense for all awards granted under the Company&#x2019;s equity incentive plans for the three months ended March 31, 2025 and 2024 was as follows:&#160;&#160;&lt;/span&gt; &lt;/div&gt;


  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align : center; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; "&gt;


      &lt;span style="font-weight: bold;"&gt;Three Months Ended March 31,&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="text-align: center;"&gt;
     &lt;div&gt;
      &lt;span style="font-style: italic;"&gt;(in thousands)&lt;/span&gt;
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;2024&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Research and development
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;39&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;17&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Plasma center operating expenses
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;77&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;39&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Selling, general and administrative
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;3,873&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;1,841&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Cost of product revenue
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;635&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;244&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td style="padding-left: 10px;"&gt;
     &lt;div&gt;
      Total stock-based compensation expense
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;4,624&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;2,141&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance
      contextRef="c2"
      decimals="-6"
      id="ixv-9855"
      unitRef="shares">10000000</us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance
      contextRef="c3"
      decimals="-6"
      id="ixv-9856"
      unitRef="shares">10000000</us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="4"
      id="ixv-9857"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="4"
      id="ixv-9858"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-9859"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-9860"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" id="ixv-9861" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" id="ixv-9862" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="4"
      id="ixv-9863"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="4"
      id="ixv-9864"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" id="ixv-9865" unitRef="shares">238532252</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" id="ixv-9866" unitRef="shares">236620545</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c2" decimals="0" id="ixv-9867" unitRef="shares">36622488</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c72"
      decimals="0"
      id="ixv-9868"
      unitRef="shares">966554</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockSharesIssued
      contextRef="c72"
      decimals="0"
      id="ixv-9869"
      unitRef="shares">866302</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c73"
      decimals="-6"
      id="ixv-9870"
      unitRef="shares">4000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockSharesIssued
      contextRef="c73"
      decimals="0"
      id="ixv-9871"
      unitRef="shares">1977514</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c74"
      decimals="0"
      id="ixv-9872"
      unitRef="shares">3388681</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockSharesIssued
      contextRef="c74"
      decimals="0"
      id="ixv-9873"
      unitRef="shares">2482205</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c75"
      decimals="0"
      id="ixv-9874"
      unitRef="shares">169651</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockSharesIssued
      contextRef="c75"
      decimals="0"
      id="ixv-9875"
      unitRef="shares">85784</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c76"
      decimals="0"
      id="ixv-9876"
      unitRef="shares">34800</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c21"
      decimals="0"
      id="ixv-9877"
      unitRef="shares">4909774</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c14"
      decimals="0"
      id="ixv-9878"
      unitRef="shares">12502906</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c21"
      decimals="2"
      id="ixv-9879"
      unitRef="usdPershares">2.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c14"
      decimals="2"
      id="ixv-9880"
      unitRef="usdPershares">2.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c2" decimals="0" id="ixv-9881" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c3" decimals="0" id="ixv-9882" unitRef="shares">966554</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-9883">The following assumptions were used to determine the fair value of options granted during the three months ended March 31, 2025 and 2024:&lt;table cellpadding="0" style="font-size: 9.5pt; border-collapse: collapse; border-spacing: 0px; width: 100%; margin-left: auto; margin-right: auto;"&gt;
 &lt;tr&gt;&lt;td style="width: 79%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td colspan="3" style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:1"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; text-align: center;" valign="top"&gt;
  &lt;div&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="padding: 0in 5.4pt 0in 5px; text-align: center;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; text-align: center;" valign="top"&gt;
  &lt;div&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="vertical-align: bottom;" valign="top"&gt;
  &lt;div&gt;Expected term&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="padding-top : 0in; padding-right : 5.4pt; padding-bottom : 0in; text-align : center; vertical-align : bottom; white-space : nowrap; " valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;5.5 - 6.3 years&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
  &lt;td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-top : 0in; padding-right : 5.4pt; padding-bottom : 0in; text-align : center; vertical-align : bottom; white-space : nowrap; " valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;5.5 - 6.3 years&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:3"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Volatility&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;66%&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
  &lt;td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;66%&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Dividend yield&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;0.0&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
  &lt;td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;0.0&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:5;mso-yfti-lastrow:yes"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Risk-free interest rate&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;4.40%&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
  &lt;td style="padding: 0in 5.4pt 0in 5px; text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; text-align: center;" valign="top"&gt; &lt;div style="margin: 0in; font-size: 11pt;"&gt;&lt;span style="font-size:9.5pt;mso-bidi-font-size:10.0pt"&gt;4.29%&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
 &lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c83" id="ixv-9884">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c84" id="ixv-9885">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c85" id="ixv-9886">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c86" id="ixv-9887">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c87" decimals="2" id="ixv-9888" unitRef="pure">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c88" decimals="2" id="ixv-9889" unitRef="pure">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c87" decimals="3" id="ixv-9890" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c88" decimals="3" id="ixv-9891" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c87" decimals="4" id="ixv-9892" unitRef="pure">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c88" decimals="4" id="ixv-9893" unitRef="pure">0.0429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-3487">&lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;A summary of the Company&#x2019;s option activity under the Company&#x2019;s equity incentive plans and related information is as follows:&lt;/span&gt; &lt;/div&gt;


  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;


      &lt;span style="font-weight: bold;"&gt;Shares&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom; white-space: nowrap;"&gt;




      &lt;span style="font-weight: bold;"&gt;Weighted &lt;br/&gt;

      Average &lt;br/&gt;

      Exercise Price&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Options outstanding, vested and expected to vest at December 31, 2024
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;5,141,516&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;3.90&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Forfeited
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;(1,101&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;1.29&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Expired
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;(10,480&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;4.89&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Granted
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;683,720&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;16.07&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Exercised
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;(39,173&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;6.61&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Options outstanding, vested and expected to vest at March 31, 2025
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;5,774,482&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;5.32&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Options exercisable
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;3,086,687&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;3.21&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c89"
      decimals="INF"
      id="ixv-9894"
      unitRef="shares">5141516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c89"
      decimals="2"
      id="ixv-9895"
      unitRef="usdPershares">3.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber
      contextRef="c87"
      decimals="INF"
      id="ixv-9896"
      unitRef="shares">-1101</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice
      contextRef="c87"
      decimals="2"
      id="ixv-9897"
      unitRef="usdPershares">1.29</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber
      contextRef="c87"
      decimals="INF"
      id="ixv-9898"
      unitRef="shares">-10480</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice
      contextRef="c87"
      decimals="2"
      id="ixv-9899"
      unitRef="usdPershares">4.89</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber
      contextRef="c87"
      decimals="INF"
      id="ixv-9900"
      unitRef="shares">683720</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice
      contextRef="c87"
      decimals="2"
      id="ixv-9901"
      unitRef="usdPershares">16.07</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber
      contextRef="c87"
      decimals="INF"
      id="ixv-9902"
      unitRef="shares">-39173</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice
      contextRef="c87"
      decimals="2"
      id="ixv-9903"
      unitRef="usdPershares">6.61</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c90"
      decimals="INF"
      id="ixv-9904"
      unitRef="shares">5774482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c90"
      decimals="2"
      id="ixv-9905"
      unitRef="usdPershares">5.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c90"
      decimals="INF"
      id="ixv-9906"
      unitRef="shares">3086687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c90"
      decimals="2"
      id="ixv-9907"
      unitRef="usdPershares">3.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c77" decimals="-5" id="ixv-9908" unitRef="usd">12700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c78" id="ixv-9909">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="c0" id="ixv-3596">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;The Company&#x2019;s RSUs generally vest annually over a period of four years for employees and semi-annually over a period of one year for directors. A summary of the Company&#x2019;s unvested RSU activity and related information is as follows: &lt;/span&gt; &lt;/div&gt;


  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;Shares&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;




      &lt;span style="font-weight: bold;"&gt;Weighted &lt;br/&gt;

      Average Grant &lt;br/&gt;

      Date Fair Value&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Balance at December 31, 2024
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;5,745,990&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Granted
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;1,658,458&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;16.11&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Vested
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;(1,455,350&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;4.17&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Forfeited
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;(93,611&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;6.64&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Balance at March 31, 2025
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;5,855,487&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;8.82&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c79" id="ixv-9910">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c80" id="ixv-9911">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c91"
      decimals="0"
      id="ixv-9912"
      unitRef="shares">5745990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c91"
      decimals="2"
      id="ixv-9913"
      unitRef="usdPershares">5.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c92"
      decimals="0"
      id="ixv-9914"
      unitRef="shares">1658458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c92"
      decimals="2"
      id="ixv-9915"
      unitRef="usdPershares">16.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c92"
      decimals="0"
      id="ixv-9916"
      unitRef="shares">1455350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c92"
      decimals="2"
      id="ixv-9917"
      unitRef="usdPershares">4.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c92"
      decimals="0"
      id="ixv-9918"
      unitRef="shares">93611</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c92"
      decimals="2"
      id="ixv-9919"
      unitRef="usdPershares">6.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c93"
      decimals="0"
      id="ixv-9920"
      unitRef="shares">5855487</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c93"
      decimals="2"
      id="ixv-9921"
      unitRef="usdPershares">8.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c81" decimals="-5" id="ixv-9922" unitRef="usd">48300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c82" id="ixv-9923">P3Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c0" id="ixv-3676">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;Total stock-based compensation expense for all awards granted under the Company&#x2019;s equity incentive plans for the three months ended March 31, 2025 and 2024 was as follows:&#160;&#160;&lt;/span&gt; &lt;/div&gt;


  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 77%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align : center; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; "&gt;


      &lt;span style="font-weight: bold;"&gt;Three Months Ended March 31,&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="text-align: center;"&gt;
     &lt;div&gt;
      &lt;span style="font-style: italic;"&gt;(in thousands)&lt;/span&gt;
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;2024&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Research and development
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;39&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;17&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Plasma center operating expenses
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;77&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;39&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Selling, general and administrative
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;3,873&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;1,841&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Cost of product revenue
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;635&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;244&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td style="padding-left: 10px;"&gt;
     &lt;div&gt;
      Total stock-based compensation expense
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;4,624&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;2,141&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensation contextRef="c94" decimals="-3" id="ixv-9924" unitRef="usd">39000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c95" decimals="-3" id="ixv-9925" unitRef="usd">17000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c96" decimals="-3" id="ixv-9926" unitRef="usd">77000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c97" decimals="-3" id="ixv-9927" unitRef="usd">39000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c98" decimals="-3" id="ixv-9928" unitRef="usd">3873000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c99" decimals="-3" id="ixv-9929" unitRef="usd">1841000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c100" decimals="-3" id="ixv-9930" unitRef="usd">635000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c101" decimals="-3" id="ixv-9931" unitRef="usd">244000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-9932" unitRef="usd">4624000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c4" decimals="-3" id="ixv-9933" unitRef="usd">2141000</us-gaap:ShareBasedCompensation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-3767">&lt;div style="text-indent: -27pt; padding-left: 27pt;"&gt;
    &lt;div style="float: left; width: 27.0pt; white-space: nowrap;"&gt;
     &lt;span style="font-weight: bold;"&gt;8.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span style="font-weight: bold; text-decoration: underline;"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: 18pt; clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;The Company leases an office building and equipment from Areth, LLC (&#x201c;Areth&#x201d;) pursuant to an agreement for services effective as of January 1, 2016, as amended from time to time, and pays monthly rent on this facility in the amount of $10,000. Either party may terminate the agreement by providing the other party with one year&#x2019;s prior written notice. Rent expense for the three months ended March 31, 2025 and 2024 amounted to $30,000. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Board, and Adam S. Grossman, the Company&#x2019;s President and Chief Executive Officer. The Company also reimburses Areth for office, warehousing and building related (common area) expenses, equipment and certain other operational expenses, which were not material to the consolidated financial statements for the three months ended March 31, 2025 and 2024.&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;During the three months ended March 31, 2025 and 2024, the Company purchased certain specialized equipment and repair services used for the collection and processing of source plasma from GenesisBPS in the amount of $34 thousand and $0.1 million, respectively. Genesis is owned by Dr. Grossman and Adam Grossman. &lt;/span&gt; &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:OperatingCostsAndExpenses contextRef="c102" decimals="0" id="ixv-9934" unitRef="usd">10000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c103" decimals="0" id="ixv-9935" unitRef="usd">30000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c104" decimals="0" id="ixv-9936" unitRef="usd">30000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c105" decimals="-6" id="ixv-9937" unitRef="usd">34000000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c106" decimals="-5" id="ixv-9938" unitRef="usd">100000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-3799">&lt;div style="text-indent: -27pt; padding-left: 27pt;"&gt;
    &lt;div style="float: left; width: 27.0pt; white-space: nowrap;"&gt;
     &lt;span style="font-weight: bold;"&gt;9.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span style="font-weight: bold; text-decoration: underline;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: 18pt; clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div&gt;
   &lt;span style="font-style: italic; text-decoration: underline;"&gt;General Legal Matters&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;From time to time, the Company is or may become subject to certain legal proceedings and claims arising in connection with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#x2019;s liquidity, results of operations or financial condition. &lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div&gt;
   &lt;span style="font-style: italic; text-decoration: underline;"&gt;Vendor Commitments&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;Pursuant to the terms of a plasma purchase agreement dated as of November 17, 2011 (the &#x201c;2011 Plasma Purchase Agreement&#x201d;), the Company agreed to purchase from its former contract manufacturer an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum volume from the counterparty, and under the original 2011 Plasma Purchase Agreement the Company was permitted to also collect high-titer RSV plasma from up to five wholly owned ADMA plasma collection facilities.&#160;&#160;During 2015, the Company amended the 2011 Plasma Purchase Agreement to (i) allow the Company to collect its raw material RSV high-titer plasma from any number of wholly owned ADMA plasma collection facilities and (ii) allow the Company to purchase its raw material RSV high-titer plasma from other third-party collection organizations, in each case, provided that the annual minimum volumes from the Company&#x2019;s former contract manufacturer were met, thus allowing the Company to expand its reach for raw material supply as it executes its commercialization plans for ASCENIV. On December 10, 2018, the Company&#x2019;s former contract manufacturer assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations Limited (&#x201c;Grifols&#x201d;) as its successor-in-interest, effective January 1, 2019. Effective October 1, 2024, the Company entered into an Amended and Restated Plasma Purchase Agreement with Grifols (the &#x201c;A&amp;amp;R Grifols Agreement&#x201d;) with a term expiring in &lt;span style="-sec-ix-hidden: hidden-fact-5"&gt;September 2039&lt;/span&gt;, after which it may be renewed for two additional multi-year periods if agreed to by the parties. Pursuant to the A&amp;amp;R Grifols Agreement, Grifols supplies, on a non-exclusive basis, to ADMA BioManufacturing a minimum of 35,000 liters of RSV plasma annually to be used in the manufacture of ASCENIV, with an escalating price per liter depending on the volume supplied in a given 12-month period, with a minimum annual price increase every 12 months. Additionally, Grifols will be entitled to receive a fixed bonus payment in the event that a specified liter amount of high-titer plasma is supplied to the Company in any 12-month period during the term of the A&amp;amp;R Grifols Agreement.&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;Effective August 6, 2024, the Company entered into a Plasma Purchase Agreement with KEDPlasma LLC (&#x201c;KEDPlasma&#x201d;) with a term expiring in &lt;span style="-sec-ix-hidden: hidden-fact-6"&gt;July 2031&lt;/span&gt;, after which it may be renewed for an additional &lt;span style="-sec-ix-hidden: hidden-fact-7"&gt;five&lt;/span&gt;-year period if agreed to by the parties (the &#x201c;KEDPlasma Agreement&#x201d;). Pursuant to the KEDPlasma Agreement, KEDPlasma supplies, on a non-exclusive basis, to ADMA BioManufacturing a minimum of 35,000 liters of RSV plasma annually commencing with the 12-month period ending July 31, 2026, with an escalating price per liter depending on the volume supplied in a given 12-month period. The price per liter of high-titer plasma supplied pursuant to the KEDPlasma Agreement is also scheduled to increase on an annual basis. Additionally, KEDPlasma will be entitled to receive a fixed bonus payment in the event that a specified liter amount of RSV plasma is supplied to the Company in any 12-month period during the term of the KEDPlasma Agreement.&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;On June 6, 2017, the Company entered into a Plasma Supply Agreement with its former contract manufacturer, pursuant to which the counterparty supplies, on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a 10-year term. On July 19, 2018, the Plasma Supply Agreement was amended to provide, among other things, that in the event the counterparty elects not to supply in excess of ADMA BioManufacturing&#x2019;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit percentage of the price that ADMA BioManufacturing pays to the counterparty, then the counterparty shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, the Company&#x2019;s former contract manufacturer assigned its rights and obligations under the Plasma Supply Agreement to Grifols, effective January 1, 2019.&lt;/span&gt; &lt;/div&gt;&lt;div&gt;
   &lt;span style="font-style: italic; text-decoration: underline;"&gt;Post-Marketing Commitments&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;In connection with the FDA&#x2019;s approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. For the three months ended March 31, 2025 and 2024, the Company incurred expenses related to this study in the amount of $0.6 million and $0.3 million, respectively. During the remainder of 2025, the Company expects to incur expenses of approximately $0.3 million to complete this study, which is required to be completed by June 2026.&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div&gt;
   &lt;span style="font-style: italic; text-decoration: underline;"&gt;Other Commitments&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#x2019;s request in such capacities. The Company&#x2019;s maximum exposure under these arrangements is unknown as of March 31, 2025. The Company does not anticipate recognizing any significant losses relating to these arrangements.&lt;/span&gt;
  &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <adma:NumberOfPlasmaCollectionFacilities
      contextRef="c107"
      decimals="0"
      id="ixv-9939"
      unitRef="Facility">5</adma:NumberOfPlasmaCollectionFacilities>
    <adma:NumberOfRenewalTerms contextRef="c109" decimals="0" id="ixv-9940" unitRef="Term">2</adma:NumberOfRenewalTerms>
    <adma:QuantityOfRespiratorySyncytialVirusPlasmaUsed contextRef="c110" decimals="0" id="ixv-9941" unitRef="L">35000</adma:QuantityOfRespiratorySyncytialVirusPlasmaUsed>
    <adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod contextRef="c108" id="ixv-9942">P12M</adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod>
    <adma:IncreaseInMinimumAnnualPriceTerm contextRef="c108" id="ixv-9943">P12M</adma:IncreaseInMinimumAnnualPriceTerm>
    <adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod contextRef="c108" id="ixv-9944">P12M</adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod>
    <adma:QuantityOfRespiratorySyncytialVirusPlasmaUsed contextRef="c111" decimals="0" id="ixv-9945" unitRef="L">35000</adma:QuantityOfRespiratorySyncytialVirusPlasmaUsed>
    <adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod contextRef="c109" id="ixv-9946">P12M</adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod>
    <adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod contextRef="c109" id="ixv-9947">P12M</adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod>
    <adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod contextRef="c109" id="ixv-9948">P12M</adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod>
    <adma:PlasmaSupplyAgreementTerm contextRef="c0" id="ixv-9949">P10Y</adma:PlasmaSupplyAgreementTerm>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c112" decimals="-5" id="ixv-9950" unitRef="usd">600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c113" decimals="-5" id="ixv-9951" unitRef="usd">300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c114" decimals="-5" id="ixv-9952" unitRef="usd">300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0" id="ixv-3858">&lt;div style="text-indent: -27pt; padding-left: 27pt;"&gt;
    &lt;div style="float: left; width: 27.0pt; white-space: nowrap;"&gt;
     &lt;span style="font-weight: bold;"&gt;10.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span style="font-weight: bold; text-decoration: underline;"&gt;SEGMENTS&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: 18pt; clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company&#x2019;s ADMA BioManufacturing operating segment reflects the Company&#x2019;s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL.&#160;&#160;The Plasma Collection Centers operating segment consists of ten&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;&#160;plasma collection facilities located throughout the United States, all of which are operational, collecting plasma and currently hold FDA licenses&lt;/span&gt;&lt;span&gt;. The Company defines its operating segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (&#x201c;CODM&#x201d;) to analyze performance and allocate resources. While not considered an operating segment, the Corporate information included in the tables below consists of certain unallocated general and administrative overhead expenses and interest expense on the Company&#x2019;s senior debt (see Note 7). The Company&#x2019;s CODM is its President and Chief Executive Officer. For the Company&#x2019;s two operating segments, the CODM uses income/loss before taxes as the measure of segment profit to determine the allocation of resources for each segment. Summarized financial information concerning reportable segments is shown in the following tables:&lt;/span&gt; &lt;/div&gt;&lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;" width="100%"&gt;
 &lt;tr&gt;&lt;td style="width: 65%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes"&gt;
  &lt;td colspan="12" style="text-align: center; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Three Months Ended March
  31, 2025&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:1"&gt;
  &lt;td style="text-align: center; vertical-align: bottom;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;i style="mso-bidi-font-style:normal"&gt;(in thousands)&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;ADMA &lt;/b&gt;&lt;/div&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;BioManufacturing&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Plasma Collection &lt;/b&gt;&lt;/div&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Centers&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Total&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Revenues&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"&gt;113,716&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"&gt;1,050&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"&gt;114,766&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:3"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Cost of product revenue&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;53,057&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;648&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;53,705&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:5"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Research and development&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;826&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;826&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:7"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Plasma center operating expenses&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;1,286&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;1,286&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:9"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Selling, marketing and distribution&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;6,044&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;6,044&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:11"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Depreciation and amortization expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;25&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;25&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:13"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;General and administrative expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;8,495&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;8,495&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:15"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Other expense, net&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(64&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(64&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:17"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Income (loss) before taxes&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;45,205&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(884&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;44,321&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:19"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Expenditures for additions to long-lived assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;4,699&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;21&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;4,720&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:21"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Total assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;330,091&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;27,644&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;357,735&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:23"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation of revenues:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment
  revenue&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;114,766&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:25"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;License revenue&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;36&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated
  revenues&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;114,802&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:27"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation
  of selling, general and administrative expense:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:29"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment
  selling, marketing and distribution expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;6,044&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment
  general and administrative expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;8,495&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:31"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Corporate
  general and administrative expense (a)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;9,540&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated
  selling, general and administrative expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;24,079&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:33"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation
  of income (loss) before taxes:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:35"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment
  income before taxes&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;44,321&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;License
  revenue &lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;36&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:37"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Unallocated
  interest expense, primarily related to interest on senior debt (see Note 6)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(1,975&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Unallocated
  interest income&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;608&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:39"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Corporate
  general and administrative expense (a)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;(9,540&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;)&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated
  income before taxes&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;33,450&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:41"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation
  of total assets:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:43"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Total
  segment assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;357,735&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Corporate
  (b)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;152,834&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:45;mso-yfti-lastrow:yes"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated
  total assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;510,569&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
&lt;/table&gt;&lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: -30.6pt; padding-left: 36pt;"&gt; &lt;div style="float: left; width: 30.6pt; white-space: nowrap;"&gt; &lt;span&gt;(a) - &lt;/span&gt; &lt;/div&gt; &lt;div&gt; &lt;span&gt;Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.&lt;/span&gt; &lt;/div&gt; &lt;/div&gt;
  &lt;div style="margin-left: 5.4pt; clear: both;"&gt;
   &lt;span&gt;&#160;&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-indent: -30.6pt; padding-left: 36pt;"&gt; &lt;div style="float: left; width: 30.6pt; white-space: nowrap;"&gt; &lt;span&gt;(b) -&lt;/span&gt; &lt;/div&gt; &lt;div&gt; &lt;span&gt;Primarily consists of cash and deferred tax assets.&lt;/span&gt; &lt;/div&gt; &lt;/div&gt;&lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;" width="100%"&gt;
 &lt;tr&gt;&lt;td style="width: 65%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes"&gt;
  &lt;td colspan="12" style="text-align: center; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Three Months Ended March
  31, 2024&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:1"&gt;
  &lt;td style="text-align: center; padding-left: 10px; vertical-align: bottom;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;i style="mso-bidi-font-style:normal"&gt;(in thousands)&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;ADMA &lt;/b&gt;&lt;/div&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;BioManufacturing&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Plasma Collection &lt;/b&gt;&lt;/div&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Centers&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Total&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Revenues&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"&gt;80,113&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"&gt;1,726&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"&gt;81,839&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:3"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Cost of product revenue&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;40,991&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;1,776&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;42,767&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:5"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Research and development&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;451&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;451&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:7"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Plasma center operating expenses&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;1,005&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;1,005&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:9"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Selling, marketing and distribution&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;4,431&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;4,431&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:11"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Depreciation and amortization expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;193&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;193&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:13"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;General and administrative expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;5,351&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;5,351&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:15"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Other expense, net&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(30&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(1&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(31&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:17"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Income (loss) before taxes&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;28,666&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(1,056&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;27,610&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:19"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Expenditures for additions to long-lived assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;2,330&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;17&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;2,347&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:21"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Total assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;278,331&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;33,990&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;312,321&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:23"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation of revenues:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment revenue&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;81,839&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:25"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;License revenue&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;36&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated revenues&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;81,875&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:27"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation of selling,
  general and administrative expense:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:29"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment selling, marketing and distribution expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;4,431&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment general and administrative expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;5,351&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:31"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Corporate general and administrative expense (a)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;5,857&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated selling, general and administrative expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;15,639&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:33"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation of income
  (loss) before taxes:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:35"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment income before taxes&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;27,610&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;License revenue &lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;36&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:37"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Unallocated interest expense, primarily related to interest
  on senior debt (see Note 6)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(3,769&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Unallocated interest income&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;381&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:39"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Corporate general and administrative expense (a)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;(5,857&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;)&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated income before taxes&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;18,401&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:41"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation of total
  assets:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:43"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Total segment assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;312,321&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Corporate (b)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;38,554&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:45"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated total assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;350,875&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;

&lt;/table&gt;&lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: -30.6pt; padding-left: 36pt;"&gt;
    &lt;div style="float: left; width: 30.6pt; white-space: nowrap;"&gt;
     &lt;span&gt;(a) - &lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span&gt;Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: 36pt; clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: -30.6pt; padding-left: 36pt;"&gt;
    &lt;div style="float: left; width: 30.6pt; white-space: nowrap;"&gt;
     &lt;span&gt;(b) - &lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span&gt;Primarily consists of cash and deferred tax assets.&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;&lt;div&gt; &lt;span&gt;Net revenues according to geographic area, based on the location of where the product is shipped, were as follows:&lt;/span&gt; &lt;/div&gt;


  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 45%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="19" style="text-align: center; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;Three&#160;&#160;Months Ended March 31, 2025&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;



      &lt;span style="font-weight: bold;"&gt;ADMA

      BioManufacturing&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;



      &lt;span style="font-weight: bold;"&gt;Plasma

      Centers&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;



      &lt;span style="font-weight: bold;"&gt;Total Segment &lt;br/&gt;

      Revenue&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;



      &lt;span style="font-weight: bold;"&gt;License

      Revenue&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;



      &lt;span style="font-weight: bold;"&gt;Consolidated

      Revenue&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      United States
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;110,609&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;85&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;110,694&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;36&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;110,730&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      International
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;3,107&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;965&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;4,072&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt; -&#160;&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;4,072&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td style="padding-left: 10px;"&gt;
     &lt;div&gt;
      Total revenues
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;113,716&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;1,050&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;114,766&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;36&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;114,802&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 45%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="19" style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;Three&#160;&#160;Months Ended March 31, 2024&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;



      &lt;span style="font-weight: bold;"&gt;ADMA

      BioManufacturing&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;



      &lt;span style="font-weight: bold;"&gt;Plasma

      Centers&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;



      &lt;span style="font-weight: bold;"&gt;Total Segment &lt;br/&gt;

      Revenue&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;



      &lt;span style="font-weight: bold;"&gt;License

      Revenue&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;



      &lt;span style="font-weight: bold;"&gt;Consolidated

      Revenue&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      United States
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;76,460&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;1,495&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;77,955&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;36&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;77,991&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      International
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;3,653&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;231&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;3,884&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt; -&#160;&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;3,884&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td style="padding-left: 10px;"&gt;
     &lt;div&gt;
      Total revenues
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;80,113&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;1,726&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;81,839&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;36&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;81,875&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <adma:NumberOfFDALicensedPlasmaCollectionFacilities
      contextRef="c0"
      decimals="INF"
      id="ixv-9953"
      unitRef="Facility">10</adma:NumberOfFDALicensedPlasmaCollectionFacilities>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c0"
      decimals="INF"
      id="ixv-9954"
      unitRef="Segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0" id="ixv-9955">Summarized financial information concerning reportable segments is shown in the following tables:&lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;" width="100%"&gt;
 &lt;tr&gt;&lt;td style="width: 65%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes"&gt;
  &lt;td colspan="12" style="text-align: center; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Three Months Ended March
  31, 2025&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:1"&gt;
  &lt;td style="text-align: center; vertical-align: bottom;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;i style="mso-bidi-font-style:normal"&gt;(in thousands)&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;ADMA &lt;/b&gt;&lt;/div&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;BioManufacturing&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Plasma Collection &lt;/b&gt;&lt;/div&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Centers&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Total&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Revenues&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"&gt;113,716&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"&gt;1,050&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"&gt;114,766&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:3"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Cost of product revenue&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;53,057&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;648&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;53,705&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:5"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Research and development&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;826&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;826&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:7"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Plasma center operating expenses&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;1,286&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;1,286&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:9"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Selling, marketing and distribution&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;6,044&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;6,044&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:11"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Depreciation and amortization expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;25&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;25&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:13"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;General and administrative expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;8,495&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;8,495&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:15"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Other expense, net&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(64&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(64&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:17"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Income (loss) before taxes&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;45,205&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(884&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;44,321&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:19"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Expenditures for additions to long-lived assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;4,699&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;21&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;4,720&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:21"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Total assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;330,091&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;27,644&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;357,735&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:23"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation of revenues:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment
  revenue&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;114,766&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:25"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;License revenue&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;36&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated
  revenues&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;114,802&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:27"&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation
  of selling, general and administrative expense:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:29"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment
  selling, marketing and distribution expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;6,044&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment
  general and administrative expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;8,495&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:31"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Corporate
  general and administrative expense (a)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;9,540&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated
  selling, general and administrative expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;24,079&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:33"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation
  of income (loss) before taxes:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:35"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment
  income before taxes&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;44,321&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;License
  revenue &lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;36&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:37"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Unallocated
  interest expense, primarily related to interest on senior debt (see Note 6)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(1,975&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Unallocated
  interest income&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;608&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:39"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Corporate
  general and administrative expense (a)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;(9,540&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;)&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated
  income before taxes&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;33,450&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:41"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation
  of total assets:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:43"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Total
  segment assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;357,735&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Corporate
  (b)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;152,834&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:45;mso-yfti-lastrow:yes"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated
  total assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;510,569&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
&lt;/table&gt;&lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: -30.6pt; padding-left: 36pt;"&gt; &lt;div style="float: left; width: 30.6pt; white-space: nowrap;"&gt; &lt;span&gt;(a) - &lt;/span&gt; &lt;/div&gt; &lt;div&gt; &lt;span&gt;Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.&lt;/span&gt; &lt;/div&gt; &lt;/div&gt;
  &lt;div style="margin-left: 5.4pt; clear: both;"&gt;
   &lt;span&gt;&#160;&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-indent: -30.6pt; padding-left: 36pt;"&gt; &lt;div style="float: left; width: 30.6pt; white-space: nowrap;"&gt; &lt;span&gt;(b) -&lt;/span&gt; &lt;/div&gt; &lt;div&gt; &lt;span&gt;Primarily consists of cash and deferred tax assets.&lt;/span&gt; &lt;/div&gt; &lt;/div&gt;&lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;" width="100%"&gt;
 &lt;tr&gt;&lt;td style="width: 65%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes"&gt;
  &lt;td colspan="12" style="text-align: center; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Three Months Ended March
  31, 2024&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:1"&gt;
  &lt;td style="text-align: center; padding-left: 10px; vertical-align: bottom;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;i style="mso-bidi-font-style:normal"&gt;(in thousands)&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;ADMA &lt;/b&gt;&lt;/div&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;BioManufacturing&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Plasma Collection &lt;/b&gt;&lt;/div&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Centers&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div style="margin: 0in;"&gt;&lt;b style="mso-bidi-font-weight:normal"&gt;Total&lt;/b&gt;&lt;/div&gt;
  &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Revenues&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"&gt;80,113&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"&gt;1,726&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; vertical-align: bottom;" valign="top"&gt;81,839&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; vertical-align: bottom;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:3"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Cost of product revenue&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;40,991&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;1,776&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;42,767&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:5"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Research and development&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;451&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;451&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:7"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Plasma center operating expenses&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;1,005&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;1,005&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:9"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Selling, marketing and distribution&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;4,431&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;4,431&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:11"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Depreciation and amortization expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;193&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;193&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:13"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;General and administrative expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;5,351&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt; &#160;-&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;5,351&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:15"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Other expense, net&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(30&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(1&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(31&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:17"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Income (loss) before taxes&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;28,666&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(1,056&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;27,610&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:19"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Expenditures for additions to long-lived assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;2,330&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;17&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;2,347&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:21"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;Total assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;278,331&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;33,990&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; margin: 0in;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;312,321&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:23"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation of revenues:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment revenue&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;81,839&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:25"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;License revenue&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;36&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated revenues&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;81,875&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:27"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation of selling,
  general and administrative expense:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:29"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment selling, marketing and distribution expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;4,431&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment general and administrative expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;5,351&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:31"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Corporate general and administrative expense (a)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;5,857&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated selling, general and administrative expense&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;15,639&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:33"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation of income
  (loss) before taxes:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:35"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Segment income before taxes&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;27,610&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;License revenue &lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;36&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:37"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Unallocated interest expense, primarily related to interest
  on senior debt (see Note 6)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;(3,769&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;)&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Unallocated interest income&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;381&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:39"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Corporate general and administrative expense (a)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;(5,857&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;)&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated income before taxes&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;18,401&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:41"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td valign="top"&gt;
  &lt;div&gt;&lt;i&gt;Reconciliation of total
  assets:&lt;/i&gt;&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:43"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Total segment assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px;" valign="top"&gt;312,321&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="padding-left: 10px;" valign="top"&gt;
  &lt;div&gt;Corporate (b)&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none;" valign="top"&gt;38,554&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 2px solid black; border-top: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="mso-yfti-irow:45"&gt;
  &lt;td style="padding-left: 20px;" valign="top"&gt;
  &lt;div&gt;Consolidated total assets&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;" valign="top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none;" valign="top"&gt;$&lt;/td&gt;&lt;td style="text-align: right; margin: 0in; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none;" valign="top"&gt;350,875&lt;/td&gt;&lt;td style="text-align: left; margin: 0in; width: 1%; border-bottom: 4px double black; border-top: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;

&lt;/table&gt;&lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: -30.6pt; padding-left: 36pt;"&gt;
    &lt;div style="float: left; width: 30.6pt; white-space: nowrap;"&gt;
     &lt;span&gt;(a) - &lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span&gt;Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: 36pt; clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: -30.6pt; padding-left: 36pt;"&gt;
    &lt;div style="float: left; width: 30.6pt; white-space: nowrap;"&gt;
     &lt;span&gt;(b) - &lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span&gt;Primarily consists of cash and deferred tax assets.&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c115" decimals="-3" id="ixv-9956" unitRef="usd">113716000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c116" decimals="-3" id="ixv-9957" unitRef="usd">1050000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c117" decimals="-3" id="ixv-9958" unitRef="usd">114766000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue contextRef="c115" decimals="-3" id="ixv-9959" unitRef="usd">53057000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c116" decimals="-3" id="ixv-9960" unitRef="usd">648000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c117" decimals="-3" id="ixv-9961" unitRef="usd">53705000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c115" decimals="-3" id="ixv-9962" unitRef="usd">826000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c116" decimals="-3" id="ixv-9963" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c117" decimals="-3" id="ixv-9964" unitRef="usd">826000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCostAndExpenseOperating contextRef="c115" decimals="-3" id="ixv-9965" unitRef="usd">0</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating contextRef="c116" decimals="-3" id="ixv-9966" unitRef="usd">1286000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating contextRef="c117" decimals="-3" id="ixv-9967" unitRef="usd">1286000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:SellingAndMarketingExpense contextRef="c115" decimals="-3" id="ixv-9968" unitRef="usd">6044000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c116" decimals="-3" id="ixv-9969" unitRef="usd">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c117" decimals="-3" id="ixv-9970" unitRef="usd">6044000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:DepreciationAndAmortization contextRef="c115" decimals="-3" id="ixv-9971" unitRef="usd">25000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c116" decimals="-3" id="ixv-9972" unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c117" decimals="-3" id="ixv-9973" unitRef="usd">25000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c115" decimals="-3" id="ixv-9974" unitRef="usd">8495000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c116" decimals="-3" id="ixv-9975" unitRef="usd">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c117" decimals="-3" id="ixv-9976" unitRef="usd">8495000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c115" decimals="-3" id="ixv-9977" unitRef="usd">-64000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c116" decimals="-3" id="ixv-9978" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c117" decimals="-3" id="ixv-9979" unitRef="usd">-64000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c115" decimals="-3" id="ixv-9980" unitRef="usd">45205000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c116" decimals="-3" id="ixv-9981" unitRef="usd">-884000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c117" decimals="-3" id="ixv-9982" unitRef="usd">44321000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c115" decimals="-3" id="ixv-9983" unitRef="usd">4699000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c116" decimals="-3" id="ixv-9984" unitRef="usd">21000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c117" decimals="-3" id="ixv-9985" unitRef="usd">4720000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:Assets contextRef="c118" decimals="-3" id="ixv-9986" unitRef="usd">330091000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c119" decimals="-3" id="ixv-9987" unitRef="usd">27644000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c120" decimals="-3" id="ixv-9988" unitRef="usd">357735000</us-gaap:Assets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c117" decimals="-3" id="ixv-9989" unitRef="usd">114766000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c121" decimals="-3" id="ixv-9990" unitRef="usd">36000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c0" decimals="-3" id="ixv-9991" unitRef="usd">114802000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SellingAndMarketingExpense contextRef="c117" decimals="-3" id="ixv-9992" unitRef="usd">6044000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c117" decimals="-3" id="ixv-9993" unitRef="usd">8495000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c122"
      decimals="-3"
      id="ix_0_fact"
      unitRef="usd">9540000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-9995" unitRef="usd">24079000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c117" decimals="-3" id="ixv-9996" unitRef="usd">44321000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c121" decimals="-3" id="ixv-9997" unitRef="usd">36000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c121" decimals="-3" id="ixv-9998" unitRef="usd">-1975000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest contextRef="c121" decimals="-3" id="ixv-9999" unitRef="usd">608000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c122"
      decimals="-3"
      id="ix_1_fact"
      unitRef="usd">-9540000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" id="ixv-10001" unitRef="usd">33450000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="c120"
      decimals="-3"
      id="ixv-10002"
      unitRef="usd">357735000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c123"
      decimals="-3"
      id="ix_4_fact"
      unitRef="usd">152834000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="-3" id="ixv-10004" unitRef="usd">510569000</us-gaap:Assets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c124"
      decimals="-3"
      id="ixv-10005"
      unitRef="usd">80113000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c125"
      decimals="-3"
      id="ixv-10006"
      unitRef="usd">1726000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c126"
      decimals="-3"
      id="ixv-10007"
      unitRef="usd">81839000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="c124"
      decimals="-3"
      id="ixv-10008"
      unitRef="usd">40991000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c125"
      decimals="-3"
      id="ixv-10009"
      unitRef="usd">1776000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c126"
      decimals="-3"
      id="ixv-10010"
      unitRef="usd">42767000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c124"
      decimals="-3"
      id="ixv-10011"
      unitRef="usd">451000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c125"
      decimals="-3"
      id="ixv-10012"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c126"
      decimals="-3"
      id="ixv-10013"
      unitRef="usd">451000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c124"
      decimals="-3"
      id="ixv-10014"
      unitRef="usd">0</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c125"
      decimals="-3"
      id="ixv-10015"
      unitRef="usd">1005000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c126"
      decimals="-3"
      id="ixv-10016"
      unitRef="usd">1005000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c124"
      decimals="-3"
      id="ixv-10017"
      unitRef="usd">4431000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c125"
      decimals="-3"
      id="ixv-10018"
      unitRef="usd">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c126"
      decimals="-3"
      id="ixv-10019"
      unitRef="usd">4431000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="c124"
      decimals="-3"
      id="ixv-10020"
      unitRef="usd">193000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c125"
      decimals="-3"
      id="ixv-10021"
      unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c126"
      decimals="-3"
      id="ixv-10022"
      unitRef="usd">193000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c124"
      decimals="-3"
      id="ixv-10023"
      unitRef="usd">5351000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c125"
      decimals="-3"
      id="ixv-10024"
      unitRef="usd">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c126"
      decimals="-3"
      id="ixv-10025"
      unitRef="usd">5351000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c124"
      decimals="-3"
      id="ixv-10026"
      unitRef="usd">-30000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c125"
      decimals="-3"
      id="ixv-10027"
      unitRef="usd">-1000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c126"
      decimals="-3"
      id="ixv-10028"
      unitRef="usd">-31000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c124"
      decimals="-3"
      id="ixv-10029"
      unitRef="usd">28666000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c125"
      decimals="-3"
      id="ixv-10030"
      unitRef="usd">-1056000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c126"
      decimals="-3"
      id="ixv-10031"
      unitRef="usd">27610000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c124"
      decimals="-3"
      id="ixv-10032"
      unitRef="usd">2330000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c125"
      decimals="-3"
      id="ixv-10033"
      unitRef="usd">17000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c126"
      decimals="-3"
      id="ixv-10034"
      unitRef="usd">2347000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:Assets
      contextRef="c127"
      decimals="-3"
      id="ixv-10035"
      unitRef="usd">278331000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c128"
      decimals="-3"
      id="ixv-10036"
      unitRef="usd">33990000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c129"
      decimals="-3"
      id="ixv-10037"
      unitRef="usd">312321000</us-gaap:Assets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c126"
      decimals="-3"
      id="ixv-10038"
      unitRef="usd">81839000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c130"
      decimals="-3"
      id="ixv-10039"
      unitRef="usd">36000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c4" decimals="-3" id="ixv-10040" unitRef="usd">81875000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c126"
      decimals="-3"
      id="ixv-10041"
      unitRef="usd">4431000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c126"
      decimals="-3"
      id="ixv-10042"
      unitRef="usd">5351000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c131"
      decimals="-3"
      id="ix_2_fact"
      unitRef="usd">5857000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c4" decimals="-3" id="ixv-10044" unitRef="usd">15639000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c126"
      decimals="-3"
      id="ixv-10045"
      unitRef="usd">27610000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c130"
      decimals="-3"
      id="ixv-10046"
      unitRef="usd">36000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c130"
      decimals="-3"
      id="ixv-10047"
      unitRef="usd">-3769000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c130"
      decimals="-3"
      id="ixv-10048"
      unitRef="usd">381000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c131"
      decimals="-3"
      id="ix_3_fact"
      unitRef="usd">-5857000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c4" decimals="-3" id="ixv-10050" unitRef="usd">18401000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="c129"
      decimals="-3"
      id="ixv-10051"
      unitRef="usd">312321000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c132"
      decimals="-3"
      id="ix_5_fact"
      unitRef="usd">38554000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c24" decimals="-3" id="ixv-10053" unitRef="usd">350875000</us-gaap:Assets>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c0" id="ixv-5251">&lt;div&gt; &lt;span&gt;Net revenues according to geographic area, based on the location of where the product is shipped, were as follows:&lt;/span&gt; &lt;/div&gt;


  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 45%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="19" style="text-align: center; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;Three&#160;&#160;Months Ended March 31, 2025&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;



      &lt;span style="font-weight: bold;"&gt;ADMA

      BioManufacturing&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;



      &lt;span style="font-weight: bold;"&gt;Plasma

      Centers&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;



      &lt;span style="font-weight: bold;"&gt;Total Segment &lt;br/&gt;

      Revenue&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;



      &lt;span style="font-weight: bold;"&gt;License

      Revenue&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;



      &lt;span style="font-weight: bold;"&gt;Consolidated

      Revenue&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      United States
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;110,609&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;85&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;110,694&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;36&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;110,730&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      International
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;3,107&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;965&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;4,072&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt; -&#160;&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;4,072&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td style="padding-left: 10px;"&gt;
     &lt;div&gt;
      Total revenues
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;113,716&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;1,050&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;114,766&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;36&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;114,802&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 45%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="19" style="text-align: center; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;Three&#160;&#160;Months Ended March 31, 2024&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;



      &lt;span style="font-weight: bold;"&gt;ADMA

      BioManufacturing&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;



      &lt;span style="font-weight: bold;"&gt;Plasma

      Centers&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none; white-space: nowrap;"&gt;



      &lt;span style="font-weight: bold;"&gt;Total Segment &lt;br/&gt;

      Revenue&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;



      &lt;span style="font-weight: bold;"&gt;License

      Revenue&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; vertical-align: bottom; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;



      &lt;span style="font-weight: bold;"&gt;Consolidated

      Revenue&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      United States
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;76,460&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;1,495&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;77,955&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;36&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;77,991&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      International
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;3,653&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;231&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;3,884&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt; -&#160;&#160;&#160; &lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;3,884&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td style="padding-left: 10px;"&gt;
     &lt;div&gt;
      Total revenues
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;80,113&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;1,726&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;81,839&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;36&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;81,875&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c133"
      decimals="-3"
      id="ixv-10054"
      unitRef="usd">110609000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c134"
      decimals="-3"
      id="ixv-10055"
      unitRef="usd">85000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c135"
      decimals="-3"
      id="ixv-10056"
      unitRef="usd">110694000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c136"
      decimals="-3"
      id="ixv-10057"
      unitRef="usd">36000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c137"
      decimals="-3"
      id="ixv-10058"
      unitRef="usd">110730000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c138"
      decimals="-3"
      id="ixv-10059"
      unitRef="usd">3107000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c139"
      decimals="-3"
      id="ixv-10060"
      unitRef="usd">965000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c140"
      decimals="-3"
      id="ixv-10061"
      unitRef="usd">4072000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c141"
      decimals="-3"
      id="ixv-10062"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c142"
      decimals="-3"
      id="ixv-10063"
      unitRef="usd">4072000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c115"
      decimals="-3"
      id="ixv-10064"
      unitRef="usd">113716000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c116"
      decimals="-3"
      id="ixv-10065"
      unitRef="usd">1050000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c117"
      decimals="-3"
      id="ixv-10066"
      unitRef="usd">114766000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c121"
      decimals="-3"
      id="ixv-10067"
      unitRef="usd">36000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c0" decimals="-3" id="ixv-10068" unitRef="usd">114802000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c143"
      decimals="-3"
      id="ixv-10069"
      unitRef="usd">76460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c144"
      decimals="-3"
      id="ixv-10070"
      unitRef="usd">1495000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c145"
      decimals="-3"
      id="ixv-10071"
      unitRef="usd">77955000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c146"
      decimals="-3"
      id="ixv-10072"
      unitRef="usd">36000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c147"
      decimals="-3"
      id="ixv-10073"
      unitRef="usd">77991000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c148"
      decimals="-3"
      id="ixv-10074"
      unitRef="usd">3653000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c149"
      decimals="-3"
      id="ixv-10075"
      unitRef="usd">231000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c150"
      decimals="-3"
      id="ixv-10076"
      unitRef="usd">3884000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c151"
      decimals="-3"
      id="ixv-10077"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c152"
      decimals="-3"
      id="ixv-10078"
      unitRef="usd">3884000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c124"
      decimals="-3"
      id="ixv-10079"
      unitRef="usd">80113000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c125"
      decimals="-3"
      id="ixv-10080"
      unitRef="usd">1726000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c126"
      decimals="-3"
      id="ixv-10081"
      unitRef="usd">81839000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c130"
      decimals="-3"
      id="ixv-10082"
      unitRef="usd">36000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c4" decimals="-3" id="ixv-10083" unitRef="usd">81875000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-5537">&lt;div style="text-indent: -27pt; padding-left: 27pt;"&gt;
    &lt;div style="float: left; width: 27.0pt; white-space: nowrap;"&gt;
     &lt;span style="font-weight: bold;"&gt;11.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span style="font-weight: bold; text-decoration: underline;"&gt;LEASE OBLIGATIONS&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: 18pt; clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;The Company leases certain properties and equipment for its ADMA BioCenters and ADMA BioManufacturing subsidiaries, which leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2033. The Company&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. &lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify; margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;The Company determines if an arrangement is an operating lease at inception. Leases with an initial term of 12 months or less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities representing the obligation to make lease payments arising from the lease. Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include options to extend or terminate the lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#x2019;s incremental borrowing rate. The Company&#x2019;s lease expense is recognized on a straight-line basis over the lease term and is reflected in Plasma center operating expenses and selling, general and administrative expenses. Aggregate lease expense for the Company&#x2019;s leases for the three months ended March 31, 2025 and 2024 was approximately $0.6 million during each such period. Cash paid for the Company&#x2019;s leases for the three months ended March 31, 2025 and 2024 was also approximately $0.6 million during each such period.&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;&#160; &lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;The Company has aggregate lease liabilities of $9.5 million and $9.8 million as of March 31, 2025 and December 31, 2024, respectively, which are comprised primarily of the leases for the Company&#x2019;s plasma collection centers and a warehouse lease for raw material storage related to the Company&#x2019;s immunoglobulin manufacturing operations. As of March 31, 2025, the Company&#x2019;s operating leases have a weighted-average remaining term of 6.6 years. Scheduled payments under the Company&#x2019;s lease obligations are as follows (&lt;/span&gt;&lt;span style="font-style: italic;"&gt;in thousands&lt;/span&gt;&lt;span&gt;):&lt;/span&gt; &lt;/div&gt;&lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; width: 60%; margin-left: auto; margin-right: auto;" width="100%"&gt;
 &lt;tr&gt;&lt;td style="width: 58%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="text-align: right; vertical-align: bottom;" valign="top"&gt;
  &lt;div&gt;Remainder of 2025&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;" valign="top"&gt;
  &lt;div&gt;$&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;" valign="top"&gt; &lt;div&gt;1,812 &lt;/div&gt; &lt;/td&gt;
  &lt;td style="border-width: initial; border-style: none; border-color: initial;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;Year ended December 31, 2026&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right;" valign="top"&gt; &lt;div&gt;&#160;2,157 &lt;/div&gt; &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;2027&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right;" valign="top"&gt; &lt;div&gt;&#160;2,041 &lt;/div&gt; &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;2028&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right;" valign="top"&gt; &lt;div&gt;&#160;2,088 &lt;/div&gt; &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;2029&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right;" valign="top"&gt; &lt;div&gt;&#160;2,109 &lt;/div&gt; &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;2030&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right;" valign="top"&gt; &lt;div&gt;&#160;1,836 &lt;/div&gt; &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;Thereafter&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt; &lt;div&gt;&#160;2,205 &lt;/div&gt; &lt;/td&gt;
  &lt;td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;Total payments&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right;" valign="top"&gt; &lt;div&gt;&#160;14,248 &lt;/div&gt; &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;Less: imputed interest&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right;" valign="top"&gt; &lt;div&gt;&#160;(4,762)&lt;/div&gt; &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;Current portion&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt; &lt;div&gt;&#160;(1,188)&lt;/div&gt; &lt;/td&gt;
  &lt;td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;Balance at March 31, 2025&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div&gt;$&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;" valign="top"&gt; &lt;div&gt;&#160;8,298 &lt;/div&gt; &lt;/td&gt;
  &lt;td style="border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="-5" id="ixv-10084" unitRef="usd">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c4" decimals="-5" id="ixv-10085" unitRef="usd">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-5" id="ixv-10086" unitRef="usd">600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c4" decimals="-5" id="ixv-10087" unitRef="usd">600000</us-gaap:OperatingLeasePayments>
    <adma:OperatingAndFinancingLeaseLiability contextRef="c2" decimals="-5" id="ixv-10088" unitRef="usd">9500000</adma:OperatingAndFinancingLeaseLiability>
    <adma:OperatingAndFinancingLeaseLiability contextRef="c3" decimals="-5" id="ixv-10089" unitRef="usd">9800000</adma:OperatingAndFinancingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-10090">As of March 31, 2025, the Company&#x2019;s operating leases have a weighted-average remaining term of 6.6 years. Scheduled payments under the Company&#x2019;s lease obligations are as follows (&lt;span style="font-style: italic;"&gt;in thousands&lt;/span&gt;&lt;span&gt;):&lt;/span&gt;&lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; width: 60%; margin-left: auto; margin-right: auto;" width="100%"&gt;
 &lt;tr&gt;&lt;td style="width: 58%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="text-align: right; vertical-align: bottom;" valign="top"&gt;
  &lt;div&gt;Remainder of 2025&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;" valign="top"&gt;
  &lt;div&gt;$&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom;" valign="top"&gt; &lt;div&gt;1,812 &lt;/div&gt; &lt;/td&gt;
  &lt;td style="border-width: initial; border-style: none; border-color: initial;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;Year ended December 31, 2026&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right;" valign="top"&gt; &lt;div&gt;&#160;2,157 &lt;/div&gt; &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;2027&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right;" valign="top"&gt; &lt;div&gt;&#160;2,041 &lt;/div&gt; &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;2028&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right;" valign="top"&gt; &lt;div&gt;&#160;2,088 &lt;/div&gt; &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;2029&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right;" valign="top"&gt; &lt;div&gt;&#160;2,109 &lt;/div&gt; &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;2030&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right;" valign="top"&gt; &lt;div&gt;&#160;1,836 &lt;/div&gt; &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;Thereafter&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt; &lt;div&gt;&#160;2,205 &lt;/div&gt; &lt;/td&gt;
  &lt;td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;Total payments&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right;" valign="top"&gt; &lt;div&gt;&#160;14,248 &lt;/div&gt; &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;Less: imputed interest&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right;" valign="top"&gt; &lt;div&gt;&#160;(4,762)&lt;/div&gt; &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;Current portion&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: right; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt; &lt;div&gt;&#160;(1,188)&lt;/div&gt; &lt;/td&gt;
  &lt;td style="border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="background-color: rgb(204, 238, 255);"&gt;
  &lt;td style="text-align: right;" valign="top"&gt;
  &lt;div&gt;Balance at March 31, 2025&lt;/div&gt;
  &lt;/td&gt;
  &lt;td valign="top"&gt;&#160;&lt;/td&gt;
  &lt;td style="border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;
  &lt;div&gt;$&lt;/div&gt;
  &lt;/td&gt;
  &lt;td style="text-align: right; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;" valign="top"&gt; &lt;div&gt;&#160;8,298 &lt;/div&gt; &lt;/td&gt;
  &lt;td style="border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;" valign="top"&gt;&#160;&lt;/td&gt;
 &lt;/tr&gt;
&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-10091">P6Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c2" decimals="-3" id="ixv-10092" unitRef="usd">1812000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c2" decimals="-3" id="ixv-10093" unitRef="usd">2157000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c2" decimals="-3" id="ixv-10094" unitRef="usd">2041000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c2" decimals="-3" id="ixv-10095" unitRef="usd">2088000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c2" decimals="-3" id="ixv-10096" unitRef="usd">2109000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c2" decimals="-3" id="ixv-10097" unitRef="usd">1836000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c2" decimals="-3" id="ixv-10098" unitRef="usd">2205000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c2" decimals="-3" id="ixv-10099" unitRef="usd">14248000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c2" decimals="-3" id="ixv-10100" unitRef="usd">4762000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-10101" unitRef="usd">1188000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-10102" unitRef="usd">8298000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-5673">&lt;div style="text-indent: -27pt; padding-left: 27pt;"&gt;
    &lt;div style="float: left; width: 27.0pt; white-space: nowrap;"&gt;
     &lt;span style="font-weight: bold;"&gt;12.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span style="font-weight: bold; text-decoration: underline;"&gt;INCOME TAXES&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;The Company uses the estimated annual effective tax rate approach as prescribed by ASC 740-270, Interim Reporting, to calculate its interim provision for income taxes. &lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 79%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align : center; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; "&gt;


      &lt;span style="font-weight: bold;"&gt;Three Months Ended March 31,&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;2024&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center; padding-left: 10px;"&gt;


      &lt;span style="font-style: italic;"&gt;(In thousands, except percentages)&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Provision for income taxes
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;6,546&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;595&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Effective tax rate
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;19.6&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;%&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;3.2&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;%&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;&lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt; &lt;span&gt;The effective tax rate for the three months ended March 31, 2025 of 19.6%, differed from the federal statutory rate primarily due to the excess tax benefits on stock-based compensation. The effective tax rate for the three months ended March 31, 2024 of 3.2%, differed from the federal statutory tax rate primarily due to the valuation allowance maintained on the Company's federal and state net deferred tax assets until December 31, 2024.&lt;/span&gt; &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-5680">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;The Company uses the estimated annual effective tax rate approach as prescribed by ASC 740-270, Interim Reporting, to calculate its interim provision for income taxes. &lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 79%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align : center; border-bottom : 2px solid black; border-top : none; border-left : none; border-right : none; white-space : nowrap; "&gt;


      &lt;span style="font-weight: bold;"&gt;Three Months Ended March 31,&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;2024&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center; padding-left: 10px;"&gt;


      &lt;span style="font-style: italic;"&gt;(In thousands, except percentages)&lt;/span&gt;
     &lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Provision for income taxes
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;6,546&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom;"&gt;595&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      Effective tax rate
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;19.6&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;%&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;3.2&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;%&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-10103" unitRef="usd">6546000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c4" decimals="-3" id="ixv-10104" unitRef="usd">595000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="3" id="ixv-10105" unitRef="pure">0.196</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c4" decimals="3" id="ixv-10106" unitRef="pure">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="3" id="ixv-10107" unitRef="pure">0.196</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c4" decimals="3" id="ixv-10108" unitRef="pure">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="c0" id="ixv-5748">&lt;div style="text-indent: -27pt; padding-left: 27pt;"&gt;
    &lt;div style="float: left; width: 27.0pt; white-space: nowrap;"&gt;
     &lt;span style="font-weight: bold;"&gt;13.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span style="font-weight: bold; text-decoration: underline;"&gt;SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: 18pt; clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;Supplemental cash flow information for the three months ended March 31, 2025 and 2024 is as follows: &lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 57%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;2024&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center;"&gt;
     &lt;div&gt;
      &lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      &lt;span style="font-weight: bold;"&gt;SUPPLEMENTAL CASH FLOW INFORMATION:&lt;/span&gt;
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td style="padding-left: 10px;"&gt;
     &lt;div&gt;
      Cash paid for interest
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;2,750&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;584&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      &lt;span style="font-weight: bold;"&gt;Noncash Financing and Investing Activities:&lt;/span&gt;
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td style="padding-left: 10px;"&gt;
     &lt;div&gt;
      Equipment acquired reflected in accounts payable and accrued liabilities
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;985&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;1,351&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0" id="ixv-5755">&lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;Supplemental cash flow information for the three months ended March 31, 2025 and 2024 is as follows: &lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;

  &lt;table cellpadding="0" style="font-size: 10pt; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-spacing: 0px;"&gt;
   &lt;tr&gt;&lt;td style="width: 57%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;2025&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 9%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;


      &lt;span style="font-weight: bold;"&gt;2024&lt;/span&gt;
     &lt;/td&gt;&lt;td style="text-align: center; width: 1%; border-bottom: 2px solid black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center;"&gt;
     &lt;div&gt;
      &lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      &lt;span style="font-weight: bold;"&gt;SUPPLEMENTAL CASH FLOW INFORMATION:&lt;/span&gt;
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td style="padding-left: 10px;"&gt;
     &lt;div&gt;
      Cash paid for interest
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;2,750&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;584&lt;/td&gt;&lt;td style="text-align: left; width: 1%; vertical-align: bottom; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top;"&gt;
    &lt;td&gt;
     &lt;div&gt;
      &lt;span style="font-weight: bold;"&gt;Noncash Financing and Investing Activities:&lt;/span&gt;
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 1%;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
    &lt;td style="padding-left: 10px;"&gt;
     &lt;div&gt;
      Equipment acquired reflected in accounts payable and accrued liabilities
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="padding-left: 10px;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;985&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%; padding-left: 10px; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;1,351&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 4px double black; border-top: none; border-left: none; border-right: none;"&gt;&#160;&lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="-3" id="ixv-10109" unitRef="usd">2750000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c4" decimals="-3" id="ixv-10110" unitRef="usd">584000</us-gaap:InterestPaidNet>
    <adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="-3" id="ixv-10111" unitRef="usd">985000</adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities>
    <adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities contextRef="c4" decimals="-3" id="ixv-10112" unitRef="usd">1351000</adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-5857">&lt;div style="text-indent: -27pt; padding-left: 27pt;"&gt;
    &lt;div style="float: left; width: 27.0pt; white-space: nowrap;"&gt;
     &lt;span style="font-weight: bold;"&gt;14.&lt;/span&gt;
    &lt;/div&gt;
    &lt;div&gt;
     &lt;span style="font-weight: bold; text-decoration: underline;"&gt;SUBSEQUENT EVENTS&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: -27pt; clear: both;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;
   &lt;span style="font-style: italic;"&gt;&lt;span style="text-decoration:underline"&gt;FDA Approval&lt;/span&gt;&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;
   &lt;span&gt;In April 2025, the FDA approved the Company&#x2019;s Prior Approval Supplement (the &#x201c;PAS&#x201d;) for its innovative yield enhancement production process benefiting both ASCENIV and BIVIGAM.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;
   &lt;span style="font-style: italic;"&gt;&lt;span style="text-decoration:underline"&gt;Share Repurchase Program&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&#160;&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt; &lt;span&gt;In May 2025, the Company's Board of Directors authorized a share repurchase program of up to $500.0 million of the Company&#x2019;s outstanding shares of common stock. Repurchases under the program may be made from time to time through open market purchases or through privately negotiated transactions subject to market conditions, applicable legal requirements, and other relevant factors. Open market repurchases will be structured to occur in accordance with the requirements of Rule 10b-18. The Company may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of shares under this authorization. The timing and number of shares repurchased under the program will depend on a variety of factors, including stock price, trading volume, and general business and market conditions. The program does not obligate the Company to acquire any particular amount of its common stock, and may be modified, suspended, or terminated at any time at the Company&#x2019;s discretion. The program has no expiration date.&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;
   &lt;span style="font-style: italic;"&gt;&lt;span style="text-decoration:underline"&gt;Debt Reorganization&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt; &lt;span&gt;On May 5, 2025, the Company borrowed $30.0 million under its revolving credit facility with Ares, which the Company used to repay an additional $30.0 million against the Company&#x2019;s term loan facility with Ares on May 6, 2025. Following such transactions, the Company had $72.5 million outstanding under its revolving credit facility and $2.5 million outstanding under its term loan facility. It is anticipated that the Company&#x2019;s cost of current outstanding debt will be reduced from these transactions.&#160;&#160;&lt;/span&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <srt:StockRepurchaseProgramAuthorizedAmount1
      contextRef="c153"
      decimals="-5"
      id="ixv-10113"
      unitRef="usd">500000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c67" decimals="-7" id="ixv-10114" unitRef="usd">30000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c66" decimals="-7" id="ixv-10115" unitRef="usd">30000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:LineOfCredit contextRef="c69" decimals="-5" id="ixv-10116" unitRef="usd">72500000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="c68" decimals="-5" id="ixv-10117" unitRef="usd">2500000</us-gaap:LineOfCredit>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c0" id="ixv-10118">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c0" id="ixv-10119">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c0" id="ixv-10120">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c0" id="ixv-10121">false</ecd:NonRule10b51ArrAdoptedFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <adma:DebtInstrumentTermOfVariableRate contextRef="c50" id="hidden-fact-2">P3M</adma:DebtInstrumentTermOfVariableRate>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration contextRef="c52" id="hidden-fact-3">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <adma:DebtInstrumentTermOfVariableRate contextRef="c53" id="hidden-fact-4">P3M</adma:DebtInstrumentTermOfVariableRate>
    <adma:AgreementWithTermExpirationDate contextRef="c108" id="hidden-fact-5">2039-09-30</adma:AgreementWithTermExpirationDate>
    <adma:AgreementWithTermExpirationDate contextRef="c109" id="hidden-fact-6">2031-07-31</adma:AgreementWithTermExpirationDate>
    <adma:PlasmaPurchaseAgreementRenewalPeriod contextRef="c109" id="hidden-fact-7">P5Y</adma:PlasmaPurchaseAgreementRenewalPeriod>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-10132">0001368514</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-10133">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-10134">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-10135">--12-31</dei:CurrentFiscalYearEndDate>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span>Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span>Primarily consists of cash and deferred tax assets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
